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Abstract
Integrin-targeting peptides have been shown to increase transfection efficiency when 
included in a number of different non-viral vectors. In the case of Lipofectin/DNA complexes 
(LD), transfection efficiency has been shown to increase on incorporation of an integrin- 
targeting peptide (Lipid/Integrin-targeting peptide/DNA complexes), as seen by a 100-fold 
increase in luciferase expression.
Efforts to improve the Lipofectin component of Lipid/Integrin-targeting peptide/DNA 
complexes continue to be made and consequently ways of increasing transfection efficiency 
through modifications to the integrin-binding peptide are also been investigated. The integrin- 
targeting peptide component of Lipid/Integrin-targeting peptide/DNA complexes investigated 
by Hart et al. has effectively three functionalities; a ‘head’ which is complimentary to a 
specific integrin, a ‘tail’ which can bind to and condense DNA and a ‘spacer’ which links the 
‘head’ and ‘tail’.
Both alternative spacers and DNA-binding motifs have been synthesised and 
incorporated into integrin-targeting peptides with the intention of investigating the effects of 
these modifications on the transfection efficiency as well as physical properties of 
Lipid/Integrin-targeting peptide/DNA complexes. In this thesis are reported the structures of 
unnatural amino acids synthesised and incorporated into integrin-targeting peptides, as well 
as some of the transfection results obtained.
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Chapter 1
2Developments in non-viral gene therapy.
1.1 Gene therapy and its goals.
The term ‘gene therapy’ can be applied to any clinical therapeutic procedure in 
which genes or some other nucleic acid agents (such as ‘antisense’ oligonucleotides or 
mRNA) are deliberately introduced into human somatic cells.1 The basic principle of 
gene therapy is the manipulation of gene expression towards a therapeutic goal. One of 
the fundamental findings of molecular medicine is that not only inherited but also most 
acquired diseases have a genetic component. Several hundred known diseases exist that 
are related to disorders of gene functioning. Hence there is the potential for these diseases 
to be treated by the delivery of deliberately constructed genetic material to cells of 
affected organs or tissues. Certainly, genetic diseases resulting from dominant mutations 
can only be effectively treated via gene targeting. Moreover, the delivery of genetic 
material to cells has the potential to not only correct inherent defects of the genome, but 
also to influence the pathological processes resulting from viral infection, disorders of the
>y
immune system and tumorigenic diseases. Hence, gene therapy may be broadly defined 
as the delivery of DNA/polynucleotides or mRNA to a patient for some therapeutic 
purpose.
Every gene therapy strategy includes three consecutive steps; the delivery of the 
therapeutic genetic material in vivo or ex vivo; the integration of this genetic material into 
a host genome; and the expression of the transgene formed.3 There are two main 
approaches, ex vivo and in vivo gene therapy. The former technique was the first to be 
developed and involves the genetic manipulation of target cells in culture prior to 
transplantation or in some cases re-implantation. This technique has some advantages, 
such as strict control of the genetic transformation of cells before they are implanted into 
the patient. However, the ex vivo approach has the disadvantage of enormous 
consumption of time and expense, and is only available for some special cases of gene 
therapy. Recent advances have stimulated the development of in vivo gene therapy, in 
which genetic material is directly delivered to target cells within the body of the patient. 
However, there still remain obstacles to successful in vivo gene delivery such as the lack 
of specific, safe or effective means of genetic material delivery.
3For a piece of genetic material to achieve a desired function, it must be targeted to 
the appropriate cell, penetrate that cell, be transported into the nucleus, and integrated into 
the cellular DNA so that it can be expressed.4 If all this is accomplished successfully, the 
genetic material may persist and function either as a template for ongoing production of 
the therapeutic protein or as an inhibitor of the production of an undesirable protein. 
Genetic material is a problematical drug to deliver because its inability to cross the cell 
membrane due to its negative charge and its susceptibility to enzymatic degradation. 
Naked DNA can also elicit an immune response. Furthermore, genes are extremely large 
in comparison to current therapeutic agents e.g. Zovirax or Mitozantrone, which have 
molecular weights of well under 103 Da.. The molecular weight of a gene is of the order 
of 106 Da. while that of an oligonucleotide is 103 Da.. There is subsequently a 
requirement to be able to deliver the genetic material across the plasma and nuclear 
membranes of the cell. Crucial to the success of any gene therapy strategy is the 
efficiency with which the genetic material is delivered, and the efficiency is dependent on 
the type of vector used for delivery.5
1.2 Vectors for in vivo gene therapy.
The essential feature of any vector must be that it can efficiently and accurately 
deliver the therapeutic DNA or mRNA with which it is associated into the target cell. In 
addition to this, an ideal vector should possess the following characteristics:
i) The combination of high safety and reliability with low cost and wide 
applicability.
ii) The ability to maintain for long a time the gene delivery competence in the blood.
iii) High selectivity for the target cell.
iv) No limitation on the size of the nucleic acid that can be accommodated and 
delivered.
v) The capability to transduce a large number of cells irrespective of their mitotic 
status.
4vi) The ability to transform the necessary fraction of cells ranging from a few percent 
to a guaranteed 100 % transformation (especially essential for the treatment of cancer 
and some viral diseases).2
vii) Suitable pharmacodynamic and pharmacokinetic properties.
viii) No unwanted interaction with other cells or systems e.g. the immune 
system leading to an inflammatory response.
Present day vectors can be divided into two broad categories, namely viral and 
non-viral (synthetic). Research using viral vectors has progressed far more rapidly than 
with non-viral vectors because viruses possess the ability to adhere themselves to, and 
enter host cells very effectively. This is reflected by the fact that in the region of 85 % of 
current clinical protocols involving gene therapy utilise vectors based on viruses.5 
However, to date none of the current vectors for nucleic acid delivery have satisfied all of 
these requirements.
1.3 Viral vectors.
The development of recombinant viruses as vectors was an important 
breakthrough in their use for gene transfer. The challenge was to disable the virus so that 
it was no longer able to replicate successfully but so that it was still sufficiently active to 
be able to incorporate its genome, containing the therapeutic gene into the target cell.4 
Several viruses are used at present as vectors; retroviruses, lentiviruses, adenoviruses, and 
the herpes simplex virus.
i) Retroviruses are RNA-containing viruses that on infecting the host immediately
act as templates for double-stranded DNA synthesis, this DNA being integrated into
the hosts’ chromosomes by a contained or encoded reverse transcriptase. The removal
of a definite gene prevents the assembly of active virus particles which reduces but 
does not exclude the risk of the appearance of virulent particles during infection of the 
host cells either in vivo or ex vivo. However most retroviral vectors are unable to
infect non-dividing cells, which limits their use for gene transfer to differentiated
cells.6 The exception to this is the lentivirus subgroup of which the HIV virus is a 
member. Lentiviral vectors are able to infect non-dividing cells and are suited for 
gene transfer to differentiated cell types.
ii) Adenoviruses and the herpes simplex virus contain double-stranded DNA and are 
capable of delivering much larger amounts of genetic material than retroviruses. They 
do not incorporate into the host genome and are eliminated during cell division.2 Both 
viral vectors are capable of infecting non-dividing cells and express transgenes at high 
levels.
Viral Vector
Retrovirus Adenovirus Gutted
adenovirus
Adeno-
associtaed
virus
Lentivirus
Genome ssRNA dsDNA dsDNA ssDNA ssRNA
Enveloped Yes No No No Yes
Insert 8-10 kb 7-8 kb 35 kb 4.5 kb ?
capacity
Integration Yes No No Unclear Yes
Duration Extended Transient Extended Extended Extended
Ease of Easy Very easy Difficult Difficult at scale Difficult
manufactur
Ac
Comments Requires Transduces Improved Excellent Transduces
dividing cells wide range of inflammatory duration in some non-dividing
cells response tissue cells
7Table 1 - Characteristics of commonly used viral vectors.
The utilisation of viruses as vectors for gene therapy suffers from several 
disadvantages. Firstly, the capsid (protein coat) of a virus can elicit an immunological 
response since the capsomeres of which it is constructed are foreign proteins. For 
example, despite the ease with which it is possible to isolate highly concentrated stocks of 
adenovirus and also the high efficiency with which this virus is capable of transfecting 
non-dividing cells, the use of this virus as a vector is consistently accompanied by the 
development of host immune responses. Adenoviral vectors elicit at least two types of
6immune response; the viral proteins and transgenes are potential anitgens, which may 
activate cellular immune functions resulting in the destruction of the corrected cell. Both 
B cells and T-helper cells can be activated by the presence of the capsid resulting in the 
production of antiviral antibodies that bind to the viral protein coat thus preventing gene 
transfer.4 This immunological response can be severe if not fatal. Furthermore viruses 
lack tissue specificity and cannot always be targeted to particular cells. Finally, the 
removal of a definite gene from a virus so as to produce a replication deficient or disabled 
virus does not completely exclude the possibility of the re-appearance of virulent particles 
during the infection of the host cell.2 The characteristics of some commonly used viral 
vectors are listed above (Table 1).
The limitations of the use of viral vectors as a result of issues such as safety, 
specificity, immunogenicity and the limitation on the size of the gene that can be 
delivered, has led to further research into artificial gene delivery vehicles.
1.4 Synthetic vectors.
Non-viral gene delivery systems are essentially based on the charge-neutralisation 
o f DNA/polynucleotides into nanometric particles/complexes by the electrostatic 
interaction between the negatively charged phosphate backbone and cationic molecules or 
polymers.8 This interaction of DNA with cationic molecules or polymers can result in the 
DNA being protected from degradation by endogenous nucleases, mechanical damage or 
immune reaction as well as lysosomal degradation. The cationic molecules or polymer 
can also impart a range of other properties to the complex depending on their nature. 
Depending on their exact nature, these complexes of DNA and cationic molecules or 
polymers can be internalised by cells by the process of either endocytosis or 
phagocytosis. For example, it has been found that cationic lipid-DNA complexes show 
optimal transfection properties when the complex bears an overall positive charge due to 
an excess of cationic lipid to DNA being present. This is the result of non-specific 
binding to the anionic proteoglycans that extend from the cell surface into the 
extracellular matrix, and subsequent spontaneous internalisation. Although this process is 
quite efficient in vitro, this is not necessarily the case in vivo however because when 
systemic delivery is employed, there is the potential for the cationic particles to interact 
with a plethora of other polyanions. Nevertheless, considerable effort has been made to 
investigate the transfection efficiencies of various cationic lipids9,10, cationic peptides
7i i,i2,i3,i4^  p0iyCationic polymers15,16 and cationic amphiphiles17. Improving the efficiency 
of synthetic vectors can be very problematic in that often in attempting to overcome one 
difficulty another is encountered that is a direct result of the previous modification.
1.4.1 Cationic lipid vectors.
ci-
DOTMA
O
0  DOPE
Figure 1. -  Structures of DOTMA and DOPE.
The first non-toxic cationic lipid, which showed high DNA-complex transfection 
efficiency, was synthesised by Feigner and colleagues.18 This charged lipid, DOTMA 
(Fig. 1) was used in combination with the naturally available neutral lipid, DOPE (Fig. 1). 
The complexation of DNA with DOTMA/DOPE resulted in a thousand-fold increase in 
transfection efficiency compared with the injection of naked DNA into the body. The list 
of cationic lipids since DOTMA has increased steadily since Feigner’s breakthrough. 
During the 1990s a large number of cationic lipids such as quaternary ammonium 
detergents, cationic derivatives of cholesterol and diacylglycerol and lipid derivatives of 
polyamines were reported.19 By 1998, more than twenty new cationic liposome
90formulations had been reported to bring about nucleic acid delivery . A large number of 
analogues of DOTMA were synthesised such as DOTAP 21, DMRIE 22, DORIE 22 and 
DORI 23,24 and indeed in some cases analogues followed from these analogues such as 
GAP-DLRIE from DMRIE 25. Several cationic liposome formulations (synthetic cationic
(K)lipid with neutral co-lipid) have been commercialised (Table 2), Feigner’s Lipofectin 
(DOTMA/DOPE 1:1) being one of them.
COMMERCIALISED. NO T COMMERCIALISED.
Cytofectin. Formulation. Cytofectin. Formulation.
DOTMA DOTMA/DOPE 1:1 
(Lipofectin®/GIBCO 
BRL)
DMRIE DMRIE/DOPE 1:1
DORIE DORIE/DOPE 1:1
DOTAP DOTAP 
(Boehringer Mannheim)
DORI DORI/DOPE 1:1
14 Dea 2 14 Dea 2
DOSPA DOSPA/DOPE
(LipofectAMINE®/GIBC
O)
GS 2888 GS 2888/DOPE 1:1
DC-ChoI DC-Chol/DOPE 6:4
DOGS DOGS 
(Transfectam /Promega)
Cholic acid 
hexamine
Choi. Hex./DOPE 
1:1
Lipid 67 Lipid 67/DOPE 1:2
Di C14 amidine Di C14 amidine/DOPE 
1:1 (Clonfectin/Clontech)
CTAP CTAP/DOPE 1:2
BGTC BGTC/DOPE 3:2
DDAB DDAB/DOPE 1:2.5 
(LipofectAce/GIBCO)
DPPES DPPES
L-PE L-PE/CePA 6:4
Cholesteryl-
spermidine
Cholesterylspermidine 
(Transfectall®/Apollo 
Inc)
2C,4-L-G1u-
c 2-n +ci
2 C 14-L-GIU-C2-
N+cr
DOTIM DOTIM/DOPE 1:1
Table 2. -  Cationic liposome formulations.20
The term ‘cytofectins’ has now been given to positively charged lipid molecules 
that interact with DNA/polynucleotides and facilitate their entry into living cells. The 
general structure of cytofectins consists of a cationic head that carries one or several 
charges, attached to a long chain hydrocarbon, hydrophobic moiety such as a fatty acid, 
fatty alcohol or sterol. Thus, they can be considered positively charged amphiphiles. 
Many of the cytofectins synthesised after DOTMA were similar in structure to it, but
other cytofectins also followed such as derivatives of cholesterol, dipalmitoyl,
00ethanolamine, glutamate, imidazole and phosphonate (see Appendix).
During continued attempts to prepare DOTMA analogues with ever improved 
transfection efficiencies it was discovered that quaternary amines could be toxic because 
they frequently depressed the activity of protein kinase C 26,27. For this reason, the
9synthesis of cationic lipids containing primary, secondary and tertiary amine functions 
began to prevail in the mid-1990s. Examples of these include DC-Chol28 and its 
analogues (Fig. 2), di C14 amidine 29’30, GS-2888 3I, Lys-Pam2-GroPEtn 32. Certain 
authors 19 believe that development of novel types of lipid molecules is reaching 
saturation and indeed recently there has been a shift towards designing new types of 
cationic lipid-DNA transfection complexes containing a third or even fourth component 
and also towards determining specific in vivo applications. Nevertheless there remains 
considerable interest in the use of cationic lipids for non-viral gene therapy and indeed the 
synthesis and testing of novel cytofectins continue to be reported in literature regularly
3 3 ,34 ,35 ,36,37
DC-Chol
Me2N'
H
N
O
Figure 2. - DC-Chol and its analogues, cholesteryl-3p-oxysuccinamido- 
ethylenedimethylamine and cholesteryl-3p-carboxyamidoethylenedimethylamine.
As has already been stated, cytofectins must be capable of binding to 
DNA/polynucleotides, imparting to the resulting complex resistance to enzymatic 
degradation, resistance to chemical damage and the ability to bind to anionic
10
proteoglycans that extend from the target cell surface. Another important feature of 
cytofectins is their ability to transiently de-stabilise and fuse with cell membranes. Thus 
cationic lipid vectors, once engulfed by an endocytotic vesicle, are able to fuse with the 
vesicle membrane and release their ‘contents’ into the cytoplasm, whilst avoiding 
degradation of that ‘contents’. This property of cytofectins is probably one of the most 
significant in terms of their transfection efficiency and is probably responsible for the 
success of cytofectins in non-viral gene therapy to date.
Generally cytofectins are formulated (see Table 2) in combination with neutral 
lipids, such as phospholipids or cholesterol. One of the reason for this is that many of the 
cytofectins mentioned are unable to form a membrane bilayer and so cannot form 
membrane vesicles that are necessary to encapsulate the DNA to which they are bound. 
Both DOTMA and DC-cholesterol are available as formulations with DOPE because it is 
one of the only lipids that has a helper activity. Formulations with DOPE were found to 
increase the transfection properties of the two cytofectins and so it was quite clear that the 
structure of a lipid-DNA vesicle in terms of the vesicle membrane was important with 
regards to its properties. Substitution of DOPE with analogues that were modified either 
at the polar head or fatty acid chain in formulations of DOTMA/DOPE or DC- 
Chol/DOPE has been observed to drastically decrease the activity of the corresponding 
cationic liposome/DNA complexes.
The simplicity of cationic liposome-DNA complexes (only two components and 
ease of formulation) led to their widespread use for gene delivery into a variety of 
primary and cultured cells in vitro. Many of the commercially available liposome 
formulations mentioned earlier (Table 2) have been used extensively mainly because of 
their broad efficacy in terms of transfecting different cell types. The simplicity of cationic 
liposome-mediated nucleic acid delivery in vitro resulted in a rapid increase in their 
application to nucleic acid delivery in vivo . It should be noted though that it has been 
observed that in vitro efficiency of cationic liposome-DNA complexes has often been a 
poor guide to in vivo efficiency. Nevertheless, to date cationic liposome-DNA complexes 
have been successfully employed to deliver plasmid DNA to lung 39, brain 40, tumour 41 
and skin 42 by local administration, and to vascular endothelial cells 43 by systemic 
administration.44
A significant disadvantage of cationic lipids/liposomes is that their complexes 
with DNA must have an excess of positive charge in order to be internalised by cells but 
this positive charge results in interaction of the complexes with polyanions present in the 
circulatory system which results in various negative side-effects. Lowering the overall
11
negative charge of these complexes results in particles that have a greater tendency to 
aggregate, which results in reduced transfection efficiency. Increasing the overall 
negative charge by increasing the lipid to DNA ratio results in particles that have a lesser 
tendency to aggregate but at the same time the toxicity of the complexes increases 
because larger amount of cationic lipid are being introduced into cells.
The majority of lipids, both natural and synthetic are capable of forming a large 
diversity of structures, the classical lipid bilayer being only one of these phases. Variables 
such as the hydration, temperature, presence of ions or other molecules affect the 
structure that lipids may form. The steric dimensions of the polar and hydrophobic 
moieties of a lipid also determine the nature of the phase that it forms. For example a lipid 
molecule may be cylindrical or conical in shape; a cylindrical lipid molecule tends to 
arrange to form a flat bilayer structure, while a conical lipid will tend to produce micellar, 
cubic or hexagonal phases. The structure of phases is therefore very much dependent on 
the shape of lipid molecules about their long axis. Liposomes used in transfection also 
express a marked ability for polymorphism among the phases formed.
Studies on the behaviour of cationic liposome-DNA complexes have shown that 
they are in effect very heterogeneous and dynamic. Both the size and shape of the 
complexes is dependent on the ratio of the cationic liposome to DNA. Moreover, it has 
been shown that the most dramatic change in structural organisation of the complex 
occurs when the positive/negative ratio of cationic lipid to anionic DNA is around one. 
Experiments carried out by Gershon et al. 45, using ethidium bromide as a fluorescent 
probe for exposed DNA base pairs demonstrated that DNA was extensively masked as 
the positive/negative ratio approached one. Similarly Struck et al. 46, upon carrying out 
lipid-mixing experiments using resonance energy transfer (RET), observed that a 
noticeable change in lipid-DNA complex behaviour, evident through changes in 
fluorescence quenching, occurred at the 1:1 charge ratio. Gershon et al. 45 interpreted this 
dramatic change in behaviour as being the point at which the cationic liposomes were 
neutralising the charge of the DNA, resulting in the collapse of the DNA structure. The 
collapsed DNA whose surface was much smaller could then be more efficiently 
encapsulated by the liposome. This interpretation was further backed up by Kleinschmidt 
metal-shadowing electron microscopy experiments also carried out by Gershon et al. 45.
At low liposome/DNA ratios (below the 1:1 charge ratio), liposomes appeared as 
localised DNA-bound spherical clusters, while at liposome/DNA ratios above the 1:1 
charge ratio, larger rod-shaped structures appeared as a result of the encapsulation of 
several DNA molecules together.
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Figure 3. -  Electron photomicrographs of lipid/DNA complexes prepared at a 
ratio o f 5:1 (w/w). (A) Plasmid DNA without lipid. (B)-(F) Various types of complexes 
observed; partially and fully complexed DNA. In (B) the open arrow shows un- 
complexed DNA. Bar indicates 100 nm. (Reproduced from Zabner et al. 49)
Two general structures have been proposed for the complexation of liposomes 
with DNA. One of these structures can be described as a ‘multilayered pie’ in which 
tightly packed lipid bilayer membranes are separated by tightly packed molecules of 
DNA. The other structure can be thought of as long, thin tubes constructed o f the lipid 
bilayer membrane, filled with DNA.2 The theory that the DNA is encapsulated by the 
liposome is support by the evidence that DNA in LD complexes is protected from 
degradation by endogenous nucleases or immune reaction. It is also consistent with the 
observation that DNA complexed to cationic lipid is highly soluble in organic solvents or 
detergents.47 The former o f these structures has been confirmed by X-ray diffraction work 
carried out by Radler and co-workers on DOPE/DOTAP liposomes (1:1) complexed with 
y-phage DNA 48 They observed that the DNA was sandwiched between cationic lipid 
bilayers resulting in the predicted highly ordered multilammelar structure. It was 
proposed that these multilamellar structures arose from initial binding o f DNA to the
surface of the cationic liposomes. The screening effect o f the DNA against the 
electrostatic repulsion between lipid bi-layers would allow the multilayer formation to 
occur. The latter tube-like structure has also been confirmed by Zabner et al. 49, who 
observed what appeared to be DNA strands coated in a thin layer o f lipid in their electron- 
micrograph studies of DOPE/DMRIE liposomes complexed to DNA (Fig. 3). There 
appears to be some debate in literature as to the state of the DNA in cationic 
liposome/DNA complexes. Early studies on the structure o f cationic liposome/DNA 
complexes suggested that the DNA in these structures was condensed or compacted. 
However, evidence against compaction/condensation has also been published and indeed 
this appears to be the stronger case. This subject will however be dealt with in more detail 
in chapter 3.
Since cationic liposome mediated DNA delivery frequently appears to be most 
efficient when the positive/negative charge ratio is around or just above one, it could be 
suggested that the highly ordered multilamellar particles containing ordered DNA are the 
principal structures responsible for delivery. However since these LD complexes are 
known to be highly dynamic and in equilibrium with smaller structures, this may not be 
necessarily accurate.20
Figure 4. -  Electron photomicrographs of COS cells transfected with gold-labelled 
DNA complexed with DMRIE/DOPE. Cells were exposed to DMRIE/DOPE /DNA 
complexes and then removed for electron microscopy at the following times; (A) 5 
minutes, (B) 30 minutes, (C) 1 hour, (D) 6 hours, (E) 24 hours. Cells transfected with 
non-gold-labelled plasmid are shown in (F). (Reproduced from Zabner et al. 49)
The conclusion of numerous studies carried out on the mechanism of lipofection is 
that LD complexes introduce the majority of their payload into the target cell after 
endocytosis and not by direct fusion with the cell membrane. The first step of the 
mechanism of delivery is thought to involve binding of the liposome to the cell surface 
via proteoglycan interaction. Mounkes et a l 50 reported that proteoglycans bearing 
heparin sulfate mediated cationic liposome/DNA complex-based gene delivery. The 
authors found that cationic liposome/DNA complexes did not efficiently transfect Raji 
cells, which lack proteoglycans, but did efficiently transfect Raji cells that had been 
previously transfected with the gene for proteoglycan, syndecan-1 50. Binding of the 
liposome to the cell surface is followed by invagination of the cell membrane at the point 
of attachment resulting in endocytosis. This process was first suggested by Behr et a l 51 
and was actually observed by Zabner et a l 49 who used electron microscopy to follow the 
cell entry of gold-labelled DNA-lipid complexes (Fig. 4).
Zabner et a l 49 transfected various cell lines with complexes formed of 
DMRIE/DOPE (1:1) and DNA, and also microinjected the complexes directly into the 
nuclei of the cells. The authors 49 observed that whereas direct injection of the complexes 
into nuclei led to poor levels of expression, transfection through endocytosis led to 
comparatively high levels of expression. Having transfected several cell lines with the 
same cationic liposome/DNA complexes, the authors 49 also observed that there appeared 
to be a cell type-dependent variability in cationic liposome/DNA complex uptake. The 
mechanism by which the DNA in the complex finally reaches the cytoplasm is not 
entirely clear, but it is believed that the neutral lipid, which along with a cytofectin 
comprises the liposome formulation, plays an important role in intracellular delivery.47
Vesicles composed only of cationic lipids and DOPE are quite unstable and in the 
presence of polyanions vesicle-vesicle fusion can occur. More importantly, these vesicles 
are able to disrupt and fuse with biological membranes that exhibit a net negative charge, 
as has been observed in lipid mixing assays and fluorescence microscopy carried out by 
Stamatos et a l 52. The disruption caused by these cationic lipid/DOPE mixtures in terms 
of structural changes within the membrane is still unknown. However, the physical 
changes that have been observed to occur give some insight into how these lipid mixtures 
might promote release of DNA from the endosome into the cytoplasm. These 
observations would lead one to suggest that LD complexes should likewise disrupt cell 
membranes and possibly cause cell death. Nevertheless, this is known not to occur and 
the explanation is that LD complexes are much less membrane interactive than cationic 
lipid/DOPE vesicles alone 47 The evidence for this comes from work by Leventis &
9 1Silvius who found that lipid mixing between cationic lipid vesicles and anionic vesicles 
was abolished by the presence of DNA in the vesicles. Furthermore, it has also been 
reported by van der Woude et al. 53 that DNA inhibits haemolysis that is induced by 
cationic lipid/PE vesicles. Although LD vesicles are capable of fusing with cell surface 
membranes, this does not occur and yet some type of interaction does occur between the 
vesicle and the membrane of the endosome into which it is engulfed. Perhaps some sort of 
processing of the vesicle occurs once inside the endosome or the endosome needs to 
‘mature’ to some extent before DNA release can occur. It could also be suggested that 
somehow the presence of the LD vesicle within the endosome alters the endosome 
activity so that it does not function or develop in the conventional manner. The 
interaction, which finally leads to DNA transfer into the cytoplasm, is not clearly 
understood.
A model for liberation of DNA from endosomes has been proposed by Zelphati 
and Szoka Jr.54, which has been backed by data obtained by Tarahovsky & Ivanitsky2.
The proposed mechanism for release (Fig. 5, following page) involves mixing and fusion 
of the lipids forming the LD vesicle with the anionic phospholipids that form the 
endosomal membrane. The anionic phospholipids displace the DNA from the cationic 
lipids thus allowing the DNA to escape into the cytoplasm. Whether the DNA would still 
be bound to cationic lipids, which hinder its transition into the nucleus, or it would be free 
and therefore susceptible to degradation is not certain.
The limiting steps of transfection appear to be the release of DNA from the lipid- 
DNA complex within the endosome and its subsequent transport to the nucleus. Zabner et 
al. 49, using confocal microscopy, observed that after internalisation of the LD complex in 
to the endosome, these complexes were found to accumulate in the perinuclear region. 
This accumulation was thought to be the result of endosome migration and fusion leading 
to coalescence of LD complexes. Although internalisation of LD complexes was 
determined to be quite efficient (at least 80 %), it was noted that only 60 % of cells that 
took up LD complexes showed gene expression. This suggested that DNA escape from 
the endosomal compartment did not always ensue. However, the reason for low gene 
expression could also be due to degradation of the DNA by cytoplasmic enzymes such as 
nucleases. If the limiting step of transfection was transport of DNA into the nucleus, then 
degradation of the DNA before entry into the nucleus could be a significant factor. So 
despite DNA being internalised and released from the endosome, gene expression would 
still be inhibited.
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Figure 5. -  Proposed mechanism for the entry of LD complexes into cells; 1) 
interaction of LD complex with cell membrane resulting in endocytosis; 2) invagination 
of cell membrane; 3) membrane de-stabilisation in early endosome; 4) displacement of 
DNA by anionic phospholipids; 5) DNA dissociation from LD complex and diffusion into 
cytoplasm. (Reproduced from Xu and Szoka55).
1.4.2 Lipopolyamine vectors.
Lipopolyamines could be considered to be a separate class of transfection agents 
from cationic lipids. Lipopolyamines differ from what are classed as cationic lipids in that 
lipopolyamines at physiological pH have an overall charge of +3 or greater. Cationic 
lipids on the other hand generally have a charge o f+1 although there are some cationic 
lipids that have a charge of +2 e.g. GAP-DLRIE 25, Lys-PAlVL-GroPEtn 32 and L-PE 56.
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One of the earliest reports of the synthesis of a lipopolyamine was published by 
Behr57. The author reported that (3-(3-amino-propylamino)-propyl)-dimethyl-octadecyl- 
ammonium chloride was capable of binding very strongly to DNA to give discrete and 
soluble molecular complexes 57. Although no reports on the transfection properties of this 
lipopolyamine were published, a subsequent report on transfection of mammalian primary 
endocrine cells with lipopolyamine-coated DNA shortly followed. In this publication, 
Behr et al. 58 reported the synthesis and testing of two novel lipopolyamines, 
dioctadecylamidoglycylspermine (DOGS) and dipalmitoyl
phosphatidylethanolamidospermine (DPPES). The authors reported that not only were 
transfection levels achieved with DOGS/DNA (N/P > 1:1) or DPPES/DNA (N/P >1:1) 
complexes and established cell lines better than with conventional cationic lipids, but also 
that these two lipopolyamine/DNA complexes were capable of transfecting sensitive 
primary cultures, which previously had not been possible with cationic liposome/DNA 
complexes. A comparison of transfection with DOGS/DNA or DPPES/DNA complexes 
and DODAC/DNA complexes also showed that the former two complexes caused much 
reduced cell death compared to the latter.
In a subsequent publication Loeffler & Behr59 reported the results of further 
studies on transfection with DOGS and DPPES. They stated that at the time over 40 cell 
lines had been successfully transfected with either DOGS/DNA or DPPES/DNA 
complexes, many of which were primary,cell lines. Reproducibility according to the 
authors was excellent and, unlike with some cationic lipids, cytotoxicity was in most 
cases not observable even at high levels of transfection agent. The authors also stated that 
they believed that these two lipopolyamines were capable of condensing/ compacting 
DNA and so by this technique there should have been no upper limit to the size of DNA 
used. Compaction/condensation of DNA by DOGS or DPPES was however not 
conclusively proved and indeed later evidence suggested that in fact this was not the case. 
However this will be discussed in greater detail in chapter 3.
In view of the success of DOGS and DPPES, many other groups followed suit by 
synthesising and testing various lipopolyamines. Zhou et al. 60 synthesised and tested 
lipopoly(L-lysine) (LPLL) and lipopoly(D-lysine) (LPDL), conjugates of N- 
glutarylphosphatidylethanolamine (NGPE) and MW 3000 poly-L-lysine or poly-D-lysine. 
Although these two lipopolyamines were up to 3-fold more efficient in transfecting 
mammalian fibroblasts than Lipofectin, this was only the case when the cells were 
mechanically scraped following the transfection period. Hawley-Nelson et al. 61 in their 
attempts to prepare novel lipopolyamines with improved transfection efficiency over
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DOGS and DPPES, synthesised 2,3-dioleoyloxy-A-(2-(sperminecarboxamido)-ethyl)- 
N,A-dimethyl-1 -propanaminium trifluoroacetate (DOSPA). Although almost nothing is 
known about the original testing of this lipopolyamine, the rapid patenting of DOSPA as 
Lipofectamine® made it apparent that the transfection efficiency of this lipopolyamine 
was a significant improvement over DOGS or DPPES. Behr et al. also continued to try 
to develop novel lipopolyamines with improved transfection properties over DOGS and 
DPPES but with little success.
The relatively high transfection efficiencies of lipopolyamines containing the 
carboxyspermine function led Byk et al. 63 to synthesise a series of lipopolyamines in 
which the polyamine ‘head’, the lipid ‘tail’ and the linker between the two were 
systematically varied. Ultimately this led to the identification of a novel lipid,
RPR120535 that possessed advantageous properties in terms of formulation and 
cytotoxicity compared to commercially available cationic lipids. However no comparison 
of the transfection efficiency of RPR 120535 was made with that of DOGS, DPPES or 
DOSPA. Other notable lipopolyamines include pcTG90 64,65 and MVL5 66, an analogue of 
DOSPA.
Figure 6 . -  SpdC and SpC lipopolyamines synthesised by Guy-Caffey et al.
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The aforementioned lipopolyamines are effectively analogues of DOGS or 
DPPES in that the ‘tail’ of all the lipopolyamines consists of two saturated or un-saturated 
aliphatic chains. Guy-Caffey et a l on the other hand reacted spermine and spermidine 
with cholesteryl chloroformate in order to prepare lipopolyamine analogues of DC-Chol 
(Fig. 6 ). These lipopolyamines, SpdC (a mixture of two isomers) and SpC were found not 
only to have higher transfection efficiencies than DOTMA/DOPE, but were also 
considerably less toxic. Shortly after the aformentioned authors had published their 
results, Moradpour et al. 68 reported the synthesis of Cholestery 1-Spermidine (Fig. 7), the 
structures of which the authors clearly stated they had based on both DOGS and DC- 
Chol. The authors claimed this lipopolyamine was a highly efficient transfection agent 
although no comparisons to established cationic lipids or lipopolyamines were given in 
the publication. Nevertheless, the efficiency of Cholesteryl-Spermidine was confirmed by 
the fact that it was rapidly patented and commercialised as Transfectall®.
Figure 7. -  Cholesteryl-Spermidine prepared by Moradpour et a l 68.
One of the most efficient lipopolyamines to date, 7V-cholesteryloxycarbonyl- 
3,7,12-triazapentadecane-1,15-diamine (CTAP) (Fig. 8 ) was synthesised by Miller et a l 
69. According to the authors CTAP/DOPE liposomes were 100 times more efficient than 
DC-Chol/DOPE liposomes at gene delivery in vivo. The authors had identified CTAP 
from a series of cholesteryl-polyamine conjugates that they had synthesised, CTAP being 
the cholesteryl-polyamine conjugate with optimal transfection activity. Interestingly 
Miller et a l 69 also separately synthesised and tested the two isomers of SpC that Guy-
fnCaffey et a l had previously prepared, but as a mixture and found that the transfection 
efficiencies of the two isomers were several orders of magnitude different.
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Figure 8 . - A-cholesteryloxycarbonyl-3,7,12-triazapentadecane-1,15-diamine 
(CTAP) synthesised by Miller et al. 69.
Only one other lipopolyamine, GL 67 (Fig. 9) which was synthesised by Lee et al. 
70, has been reported to function at a similar level of efficacy to CTAP. However, in the 
case of GL 67 there was a lack of correlation between in vitro and in vivo biological 
activity, which was not the case for CTAP. GL 67 and CTAP still remain to date two of 
the most efficient transfection agents.
Figure 9. -  Structure of GL 67.
A brief mention should be given to multiple guanidinium function-containing 
transfection reagents although these lipids probably should not be considered along with 
lipopolyamines strictly speaking. Two of the earliest guanidinium cationic lipids were 
synthesised and tested by Vigneron et al. 71, both of these being analogues of DC-Chol. 
Bis-guanidinium-spermidine-cholesterol (BGSC) and bis-guanidinium-tris-(2- 
aminoethyl)-amine-cholesterol (BGTC) were prepared from cholesteryl chloroformate 
and (4-(3-ter£-butoxycarbonylamino-propylamino)-butyl)-carbamic acid tert-butyl ester
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or tris-(2 -aminoethyl)-amine respectively, followed by treatment with l//-pyrazole-l- 
carboxamidine hydrochloride (Figs. 10 & 11).
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Figure 10. -  Synthesis of 3y^ -(4AL(1A^ ,8Ar-diguanidino spermidine)-carbamoyl)- 
cholesterol (BGSC) by Vigneron et al. 71.
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Figure 11 .- Synthesis of 3/?-((Af',Af-diguanidinoethyl-aminoethane)-carbamoyl)- 
cholesterol (BGTC) by Vigneron et al. 71.
The authors reported that only BGTC was able to form true micellar solutions and 
so its was tested as a transfection agent without ‘helper’ lipid. As BGSC could not form 
true micellar solutions, it was tested as a liposome formulation with DOPE. For 
comparison BGTC was also tested as a liposome formulation with DOPE. Results of 
testing on a variety of cell lines (HeLa, A549, COS-7, MDCK-1, ROS, NB2 A and NIH
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3T3) showed that the transfection efficiencies of BGSC/DOPE/DNA and 
BGTC/DOPE/DNA complexes was comparable to the transfection efficiency of 
Lipofectin/DNA complexes. BGTC/DNA complexes possessed 2-fold lower transfection 
efficiency than Lipofectin/DNA complexes. Since the transfection efficiencies of these 
novel lipids were comparable to Lipofectin, which by this time had already been much 
improved upon with the advent of DOGS and DPPES, little attention was paid to this 
class of lipids.
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Figure 12. -  Structures of headgroup of guanidinium-containing cationic lipids
77synthesised by Bradley et al. . R = hydrophobic tail.
Eight years later the use of guanidinium cationic lipids as transfection agents was 
re-examined by Bradley et al. 72. The authors reported the solid-phase synthesis and 
testing of a library of guanidinium-containing cationic lipids. Effectively three series of 
guanidinium-containing cationic lipids were prepared; lipids with one guanidinium polar 
headgroup and one hydrophobic tail, lipids with two guanidinium headgroups and one 
hydrophobic tail and lipids with one guanidinium headgroup and two hydrophobic tails 
(Fig. 12 & 13).
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Figure 13. - Structures of tail of guanidinium-containing cationic lipids 
synthesised by Bradley et al. . R’ = guanidinium headgroup. X = 1, 2 or 3 (Fig. 12).
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77Bradley et al. compared the transfection efficiencies formulations of their novel 
cationic lipids with DOPE to the transfection efficiency of the commercial transfection 
reagent (not a liposomal formulation), Effectene (Qiagen) for transfection of 293T cells. 
Several of the lipids synthesised by the authors in formulation with DOPE, namely 2.24, 
2.26, 2.27 and 3.27 showed transfection efficiencies comparable to or greater than that for 
Effectene. The two best novel lipids, 2.24 and 2.27 (with and without DOPE) were 
compared with Effectene for cytotoxicity and the authors reported that levels of 
cytotoxicity were again comparable.
The structures of lipopolyamine/DNA complexes have not been extensively 
investigated unlike cationic liposome/DNA complexes. Although some authors proposed 
that lipopolyamines were capable of condensing/compacting DNA, other authors 
concluded from experimental evidence that for certain lipopolyamines this is certainly not 
the case, but again this will be discussed in greater detail in chapter 3.
1.4.3 PEG-liposome vectors.
Although PEG-liposomes, otherwise known as Stealth liposomes were developed 
over a decade ago for the purpose of drug delivery, their application to gene therapy has 
only been fairly recent and has been fairly limited. The poor in vivo efficiency of 
liposome-mediated drug delivery due to rapid clearance of liposomes composed of 
neutral lipids by the reticulo-endothelial system (RES) posed a serious obstacle for their 
application to tumour therapy. Indeed liposomal drug delivery to any other cells or tissues 
other than those of the reticulo-endothelial system proved very difficult . In view of the 
fact that the covalent attachment of polyethyleneglycol (PEG) to proteins significantly 
prolonged the circulation half-life of the protein 74, Klibanov et al. 73 applied this 
approach to liposomes. The authors synthesised dioleoyl /V-(monomethoxy 
polyethyleneglycol succinyl)-phosphatidylethanolamine (PEG-PE, PEG MW ~ 5000) and 
then prepared liposomes composed of phosphatidylcholine/cholesterol ( 1 :1) with and 
without 7.4 mol% PEG-PE. The biodistribution of the liposomes with and without PEG- 
PE was evaluated in male Balb/c mice over a 14-hour period and the authors reported that 
they observed a much reduced uptake of the PEG-liposomes by the reticulo-endothelial 
system as well as an increased circulation half-life.
nc
Papahadjopoulos et al. prepared PEG-liposomes containing polyethyleneglycol 
conjugated to distearoyl phosphatidylethanolamine by a carbamate linkage (PEG-DSPE,
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PEG MW ~ 1900) 76. The authors prepared liposomes composed of egg 
phosphatidylcholine/cholesterol (2 :1), phosphatidylglycerol/egg phosphatidylcholine/ 
cholesterol (0.15:1.85:1) and PEG-DSPE/egg phosphatidylcholine/cholesterol 
(0.15:1.85:1). These liposmes were loaded with Desferal-67Gallium and then administered 
to Sprague-Dawley rats. The results clearly showed a much-increased circulation half-life 
of Desferal-67Gallium loaded into PEG-liposomes compared with the circulation half-life 
of Desferal-67Gallium loaded into the other two liposomes.
Development of PEG-liposomes for drug delivery continued for several years 
77,78,79,80^  kut jt was on]y recently that the incorporation of PEG-lipids or PEG-cationic 
lipids into liposome formulations for gene therapy was realised. The increased application 
of cationic liposomes for in vivo gene delivery soon made it apparent that interaction of 
cationic liposome/DNA complexes with serum had a considerable negative effect on
Q 1
lipofection . Binding of cationic liposome/DNA complexes to anionic serum proteins 
resulted in increased plasma elimination rates, increased phagocytic cell uptake, 
perturbations of the membrane structure of the cationic liposome/DNA complexes and 
complement activation . A further problem encountered with cationic liposome/DNA 
complexes was that the complexes tended to aggregate rapidly when prepared in serum 
and so in clinical trials it was often necessary to mix the DNA and cationic liposome 
formulation at the bed-side for immediate use
Papahadjopoulos et al. 84 was one of the first groups to employ PEG-liposomes for 
gene therapy, having previously observed the improvements in liposome-mediated drug 
delivery with these PEG-liposomes. The authors prepared complexes composed of 
dimethyldioctadecylammonium bromide/cholesterol and pCMV/IVS-luc+ with and 
without 1 mol% PEG-PE. The two complex types were then administered to CD1 mice 
and reporter gene expression in the mouse lung was assayed after 24 hours. However, the 
authors reported that there did not appear to be a significant difference between the two 
complex types in terms of transfection efficiency.
89Bally et al. also reported their results from initial studies on cationic 
liposome/DNA complexes assembled with various percentages of PEG-DSPE. The 
authors stated that they observed a significant decrease in transfection activity upon 
increasing the percentage of PEG-DSPE incorporated into cationic liposome/DNA 
complexes (Fig. 14), which correlated with a decrease in cell binding as well as 
internalisation. These results suggested that PEG-liposomes would have very limited use 
in gene therapy if any at all, but the authors where optimistic about these results and
27
concluded that it would be necessary to develop PEG-liposomes that were capable of 
shedding their PEG-coating at the right time.
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Figure 14. -  The effect on transfection activity o f incorporation of PEG-lipids into 
cationic liposome/DNA complexes. Cationic liposome formulations were composed of 
DODAC and DOPE with and without increasing percentage of PEG-DSPE. Insert shows 
estimation of mean fluorescence intensity resulting from liposome/DNA complex binding 
to cells using flow cytometric analysis. (Reproduced from Bally et al. )
The need to overcome the loss in transfection activity due to the incorporation of
o r
PEG-lipids into cationic liposome formulations led Harvie et al. to consider the use of 
PEG-lipids that can be transferred from one lipid membrane to another. Earlier work had 
shown that modification o f the acyl chain composition of PEG-lipids resulted in changes
o /  on
in rate of PEG-lipid transfer from the surface o f liposome/DNA complexes ’ . The 
authors speculated that PEG-lipids with desirable transfer properties could be used to
Of ^
regulate the surface attributes of liposomal carrier systems . In principle a PEG- 
liposome that has a greater circulatory half-life than a liposome but has a much-decreased 
ability to bind to cell surfaces would gradually be transformed into a liposome through 
loss of PEG during circulation.
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Figure 15. -  CAT activity following transfection of B16/BL6 melanoma cells with 
cationic liposome/DNA complexes containing different percentages of PEG-lipids. 
(Reproduced from Harvie et al. 85)
The authors therefore examined three commercially available PEG-lipids for their 
transfer properties; PEG-DSPE, PEG-DOPE and PEG-DMPE. Cationic liposomes were 
prepared by mixing DOPE and DODAC with varying percentages of either PEG-DSPE, 
PEG-DOPE or PEG-DMPE and then mixing the resulting liposome formulations with 
DNA (pInexCATv2.0). B16/BL6 melanoma cells were then incubated with these 
complexes in the presence of foetal bovine serum for 4 hours after which time the 
transfection medium was replaced by fresh medium (not containing cationic PEG- 
liposome complexes) and the cells were left for a further 48 hours. The cells were then 
assayed for chloramphenicol acetyl transferase activity (Fig. 15). The results of Harvie et
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al. 85 showed that in the case of PEG-DSPE and PEG-DOPE, increasing the percentage of 
these two incorporated into the cationic liposome/DNA complexes had a negative effect 
on transfection efficiency, CAT activity clearly decreasing with increasing PEG-DSPE or 
PEG-DOPE content (Fig. 15 -  A & B). This was not the case however for cationic 
liposome/DNA complexes prepared with PEG-DMPE. Addition of 0.5 % and 1.0 % of 
PEG-DMPE to DODAC/DOPE had a beneficial effect on the transfection activity of the 
corresponding cationic liposome/DNA complexes (Fig. 15 - C). The authors stated that 
these results correlated fairly well with previous studies that had shown that PEG-DSPE 
and PEG-DOPE are retained well by liposomal membranes whereas PEG-DMPE is not.
R -  C 12H25 
R = C , 4H 29 
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Figure 16. -  Structure of PEG-SAINT lipids synthesised by Rejman et a l 88.
The development of ‘transferable’ PEG-lipids was continued by Rejman et al. 88 
who synthesised a series of novel ‘transferable’ PEG-lipids called PEG-SAINT (SAINT = 
A-methyl-4-alkylpyridium bromide) (Fig. 16). However no significant advances in 
‘transferable’ PEG-liposome-mediated gene transfer were reported in this publication. At 
the same time the development of PEG-liposomes also continued with Sanders et al. 89 
demonstrating that cationic liposomes composed of GL67/DOPE /PEG-DMPE retained 
their gene transfection efficiency after exposure to components of cystic fibrosis mucus 
whereas cationic liposomes composed of DOTAP/DOPE did not. The two cationic 
liposome/DNA complex types were exposed to varying levels of albumin, mucin and 
Alveofact, all of which are components of lung mucus. In all cases GL67/DOPE/PEG- 
DMPE/DNA complexes generally retained their transfection activity better in the 
presence of these three components than DOTAP/DOPE/DNA complexes. The authors 
did however admit that there was the possibility that DOTAP/DOPE/DNA complexes 
were inherently more susceptible to sputum components than GL67/DOPE/PEG- 
DMPE/DNA complexes and that a comparison with GL67/DOPE/DNA complexes would
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onhave been more appropriate. Another in vitro study by Kim et al. examined the effect 
on transfection efficiency of either adding PEG-DSPE to the cationic liposome 
formulation prior to mixing with DNA (referred to as grafting) or adding PEG-DSPE to 
the cationic liposome/DNA complex (referred to as adding). The transfection efficiencies 
of these two types o f PEG-liposome/DNA complexes were then compared to the 
transfection efficiency of conventional DOTAP/DOPE/DNA complexes in the presence 
and absence of serum.
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Figure 17. -  Comparison of in vitro transfection efficiencies of conventional 
transfection complexes (DOTAP/DOPE/DNA), grafted PEG-DSPE/DOTAP/DOPE/
DNA complexes and added PEG-DSPE/DOTAP/DOPE/DNA complexes on addition to 
SW480 cells immediately after preparation (A) and 2 weeks after preparation (B) in the
onpresence and absence o f serum. (Reproduced from Kim et al. )
The results o f transfection o f SW480 cell with liposomes immediately after 
preparation in the absence o f serum showed that DOTAP/DOPE/DNA complexes had 
greater transfection activity than the other two PEG-liposome/DNA complexes as was 
expected. However in the presence o f serum this was reversed and transfection levels 
achieved with grafted PEG-DSPE/DOTAP/DOPE/ DNA complexes and added PEG- 
DSPE/DOTAP/DOPE/DNA complexes were almost two-fold greater than that achieved 
with DOTAP/DOPE/DNA complexes. In the case o f transfection with complexes that had 
been stored for two weeks prior to transfection of SW480 cells, the PEG-liposome/DNA 
complexes achieved two-fold greater transfection levels than DOTAP/DOPE/DNA 
complexes both in the presence and absence of serum. This latter result suggested that
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PEG-liposome/DNA complexes had a much lower tendency to aggregate upon prolonged 
storage than cationic liposome/DNA complexes, a property that was clearly due to the 
presence of the PEG-lipid component.
1.4.4 Targeted liposome vectors.
Although there were many attempts to improve non-viral gene transfer with 
liposomes composed of neutral lipids (Wong et al. 91, Fraley et a l 92 and Schaefer- Ridder 
et al. 93) these were met with little success. Transfection efficiencies of neutral 
liposome/DNA complexes remained of the same order of magnitude as transfection 
efficiencies achieved by treatment with DEAE-dextran or calcium phosphate 
precipitation. An alternative strategy was conceived that of incorporating targeting 
ligands into complexes so that the complexes would bind to specific cell surface receptors 
and be taken up by receptor-mediated processes. Soriano et al. 94 adopted such an 
approach and attempted to increase the transfection efficiency of liposome-mediated gene 
delivery by incorporating lectin-targeting ligands. The authors postulated that by 
incorporating the glycolipid, lactosylceramide into the lipid bilayer of liposomes, they 
would be able to increase uptake of the liposome/DNA complexes by specific cells, in 
this case hepatocytes. The authors prepared liposomes composed of egg 
phosphatidylcholine, phosphatidylserine and cholesterol (4:1:5) with and without 17 
mol% of dihydro-lactosylceramide (LacCer). The two liposome formulations were mixed 
with [ P] DNA and the resulting complexes were injected into Wistar rats. The 
hepatocytes, Kupfer cells and endothelial cells were harvested 4 hours after injection and 
assayed for DNA content. Although there was no significant difference between the 
overall level of [32P] DNA taken up, there was a significant difference in the distribution 
of the [32P] DNA between the three cell types for liposome/DNA complexes with and 
without LacCer, which clearly indicated some degree of targeting by the LacCer- 
liposomes.
Little progress was made with the development of targeted liposome-mediated 
gene delivery over the next few years. The publication of the synthesis and remarkable (at 
the time) transfection properties of DOTMA by Feigner and colleagues resulted in an 
almost complete loss of interest in targeted liposomes. Although DOTMA/DOPE/DNA 
complexes were not cell specific, their transfection efficiency far exceeded that of the 
liposome/DNA complexes prepared by Wong et al. 91, Fraley et al. 92, Schaefer-Ridder et
32
al. 93 or Soriano et al. 94. Nevertheless research into targeted liposomes continued with a 
few reports of non-viral gene transfer with antibody-targeted liposomes 95’96,97 and folate-
ORtargeted liposomes being published over the next decade. However, several years after 
the emergence of DOTMA and various other cationic lipids, the lack of cell-specificity of 
cationic liposome/DNA complexes became an issue again and the development of 
targeted cationic liposome/DNA complexes commenced.
During the years following the emergence of DOTMA, the rapid development of 
targeted liposomes for drug delivery continued nevertheless since cationic lipids were of 
little relevance to liposomal drug delivery. Significant progress was made in the 
development of targeted liposomal drug delivery vectors, which will be discussed more 
extensively in the introduction to chapter 2. The desire to generate cell-specific cationic 
liposomes/DNA complexes renewed interest in targeted liposomes for gene therapy and 
one of the earliest reports of the preparation of targeted cationic liposome/DNA 
complexes was published by Kao et al. 99. The authors prepared cationic liposomes 
associated with monoclonal antibodies and asialofetuin and formed complexes of these 
targeted cationic liposomes with the /?-galactosidase reporter gene. The authors reported 
that with monoclonal antibody-targeted cationic liposome complexes they observed 
significant increases in gene expression in both human adenocarcinoma cells and human 
T-lymphoma cells, and with asialofetuin-targeted cationic liposomes they observed 
significant increase in gene expression in human hepatoma cells compared with non­
targeted cationic liposomes. The authors concluded that they believed that site-specific 
targeting of cationic liposomes was a good strategy for not only increasing selectivity of 
DNA delivery to cells but also efficiency.
Evidence in support of the observations of Kao et al. 99 came from Yonemitsu et 
al. 100 but as the vector prepared by the authors is not technically a non-viral vector, it will 
not be discussed in great detail. The authors reported their application of 
haemagglutinating virus of Japan (HVJ)-cationic liposomes, liposomes which were 
composed of A-(a-trimethylammonioacetyl)-didodecyl-D-glutamate chloride, 
phosphatidylcholine and cholesterol, fused with HVJ, for gene transfer. The authors 
showed that this vector was able to both increase selectivity of lacZ gene delivery to 
bronchial epithelial cells and alveolar macrophages but also efficiency.
The cell specificity and greater efficiency of targeted cationic liposomes compared 
to standard cationic liposomes was clearly demonstrated by Pagnan et al.m  who 
employed targeted cationic liposomes to deliver c-myb antisense oligodeoxynucleotides 
to human neuroblastoma cells. The authors prepared ‘coated’ cationic liposomes by first
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mixing DOTAP with the c-myb antisense oligodeoxynucleotides (myb-as) in 
methanol/water/chloroform, extracting the resulting complexes with chloroform and then 
adding cholesterol, hydrogenated soy phophatidylcholine (HSPC) and PEG-DSPE (non­
targeted) or maleimide-PEG-DSPE (targeted). Anti-GD2 monoclonal antibodies (directed 
against the disialoganglioside GD2) were activated by treatment with 2-iminothiolane and 
the resulting activated monoclonal antibodies were then incubated with maleimide-PEG- 
DSPE/Chol /DOTAP /myb-as complexes. Thus targeted cationic liposome/myb-as 
complexes (aGD2-CCL-myb-as) and non-targeted cationic liposome/myb-as complexes 
(CCL-myb-as) were prepared.
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Figure 18. -  Cellular uptake of c-myb antisense oligodeoxynucleotides (myb-as) 
by GD2-positive human neuroblastoma cell lines (GI-LI-N and CAN) and GD2-negative 
cell line (HeLa). (A) Percentage of oligodeoxynucleotide uptake after 2 hour incubation 
period; uptake is expressed as a percentage of the uptakes of free myb-as which was taken 
as 100 %. (B) Time-dependent uptake into GI-LI-N cells of myb-as. (Reproduced from 
Pagnane/a/. 101)
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Initially the authors treated three cell types w ith these cationic liposom es; G D 2 - 
positive hum an neuroblastom a cell lines G I-LI-N  and CA N, and G D 2 -negative cell line 
HeLa. The cells w ere incubated for either 2 hours w ith the tw o types o f  cationic liposom e 
or w ith free m yb-as and then assayed for m yb-as uptake or incubated for 2, 5, 12 or 24 
hours and then assayed for m yb-as uptake in order to determ ine tim e-dependent uptake 
(Fig. 18). Free anti-G D 2 m onoclonal antibodies w ere also added along w ith aG D 2-C C L- 
m yb-as com plexes in order to observe the effect o f  com petitive binding. The results 
show ed clearly  that antisense o ligodeoxynucleotide (m yb-as) uptake by G D 2 -positive 
hum an neuroblastom a cells resulting  from  targeted cationic liposom e delivery  (aG D 2- 
C C L-m yb-as) was m ore than 4-fold  greater than m yb-as uptake resulting  from  non­
targeted cationic liposom e delivery  (C C L-m yb-as) or incubation w ith free m yb-as (Fig.
18-A). A ddition o f  free anti-G D 2 m onoclonal antibodies to the incubation m ixture 
resulted in aG D 2-C C L-m ediated  m yb-as uptake by G D 2 -positive hum an neuroblastom a 
cells decreasing to levels com parable to C C L-m ediated m yb-as uptake, m yb-as uptake by 
G D 2 -negative cells w as equal for all m ethods o f  transfection, w hich further supported  the 
role o f  the targeting ligand in increasing transfection efficiency. The authors also 
exam ined tim e-dependent m yb-as uptake by G I-LI-N  cells; G I-L I-N  cells w ere incubated 
w ith free m yb-as, C C L-m yb-as com plexes and aG D 2-C C L-m yb-as com plexes for 
betw een 2 to 24 hours, and then cells w ere assayed for m yb-as content. The results 
show ed again that transfection w ith the targeted cationic liposom e/m yb-as com plexes was 
m uch m ore efficient than transfection w ith free m yb-as or non-targeted cationic 
liposom e/m yb-as com plexes (Fig. 18-B).
The effect o f  delivery  o f  oligodeoxynucleotides by the tw o vectors on the 
proliferation o f  G I-LI-N  cell and H eLa cell was also investigated. Cells w ere incubated 
w ith vectors contain ing either c-m yb antisense (m yb-as) or sense (m yb-s) 
o ligodeoxynucleotides under tw o different O D N  adm inistration regim es, the latter being 
expected to have no effect on cell proliferation. The two cell types w ere also incubated 
w ith free m yb-as and free m yb-s for the purpose o f  com parison. The results o f  this 
experim ent (Fig. 19-A to D) clearly  show ed that greatest inhibition o f  proliferation o f  GI- 
LI-N cells occurred w hen the cells w ere treated w ith aG D 2-C C L-m yb-as com plexes 
(targeted). Inhibition o f  H eLa cell proliferation on the o ther hand w as neglig ib le i f  at all 
w hen these cells w ere treated w ith aG D 2-C C L-m yb-as com plexes. In teresting ly  the type 
o f  O D N  adm inistration regim e appeared to have a significant effect on the transfection 
levels achieved w ith C C L-m yb-as com plexes (non-targeted) and free m yb-as in G I-LI-N  
cells (com pare Fig. 19-A  and Fig. 19-C).
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Figure 19. - Growth inhibition of neuroblastoma cells by c-myb antisense 
oligodeoxynucleotides. (Reproduced from Pagnan et al. I0!)
In view of the initial success that Pagnan et al. 101 had with their targeted cationic 
liposomes, the authors investigated the biodistribution and pharmacokinetic properties of 
their novel liposomes. In a subsequent publication Ponzoni et al. 102 examined the 
differences between aGD2-CCL-3H-myb-as complexes, CCL-3H-myb-as complexes and 
free 3H-myb-as in terms of pharmacokinetics and biodistribution. It was shown that 
whereas free 3H-myb-as was equally distributed between organs and blood within a short 
period following injection (Fig. 20-A), a large fraction of aGD2-CCL-3H-myb-as 
complexes and CCL-3H-myb-as complexes remained in the blood for up to 24 hours (Fig. 
20-B & C). Uptake by the spleen of aGD2-CCL-3H-myb-as complexes was slightly 
greater than for CCL-3H-myb-as complexes, but at the same time liver uptake of CCL-3H-
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myb-as complexes was greater than liver uptake of aGD2-CCL-3H-myb-as complexes. 
Examination of the blood clearance of the two complex types and free 3H-myb-as showed 
that levels of free 3H-myb-as in the blood decreased rapidly following injection while 
levels o f aGD2-CCL-3H-myb-as complexes and CCL-3H-myb-as complexes decreased 
much more slowly (Fig. 20-D).
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Figure 20. -  Biodistribution (A-C) and pharmacokinetics (D) o f free or liposome 
entrapped 3H-myb-as following injection into tail vein of BALB/c mice. (Reproduced 
from Ponzoni et al. 102).
Folate receptor-targeting ligands have also been extensively employed for the 
preparation of folate-targeted liposomes as well as folate-targeted cationic liposomes. 
Amplification of the folate receptor expression occurs frequently in a variety of human 
cancers (ovarian, endometrial, colorectal, breast, lung and renal cell carcinomas as well as 
brain metastases)103. Although anti-folate receptor antibodies have been used as targeting 
ligands, folate itself has also been used as a targeting ligand being coupled to liposomes 
via its y-carboxyl I03. Xu et al. 104 used cationic liposomes conjugated to folate to deliver
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the tumour suppresor gene, p53 to JSQ-3 cells in order to render the cells more sensitive 
to the induction of apoptosis by conventional chemotherapeutic agents or radiation. 
Hofland et al. 105 derivatised cationic PEG-liposomes with folate in order to restore the 
transfection efficiency of these liposomes towards tumour cells in mice. In order to 
improve the pharmacokinetic properties of cationic liposomes the authors had added 
PEG-lipids to their cationic liposome formulations but this had resulted in PEG- 
liposomes/DNA complexes with decreased uptake not only by various organs but also by 
the tumours. Derivatisation of the PEG-termini of a certain percentage of the PEG-lipids 
in the complexes restored the uptake of targeted cationic PEG-liposomes by tumour cells 
to levels comparable to cationic PEG-liposome/DNA complex uptake, but did not restore 
uptake levels in other organs. Dauty et a l 106 also attempted to use a similar strategy in 
order to confer targeting properties to their thiol-containing-detergent-condensed DNA 
particles.
1.4.5 Cationic polymer vectors.
The first cationic polymers to be used for non-viral gene transfer were cationic 
peptides such as poly-L-arginine, poly-L-lysine and poly-L-omithine, which are capable 
of binding to and condensing nucleic acids (condensation of nucleic acids by cationic 
polymers will be discussed in chapter 3). Henner et al. 107 transfected Escherichia Coli 
spheroplasts with phage DNA by mixing the DNA with poly-L-arginine, poly-L-lysine or 
poly-L-omithine and then incubating the spheroplasts with the resulting complexes. 
However in vitro transfection efficiencies with such cationic peptide/DNA complexes 
were very low, the efficiencies being only 19-fold to 26-fold greater than incubation with 
naked phage DNA. The authors also formed complexes of phage DNA with protamine 
sulphate (MW 10,000 -  50,000), a peptide containing mostly lysine and arginine residues, 
and incubation of spheroplasts with these complexes resulted in a 200-fold higher
transfection efficiency than incubation with naked phage DNA. A few years later Bond &
108Wold demonstrated that the efficiency of poly-L-omithine-mediated transfection was 
comparable to that of DEAE-dextran-mediated transfection.
Transfection levels achieved by liposome-mediated gene delivery and then 
targeted liposome-mediated gene delivery soon surpassed the low transfection levels 
achieved with cationic peptides. For this reason cationic peptide-mediated gene delivery 
did not develop significantly. As with liposomes, coupling of cationic peptides to
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targeting ligands resulted in conjugates with improved transfection efficiencies compared 
to cationic peptides alone. Wu & Wu 109 prepared a conjugate of a galactose-terminal 
asialo-glycoprotein, asialoorosomucoid (AsOR) covalently linked to poly-L-lysine (PLL, 
MW ~ 59,000). The authors initially determined the ratio of conjugate to plasmid DNA 
(pSV2 CAT) that resulted in complete retardation of the pDNA during gel electrophoresis 
to be 2:1 (conjugate:pDNA). The in vivo transfection activities of [125I]-AsOR-PLL/[32P]- 
pDNA complexes (2:1), PLL/[32P]-pDNA complexes, [125I]-AsOR or naked [32P]-pDNA 
were then assessed.
Organs [32P]-pDNA
Fraction of injected counts/ %
[I25I]-AsOR-PLL/[32P]-pDNA [i25I]-AsOR
Blood 46 ± 5.0 5.0 ± 1.5 8.5 ± 1.0
Liver 17± 1.5 85 ± 5.0 89 ±3.5
Brain 0.7 ±0.5 0.5 ± 0.2 0.1 ±0.1
Heart 6.1 ± 1.0 0.4 ±0.1 0.1 ±0.1
Spleen 4.7 ± 4.3 5.3 ± 1.0 0.5 ±0.1
Lung 1.5 ±0.5 1.4 ±0.2 1.6 ± 0.1
Kidney 24 ± 2.0 2.4 ±0.2 0.2 ±0.1
Table 3. -  Organ distribution of radioactivity ten minutes after intravenous 
injection into rats.
The distribution of [ P]-pDNA in the organs (liver, kidney, brain, heart, spleen 
and lung) and blood ten minutes after injection of [125I]-AsOR-PLL/[32P]-pDNA 
complexes, as determined by autoradiography, differed quite markedly from the 
distribution of naked [32P]-pDNA (Table 3). The results indicated that the [125I]-AsOR-
'X'JPLL/[ P]-pDNA complexes did not dissociate to any great extent on intravenous 
injection. Levels of [32P]-pDNA in the liver following injection of PLL/[32P]-pDNA 
complexes were shown to be negligible. CAT assays of the liver, kidney, spleen and lung 
24 hours post-injection confirmed that [l25I]-AsOR-PLL/[32P]-pDNA complexes were 
almost exclusively taken up by the liver. These results indicated that not only could 
pDNA be targeted to particular organs by complexation with targeted cationic peptides 
but also that targeted cationic peptides were more efficient vectors than simple cationic 
peptides.
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Other targeting ligands were also conjugated to cationic peptides used for the 
purpose of non-viral gene transfer. Zenke et al. 110 employed transferrin-poly-L-lysine 
and transferrin-protamine to transfect avian erythroblasts and primary hematopoietic cells 
with pRSVL but this was less efficient than DEAE-dextran-mediated pRSVL transfer.
Midoux et al. 111 used lactosylated-poly-L-lysine to transfect HepG2 cells with pSV2Luc.
112Ferkol et a l delivered pRSVCAT into primary human tracheal epithelial cells with 
Fab-poly-L-lysine. Plank et a l 113 prepared a series of branched cationic peptides that 
differed in terms of the number and type of cationic residues, and conjugated these to 
transferrin. The authors then examined the influence of the structure of the conjugates on 
transfection efficiency. Some groups even continued to investigate the transfection 
properties of cationic peptides 114115. Despite efforts to increase the transfection 
efficiencies of cationic polypeptides or cationic peptide conjugates, they remained low 
compared to liposome-mediated methods (standard, cationic or targeted) partly because 
of the fact that most cationic peptides are substrates for proteolytic enzymes and so the 
complexes are comparatively rapidly degraded in vivo. Cationic peptide-mediated gene 
delivery also has the disadvantage that in order to achieve reasonable transfection levels it 
is necessary to add endosome disrupting or lysomotrophic agents such as chloroquine, 
which is practical in vitro but impractical in vivo.
Non-viral gene transfer with cationic polymers advanced significantly with the 
discovery of polyamidoamine cascade polymer-mediated transfection by Haensler & 
Szoka ,16. The authors prepared several generations of polyamidoamine (PAMAM) 
dendrimers and used them directly to form complexes with pCLUC4 or pCMV-/?Gal as 
well as conjugating the dendrimers to the amphipathic peptide GALACys 117 and then 
using them to form complexes with the pDNA. The authors reported that transfection 
with these PAMAM dendrimers was highly efficient and at the same time was not 
affected by addition of lysomotrophic agents. This led the authors to speculate that the 
dendrimers possessed an inherent buffering capacity that served to protect the complexed 
DNA from degradation in the endolysosome.
The observations of Haensler & Szoka 116 that PAMAM dendrimer-mediated
transfection was unaffected by lysomotrophic agents led Boussif et al. 118 to investigate
the polymer, polyethylenimine (PEI) for transfection activity. Like PAMAM dendrimers,
PEI contains residues that are still protonable at physiological pH which the authors at the
time speculated could result in PEI being able to buffer pH changes within an 
118endolysosome . PEI was at the time widely commercially available in both a range of 
molecular weights as well as either branched or linear. The authors used 800 kDa and 50
kDa PEI for their studies and complexed these two PEIs to pGL2-Luc, pCMV-Luc, 
pT3RE-Luc or an antisense oligonucleotide. Initially the authors determined the optimal 
N/P ratio in terms of transfection efficiency in murine 3T3 fibroblasts; for 800 kDa PEI 
this was determined to be N/P = 9:1. The transfection efficiency of complexes of 800 kDa 
PEI and pCMV-Luc (N/P = 9:1) was then compared to that of PLL/pCMV-Luc 
complexes (N/P = 9:1) and DOGS/pCMV-Luc complexes (N/P = 6:1, optimal for 
DOGS). The transfection level achieved with 800 kDa/pCMV-Luc complexes in 3T3 
cells was approximately 20,000-fold greater than that achieved with PLL/pCMV-Luc 
complexes and was equal to that achieved with DOGS/pCMV-Luc complexes, which at 
the time was the leading non-viral transfection agent. The authors attributed the 
remarkable transfection properties of PEI not only to its ability to condense DNA into 
nanometric particles and protect the DNA from degradation but also to its ability to 
behave as a ‘proton sponge’ 119 in endolysosomes.
PEI and to a lesser extent PAMAM dendrimers subsequently were employed by 
many groups for non-viral gene transfer with a great deal of success. As with cationic 
peptides, PEI, PAMAM dendrimers and other similar polymers were also derivatised with 
targeting ligands in order to endow targeting properties to complexes of these polymers 
with DNA. Examples of the application of these types of cationic polymers, both targeted 
and non-targeted for non-viral gene therapy will be given in chapter 3.
1.4.6 Cationic liposome-cationic polymer vectors.
Whereas the need to improve upon cationic liposome-mediated gene transfer led 
some groups to synthesise new cationic lipids or lipopolyamines, other groups chose to 
investigate the effects of combining already existing vectors in order to incorporate their 
advantageous properties into one vector. Such an approach was chosen by Huang et al. 
120,121 who realised that cationic liposomes were unable to ‘condense’ DNA as effectively 
as cationic polymers such as cationic peptides. The authors concluded this from freeze- 
fracture electron micrographs of freshly prepared DC-Chol/DOPE/DNA complexes l22, 
comparing them to micrographs of cationic polymer condensed nucleic acids. The freeze-
1 99fracture electron micrographs showed what the authors termed ‘spaghetti and
1 9 Imeatballs’ structures which led the authors to believe that the DNA molecules in DC- 
Chol/DOPE/DNA complexes were in the extended conformation. Furthermore, the
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authors 121 observed that at the DNA to cationic liposome ratio that was optimal for 
transfection efficiency, the complexes that were formed were relatively large (0.6-1 pm).
Figure 21. -  Potentiation of cationic 
liposome-mediated transfection by 
PLL. CHO cells were incubated for 
4 hours with 1 pg of pRSV-Luc 
complexed with the indicated 
amount of cationic liposomes and 
PLL. 36 hours after transfection, 
luciferase activity was measured 
over 20 seconds using 2 pg of 
protein from each cell lysate. 
Symbols: (a) #3.3 nmol, b6.6 nmol, 
olO nmol, ▲ 12.5 nmol, x no DC- 
Chol/DOPE (4.5/5.5, mol/mol); (b) 
•4.5 nmol, b6.0 nmol, o 8.5 nmol,
▲ 10 nmol Lipofectin; (c) »4 nmol, 
■6 nmol, o8.5 nmol, ▲ 10 nmol 
LipofectAMINE. 121
191Gao & Huang therefore hypothesised that the introduction of cationic polymers 
at appropriate ratios to cationic liposomes and DNA would result in complexes with 
structures different from that of cationic liposome/DNA complexes and consequently 
different biological activity. The authors prepared complexes composed of pRSV-Luc 
and varying amounts of poly-L-lysine with and without cationic liposomes (DC- 
Chol/DOPE, Lipofectin or LipofectAMINE) and used these to transfect CHO cells. When 
PLL was not included, the transfection efficiency of the three cationic liposome 
formulations followed the order LipofectAMINE > DC-Chol > Lipofectin. Addition of 
PLL to the DC-Chol/DOPE and DNA or Lipofectin and DNA mixtures resulted in 
complexes with significantly enhanced transfection efficiencies as observed by an 
increase in luciferase gene expression in relevant CHO cells (Fig. 21 a-c). Transfection 
levels achieved with complexes composed of PLL/DNA (0.5-1:1, w/w) and DC- 
Chol/DOPE (3.3 and 6.5 nmol of total lipid) or Lipofectin (4.5 and 6 nmol of total lipid) 
were 3- to 10-fold higher than the maximal levels achieved with DC-Chol/DOPE/DNA or
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Lipofectin/DNA complexes formulated at optimal lipid to DNA ratios (Fig. 21 a & b). 
Potentiation of Lipofectamine-mediated transfection by addition of PLL was however 
more moderate (Fig. 21 c). PLL complexed to DNA without addition of cationic liposome 
only achieved background levels of transfection.
Other cell lines were transfected with these cationic liposome/PLL/DNA 
complexes and similar results were observed with increases in transfection ranging from 
1.7-fold to 7.8-fold depending on cell type. Interestingly, the authors reported that mouse 
lungs cells that were poorly transfected by DC-Chol/DOPE/DNA complexes were readily 
transfected by DC-Chol/DOPE/PLL/DNA complexes, a 28-fold increase in transgene 
expression being observed (Fig. 22-A).
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Figure 22. -  A) Potentiation of DC-Chol/DOPE-mediated transfection of mouse 
lung cells by PLL; mouse lung cells were incubated with 1 pg of pRSV-Luc complexed 
with indicated amount of DC-Chol/DOPE (3:2, mol/mol) (o) or 0.5 pg of PLL and 
indicated amount of DC-Chol/DOPE (3:2, mol/mol) (•). B) Effect of mixing protocol on 
the transfection activity of complexes; CHO cells were treated with 1 pg of pRSV-Luc 
complexed with (A) 6 nmol of Lipofectin (open bar) or DC-Chol/DOPE (slashed bar) and 
then 0.5 pg of PLL, (B) 0.5 pg of PLL and then 6 nmol of Lipofectin or DC-Chol/DOPE, 
(C) 0.5 pg of PLL and 6 nmol of Lipofectin or DC-Chol/DOPE simultaneously. 
(Reproduced from Gao & Huang l21)
The authors also investigated the effect of the order of addition of cationic 
liposome, PLL and DNA on the transfection activity of the final complexes. As both 
cationic liposomes and PLL would compete for binding to DNA, the order of addition 
would determine the structure of the complexes and consequently the transfection
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efficiency. The authors therefore devised three protocols for mixing the three 
components. DNA was either mixed with PLL or cationic liposome first, incubated for 10 
minutes and then the third component was added. After a further 10 minutes the 
complexes were added to CHO cells. Alternatively, DNA, PLL and cationic liposome 
were mixed simultaneously, incubated for 10 minutes and then added to CHO cells. The 
results showed that if PLL was added after mixing of cationic liposome and DNA, there 
was no potentiation effect. Incubation of DNA with PLL first followed by addition of 
cationic liposome resulted in complexes with only 80 % of the transfection efficiency of 
complexes formed by mixing all three components simultaneously (Fig. 22-B).
Figure 23. -  Effect of PLL and 
protamine on particle size of 
complexes containing DNA and 
DC-Chol/DOPE. 2 pg of pRSV- 
Luc was mixed with the 
indicated amount of DC-Chol/ 
DOPE (4.5:5.5, mol/mol) (o) or 
with the indicated amount of 
liposome and 1 pg PLL (□) or 2 
pg protamine (A).  (Reproduced 
from Gao & Huang m )
Other cationic polymers such as higher molecular weight poly-L-lysine, poly-D- 
lysine, poly-L-omithine, polybrene, histone and protamine were also examined for their 
ability to potentiate cationic liposome-mediated transfection and were found to be active. 
Generation 6 PAMAM dendrimer was, surprisingly found to be inactive. The authors also 
determined the size of DC-Chol/DOPE/DNA and DC-Chol/DOPE /PLL/DNA complexes 
by laser dynamic light scattering. This revealed that there was a considerable difference in 
size between DC-Chol/DOPE/DNA complexes prepared at the ratio of lipid to DNA that 
gave optimal transfection (~ 1250 nm) and DC-Chol/DOPE /PLL/DNA complexes 
prepared at the ratio of lipid to DNA that gave optimal transfection (~ 125 nm). 
Furthermore, whereas DC-Chol/DOPE/DNA complex size varied considerably with lipid 
to DNA ratio, DC-Chol/DOPE /PLL/DNA complexes remained the same size at all lipid 
to DNA ratios (Fig. 23). The cationic polymer, protamine had a similar effect (Fig. 23). 
Finally, the authors observed that DNA in these cationic liposome/polymer/DNA (LPD)
1500-
1000-
500-
Liposomes (nmoles)
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complexes was better protected from degradation by nucleases than DNA complexed to
cationic liposomes only. Details of the authors’ observations will be given in chapter 3.
120Other groups had also adopted the same approach as Gao & Huang , such as 
Vitiello et a l 123 and Gottschalk et al. 124 and also observed improvements in transfection 
efficiencies over cationic liposome/DNA complexes. At almost the same time as Gao & 
Huang 120 reported the preparation and transfection properties of LPD complexes, Lee & 
Huang 98 reported the preparation and transfection properties of complexes composed of 
poly-L-lysine, anionic lipid, folate-PEG-lipid and DNA, which according to the authors 
had transfection efficiencies much greater than LPD complexes. Nevertheless Huang et
I
al continued to develop their LPD complexes and in the following year Li & Huang 
reported the use of LPD for in vivo gene delivery.
Li & Huang 125 found that replacing poly-L-lysine with protamine sulfate in LPD 
complexes resulted in complexes with greater transfection efficiency. Furthermore, 
replacing DC-Chol/DOPE with DOTAP also had a similar effect. LPD complexes were 
formed by initially mixing cationic polymer (PLL hydrobromide, protamine sulphate, 
protamine phosphate or protamine free-base) with DNA (pCMV-Luc) and then after 10 
minutes adding DOTAP. For comparison DOTAP/DNA and protamine sulphate/DNA 
complexes were also prepared. CD-I mice were injected intravenously with the various 
complexes as well as naked DNA and then after 24 hours the organs were harvested.
In vivo transfection experiments with the various complexes prepared by the 
authors showed that in all cases the ratios of the levels of gene expression in lung spleen 
and liver achieved with the various complexes were approximately the same (Fig. 24). 
Levels of gene expression in the three organs achieved with Protamine/ DOTAP/DNA, 
Protamine phosphate/DOTAP/DNA and PLL.HBr/DOTAP/DNA complexes were 
approximately equal to those achieved with DOTAP/DNA complexes. Unexpectedly the 
levels of gene expression achieved with Protamine sulphate/DOTAP/DNA complexes in 
all three organs were approximately 10-fold higher than the levels achieved 
DOTAP/DNA complexes even though protamine sulphate/DNA complexes gave no 
noticeable levels of gene expression in any of the organs.
The authors were unable to explain why LPD complexes formed with protamine 
sulphate possessed higher transfection efficiencies than those formed with protamine free- 
base or protamine phosphate. Nonetheless it was clear from these results that LPD 
complexes were more efficient vectors than LD vectors containing the same cationic 
lipid/liposome formulation. The authors stated that although it was not fully understood 
why LPD vectors were more efficient, their results of the determination of luciferase
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DNA in tissues by Southern blot analysis confirmed that the DNA in LPDs was better 
protected from enzymatic degradation than DNA in LDs.
100 L eft ■  lung spleen B  livor R ight
.0 0 1 ^ 111 1 1 1
LPD (1) LPD (2) LPD (3) LPD (4) PD LD Naked DNA
Figure 24. -  Levels of gene expression achieved in organs following injection of 
various complexes as well as naked DNA into CD-I mice. LPD (1) = PLL.HBr/DOTAP/ 
DNA, LPD (2) = Protamine/DOTAP/DNA, LPD (3) = Protamine phosphate/DOTAP/ 
DNA, LPD (4) = Protamine sulphate /DOTAP/DNA, PD = Protamine sulphate/DNA, LD 
= DOTAP/DNA. (Reproduced from Li & Huang 125)
In view of the fact that Gottschalk et a 124 had reported that poly-L-lysine (MW ~
f OA12,000-24,000) was toxic and activated the complement system, Schwartz et al. 
synthesised a series of low molecular weight DNA-condensing peptides (MW ~ 1,000- 
3,000) the sequences o f which were derived from naturally occurring proteins (Table 4). 
These peptides were then complexed with DNA and their ability to bind to the DNA and 
retard its migration during gel electrophoresis as well as protect the DNA from enzymatic 
degradation was assessed. Three of these peptides, H9-2, nls-H9-2 and nls were used to 
form LPD complexes with DOGS and pCMV-Luc (P:D ratio = 1:1). Murine 3LL lung 
carcinoma cells were subsequently incubated with these complexes.
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Sequence Origin Residues Name
KTPKKAKKP Human histone 
HI
9 H9
(KTPKKAKKP)2 Human histone HI 18 H9-2
(KTPKKAKKP)3 Human histone H 1 27 H9-3
(KTAKKAKKA)2 Mutated H 1 18 H9-2'
KKSAKKTPKKAKKP Human histone H 1 14 H14
KKKKKKKKKK Not natural 10 K10
KKKKKKKKKKKK Not natural 12 K12
KKKKKKKKKKKKKKKKKK Not natural 18 K18
(ATPAKKAA)2 Human nucleolin 16 N8-2
SRSRYYRQRQRSRRRRRR Human protamine 1 18 Prl8
RRRLHRIHRRQHRSCRRRKRR Human protamine 2 21 Pr21
PKKKRKV SV40 nls 7 nls
PKKKRKV-PA-(KTPKKAKKP)2 Chimeric 26 nls-H9-2
1 96Table 4. -  Peptides synthesised by Schwartz et al. and tested for their ability to 
enhance cationic lipid-mediated gene transfer in vitro.
Figure 25. -  Effect of addition of 
cationic peptides to DNA prior to 
addition of cationic lipid on DOGS- 
mediated transfection. Murine 3LL 
lung carcinoma cells were 
transfected with or without pre­
condensation of DNA with peptide at 
a ratio of 1:1 (w/w) before the 
addition of DOGS. (Reproduced 
from Schwartz et al. 126)
Following incubation with the various complexes (DOGS/pCMV-Luc, H9- 
2/DOGS/pCMV-Luc, nls-H9-2/DOGS/pCMV-Luc and nls/DOGS/pCMV-Luc), the 
murine 3LL lung carcinoma cells were assayed for luciferase activity (Fig. 25). Out of the 
three peptides used to form LPD complexes, only H9-2 and nls-H9-2 potentiated DOGS- 
mediated transfection. The peptide, nls had no potentiating effect whatsoever and 
furthermore the potentiating effects of nls-H9-2 and H9-2 were equal which suggested
108
3LL
without peptide 
H9-2 (1 w/w) 
nls-H9*2 (1 w/w) 
nls (1 w/w)
105
DOGS, nmol/pg DNA
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that nls had no beneficial effect at all in terms of transfection efficiency. Increasing the 
ratio of cationic peptide to pCMV-Luc from 1:1 to 2:1 resulted in LPD complexes with 
yet more increased transfection efficiencies (Table 5).
Peptide/DNA (w/w) H9-2 nls-H9-2 nls N8-2
0 2 1 1 1
0.5 20 43 16 5
1 37 48 6 13
2 48 90 9 7
Table 5. -  Enhancement of DOGS-mediated transfection (1.8 nmol DOGS/pg 
DNA) by pre-condensation o f pCMV-Luc with varying amounts o f peptide. Values 
shown are fold-increases over values obtained in the absence o f peptide.
_  10
H 4 6 0 b 3LL
« 10
ii
o 10
LJ
0 0.01 0.1 0.5 1 1.5 0 0.01 0.1 0.5 1 1.5
Peptide / DNA ratio (w/w)
0.1 0.2 0.5 1
■ no peptide
■ H 9
□ H 9-2
□ H 9-3
□ Pr21
Figure 26. -  Comparison of monomeric, dimeric and trimeric forms of H9 peptide 
and Pr21 peptide for their ability to potentiate transfection in the presence of 10 % serum. 
For H460 and 3LL cells cationic lipid used was RPR115535 (a & b) and for 3LL cells 
RPR 120535 (c) was also used. (Reproduced from Schwartz et al. I26)
The authors also assessed some of the other peptides for their transfection 
potentiating ability (Fig. 26). The dimeric and trimeric forms of peptide H9 were found to 
be particularly effective at potentiating RPR115535-mediated transfection (Fig. 26 -  a & 
b). Assessment of the various peptides they had synthesised led the authors to conclude
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that in order for peptides to potentiate cationic lipid-mediated transfection they must be at 
least 12 or 14 amino acid residues long and contain at least 50-60 % lysine residues.
The same concept of combining two vectors in order to incorporate their 
advantageous properties into one vector was eventually extended to the cationic polymer, 
polyethylenimine. Although both cationic peptides and PEI are capable of condensing 
DNA, PEI also has the advantageous properties of being non-degradable by enzymes and 
also of acting as a ‘proton sponge’. Therefore two other beneficial properties could be 
incorporated into LPD vectors by replacing cationic peptide with PEI. Such an approach
1 97was adopted by Oku, Nango et al. who prepared and tested complexes composed of 
DNA, liposome and cationic polymer. Over a decade earlier Oku, Nango et al. 128 had 
investigated the effect of incorporating a cetylated proton-sensitive polymer into
1 77liposomes for the purpose of drug delivery. The authors applied the same approach to 
liposome-mediated gene delivery, using cetylated PEI in place of cationic peptides.
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Figure 27. -  Transfection of COS-1 cells with cetyl-PEI600/DOPE/DNA and 
cationic liposome/DNA complexes. (A) Influence of the DNA to cationic lipid/liposome 
or cetyl-PEI600/DOPE ratio on transfection; •  cetyl-PEI600/DOPE, o DMRIE/DOPE, □ 
DOTAP/DOPE or A LipofectAMINE. (B) Transfection of COS-1 cells with cetyl- 
PEI600/DNA, cetyl-PEI600/DOPE/DNA, cetyl-PEI600/EPC/DNA or cetyl- 
PEI600/DPPC/Chol/DNA complexes. (Reproduced from Oku, Nango et al. 127)
Oku, Nango et al. 127 prepared polyethylenimine (MW ~ 600, PEI600) grafted 
with 22 mol% cetyl groups by refluxing PEI with the appropriate amount of cetyl 
bromide. The cetylated-PEI600 was mixed with lipids (DOPE at 065:1 ratio, EPC at
0.65:1 ratio, DPPC and Choi at 0.65:1:1 ratio) and then plasmid DNA (pEGFP-Cl or 
pCAG-LZ15) was added. For comparison, cationic liposome/DNA complexes were also 
prepared that were composed of DMRIE/DOPE (1:1, mol/mol), DOTAP/DOPE (1:1, 
mol/mol) or LipofectAMINE/PE (3:1, w/w) and these were also mixed with DNA 
(pEGFP-Cl or pCAG-LZ15). The resulting cetyl-PEI600/lipid/DNA and cationic 
liposome/DNA complexes were incubated with a variety of cell types (COS-1, MCF-7 
breast adenocarcinoma, MCA-MB-435S breast ductal carcinoma, BxPC-3 pancreatic 
adenocarcinoma, PANC-1 pancreatic epithelioid carcinoma, U87 glioblastoma, U-20S 
osteosarcoma, HepG2 hepatoma, C2C12 mouse myoblast, and BBMC bovine brain 
endothelial cells). Incubation of the cells with the complexes for 3 hours was followed by 
washing to remove complexes and then incubation in fresh medium for another 48 hours. 
Cells were then either assayed for GFP expression by fluorescence spectrophotometry or 
for galactosidase activity.
Comparison of the transfection levels achieved with cetyl-PEI/DOPE/DNA 
complexes and the three cationic liposome/DNA complexes formulated at different ratios 
(Fig. 27-A) showed that the highest transfection levels were achieved with cetyl- 
PEI/DOPE/DNA complexes at a cetyl-PEI/DOPE to DNA ratio of approximately 1:1. 
Transfection levels achieved with cetyl-PEI/DOPE/DNA complexes were certainly higher 
than those achieved with DMRIE/DOPE/DNA or DOTAP/DOPE/DNA complexes. 
However it is unclear whether cetyl-PEI/DOPE /DNA complexes were more efficient 
than LipofectAMINE/DNA complexes as it is unclear whether the authors transfected 
COS-1 cells with LipofectAMINE/DNA complexes prepared at the known optimal DNA 
to LipofectAMINE ratio. The authors demonstrated that the addition of lipid to cetyl- 
PEI600 and DNA had a significant effect on the transfection activity of cetyl- 
PEI600/DNA complexes (Fig. 27-B). Complexes composed of cetyl-PEI600/DOPE/DNA 
were more than 5 times as efficient as those composed of only cetyl-PEI600/DNA. 
Addition of DPPC/Chol or EPC to cetyl-PEI600/DNA also had a significant effect on 
transfection efficiency (approximately 3-fold increase).
Incubation of other cell lines with cetyl-PEI600/DOPE/DNA or 
LipofectAMINE/DNA complexes in the presence or absence of serum gave some 
interesting results. For all cell lines LipofectAMINE-mediated transfection decreased 5- 
to 50-fold when 50 % serum was added to the incubation medium (Fig. 28). Surprisingly, 
cetyl-PEI600/DOPE-mediated transfection was not only unaffected by addition of 50 % 
serum to the incubation medium, but in many cases actually increased up to 10-fold (Fig.
28). This led the authors to examine the effect of varying the percentage of serum added
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to the incubation medium on the transfection efficiency of cetyl-PEI600/DOPE/DNA, 
DMRIE/DOPE/DNA, DOTAP/DOPE/DNA and LipofectAMINE/DNA complexes in 
COS-1 cells.
MCK-7 MDa M M W S  RsPT-3 PANC-1 SK-N-VK' 1*7 U-20S H«pC2 C2C12 M M C
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Figure 28. -  Transfection of various cell lines with cetyl-PEI600/DOPE/DNA or 
LipofectAMINE/DNA complexes in the presence or absence of serum. Open bar: cetyl- 
PEI600/DOPE/DNA in absence of serum; closed bar: cetyl-PEI600/DOPE/DNA in 
presence of serum; hatched bar: LipofectAMINE in absence of serum; grey bar: 
LipofectAMINE in presence of serum. (Reproduced from Oku, Nango et al. 127)
The transfection efficiencies of DOTAP/DOPE/DNA and LipofectAMINE/DNA 
complexes markedly decreased upon addition of serum to the incubation medium (Fig.
29). DMRIE/DOPE-mediated and cetyl-PEI600/DOPE-mediated transfection on the other 
hand increased on addition of serum, cetyl-PEI600/DOPE-mediated transfection 
increasing on the addition of up to 50 % serum, whilst DMRIE/DOPE-mediated 
transfection continued to increase on addition of a higher percentage of serum (Fig. 29). 
The authors were surprised to find that serum potentiated cetyl-PEI600/DOPE-mediated 
transfection and so investigated this further. They reported that formation of cetyl- 
PEI600/DOPE/DNA complexes in the presence of serum resulted in smaller, more 
compact particles that tended to aggregate less and speculated that this could explain the 
observed increase in transfection. However the authors did not clarify whether cells were 
incubated in serum with complexes that had been prepared in serum or if the complexes
only came into contact with serum at the incubation stage after they had already been 
formed.
Figure 29. -  Effect of varying the 
percentage of serum in the incubation 
medium on the transfection activity of 
cetyl-PEI600/DOPE/DNA (•), 
DMRIE/DOPE/DNA (o), 
DOTAP/DOPE/DNA (□) and 
LipofectAMINE/DNA (A) complexes. 
COS-1 cells incubated for 3 hours with 
complexes and serum. (Reproduced
197from Oku, Nango et al. )
In a subsequent publication Oku, Nango et al. 129 reported their syntheses of other 
cetyl derivatised polyethylenimines (PEI600, PEI 1800 and PEI25000). The degree of 
cetyl derivatisation was varied from 5 % to 24 % to produce seven different cetyl-PEI 
conjugates. These conjugates were assessed for their ability to potentiate liposome- 
mediated transfection in a similar manner to cetyl-PEI600 and some of the conjugates 
were found to potentiate liposome-mediated transfection even more than cetyl-PEI600 
(22 mol% derivatised). Toxicity of cetyl-PEI/DOPE/DNA complexes was also 
determined by the authors and was reported to be low.
Lampela et al. 130 formed LPD complexes with conventional PEI-2K (MW ~ 
2,000) and DOSper in an attempt to obtain a synergistic increase in transfection.
Although the PEI-2K/DOSper/DNA complexes of Lampela et al. 130 did show higher 
transfection efficiencies than PEI-2K/DNA complexes, they did not show higher 
transfection efficiencies than PEI-25K/DNA complexes. Indeed PEI-25K/DNA 
complexes were considerably more efficient than PEI-2K/DOSper/DNA complexes. PEI- 
2K/DOSper/DNA complexes also showed higher transfection activity than DOSper/DNA 
complexes. This difference in transfection efficiencies of PEI-2K/DNA complexes and 
PEI-25K/DNA complexes was not unexpected as it was already known that different 
sizes of PEI as well as types (branched and linear) possessed different transfection 
activities. It would have been appropriate for Lampela et al. 130 to also compare PEI- 
25K/DOSper/DNA complexes with PEI-25K/DNA complexes. Lampela et al. 131 
subsequently reported the preparation of LPD complexes composed of DNA and PEI700
E
Serum (%)
(MW ~ 700) or PEI-2K (MW ~ 2,000) with other cationic lipids/liposome formulations 
such as DOTAP, SuperFect and LipofectAMINE. However, in this publication the 
authors did not compare transfection efficiencies of these complexes with that of 
PEI/DNA complexes. Interestingly transfection levels achieved with PEI700/lipid/DNA 
and PEI-2K /lipid/DNA complexes varied depending on the cell type being transfected as 
well as the cationic lipid used.
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Figure 30. -  Comparison of the transfection efficiencies of complexes composed 
of pCMV-Luc and increasing amounts of either PEI800 or PEI-25K with complexes 
composed of DOTAP/Chol/DNA. (Reproduced from Lee et al. l32)
Lee et al. l32, in examining the synergistic effect of PEI and cationic liposomes, 
formed LPD complexes with PEI800 or PEI-25K as well as poly-L-lysine or protamine 
for comparison. Initially the authors prepared complexes composed of DNA and 
DOTAP/Chol or DNA and increasing amounts of PEI800 or PEI-25K. The results of in 
vitro transfection of HeLa cells with these complexes indicated that PEI-25K was a more 
efficient vector than PEI800. At PEI-25K to DNA ratios of 0.65:1 or more, the levels of
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luciferase activity obtained with PEI-25K/DNA complexes were comparable to that 
obtained with DOTAP/Chol/DNA complexes (Fig. 30).
In view of the fact that PEI-25K appeared to be a much more efficient vector, the 
authors chose to prepare LPD complexes with PEI-25K instead of PEI800. The 
transfection activity of PEI-25K/DOTAP/Chol /DNA complexes formulated at the 
optimal cationic polymer to DOTAP/Chol/DNA ratio was found to be approximately 50- 
fold greater than the transfection activity of similar protamine/DOTAP/Chol/DNA or 
PLL/DOTAP/Chol/DNA complexes (Fig. 31).
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Figure 3 1 .-  Effect of different ratios of cationic polymer to DOTAP/Chol/DNA 
on the transfection efficiency of LPD complexes. HeLa cells were incubated for 1 hour 
with complexes and then incubated in fresh medium for 24 hours. (Reproduced from Lee 
e ta l .m )
In order to determine whether the transfection efficiency of LPD complexes 
containing cationic liposome and PEI-25K could be further improved by replacing 
DOTAP/Chol with other cationic liposome formulations, the authors formed LPD 
complexes with DOTAP/DOPE, DDAB/Chol and DDAB/DOPE. The four complexes 
were prepared at what had been determined to be the optimal cationic polymer to cationic 
liposome to DNA ratio and were then compared for their ability to transfect HeLa cells. 
Out of the four complexes PEI-25K/DOTAP/Chol /DNA complexes were found to have 
the highest transfection activity towards HeLa cells.
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The effect of the order of mixing of the three components, a factor which had been 
shown previously to have a significant impact on the transfection activity of ternary non- 
viral gene transfer vectors, was also investigated by the authors. The order of mixing was 
indeed found to have a very significant impact on the transfection efficiency of the 
resulting complexes. Mixing and incubation of pCMV-Luc and PEI-25K prior to addition 
of DOTAP/Chol resulted in 100-fold greater luciferase activity in HeLa cells compared to 
complexes prepared by mixing DOTAP/Chol with DNA before adding PEI-25K or 
compared to complexes prepared by mixing PEI-25K and DOTAP/Chol first and then 
adding pCMV-Luc (Fig. 32).
Figure 32. -  Effect of the order of 
mixing of the three components 
on the transfection activity of the 
resulting LPD complexes. 
Complexes were prepared at the 
optimal cationic polymer to 
cationic liposome to DNA ratio 
(0.65 pg:10 nmol:l pg). HeLa 
cells were incubated for 1 hour 
with complexes and then 
incubated in fresh medium for 24 
hours. (Reproduced from Lee et 
al. I32)
Similar, although not so pronounced results were obtained when other cell lines 
were incubated with PEI-25K/DOTAP/Chol /DNA, PLL/DOTAP/Chol/DNA, 
protamine/DOTAP/Chol/DNA or DOTAP/Chol/DNA complexes. The authors concluded 
that this synergism between cationic polymers and cationic liposomes held considerable 
promise for non-viral gene therapy.
1.4.7 Integrin-targeted vectors.
LPD-mediated transfection had been shown to be more efficient than cationic 
liposome-mediated or cationic polymer-mediated transfection and so was a significant
fxo.001
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step forward for non-viral gene transfer. However LPD-mediated gene transfer had the 
disadvantage that it was non-specific, as there was no targeting function in such a ternary 
system. In such ternary systems a targeting ligand could have either been coupled to the 
lipid component or to the polymer component. Addition of a targeting ligand to LPD 
complexes could have not only resulted in complexes possessing cell specificity but also 
could have resulted in complexes with increased transfection activities as had been the 
case with targeted liposomes.
Subunits. Ligands and counter-receptors. Recognition
P. ai Collagens, laminin.
a2a Collagens, laminin. DGEA
a3 Collagens, fibronectins, laminin. RGD
04 Fibronectins (V25), VCAM-1. EILDV
os Fibronectin (RGD). RGD
06 Laminin.
Oi Laminin.
a8 ?
av Vitronectin, fibronectin. RGD
P2 ai ICAM-1, ICAM-2.
aM C3b component of complement, fibrinogen,
ox C3b component of complement, fibrinogen. GPRP
P3 Glib Fibrinogen, fibronectin, von Willebrand RGD,
av Fibrinogen, fibronectin, von Willebrand RGD
P4 a6 Laminin.
Ps av Vitronectin. RGD
P6 av Fibronectin. RGD
P7 (X4 Fibronectin. EILDV
Ps av ?
Table 6. -  The integrin receptor family.
The principal receptors on animal cells responsible for cell-cell and cell- 
extracellular matrix protein interactions are the integrins, a family of homologous 
transmembrane linker proteins. Integrins play a critical role in a variety of biological 
processes including organogenesis, tissue re-modeling, thrombosis and leukocyte 
migration. They are heterodimers, in that they consist of two subunits, an a-chain (120- 
180 kD) and a p-chain (90-110 kD). The presence of divalent cations as well as both 
chains is required for ligand binding.133 More than twenty integrins have been 
characterised as a result of cloning (see Table 6). The receptor binding properties of
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different integrins range from highly specific (involving short amino acid sequences on 
cell membranes and extracellular matrix proteins) to comparatively non-specific.134
Several strategies for selective transfection based on natural receptor-mediated 
endocytosis have been investigated. Several examples of the use of receptor ligands for 
targeting of non-viral vectors to specific cell types have already been given. One such 
strategy that has not been mentioned yet involves the use of integrin-targeting peptides to 
target vectors to specific cells. Early work carried out by Hart et al. 135136 demonstrated 
that integrin-targeting peptide-DNA complexes (ID complexes) were capable of 
transfecting epithelial cells in vitro. The authors had used two av integrin-targeting 
peptides which consisted of a cyclic arginine-glycine-aspartic acid (RGD) containing 
head group and a ten-lysine or sixteen-lysine tail (amino acid sequence -  
KxGAC*RGDMFGC* where X = 10 or 16). The sequence C*RGDMFGC* in which the 
two cysteine residues are covalently linked by a disulphide bridge, denoted by asterisks
1 77 1 7Rforthwith, had been shown to have particularly high binding affinity for integrins 
and peptides containing around 12-14 lysine residues were known to be able to bind to 
and condense DNA. The resulting complexes, KioGAC*RGDMFGC*/pGL2-Luc or 
Ki6GAC*RGDMFGC* /pGL2-Luc were compared to Kio/pGL2-Luc complexes for their 
ability to transfect ECV304 or COS-7 cells. The authors observed a 5-fold difference in 
transfection activity between targeting-peptide/DNA and non-targeting-peptide/DNA 
complexes.
In a subsequent publication, Harbottle et al. 139 reported their synthesis of the 
peptide Ki6GGC*RGDMFGC*A and demonstrated that it could efficiently bind to and 
condense DNA plasmids. Furthermore, complexation of the peptide to pDNA was shown 
to result in protection of the condensed DNA from nuclease degradation. Complete 
protection of complexed pDNA only occurred at and above peptide to pDNA ratios at 
which the pDNA was shown to be fully retarded during gel electrophoresis. The optimal 
ratio of peptide to pDNA in terms of transfection efficiency was however found to be 
twice that at which DNA migration was completely retarded i.e. +/- ratio = 4.28:1,139 
Even at this ratio of peptide to pDNA the transfection efficiency of the ID complexes was 
only 1 % of the level obtained with LipofectAMINE. The transfection efficiency of these 
complexes was dramatically increased by the addition of the lysomotrophic agent, 
chloroquine (Fig. 33). Indeed at a concentration of 250 pM chloroquine in the incubation 
mixture, transfection levels achieved with ID complexes became comparable to 
transfection levels achieved with LipofectAMINE. Harbottle et al. 139 also compared a 
sixteen-lysine peptide and a non-integrin-targeting peptide (Ki6GGC*RGEMFGC*A)
57
with the integrin-targeting peptide for their abilities to mediate gene transfer. At the 
peptide to pDNA ratio that was known to be optimal for integrin-targeting peptide- 
mediated transfection, the efficiency of ID complexes was approximately 10- to 12-fold 
greater than the Kj^pDNA or non-ID/pDNA complexes.
>iM Chloroquine (K]i6 [K]i6RGD [K]i6RGE 
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Figure 33. -  Left -  Effect of chloroquine on gene transfer mediated by peptide 
Ki6GGC*RGDMFGC*A. ID complexes were formed at a +/- ratio of 4.28:1 (previously 
established as optimal). CaCo2 cells were incubated with ID complexes with and without 
chloroquine or with LipofectAMINE/pDNA complexes or with pDNA only for 4 hours. 
After 48 hours cells were assayed for luciferase activity. Right -  Comparison of 
transfection efficiencies of K^pDNA, non-targeting Ki6GGC*RGEMFGC*A/pDNA and 
targeting Ki6GGC*RGDMFGC*A/pDNA complexes relative to the transfection 
efficiency of LipofectAMINE/pDNA complexes, in CaCo2 cells. (Reproduced from 
Harbottle et a l 139)
The process by which these ID complexes transfect cells is different from that for
cationic lipid/DNA or cationic polymer/DNA complexes. Whilst cationic lipid/DNA or
cationic polymer/DNA complexes undergo endocytosis as a result of interaction with
proteoglycans, internalisation of ID complexes occurs through a process that is more
similar to phagocytosis. Integrin-mediated internalisation of particles is thought to occur
through a ‘zipper’ mechanism; cellular integrins bind to several ligands on a particle to
1produce a phagosome. One of the advantages of this process is that much larger 
particles can be internalised as compared to endocytosis. The advantages of peptide-based
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vectors are that they are non-toxic, straightforward to synthesise, have a well-defined 
sequence and are easily purified. One major disadvantage however is that these ID 
complexes are susceptible to endosomal degradation. This causes poor transfection 
efficiency and co-factors, such as the lysomotrophic agent chloroquine, are usually 
required to achieve significant levels of transfected gene expression. The use of co-factors 
is obviously not compatible with in vivo application of these complexes.
1.4.8 LID vectors.
As was mentioned earlier, ID complexes suffer from the disadvantage that they 
are susceptible to endosomal degradation and this susceptibility was found to be a major 
limitation on their transfection efficiency. Conversely, lipid-DNA complexes are known 
not to be susceptible to endosomal degradation, but the overall positive charge that they 
need to have in order to be capable of transfecting cells efficiently can result in unwanted 
serum interactions. The solution to this problem was the same as for LPD complexes, to 
combine both cationic lipids/liposomes with integrin-targeting peptides to generate Lipid- 
Integrin-binding peptide-DNA (LID) complexes. Such LID complexes would be less 
susceptible to undesirable serum interactions because complexes could be prepared that 
had a lower overall positive charge since cell binding would be integrin-mediated rather 
than proteoglycan-mediated. The degree of cell-specificity of LID complexes would 
depend on the nature of the integrin-targeting peptide used. Furthermore, the presence of 
fusogenic lipid would limit degradation of the DNA in the endosome as a result of 
fusogenic lipid-induced release of the endosomal contents into the cytoplasm. Such LID 
complexes would therefore possess the advantages of LPD complexes but could also be 
targeted to specific cells.
The concept of combining cationic liposomes and integrin-targeting peptides into 
one vector was first proposed by Hart et al. 140 who demonstrated that the transfection 
efficiency of an integrin-targeting peptide-DNA complex was enhanced by the addition of 
optimised amounts of the cationic liposome, Lipofectin. Hart et al. 140 prepared cationic 
liposome/DNA, cationic polymer/DNA, integrin-targeting peptide/DNA and LID 
complexes and compared their transfection efficiencies on ECV304 cells. The results 
showed that presence of both cationic liposome and the integrin-targeting peptide had a 
synergistic effect and markedly improved transfection (Fig. 34). The luciferase gene 
expression levels achieved with LID complexes were approximately 50-fold greater than
levels achieved with integrin-targeting peptide/DNA complexes and approximately 7-fold 
higher than levels achieved with either Lipofectin/DNA or Lipofectin/K^DNA 
complexes.
Figure 34. -  Transfection of 
ECV304 cells with; LD -  
Lipofectin/DNA. KD -  
Kie/DNA. LKD -  
Ki6/Lipofectin/DNA. ID -  
Peptide 1, 5 or 6/DNA. LID -  
Peptide 1, 5 or
6/Lipofectin/DNA. Luciferase 
reporter gene expression is on a 
logarithmic scale. (Reproduced 
from Hart et al. 140).
The authors also prepared transfection complexes composed of fixed amounts of 
peptide (4 pg, Ki6GAC*RGDMFGC*A) and pGL2 pDNA (1 pg) and varying amounts of 
Lipofectin (0-10 pg). ECV304 cells were incubated with these ID and LID complexes for 
12 hours, the incubation medium was replaced and then cells were assayed for luciferase 
activity 48 hours later. Cells incubated with the LID complexes containing 1 pg of 
Lipofectin per pg of pDNA showed around 80-fold higher luciferase reporter gene 
expression than cells incubated with ID complexes (Fig. 35).
Figure 35. -  Enhancement of ID 
complex transfection efficiency with 
Lipofectin. ECV304 cells were 
incubated for 12 hours with ID 
complexes with and without varying 
amounts of cationic liposome added. 
The incubation medium was then 
replaced and cells were assayed for 
luciferase activity 48 hours later. 
(Reproduced from Hart et a l 140).
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Further investigation by Hart et al. 140 showed that the optimal ratio o f Lipofectin 
to plasmid DNA was between 50-75 % (0.5-0.75 pg Lipofectin per microgram of DNA). 
Moreover, transfection efficiency was highest for those complexes prepared by adding 
integrin-targeting peptide to Lipofectin followed by addition of DNA. The LID 
complexes were also analysed by atomic force microscopy, which revealed that like ID 
complexes they formed homogenous spherical particles. This similarity between the two 
complexes, despite the presence o f cationic liposome in one of them suggests that it was 
the association of peptide with DNA that determined the structure. The charge 
contribution of Lipofectin to LID complexes was minimal, so it was unlikely that the 
increase in transfection efficiency was due to LID complexes undergoing cellular 
internalisation by a similar mechanism to LD complexes. Internalisation of LID 
complexes must still have occurred by an integrin-mediated pathway, the evidence in 
support of this being that LKD complexes showed much lower transfection efficiency 
(Fig. 34).
Harbottle et al. 141 investigated other integrin-targeting peptides for their ability to 
enhance cationic lipid-mediated or for that matter LPD-mediated transfection. During 
their investigations they identified a peptide sequence (PLAEIDGIELTY) with high 
affinity for the a9pi-integrin. This sequence was incorporated into a DNA-condensing 
peptide to give the linear peptide K 16GGPLAEIDGIELGA or the cyclic peptide 
Ki6GC*PLAEIDGIELC*A. However assessment of the ability o f these peptides to bind 
to (X9 P1 -integrins showed that attachment of the sixteen-lysine tail to the integrin-targeting 
motif resulted in a dramatic reduction of binding affinity. This reduction was most 
pronounced for the linear form o f the integrin-targeting motif and surprisingly less 
pronounced for the cyclic form of the integrin-targeting motif. The authors therefore 
chose to use the cyclic peptide, Ki6GC*PLAEIDGIELC*A for the formation of LID 
complexes.
The authors initially determined the ratio of cyclic peptide to DNA that resulted in 
complete retardation of migration o f the DNA during gel electrophoresis. The transfection 
activities of complexes composed o f pDNA and varying amount of 
Ki6GC*PLAEIDGIELC*A (one-, two- and four-times the amount o f peptide that 
inhibited migration) were then determined in order to find the optimal peptide to pDNA
• 1 ^ 7ratio. As observed by Harbottle et al. , the optimal ratio of cyclic peptide 
(Ki6GC*PLAEIDGIELC*A) to pDNA in terms of transfection efficiency was found to be 
twice that at which DNA migration was completely retarded (Fig. 36).
Figure 36. -  Effect of the 
ratio of cyclic peptide to 
pDNA on the transfection 
activity of the resulting 
complexes. SW80 cells 
were incubated with 
complexes for 48 hours, 
cells were then lysed and 
luciferase activity of 
lysates was measured. 
(Reproduced from 
Harbottle et a l 141)
Having determined the ratio of cyclic peptide to pDNA that resulted in complexes 
with optimal transfection activity, the authors then prepared LID vectors composed of the 
cyclic peptide, LipofectAMINE and pDNA. In order to verify that the uptake of the LID 
complexes by SW80 cells was integrin-mediated, the authors compared the levels of 
luciferase activity in SW80 cells displaying the agpi-integrin and SW80 cells lacking the 
agpi-integrin following incubation with the LID vectors. A comparison was also made 
between LipofectAMINE/pDNA, LipofectAMINE/Ki6/pDNA and LipofectAMINE/ 
Ki6GC*PLAEIDGIELC*A/pDNA complexes.
Figure 37. -  Comparison of 
transfection activities of three 
vectors in SW80 cells displaying 
and SW80 cells lacking the 
a9pi-integrin. Black column = 
LipofectAMINE/pDNA; grey 
columns = LipofectAMINE/ 
Ki6GC*PLAEIDGIELC*A/pD 
NA; white columns = 
LipofectAMINE/ IWpDNA. 
(Reproduced from Harbottle et 
a l 141)
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The results of transfection of SW80 cells displaying the a9pi-integrin and SW80 
cells lacking the agpi-integrin clearly showed that the LID complexes possessed higher 
transfection activity towards ligand-receptor-displaying cells than cationic lipid/pDNA 
complexes. Furthermore the role of the integrin-targeting motif in increasing the 
transfection activity of LID complexes compared to LPD complexes was also quite 
apparent from the results. The efficiency of gene delivery to SW80 cells lacking the (X9P1- 
integrin by LID complexes was however surprisingly high suggesting that the cationic 
lipid component of the LID complexes possibly interfered with integrin-mediated uptake 
of LID complexes.
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Figure 38. -  Effect of pre-treatment of cells with integrin-blocking antibodies on 
GGC*RGDMFGC*GGKi6/DC-Chol/DOPE-mediated gene transfer. Cells were pre­
treated for 1 hour with antibodies against av integrin subunit, the Pi integrin subunit or the 
(X5P1 integrin. Cells were then incubated with LID complexes for 48 hours after which 
time they were assayed for luciferase activity. (Reproduced from Scott et al. 142)
Scott et al. 142 carried out very similar studies to those carried out by Harbottle et 
al. 141, on transfection with LID complexes. In place of the integrin-targeting peptides 
used by Harbottle et al. 141, the authors used the av integrin-targeting peptide 
GGC*RGDMFGC*GGKi6 as well as the non-targeting peptide
GGC*RGEMFGC*GGKi6 and the peptide Ki6 to prepare their LID and LPD complexes. 
Additionally the cationic liposome formulation DC-Chol/DOPE was used in place of 
LipofectAMINE. Human bronchial epithelial (16HBE) cells were incubated with the
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resulting DC-Chol/DOPE/peptide/pCMV-Luc complexes and then assayed for luciferase 
activity. The results obtained were very similar to those observed by Harbottle et a l 141 
despite the difference in peptide sequences. The authors did however further confirm the 
role of integrin-mediated LID uptake by pre-treating cells that were to be incubated with 
the LID complexes with antibodies against av integrin subunit, the Pi integrin subunit or 
the aspi integrin. The pre-treatment of cells with any one of these antibodies resulted in at 
least a 2-fold decrease in transfection as demonstrated by a 2-fold decrease in luciferase 
activity (Fig. 38). Such a decrease was not observed for DC-Chol/DOPE-mediated gene 
delivery.
More recently Hart et a l 143 ,44 have published the results of further studies on 
LID vectors previously described (Hart et a l 140). In these publications the influence of 
plasmid size on LID complex transfection activity was examined 143 and the ability of the 
LID vectors to transfect haematopoietic cell lines or dendritic cells was assessed l44. The 
use of integrin-targeting peptides has recently been extended to the preparation of 
targeted PEG-LPD vectors. Harvie et a l 145 synthesised an integrin-targeting peptide- 
polyetheylene glycol-lipid conjugate (DSPE-PEG5000-succinyl-ACDCRGDCFCG) 
which was incorporated into LPD formulations. This resulted in a 5-fold increase in 
binding of PEG-LPD complexes to cells and a 15-fold increase in uptake of the 
complexes into cells.
1.5 Conclusions.
The potential for clinical benefit from gene therapy is enormous, the current 
limitation being the properties of vectors currently available. Development of synthetic 
vectors for the purpose of gene therapy has advanced to the level where these vectors are 
a viable alternative to viral vectors. Synthetic vectors however hold several advantages 
over viral vectors, especially with regard to safety and the size of gene capable of being 
delivered. There remains nevertheless wide scope for improvement in the transfection 
efficiency and specificity of synthetic vectors, and improvement will be necessary before 
these vectors can be developed into a successful clinical therapy.
Achieving transfection efficiencies with non-viral vectors that are comparable 
with viral vectors perhaps not only depends on the synthesis of ‘better’ cationic lipids or 
‘better’ cationic polymers but also on the discovery of synergistic interactions between 
the great multitude of vectors that already exist. This has already been demonstrated to 
some extent with the development of targeted cationic liposomes and LID vectors.
C h a p
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2.1 Project aims.
LID complexes have already shown great promise in terms o f their ability to 
deliver genetic material into cells. Nonetheless, scope remains for improvement in terms 
of toxicity, specificity and efficiency. Efforts are being made to optimise the components 
of LIDs in order to produce vectors with superior properties. It is the aim of this project to 
investigate the effects of modifications to the peptide component o f LIDs.
Work undertaken by Hart et al. I35’138-140’143’144 established that complexes 
consisting of plasmid DNA, the cationic liposome formulation, Lipofectin® and an asp 1- 
integrin-targeting peptide (sequence -  K 16GACRRETAWACG) showed encouraging 
transfection efficiency. Efforts continue to be made in order to enhance the efficacy of 
this LID vector, both by optimising the lipid and the integrin-targeting peptide 
components.
The asp\-intergin-targeting peptide mentioned above has two component features, 
namely a sixteen L-lysine tail and a cyclic head group. The lysine tail is essential for 
DNA condensation, whilst the head group mediates the interaction of the peptide with 
as/fi-integrins. The recognition sequence of the head group lies within the CRRETAWAC 
portion of the peptide, the sequence being cyclised via a disulphide bridge between the 
two cysteines. The purpose of the glycine-alanine residues (-GA-) is essentially to act as a 
‘spacer’ between the head group and the tail.
The proposed models of the structure of LID complexes envisage the DNA as the 
central core of the complex, this DNA core being surrounded by lipid. The integrin- 
targeting peptide on the other hand spans the complex from the core to the surface, the 
sixteen L-lysine tail being bound to DNA whilst the head group situated on or in the lipid- 
surface of the complex. It has been suggested that, by increasing the separation of the 
head group from the tail, the resulting projection of the integrin-targeting head group 
from the complex could increase its affinity for target integrin. The aim o f this project 
was therefore to investigate the influence of the insertion of additional linker amino acids 
into the integrin-targeting peptide on the transfection efficiency o f the LID complexes 
into which the modified peptides have been incorporated. The influence of linker polarity, 
conformation and length was examined.
The secondary aim of this project was that the linker molecules that were to be 
inserted into the integrin-targeting peptide would be amino acids so that the linkages with 
preceding and subsequent amino acid residues in the peptide would be amide bonds. The
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incorporation of these linkers into the integrin-targeting peptide was also to proceed by 
the Fmoc-based solid-phase procedure, so all linker amino acids that were to be prepared 
had to be Fmoc-protected with the carboxylic acid function free.
The rationale for the design of the ‘backbone’ of these linker amino acids was that 
they should incorporate one o f the following three properties;
• A high degree of solubility in aqueous media and an unrestricted 
conformation.
• A high degree of solubility in organic media and an unrestricted conformation.
• A partially restricted conformation and high degree o f solubility in organic 
media similar to that of the lipid ‘tail’ of DOTMA and DOPE i.e. incorporating a cis- 
double bond approximately in the middle of the alkyl chain.
FmocHNNHFmoc
HO
OH
FmocHN
Figure 1. -  General structures o f target protected amino acid linker molecules.
In view of precedent work in the literature, most notably that of Ulysse & 
Chmielewski 146 and Thumshim et al. 147, it was envisaged that three types o f linkers 
would be synthesised and incorporated into asp\-integrin-targeting peptides. The linkers 
would be either PEG-based, saturated alkyl chain-based or unsaturated alkyl chain-based 
(Fig. 1). It was also envisaged that these linker amino acids would be prepared in various 
lengths so as to also probe the influence of the separation of the ‘head’ of a peptide from 
its ‘tail’ on the transfection efficiency of resulting LID complexes. The intention was also 
to devise synthetic routes to the target structures that were both inexpensive and could be 
conveniently reproduced on a large scale since solid-phase peptide synthesis is generally
quite wasteful in terms of reagents. It is generally recommended that 4 equivalents of 
Fmoc-protected amino acid are used for every coupling step during automated solid- 
phase peptide synthesis, effectively 3 equivalents being superfluous to some extent.
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2.2 Synthesis of Fmoc-amino acid linkers and 
their incorporation into peptides.
2.2.1 Synthesis of (Z) 16-(9-fluorenylmethyloxycarbonyl- 
amido)-hexadeca-7-enoic acid.
The synthetic route to (Z) 16-(9-fluorenylmethyloxycarbonylamido)-hexadeca-7- 
enoic acid (14) was partly based on the synthesis of cis-alkenyl-tethers by Ulysse & 
Chmielewski 146 via symmetrical alkynes (Schemes 1 & 2-A) and partly based on the 
synthesis of <y-acetylenic acids by DeJarlais & Emken 148 (Scheme 2-B).
OTBDMSOTBDMS
66 % n-BuLi, HMPA, 7HF
TBDMSO
OTBDMS
1) TBAF
2) Q03,
3) NH$ DCC
Scheme 1. -  Synthesis of an alkynyl-precursor and followed by its three step 
conversion to a di-A-hydroxysuccinimide ester, by Ulysse & Chm ielewski146.
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A)
91 %Hj, Lindlar's catalyst
B)
HO
UCCHtCHjNH^, 
HMPA, THF
78 -100 %
O
HO
Scheme 2. -  (A) Conversion of an alkynyl-di-A-hydroxysuccinimide ester to an
c/s-alkenyl-di-A-hydroxysuccinimide ester, by Ulysse & Chmielewski l46. (B) Synthesis
of 6>-acetylenic acids by DeJarlais & Emken 148
Ulysse & Chmielewski 146 had prepared alkynyl and alkenyl di-carboxylic acids 
and so having formed their TBDMS-protected symmetrical alkynyl-diols, they simply 
deprotected the hydroxyl functions and oxidised them to the acids. Subsequent catalytic 
hydrogenation of the symmetrical alkynyl-dicarboxylic acid A-hydroxysuccinimidyl 
esters had furnished the desired symmetrical alkenyl-dicarboxylic acid N- 
hydroxysuccinimidyl esters. In order to prepare (14) it would be necessary to synthesise 
an alkynyl bearing both a carboxyl group and an amino group. Furthermore, the synthesis 
of (14) required a protection strategy in order to introduce the Fmoc-amino-group and the 
carboxylic acid function. The carboxyl-group of the iodo-carboxylic acid and the 
hydroxyl-group of the iodo-alcohol that would be used to prepare the hydroxy-acetylenic 
acid had to be protected before the organolithium reactions. The synthetic strategy 
depicted below was initially envisaged for the synthesis of (Z) Fmoc-aminoalkenoic acids 
(Scheme 3).
FmocHN
O
FmocHN
OH
Scheme 3. -  Envisaged synthetic pathway to (Z) Fmoc-aminoalkenoic acids.
The carboxylic acid function had to be protected with a group that was stable to 
hydrogenation but could be easily removed in the presence of a Fmoc group. The addition 
of a Fmoc group before deprotection of the carboxylic acid was necessary as Fmoc- 
protection of a long alkyl-chain amino acid in aqueous conditions was not desirable. 
Effectively only the tert-butyl protection could be suitable for carboxyl group even 
though it was uncertain if this group would withstand the organolithium reagents used. 
The hydroxyl function of the iodo-alcohol to be introduced also had to be protected and 
the group chosen for this purpose had to be stable to organometallic reagents. 
Furthermore, the tert-butyl group would have to be stable to the conditions for removing 
the hydroxyl-protecting group, as conversion of the hydroxyl group to an amine and 
subsequent Fmoc-protection would be carried out while the carboxyl group was still 
protected. The deprotection conditions of the hydroxyl-protecting group would also have 
to not affect the triple bond. The very acid sensitive 9-(9-phenyl)-xanthenyl group was 
chosen for this purpose as it can be removed under very mild acid conditions (0.1 M
dichloroacetic acid in dichloromethane), while ter/-butyl group removal requires more 
stronger acid conditions (>50 % TFA). Consequently, under the conditions required to 
remove a 9-(9-phenyl)-xanthenyl group, removal of a tert-butyl group should be 
negligible.
Br
Mg, BjO
Reflux
HO
Scheme 4. - Preparation of 9-phenylxanthen-9-ol (1).
The large-scale preparation of 9-phenylxanthen-9-ol (1) was carried out following 
a procedure by Weber et al. 149. Formation of benzyl magnesium bromide followed by 
treatment of this with relatively inexpensive xanthone gave (1) in 78 % yield after work­
up and re-crystallisation (Scheme 4).
HO \ /8  OH
HB-,
Toluene.
99%
Br
100%
8 OH (2)
9-Pheny lxanthen-9-ol, 
AcOH
(3)
Br
Scheme 5. -  Synthesis of l-bromo-8-(9-phenyl-xanthen-9-yloxy)-octane (3).
The synthesis of l-bromo-8-(9-phenyl-xanthen-9-yloxy)-octane (3) was initially 
attempted by synthesising the mono-protected diol, 8-(9-phenyl-xanthen-9-yl)-octan-l-ol
72
and then converting this to (3). This however proved unsuccessful as, although the mono­
protected diol was effectively synthesised, the 9-phenylxanthyl protecting group proved 
to be unstable to the conditions required to convert the hydroxyl group to a bromo group 
(CBr4, PPI13 in DCM). The approach was therefore reversed and instead, following a 
procedure developed by Chong et al. 15°, 8-bromooctan-1-ol (2) was synthesised first 
(Scheme 7). This procedure was straightforward and involved refluxing a solution of 1,8- 
octanediol in toluene with a given volume of hydrobromic acid (48 %), to produce (2) in 
99 % yield. Protection of the hydroxy group of (2) was then carried out using glacial 
acetic acid as both a proton source and as an azeotrope for water formed in the reaction, 
following a procedure by Gaffney & Reese 15'. Addition of glacial acetic acid to (2) and 
9-phenylxanthen-9-ol (1) and its subsequent evaporation, repeated several times gave the 
product, (3) in 100 % yield (Scheme 5).
Initial attempts at the synthesis of 8-bromohexanoic acid tert-butyl ester (4) using 
perchloric acid and tert-butyl acetate, following a procedure by Jost & Rudinger 152 were 
low yielding and slow. The low boiling point of (4) proved to be problematic during work 
up and purification by this method. The reaction was also slow, taking at least five days to 
go to completion. The DCC-mediated coupling of /ert-butanol with the carboxylic acid, 
following a procedure by Li et al. was therefore chosen (Scheme 6) the advantages of 
this method being that the product was easier to recover and the reaction time was less 
than 24 hours.
Br
OH
O
DCC, DMAP, 
tBuOH, DCM.
78%
Br
o- (4)
o
Scheme 6. -  Synthesis of 8-bromohexanoic acid tert-butyl ester (4).
The next step in the route to (14) required the formation of the alkyne, 2- 
methylprop-2-yl 16-(9-phenyl-xanthen-9-yloxy)-hexadeca-7-ynoate (8). For the synthesis 
of (8), both (4) and (3) had to be converted to their corresponding iodides, (5) and (6) 
which was accomplished by treatment with a large excess of sodium iodide in acetone 
(Scheme 7) following a procedure by Castellanos et a l 154.
97% Nal, Acetone. 93% Nal, Acetone.
(6) OPx
OtBu (5)
O
Scheme 7. -  Synthesis of l-iodo-8-(9-phenyl-xanthen-9-yloxy)-octane (6) and 6- 
iodohexanoic acid /-butyl ester (5).
The iodo-derivatives, (5) and (6) were synthesised because, following a procedure 
by DeJarlais & Emken 148, treatment of co-iodoacids with lithium acetylide 
ethylenediamine complex (LAEDA) gave much higher yields of co-acetylenic acids (98- 
100 %) than treatment of co-bromoacids with LAEDA (3-78 %). The synthesis of l-(9- 
phenyl-xanthen-9-yloxy)-dec-9-yne (7) was accomplished by a procedure adapted from 
that published by DeJarlais & Emken 148 (Scheme 8). A slurry of lithium acetylide 
ethylenediamine in tetrahydrofuran and hexamethylphosphoramide was prepared at 
-78°C and to this was added (6), the reaction yielding (7) in 98 %.
UCCHfOijNH^,
98%
(6) (7)
Scheme 8. -  Synthesis of l-(9-phenyl-xanthen-9-yloxy)-dec-9-yne (7).
Compound (8) was then prepared by reacting the organolithium derivative of (7) 
with (5) (Scheme 9), initially to give (8) in 50 % yield. The organolithium derivative was 
prepared by adding n-butyllithium to (7) in THF and HMPA at -78°C, and this was 
followed by addition of (5). The yield of this reaction was increased to 70 % by ensuring 
that reagents (7) and (5) were purified and used within a short period of carrying out the 
subsequent synthesis and also by distilling tetrahydrofuran from sodium wire without the
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use of benzophenone. Fortuitously, the tert-butyl group of (5) or (8) appeared to 
withstand the use of H-butyllithium under the conditions of this reaction. 
Chromatographic separation of (8) from (7) was problematic as the two compounds had 
almost identical Rf values on normal phase silica. A second purification by 
chromatography was required to remove all traces of (7) from (8).
Scheme 9. -  Synthesis of 2-methylprop-2-yl 16-(9-phenyl-xanthen-9-yloxy)- 
hexadeca-7-ynoate (8).
The selective removal of the 9-(9-phenyl)-xanthenyl group from (8) was achieved 
with 0.1 M dichloroacetic acid in dichloromethane using pyrrole as the scavenger, 
following the procedure of Gaffney & Reese 151, to give 2-methylprop-2-yl 16-hydroxy- 
hexadeca-7-ynoate (9) in 95 % yield (Scheme 10). A small amount of the tert-butyl group 
was removed under these conditions (detected by TLC analysis of the crude reaction 
mixture) but this was less than 5 %.
7HF7HMPA.
OtBu
(8)
OtBu
0.3 M DCA, 
pyrrole, DCM. ho
95% OtBu
(8) (9)
Scheme 10. -  Selective deprotection of 2-methylprop-2-yl 16-(9-phenyl-xanthen- 
9-yloxy)-hexadeca-7-ynoate (8).
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Conversion of (9) to (Z)-2-methylprop-2-yl 16-hydroxy-hexadeca-7-enoate (10) 
was achieved by catalytic hydrogenation at atmospheric pressure using Lindlar catalyst in 
methanol and hexane (Scheme 11) following a procedure by Dr E.Guenin. Reduction of 
the triple bond of (9) to the c/s-double bond of (10) was accomplished in less than 4 hours 
under these conditions.
OtBu
(9)
Lindlar'scat, Hj 
MeOH/Hex.
100%
OtBu
HO
NaN3>
N.
(11)
OtBu DMF.
90%
2 steps
MsO
OtBu
O
Scheme 11. -  Synthesis of (Z)-2-methylprop-2-yl 16-azido-hexadeca-7-enoate 
(11) in three steps from 2-methylprop-2-yl 16-hydroxy-hexadeca-7-ynoate (9).
The aim was then to substitute an amine group for the hydroxyl group of (9). The 
route that was chosen proceeded via the azide derivative of (9) which was synthesised by 
mesylating (9) and then displacing the mesyloxy group with sodium azide, following a 
procedure by Trost et al. I55. (Z)-2-Methylprop-2-yl 16-0-methanesulfonyl-hexadeca-7- 
enoate was prepared from (9) by treating a solution of (9) in triethylamine 
/dichloromethane with methanesulfonyl chloride. The methanesulfonyl group was then 
displaced by reacting with sodium azide in dimethylformamide (Scheme 11). (Z)-2- 
Methylprop-2-yl 16-azido-hexadeca-7-enoate (11) was recovered in 90 % yield. In the 
next step, it was necessary to reduce the azido group of (11) to give the amine, but 
without reducing the carbon-carbon or carbon-oxygen double bonds. Therefore, neither 
catalytic hydrogenation nor lithium aluminium hydride could be employed.
The reduction of (11) to the corresponding amine, (Z)-2-methylprop-2-yl 16- 
amino-hexadeca-7-enoate (12) (Scheme 12) was accomplished using a procedure based 
on one published by Foucaud & El Guemmout156. The authors were faced with a similar 
problem in their synthesis of allylic amines, so they used triphenylphosphine to reduce
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their azides. The first attempt at the reduction of (11) following the procedure given by 
Foucaud & El Guemmout156 gave 80 % yield. This was by adding water and 
triphenylphosphine at the same time to (11) in THF. A slight modification to the 
procedure, adding PPh3 first and leaving to stir for 5 hours before adding water increased 
the yield to 93 %.
PPh^HjO 
THFOtBu m r  ^OtBu
* r \  / r = ^ \  /sir -------  h2n \ /8 x /si
O 93%  &
(11) (12)
Scheme 12. -  Staudinger reduction of (Z)-2-methylprop-2-yl 16-azido-hexadeca- 
7-enoate (11).
The Fmoc-protection of the amino group of (12) was carried out before the 
removal of the /-butyl group in order for it to be possible to carry out the reaction in dry 
organic solvent. The subsequent removal of the /er/-butyl group would not be 
complicated by the presence of the Fmoc group as the two groups are removed under 
completely different conditions. The Fmoc protection of (12) (Scheme 13) was achieved 
using fluorenylmethyl chloroformate and A-methylmorpholine in THF, following a 
procedure by Ayi et a l 15?. Following purification, (Z)-2-methylprop-2-yl 16-(9- 
fluorenylmethyloxy-carbonylamido)-hexadeca-7-enoate (13) was recovered in 89 % 
yield.
The removal of the /-butyl group of (13) was accomplished using TFA with 5 % 
water and 1,3-propanedithiol as the /-butyl cation scavenger (Scheme 13). This protocol 
was based on a procedure described by Wattanasin et al. I58. The target molecule, (Z) 16- 
(9-fluorenylmethyloxycarbonylamido)-hexadeca-7-enoic acid (14) was recovered in 95 % 
yield after purification by column chromatography. Compound (14) could then be 
incorporated into a peptide by any Fmoc-protecting group compatible coupling 
procedure. Analysis of compound (14) by NMR and MS showed that the compound had 
been successfully isolated. It was however not possible to obtain microanalysis results for 
the compound (14) that were within the permissible error limits, despite efforts to obtain a 
pure sample by re-crystallisation. The successful incorporation of the compound into a
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peptide further confirmed that the compound had been successfully made. High resolution 
MS further confirmed (14) had been made.
H,N \ f t
OtBu (12)
89%
FmocCl, 
NMM, 
THF.
O
c A -O N \ / s'
H
° tBU (13)
o
95% TFA, PDT,HJO.
Scheme 13. -  Synthesis of (Z)-2-methylprop-2-yl 16-(9-fluorenylmethyloxy- 
carbonylamido)-hexadeca-7-enoate (13) and subsequent deprotection to give (Z)-2- 
methylprop-2-yl 16-(9-fluorenylmethyloxycarbonylamido)-hexadeca-7-enoate (14).
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Scheme 14. -  Summary of synthetic route to (Z)-2-methylprop-2-yl 16-(9- 
fluorenylmethyloxycarbonylamido)-hexadeca-7-enoate (14).
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2.2.2 Synthesis of 20-(9-fluorenylmethyloxycarbonylamido)-
3,6,9,12,15,18-hexaoxaeicosanoic acid.
Although Boumrah et al. 159 had previously described a route for the synthesis of 
1 l-(9-fluorenylmethyloxycarbonylamido)-3,6,9-trioxaundecanoic acid, they had the 
advantage of using 2-(chloroethoxy)-ethoxy-ethanol as their starting material, a 
compound that although expensive is readily available. Unfortunately no such derivative 
of hexaethylene glycol was commercially available and so a procedure for mono- 
substituting hexaethylene glycol had to be used. The first step in the synthesis of 20-(9- 
fluorenyl-methyloxycarbonylamido)-3,6,9,12,15,18-hexaoxaeicosanoic acid was to 
mono-protect hexaethylene glycol.
HO
O
OH
HO
75%
(1 )
HO
O
5 OPx (15)
Scheme 15. -  Synthesis of 17-(9-phenyl-xanthen-9-yloxy)-3,6,9,12,15- 
pentaoxaheptadecan-l-ol (15).
The mono-protection of hexaethylene glycol was achieved by reacting a 11-fold 
excess of hexaethylene glycol with 9-phenylxanthen-9-ol (1) in the presence of 
toluenesulfonic acid monohydrate (Scheme 15), following a procedure by Gaffney & 
Reese 160. This afforded 17-(9-phenyl-xanthen-9-yloxy)-3,6,9,12,15-pentaoxahepta- 
decan-l-ol (15) in 75 % yield. The free hydroxyl group of (15) was then converted to an 
azido group employing the same method as in the synthesis of (11) (Trost et al. 155). 
Methanesulfonyl chloride was added to compound (15) in dichloromethane /pyridine to 
give the desired mesylate, which was then treated with a four equivalents of sodium azide 
in DMF, over three days (Scheme 16) to give 17-(9-phenyl-xanthen-9-yloxy)-l-azido-
3,6,9,12,15-pentaoxaheptadecane (16) in 85 % yield.
(15) 85 % over 
2  steps NaN3, DMF.
(16) PxO 3
Scheme 16. -  Synthesis of 17-(9-phenyl-xanthen-9-yloxy)-l-azido-3,6,9,12,15- 
pentaoxaheptadecane (16).
The removal of the 9-(9-phenyl)-xanthenyl group of (16) was accomplished using 
a 0.24 M solution of dichloroacetic acid in water/acetonitrile (9:1) (Scheme 17). Pyrrole 
was again used as a scavenger for the phenylxanthyl cation. The reason for carrying out 
the deprotection in the water/acetonitrile mixture was that once the reaction was 
complete, removal of the acetonitrile resulted in precipitation of the pyrrole- 
phenylxanthyl adduct. Thus the reaction only had to be filtered and then neutralised, the 
low boiling pyrrole that remained being removed under vacuum. Although after carrying 
out the deprotection, purification by column chromatography was not strictly necessary, 
17-azido-3,6,9,12,15-pentaoxaheptadecan-l-ol (17) was nevertheless purified by 
chromatography for the purpose of analysis, the yield after chromatography being 99 %.
a 2 CHC02 H, pyrrole, 
Hp/MeCN.
99%
(16) (17)
Scheme 17. -  Deprotection of 17-(9-phenyl-xanthen-9-yloxy)-l-azido-
3,6,9,12,15-pentaoxaheptadecane (16).
The next step in the synthesis was to try to introduce an ethanoic acid moiety at 
the hydroxy terminus of (17). This however initially proved quite difficult. One attempt at 
the synthesis of 20-azido-3,6,9,12,15,18-hexaoxaeicosanoic acid (19) involved reacting
(17) with bromoacetic acid and sodium hydride, following a procedure by Snider et al.
161. Another similar attempt involved treatment of (17) with bromoacetic acid ter/-butyl 
ester and sodium hydride, following a procedure by Svedhem et al. . Limited success 
was had with either of these methods and it was observed that the azido-group seemed not 
to withstand the conditions of these reactions. The *H NMR of the crude reaction 
products of both the reactions with sodium hydride showed much smaller signals for the 
protons on the carbon adjacent to the azido-group than would be expected, suggesting 
displacement of the azido-group rather than the bromo-group of bromoacetic acid.
Boumrah et al. 159 had succeeded in synthesising ethyl 2-{2-(2-(chloroethoxy)- 
ethoxy)-ethoxy}acetate from 2-(chloroethoxy)-ethoxyethanol in 85 % yield using ethyl 
diazoacetate and boron trifluoride etherate. Initial attempts to utilize this procedure for the 
synthesis of ethyl 20-azido-3,6,9,12,15,18-hexaoxaeicosanoate (18) (Scheme 18) proved 
low yielding (circa 30 %). However, after several further attempts, the conditions were 
optimised and the yield was increased to 54 %.
n 2 c h c o 2 b,
(17) (18)
Scheme 18. -  Synthesis of ethyl 20-azido-3,6,9,12,15,18-hexaoxaeicosanoate
(18).
Although (18) had been successfully synthesised, the yield of the reaction was 
nonetheless low and the chromatographic separation of the product from the many 
reaction by-products was very difficult. Therefore another method for introducing an 
ethanoic acid moiety at the hydroxy terminus of compound (17) was chosen.
Schwabacher et al. 163 succeeded in synthesising 17-azido-3,6,9,12,15-pentaoxahepta- 
decanoic acid from 14-azido-3,6,9,12-tetraoxatetradecan-l-ol using potassium 
bromoacetate and potassium hydroxide in DMF. They recovered the desired product in 91 
% yield without the need for purification by column chromatography. Using exactly the 
same procedure, 20-azido-3,6,9,12,15,18-hexaoxaeicosanoic acid (19) was synthesised 
from (17) in 73 % yield also without the need for purification by column chromatography 
(Scheme 19).
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Scheme 19. -  Synthesis of 20-azido-3,6,9,12,15,18-hexaoxaeicosanoic acid (19).
The hydrolysis of ester (18) to give 20-azido-3,6,9,12,15,18-hexaoxa-eicosanoic 
acid (19) was carried out using the same procedure employed by Boumrah et al. 159. 
Compound (18) was hydrolysed in a 1.0 M solution of lithium hydroxide in 66 % aqueous 
methanol (Scheme 20). The product was recovered in 99 % yield without any need for 
chromatographic purification.
1.0M LiOH,
H 0Y i ' 0 ' M r N'
o  o
(18) 99% (19)
Scheme 20. -  Synthesis of 20-azido-3,6,9,12,15,18-hexaoxaeicosanoic acid (19).
The reduction of the azido group of (19) was carried out using palladium on 
carbon as the catalyst (Scheme 21) following a procedure by Nair et al. 164 instead of the 
procedure of Foucaud & El Guemmout156. The former was the method of choice as the 
azido group was the only functional groups in compound (19) that could be reduced under 
Pd/C and H2 conditions. The catalytic hydrogenation was carried out in propan-2-ol and 
the product, 20-amino-3,6,9,12,15,18-hexaoxaeicosanoic acid (20) was recovered in 100 
% yield without any need for further purification.
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Scheme 21. -  Synthesis of 20-amino-3,6,9,12,15,18-hexaoxaeicosanoic acid (20).
Initial attempts to Fmoc-protect the amino group of (20) using fluorenylmethyl 
chloroformate and sodium hydrogencarbonate in dioxane/water, following a procedure by 
Stanley 165 resulted in very low yields (<20 %) of (20) obtained. Similarly Boumrah et al. 
159 utilised this procedure in their synthesis of 1 l-(9-fluorenylmethyloxycarbonylamido)-
3,6,9-trioxaundecanoic acid and although they obtained their target compound by this 
route, their published yield for this step was only 50 %. The use of fluorenylmethyl 
chloroformate and sodium bicarbonate in dioxane/water resulted in a slight increase (~5 
%) in the yield of 20-(9-fluorenylmethyloxycarbonylamido)- 3,6,9,12,15,18- 
hexaoxaeicosanoic acid (21). Ultimately addition of a further equivalent of 
fluorenylmethyl chloroformate and sodium bicarbonate in aliquots of 0.1 equivalents over 
a period of 8 hours improved the yield of (21) to 56 % (Scheme 22). The use of 9- 
fluorenylmethyl-jV-succinimidyl carbonate in place of fluorenylmethyl chloroformate did 
not improve the yield of (21).
FmocO, Na2 C03, 
dioxane/water.
Scheme 22. -  Synthesis of 20-(9-fluorenylmethyloxycarbonylamido)- 
3,6,9,12,15,18-hexaoxaeicosanoic acid (21).
Compound (21) could then be incorporated into a peptide by any Fmoc-protecting 
group compatible coupling procedure. Analysis of compound (21) by NMR and MS 
showed that the compound had been successfully isolated. It was however not possible to 
obtain microanalysis results for the compound (21) that were within the permissible error 
limits, despite efforts to obtain a pure sample. Since the product was a very viscous oil, it 
was most probable that solvent retention by the product was a factor. The incorporation of 
the compound into a peptide was easily realised, this being further confirmation that the 
compound had been successfully made.
The overall yield (over six steps) for the synthesis of 20-(9-fluorenyl- 
methyloxycarbonylamido)-3,6,9,12,15,18-hexaoxaeicosanoic acid (21) was 26 %
(Scheme 23). This yield was disappointingly low since for solid-phase peptide synthesis a 
four-fold excess of Fmoc-amino acid was required for every coupling step. Therefore a 
costly 3 equivalents of the Fmoc-amino acid would be ‘wasted’ each time it was 
incorporated into a peptide.
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Scheme 23. - Summary of synthetic route to 20-(9-fluorenylmethyloxy- 
carbonylamido)- 3,6,9,12,15,18-hexaoxaeicosanoic acid (21).
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2.2.3 Synthesis of ll-(9-fluorenylmethyloxycarbonyl- 
amido)-3,6,9-trioxaundecanoic acid.
The overall yield for the synthesis of 20-(9-fluorenylmethyloxy-carbonylamido)- 
3,6,9,12,15,18-hexaoxaeicosanoic acid (21) was quite low (26 % over six steps). The 
lowest of these steps was the final Fmoc protection of the amino acid (20) for which the 
yield was at best 56 %. This low yield was unexpected, as (20), like many amino acids, 
was very water-soluble. One possible explanation was that (20) chelated to metal ions in 
solution although this was difficult to accept as the Fmoc-protection was carried out in the 
presence of sodium salts and sodium does not normally form chelates. Nevertheless the 
concern was that if it were desirable to synthesise longer versions of (21), the longer 
amino acids might Fmoc-protect in even poorer yield.
An alternative route was sought for the synthesis of Fmoc-protected amino-PEG 
acids, which would avoid Fmoc-protection of a free amino acid. One alternative was to 
protect the carboxylic acid function of the amino-PEG acid prior to Fmoc-protection thus 
allowing the reaction to be carried out in dry, aprotic organic solvent. The only suitable 
protecting group was the tert-butyl group as it is stable to the basic conditions required 
for Fmoc-protection and can be removed in the presence of the Fmoc group. Attempts to 
protect the carboxylic acid function of (20) using perchloric acid and ter/-butyl acetate 
were unsuccessful; the tert-butyl group had to be introduced earlier in the synthesis. 
Thumshim et al. 147 accomplished this by reacting a PEG-diol with te/Y-butyl 
bromoacetate in the presence of boron trifluoride diethyl etherate but their yield for this 
step was unpublished. When the reaction of hexaethylene glycol with /er/-butyl 
diazoacetate in the presence of boron trifluoride diethyl etherate (Scheme 24) was 
attempted following the procedure by Thumshim et al. 147, the desired product was indeed 
recovered. However this product appeared, as determined by mass spectroscopy, to be 
contaminated with two other products that possessed almost identical Rf values on TLC 
and so could not be distinguished from the target compound (these products could not be 
observed by NMR as would be expected). These by-products were inseparable from the 
desired product by standard column chromatography and it was envisaged that for longer 
PEG chains such as nonaethylene glycol and dodecaethylene glycol, the formation of 
these kinds of by-products could be an even greater problem.
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Scheme 24. - Reaction of hexaethylene glycol with tert-butyl diazoacetate
following the procedure of Thumshim et al. 147
Another problem with Fmoc-protecting amino-PEG acids was the possibility of 
the formation of Fmoc-protected peptide by-products (dipeptides, tripeptides etc.). The 
formation of Fmoc-protected peptide by-products is known to occur (Boumrah et al. 159) 
when the Fmoc-protection of certain amino acids such as 11-aminoundecanoic acid is 
attempted (Scheme 25). Although generally only small amounts of Fmoc-protected 
peptide by-products are formed, mainly the Fmoc-protected dipeptide, it is nevertheless 
difficult to separate these from the desired Fmoc-amino acid by standard chromatography. 
These can be easily seen by mass spectroscopy although they are not always so apparent 
by NMR. Occasionally the formation of the Fmoc-dipeptide is so considerable that it can 
even be clearly seen by NMR. In the case of the Fmoc-protection of longer amino-PEG 
acids (i.e. 26-amino-3,6,9,12,15,18,21,24-octaoxahexaeicosanoic acid, 35-amino- 
3,6,9,12,15,18,21,24,27,30,33-undecaoxa-pentatriacontanoic acid) this was another 
problem that could have been encountered.
Dioxane, Yip, 
Na2 C03
u
FmocHN FmocHN
Minor
Scheme 25. -  Formation of by-products during direct Fmoc-protection of 11- 
aminoundecanoic acid as reported by Boumrah et al. 159.
Ultimately no satisfactory routes to Fmoc-protected amino-PEG acids could be 
found in the literature. It was apparent from a publication by Maguire et a l 166 that Fmoc- 
amino-alcohols were easily prepared from corresponding amino-alcohols in very good 
yields. One possibility therefore was to introduce the Fmoc-group before the carboxylic 
acid moiety. This could obviously not be achieved by any coupling to a molecule that 
already had a carboxylic acid moiety as had been done before, since the Fmoc-group 
would not withstand the coupling reaction conditions. However the carboxylic acid 
function could be derived from the hydroxyl terminus of the PEG-chain. As is well 
known, many methods exist in literature for oxidising primary alcohols to their 
corresponding carboxylic acids. However fewer procedures have been reported in which 
primary alcohols were oxidised to their carboxylic acids in the presence of Fmoc- 
protected amines. Even fewer procedures could be found in literature in which PEG- 
alcohols were oxidised to their carboxylic acids in the presence of other functional 
groups. A number of procedures (e.g. Palian et al. 167, Timmers et al. 168, LePlae et al. 169) 
detailed the oxidation of primary alcohols in the presence of Fmoc-protected amines 
using TEMPO and sodium hypochlorite. However this method would have been of no use 
as Tessier et al. 170 had conclusively shown that treatment of PEG-chains with sodium
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hypochlorite resulted in extensive ether linkage cleavage at the same time as oxidation. 
The oxidation of a hydroxyl group of a Fmoc-amino-PEG alcohol was however further 
complicated because of the likelihood of PEG chain ether linkage cleavage by Lewis 
acids, many oxidising agents being Lewis acids. It was unclear which oxidising agents 
could effect the cleavage of PEG-chain ether linkages and so it was necessary to carry out 
test reactions. For this purpose 1 l-phenylmethyloxy-3,6,9-trioxaundecan-l-ol (22) was 
prepared by reacting tetraethylene glycol with benzyl chloride in the presence of sodium 
hydride and tetrabutylammonium bromide (Scheme 26).
Scheme 26. -  Preparation of 1 l-phenylmethyloxy-3,6,9-trioxaundecan-l-ol (22). 
Oxidation procedures that were predicted to be compatible with the Fmoc
171 177protecting group were tested on (22). Oxidation with potassium dichromate ,
PEG-chain cleavage (as determined by mass spectroscopy and NMR) or afforded the 
desired product in low yield. Oxidation with sodium hypochlorite was already known to 
be unsuitable and so was not attempted. Oxidation of (22) with chromium trioxide in
cleavage could be detected either by mass spectroscopy or by NMR. Further investigation 
of this oxidation reaction using an excess of chromium trioxide and/or an excess of 
sulphuric acid (pH not varied) further confirmed that PEG-chain ether cleavage did not 
occur with this method. The yield for the oxidation of (51) to 1 l-phenylmethyloxy-3,6,9- 
trioxaundecanoic acid (23) was 84 % (Scheme 27).
Cl
+
99 % NaH, TBABF, THF
(22)
potassium permanganate 173’174’175 and silver (II) oxide 176 were tested but all either caused
sulphuric and acetic acid (Kiliani reagent177) was tested and initially no PEG-chain
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Scheme 27. -  Synthesis of 1 l-phenylmethyloxy-3,6,9-trioxaundecanoic acid (23).
The first Fmoc-amino-PEG acid to be synthesised by means of oxidation with 
chromium trioxide was 1 l-(9-fluorenylmethyloxycarbonylamido)-3,6,9-trioxaundecanoic 
acid. This Fmoc-protected amino acid had already been prepared by Boumrah et al. 159 by 
a five-step synthesis but the overall yield was only 37 % largely due to the poor yield of 
the final step.
Scheme 28. -  Synthesis of 1 l-triphenylmethyloxy-3,6,9-trioxaundecan-l-ol (24).
The starting material for the synthesis, tetraethylene glycol is commercially 
available and inexpensive. The first step in the synthesis was the mono-protection of this 
diol (Scheme 28). The trityl-protecting group was chosen for this primarily because of the 
ease of its removal with low concentrations of trifluoroacetic acid to which Fmoc is 
stable. Furthermore, the product, 1 l-triphenylmethyloxy-3,6,9-trioxaundecan-l-ol (24) 
could be easily separated from the large excess of starting material that needed to be used 
to achieve mono-protection by means of a simple work-up. Traces of the di-protected by­
product on the other hand could be easily separated by column chromatography. The
presence of the trityl group in (24) imparted a degree of solubility in organic solvents that 
also made subsequent work-ups more convenient.
TrtO '
91 %
(25) TrtO
i) M sa, B 3N , DCM 
ii) NaN3, DMF
(24)
Scheme 29. -  Synthesis of 1 l-triphenylmethyloxy-l-azido-3,6,9-trioxaundecane
(25).
1 l-Triphenylmethyloxy-3,6,9-trioxaundecan-l-ol (24) was then converted to 11- 
triphenylmethyloxy-l-azido-3,6,9-trioxaundecane (25) using the same procedure as for 
the synthesis of compounds (11) and (16) (Trost et al. 155). Using this reliable procedure
(25) was obtained in 91 % yield (Scheme 29).
Scheme 30. -  Reduction of 11 -triphenylmethyloxy-1 -azido-3,6,9-trioxaundecane
(26).
11-Triphenylmethyloxy-l-azido-3,6,9-trioxaundecane (25) was reduced to 11- 
triphenylmethyloxy-1-amino-3,6,9-trioxaundecane (26) employing the procedure adapted 
from the method published by Foucaud & El Guemmout156, as reduction by 
hydrogenation was not possible in the presence of the trityl group (Scheme 30). 
Purification of (26) was facile by column chromatography, with a yield of 96 % and the
problem of contamination of the isolated product with traces of triphenylphosphine oxide 
was not encountered.
FmooCI, NMM, DCM
NHFmoc
Scheme 31. -  Fmoc protection of 11-triphenylmethyloxy-1-amino-3,6,9- 
trioxaundecane (26).
At this stage it was decided to Fmoc-protect 11-triphenylmethyloxy-1-amino-
3,6,9-trioxaundecane (26) since removal of the trityl group at this stage would furnish 11- 
amino-3,6,9-trioxaundecan-l-ol. This amino alcohol would be difficult to recover from 
any aqueous solution and would also be difficult to isolate by column chromatography. 
Fmoc protection of (26) was carried out under non-aqueous conditions, following a 
procedure by Jackson 178. Thus compound (26) was treated with fluorenylmethyl 
chloroformate in the presence of A-methylmorpholine in dichloromethane (Scheme 31).
11 -T riphenylmethyloxy-1 -(9-fluorenylmethyloxy-carbonylamido)-3,6,9-trioxaundecane
(27) was recovered in excellent yield (95 %) after easy purification by chromatography.
NHFmoc
i) TFA, DCM, B3 SH 
\  ii) NaHC03  aq.
NHFmoc
Scheme 32. -  Deprotection of 11-triphenylmethyloxy-1-amino-3,6,9- 
trioxaundecane (27).
Removal of the trityl group from (27) was carried out with 0.1 M trifluoroacetic 
acid in dichloromethane, triethylsilane being added as the cation scavenger (Scheme 32). 
However once the deprotection had gone to completion, the reaction could not be 
concentrated in vacuo immediately as this would have lead to the formation of a certain 
amount of the trifluoroacetic acid ester. Clearly it would not be possible to simply treat 
the reaction with aqueous base or an amine to remove the trifluoroacetate group. In order 
to avoid the formation of trifluoroacetic acid 1 l-(9-fluorenyl-methyloxycarbonylamido)-
3,6,9-trioxaundecanyl ester, once deprotection was complete the reaction was carefully 
neutralised with aqueous sodium hydrogencarbonate prior to concentrating in vacuo. 11 - 
(9-Fluorenylmethyloxy-carbonylamido)-3,6,9-trioxaundecan-l-ol (28) and the trityl by­
product were then easily separated by column chromatography, (28) being isolated in 94 
% yield.
NHFmoc
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Scheme 33. -  Chromium trioxide and aqueous sulphuric/acetic acid oxidation.
The final step of the synthesis of 1 l-(9-fluorenylmethyloxycarbonylamido)-3,6,9- 
trioxaundecanoic acid (29) was the oxidation of the hydroxy-terminus of (28) to the 
corresponding carboxylic acid. Chromium trioxide in sulphuric and acetic acid had 
already been determined to be suitable for the oxidation of PEG-alcohols and according 
to literature the Fmoc protecting group should have been stable to oxidation with this 
reagent. Initial attempts to convert (28) to (29) although successful, were low yielding. 
The first oxidation attempted involved slow addition of an aqueous solution of chromium 
trioxide (3 equiv.) in 1.5 M sulphuric acid (9 equiv.) to (28) in an aqueous acetic acid (1:1 
water/acid) (Scheme 33), the high percentage of acetic acid being necessary to dissolve
(28) in aqueous sulphuric acid. The desired product, (29) was isolated in only 34 % yield 
at best by this method and no starting material was recovered. It was also clear that to
some extent Fmoc deprotection had occurred since deprotection by-products could be 
seen by TLC analysis of the reaction.
Changing the reaction co-solvent from acetic acid to acetone marginally increased 
the yield of the oxidation reaction to 41 % at best. Compound (28) was dissolved in 1.5 M 
sulphuric acid (9 equiv.) and acetone (1:1 volume ratio)(Scheme 34) and as before an 
aqueous solution of chromium trioxide (3 equiv.) was slowly added. With this procedure 
around 10 % starting material was also recovered, however it was observed that again 
some Fmoc deprotection had occurred.
NHFmoc
NHFmoc
Scheme 34. -  Chromium trioxide and aqueous sulphuric acid/acetone
oxidation.
The Bowman 179 (Fieser’s reagent180) oxidation was also tried on (28) and a 
significant improvement in the yield of (29) was obtained. The procedure involved 
dissolving (28) in anhydrous acetic acid and then adding a solution of chromium trioxide 
in anhydrous acetic acid to this solution.
HO'
O. ^O,
O' “NHFmoc (28)
(29)
57%
HO NHFmoc
Scheme 35. -  Chromium trioxide and acetic acid oxidation.
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After several attempts at the Bowman oxidation procedure, an optimised yield 
of 57 % was achieved (Scheme 35). The reaction however had the disadvantage of being 
relatively slow, taking up to one week to reach completion (no starting material 
remaining) and of being inconvenient to work up.
1 O 1
Finally the Jones oxidation was attempted on compound (28). This oxidation 
method had been successfully applied to the conversion of PEG-alcohols possessing 
various functional groups to their corresponding carboxylic acids. Examples of this type 
of oxidation include benzoic acid 2-(2-hydroxyethoxy)-ethyl ester 182 and 8-phthalimido-
3,6-dioxaoctan-l-ol183. Furthermore, the Jones oxidation had also been successfully used 
in the conversion of other primary alcohols to carboxylic acids in the presence of Fmoc-
1 84protected amines. Examples of this can be found in publications by Bertozzi et a l , 
Virta et a l 185, Ohnishi et a l 186 and Spino et a l 187.
The procedure for the oxidation of (28) to (29) in this case involved the very slow 
addition of a solution of chromium trioxide (3 equiv.) in sulphuric acid (1.5 M, 9 equiv.) 
to a dilute solution of (28) in acetone (circa 0.05 M) (Scheme 36). Initially yields of 
around 60 % were obtained without any optimisation. Most modifications of this 
procedure had little effect on the yield. The highest yield of 68 % was obtained when the 
oxidising agent was added over 12 hours, with a reaction time of 24 hours.
NHFmoc
181Scheme 36. -  Jones oxidation of 1 l-(9-fluorenylmethyloxycarbonylamido)-
3,6,9-trioxaundecan-l-ol (28).
With the yield for the final step being a reasonable 68 %, the overall yield of the 
synthesis of 1 l-(9-fluorenylmethyloxycarbonylamido)-3,6,9-trioxaundecanoic acid (29) 
over six steps was 51 %. This was a marked improvement compared with the synthesis of 
20-(9-fluorenylmethyloxycarbonylamido)-3,6,9,12,15,18-hexaoxaeicosanoic acid (21) for
which the yield of 26 % over 6 steps was achieved. This synthetic route was also an
1 SSimprovement over the routes of Dekker et al. (11.3 % over 6 steps) and Boumrah et al 
159 (37 % over 5 steps) in their syntheses of 1 l-(9-fluorenylmethyloxycarbonylamido)-
3.6.9-trioxaundecanoic acid. Furthermore, the route to (29) avoided the ether coupling 
step with boron trifluoride used by the aforementioned and so throughout the synthesis of
(29) no detectable PEG-chain cleavage by-products were produced that would have been 
difficult to separate from the desired products, especially when synthesising (29) on large 
scale. This was essential, as the purpose of synthesising Fmoc-amino-PEG acids was to 
incorporate amino-PEG acid residues of specific length into peptides; even by HPLC it 
would have been near impossible to separate a 28-residue peptide containing a 11-amino-
3.6.9-trioxaundecanoic acid residue from a 28-residue peptide containing a 8-amino-3,6- 
dioxaoctanoic acid residue.
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Scheme 37. -  Summary of synthetic route to 1 l-(9-fluorenylmethyloxy- 
carbonylamido)-3,6,9-trioxaundecanoic acid (29).
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2.2.4 Synthesis of 26-(9-fluorenylmethyloxycarbonyl- 
amido)-3,6,9,12,15,18,21,24-octaoxahexaeicosanoic acid.
Following the success of the synthesis 1 l-(9-fluorenylmethyloxy-carbonylamido)-
3,6,9-trioxaundecanoic acid (29) by the route described earlier, it was envisaged that 26- 
(9-fluorenylmethyloxycarbonylamido)-3,6,9,12,15,18,21,24-octaoxahexaeicosanoic acid 
could be synthesised by the same oxidation method. However unlike tetraethylene glycol 
and hexaethylene glycol, nonaethylene glycol was not commercially available and so 
needed to be synthesised. One possibility was to prepare the nonaethylene glycol 
structure by coupling commercially available hexaethylene glycol and triethylene glycol. 
The disadvantage of this was the relatively high cost of hexaethylene glycol as initial 
mono-protection required the use of a large excess of the diol. The cost of hexaethylene 
glycol was sufficiently high to make it necessary to recover unreacted starting material, 
which was a laborious process and did not result in complete recovery. Another 
alternative was to couple three triethylene glycol units to give the desired nonaethylene 
glycol structure. The low cost of triethylene glycol made this the more suitable route 
despite the fact that the synthesis would require several more steps (Scheme 38).
Scheme 38. -  Possible routes to nonaethylene glycol derivatives.
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The first attempt at the synthesis of 26-(9-fluorenylmethyloxycarbonyl-amido)-
3,6,9,12,15,18,21,24-octaoxahexaeicosanoic acid entailed a convergent synthesis of three 
triethylene glycol derivatives (Scheme 39). The first two triethylene glycol units were 
coupled to make a hexaethylene glycol unit and this was then coupled to a triethylene 
glycol unit already possessing a protected amine moiety to give a protected amino-PEG 
alcohol.
Scheme 39. -  Convergent synthesis of nonaethylene glycol derivative.
The idea behind the convergent synthesis was to introduce an amine moiety at the 
stage of formation of the nonaethylene glycol unit and not after, thus reducing the number 
of synthetic steps after formation of the nonaethylene glycol unit. The protecting group 
strategy for the synthesis would have to be such that all groups would be stable to the 
coupling conditions. Furthermore, one of the protecting groups on the first unit formed 
would have to be selectively removable, whilst the protecting groups on the second unit 
would have to be removable under the same conditions. With this in mind O-trityl and O- 
benzyl protection were chosen for the formation of the first unit, whilst O-benzyl and 
N, Wdibenzyl protection were chosen for the formation of the second unit. In the former 
case a trityl group could be easily removed in the presence of a benzyl group and in the 
latter case both O- and vV-benzyl groups would be removed simultaneously by catalytic 
hydrogenation.
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Scheme 40. -  Synthesis of 8-triphenylmethyloxy-3,6-dioxaoctyl methanesulfonate
(31).
8-Triphenylmethyloxy-3,6-dioxaoctyl methanesulfonate (31) was prepared by first 
reacting a large excess of triethylene glycol with triphenylmethyl chloride to give 8- 
triphenylmethyloxy-3,6-dioxaoctan-l-ol (30) in 100 % yield, and then converting this to 
(31) in 99.8 % yield by reacting with methanesulfonyl chloride (Scheme 40).
TrtO'
.0 .
“O'
.OMs (31)
85 % \  NaN3, DMF
TrtO'
.0.
‘O' N3 (32)
91 % \  PPh3, THF, K^O
(33) TrtO'
.0 .
O'
.NH.
Scheme 41. - Synthesis of 8-triphenylmethyloxy-l-amino-3,6-ethoxaoctane (33).
Treatment of (31) with sodium azide in dimethylformamide gave 28- 
triphenylmethyloxy-l-azido-3,6-dioxaoctane (32) in 85 % yield (Scheme 41). The
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reduction of (32) to 8-triphenylmethyloxy-1 -amino-3,6-ethoxaoctane (33) was 
accomplished using the procedure adapted from the method published by Foucaud & El 
Guemmout156, with a yield of 91 % (Scheme 41). Compound (31) was also used to 
prepare S-A^N-dibenzylamino^b-dioxaoctan-l-ol (35) (Scheme 42).
Scheme 42. -  Synthesis of 8-A^,A^-dibenzylamino-3,6-dioxaoctan-l-ol (35).
7V,7V-Di-benzylation of (33) by stirring with benzyl bromide and potassium 
carbonate in dimethylformamide at 90°C afforded A^A^-dibenzyl-8-triphenylmethyloxy-
3,6-dioxa-l-octanamine (34) in 80 % yield (Scheme 44). Removal of the trityl group of
(34) was achieved using 0.1 M trifluoroacetic acid in dichloromethane with triethylsilane 
as the cation scavenger followed by treatment with saturated aqueous sodium bicarbonate 
to give 8-A^ ,Ar-dibenzylamino-3,6-dioxaoctan-l-ol (35) (Scheme 42).
Finally, 8-phenylmethyloxy-3,6-dioxaoctan-l-ol (36) was prepared in 99 % yield 
by the same method as for the preparation of 1 l-phenylmethyloxy-3,6,9-trioxaundecan-l- 
ol (22) (Scheme 43). The sodium salt of compound (36) was then reacted with compound 
(31) to give 1-triphenylmethyloxy-17-phenylmethyloxy-3,6,9,l2,15-pentaoxaheptadecane 
(37) (Scheme 43). Initially tetrahydrofuran was used as the solvent for this reaction but on 
changing to dimethylformamide higher yields were obtained (62 % —> 74 %).
Scheme 43. -  Synthesis of 1 -triphenylmethyloxy-17-phenylmethyloxy-
3,6,9,12,15-pentaoxaheptadecane (37).
1 -Triphenylmethyloxy-17-phenylmethyloxy-3,6,9,12,15-pentaoxaheptadecane 
(37) was then deprotected by the standard trifluoroacetic acid procedure (Scheme 44). 
However, instead of separating the trityl by-product from the desired product by 
chromatography, purification could be conveniently achieved by partitioning between 
water and hexane. The poor solubility of 17-phenylmethyloxy-3,6,9,12,15- 
pentaoxaheptadecan-l-ol (38) in hexane and good solubility in water meant that this 
method of purification could be employed. In the subsequent step (38) had to be coupled 
to (35) in the same manner as (36) was coupled to (31) and this meant that either (38) or
(35) had to be converted to the methanesulfonate. It was decided to convert (35) to the 
methanesulfonate as this product would be less water soluble and therefore the mesylation 
reaction would be easier to work up. The methanesulfonate of (35) was reacted with the 
sodium salt of compound (38) in dimethylformamide to give 26-dibenzylamino-l- 
phenylmethyloxy-3,6,9,12,15,18,21,24-octaoxahexaeicosane (39) in 64 % yield (Scheme
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Scheme 44. -  Synthesis of 26-dibenzylamino-l-phenylmethyloxy-
3,6,9,12,15,18,21,24-octaoxahexaeicosane (39).
The removal of the benzyl protecting groups of (39) was attempted first with 
palladium on carbon as the catalyst. The reaction was carried out in tetrahydrofuran with 
hydrogen at atmospheric pressure. After several days stirring under hydrogen, no starting 
material could be detected by TLC and so the reaction was filtered and concentrated. 
Analysis of the reaction showed however that the only product that had formed was 26- 
phenylmethyloxy-l-amino-3,6,9,12,15,18,21,24-octaoxahexaeicosane (40). Attempts to 
remove the 0-benzyl protecting group by stirring with palladium on carbon under 
hydrogen at atmospheric pressure over a period of three weeks proved futile and only 26- 
phenylmethyloxy-1 -amino-3,6,9,12,15,18,21,24-octaoxahexa-eicosane (40) was 
recovered. Hydrogenation at higher pressure (150 p.s.i.) as well as changing the catalyst 
to palladium hydroxide or Raney nickel were also tried but with no success. Transfer 
hydrogenation with cyclohexene or formic acid as the hydrogen source was finally tried 
but again to no avail. It was apparent that for some reason the removal of the 0-benzyl 
group by hydrogenation was being inhibited.
Investigation in literature of this phenomenon revealed that indeed the presence of
1 RQnon-aromatic amines inhibited 0-benzyl hydrogenolysis. Czech and Bartsch had 
observed this during one of their investigations of preparative routes to aza crown ethers.
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On trying to deprotect 13-benzyl-5-benzyloxymethyl-l,4,7,10-tetraoxa-13-aza- 
cyclopentadecane they noticed that the only product recovered was 5-benzyloxymethyl- 
l,4,7,10-tetraoxa-13-aza-cyclopentadecane. Their further investigations confirmed that 
only non-aromatic amines specifically inhibited O-debenzylation of alkyl benzyl ethers. It 
was clear from this publication that 26-hydroxyl-1-amino-3,6,9,12,15,18,21,24- 
octaoxahexaeicosane (41) could not be obtained from (39) by catalytic hydrogenation.
The complete debenzylation of (39) could only be achieved by dissolving metal reduction 
and the problem with this method would be that the resulting amino-PEG alcohol would 
be impossible to recover from an aqueous solution. The next step after formation of the 
amino-PEG alcohol would have been Fmoc-protection which it was envisaged would be 
carried out under non-aqueous conditions as in the synthesis of (27). Debenzylation by 
this method was therefore not acceptable.
An alternative route to 26-hydroxyl-1-amino-3,6,9,12,15,18,21,24- 
octaoxahexaeicosane (41) was desired which would not require any aqueous work-up in 
the final preparation of (41). To change the hydroxyl protecting group to a group other 
than benzyl was not really an option. There were no other suitable protecting groups that 
would not only be as robust (stable to the acid, base and nucleophiles employed in the 
synthesis), but could also be removed without the use of Lewis acids and at the same time 
would be inexpensive. Protection of the amine function with groups other than benzyl that 
would be stable to hydrogenolysis and thus would inhibit the effect of the amine on O- 
benzyl hydrogenolysis was also a possibility, but this would have required an extra de­
protection step after O-debenzylation.
3
X = cydic or acydic non-aromatic HCL .NH2
Scheme 45. -  Simultaneous O-debenzylation and azide reduction by catalytic 
hydrogenation of cyclic or acyclic O-benzyl alkyl azides.
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Several groups had succeeded in preparing amino alcohols from O-benzyl azides 
using both catalytic hydrogenation as well as catalytic transfer hydrogenation in good 
yields (Effenberger et al. 19°, Kuzuhara et al. 191 ’192, Tadanier et al. I93, Hasegawa et al.
194) (Scheme 45). More notably, Gartiser et al. 195,196 had published a paper in which they 
detailed their synthesis of amino-PEG-alcohols via O-benzyl-PEG-azides for the 
preparation of non-ionic polyfluorinated surfactants (Scheme 46). However, Svedhem et 
al. 162 had reported that they had followed the procedure of Gartiser et al. 195, but in their 
hands it had failed to work. It was uncertain therefore whether catalytic hydrogenation in 
the presence of palladium would effect the deprotection and reduction of the O-benzyl- 
PEG-azide in question, so the only recourse was to try the procedure.
n = 4, 3, 2,1
•cx
HO' n O'
.NH,
Scheme 46. -  Hydrogenolysis of O-benzyl-PEG-azides by Gartiser et al. 195
In order to carry out the aforementioned reaction 26-phenylmethyloxy-l-azido-
3.6.9.12.15.18.21.24-octaoxahexaeicosane (44) had to be prepared (Scheme 47). This was 
conveniently achieved using some of the compounds that had previously been prepared. 
Addition of 8-triphenylmethyloxy-3,6-dioxaoctyl methanesulfonate (31) to the sodium 
salt of 17-phenylmethyloxy-3,6,9,12,15-pentaoxaheptadecan-l-ol (38) in 
dimethylformamide afforded 1 -triphenylmethyloxy-26-phenylmethyloxy-
3.6.9.12.15.18.21.24-octaoxahexaeicosane (42) in 74 % yield. Compound (42) was then 
deprotected in the same manner as compound (37) to give 26-phenylmethyloxy-
3.6.9.12.15.18.21.24-octaoxahexaeicosan-l-ol (43) quantitatively. Compound (43) was 
converted to the methanesulfonate, which was subsequently treated with sodium azide in 
dimethylformamide. Thus 26-phenylmethyloxy-1 -azido-3,6,9,12,15,18,21,24- 
octaoxahexaeicosane (44) was prepared in good yield by the same procedure as for the 
preparation of compounds (25) and (32).
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Scheme 47. -  Synthesis of 26-phenylmethyloxy-l-azido-3,6,9,12,15,18,21,24- 
octaoxahexaeicosane (44).
The hydrogenolysis of (44) was first tried following the procedure of Kuzuhara et 
al. 191 (Scheme 48); (44) was stirred with palladium on carbon in methanol, under 
hydrogen at atmospheric pressure. After several days, when no further change could be 
seen by TLC the reaction was filtered and concentrated in vacuo. Analysis of the material 
recovered revealed that it was largely composed of 26-phenylmethyloxy-
3,6,9,12,15,18,21,24-octaoxahexaeicosamine (40) with only a trace of 26-hydroxyl-1- 
amino-3,6,9,12,15,18,21,24-octaoxahexaeicosane (41).
Hj, Pd/Q MeOH
BnO
N H 2 (40) - Major
HO N H 2  (41)-Minor
Scheme 48. -  Attempted hydrogenation/deprotection of 26-phenylmethyloxy-1 - 
azido-3,6,9,12,15,18,21,24-octaoxahexaeicosane (44) following the procedure of 
Kuzuhara et al. 191.
The method of Hasegawa et al. 194 was then tried (Scheme 49); compound (44) 
with two equivalents of acetic acid was stirred with palladium on carbon in methanol, 
under hydrogen at atmospheric pressure. After one week, when no further change could 
be seen by TLC the reaction was filtered and concentrated in vacuo. By this method 
however both 26-phenylmethyloxy-3,6,9,12,15,18,21,24-octaoxahexa-eicosamine (40) 
and 26-hydroxyl-l-amino-3,6,9,12,15,18,21,24-octaoxahexaeicosane (41) were obtained 
but unfortunately in 73 % and 20 % yields respectively.
(44)
Hj, Pti/C, MeOH
(40) - 73 %
(41) - 20 %
Scheme 49. - Attempted hydrogenation/deprotection of (44) following the
procedure of Hasegawa et al. 194.
The catalytic transfer hydrogenation procedure of Gartiser et al. 195)196 was also 
attempted but only (40) was recovered. Catalytic hydrogenation with palladium on carbon 
and ethanol as the solvent was also attempted at increased hydrogen pressure (150 p.s.i.) 
but this also failed. Finally the hydrogenation was repeated but this time using both 
palladium on carbon and Raney nickel. The procedure involved stirring (44) with 
palladium on carbon in methanol, under hydrogen at atmospheric pressure for 24 hours, 
then adding more Pd/C and leaving to stir for another 24 hours. After 48 hours, Raney 
nickel and 1.25 equivalents of acetic acid was added and the reaction was left to stir under 
hydrogen at atmospheric pressure for 5 days, then after one week the reaction was filtered 
and concentrated in vacuo (Scheme 50).
B nO ”
(44)
Pd/C, Hj, MeOH 
24 hrs
+ Pd/C 
24 hrs
+ Raney Ni, AcOH 
X 5 days
HO'
-O,
7 o '
, n h 2  (41)
Scheme 50. -  Preparation of 26-hydroxyl-1-amino-3,6,9,12,15,18,21,24- 
octaoxahexaeicosane (41).
NMR analysis of the reaction showed that the desired compound, 26-hydroxyl-1- 
amino-3,6,9,12,15,18,21,24-octaoxahexaeicosane (41) had been recovered. However the 
isolated material was dark blue in colour and showed impurities. MS analysis of the 
compound showed the desired product to be present but it also showed a significantly 
large peak at m/z = 471 which corresponded to M+Ni. The colour of the compound, the 
yield in excess of 100 % and MS signal corresponding to M+Ni all indicated that the 
amino-PEG-alcohol had probably complexed to nickel. A flame test of the recovered 
compound subsequently confirmed this. Treatment with ammonia, amines, EDTA or
strong acid (HC1) would not have worked, as it would not have been possible to isolate 
(41) after treatment because of its poor solubility in most organic solvents and good 
solubility in water. Initial attempts to purify 26-hydroxyl-1-amino-3,6,9,12,15,18,21,24- 
octaoxahexaeicosane (41) by column chromatography using chloroform/methanol/ 
aqueous ammonia were unsuccessful and only the same dark blue oil was recovered. 
Subsequent attempts to purify the compound by column chromatography eluting with 
chloroform and methanol saturated with ammonia (80:20) gave a colourless oil. A flame 
test indicated the absence of nickel, however the yield was only 40 %. Fmoc-protection of 
the crude compound (no chromatography) by addition of a solution of fluorenylmethyl 
chloroformate in acetone to the compound dissolved in water/acetone also gave a low 
yield of 26-(9-fluorenylmethyloxycarbonylamido)-3,6,9,12,15,18,21,24- 
octaoxahexaeicosan-l-ol (45) (< 40 %). This disappointingly low yield in the penultimate 
step of the synthesis was difficult to accept.
Not isolated
FmocCI, NaHC03, 
\  Dioxane/water.
8 8  % over 2  steps
NHFmoc
Scheme 5 1 .-  Synthesis of 26-(9-fluorenylmethyloxycarbonylamido)-
3,6,9,12,15,18,21,24-octaoxahexaeicosan-1 -ol (45).
As a last resort it was decided to attempt to prepare (45) from (40) which had been 
isolated in place of the desired product by hydrogenolysis of (41). The O-debenzylation 
of (40) would have to be carried out using the Birch reduction and the intermediate would 
not be isolated but would be directly Fmoc-protected to give (45) (Scheme 51). O-
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Debenzylation of (40) was carried out using a procedure adapted from that published by 
Bertozzi et al. 197; (40) was dissolved in tetrahydrofuran and ammonia at -78°C and 
sodium was added until a blue colour persisted. The reaction was then quenched with 
methanol rather than saturated methanolic ammonium chloride. Once the reaction had 
been concentrated in vacuo, it was kept under high vacuum for 24 hours to ensure that as 
little ammonia as possible was present in the remaining residue. After adjusting the pH of 
the solution of this residue in water/dioxane (1:1), the residue was treated with 
fluorenylmethyl chloroformate in dioxane to give (45) in 88 % yield.
Scheme 52. -  Staudinger reduction of 26-phenylmethyloxy-l-azido-
3.6.9.12.15.18.21.24-octaoxahexaeicosane (44).
Since more of compound (40) was required, it was decided that instead of 
preparing it from 26-dibenzylamino-l-phenylmethyloxy-3,6,9,12,15,18,21,24- 
octaoxahexaeicosane (39), it would be more convenient to prepare it from 26- 
phenylmethyloxy-l-azido-3,6,9,12,15,18,21,24-octaoxahexaeicosane (44) by the method 
already described for compounds (33) and (26) (Foucaud & El Guemmout156) (Scheme 
52).
The oxidation of 26-(9-fluorenylmethyloxycarbonylamido)-3,6,9,12,15,18,21,24- 
octaoxahexaeicosan-1-ol (45) to 26-(9-fluorenylmethyloxy-carbonylamido)-
3.6.9.12.15.18.21.24-octaoxahexaeicosanoic acid (46) was achieved using the Jones 
oxidation procedure already previously described (Scheme 53). As with the oxidation of 
(28), 26-(9-fluorenylmethyloxycarbonylamido)-3,6,9,12,15,18,21,24- 
octaoxahexaeicosanoic acid (46) was recovered in reasonably good yield (70 %).
Cr03, 1.5 M H2SOd 
\  Acetone
FmocHN
Scheme 53. -  Jones oxidation of 26-(9-fluorenylmethyloxycarbonylamido)-
3,6,9,12,15,18,21,24-octaoxahexaeicosan-1 -ol (45).
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Scheme 54. -  Summary of synthetic route to 26-(9-fluorenylmethyloxy-
carbonylamido)-3,6,9,12,15,18,21,24-octaoxahexaeicosanoic acid (46).
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2.2.5 Alternative route to 20-(9-fluorenylmethyloxy- 
carbonylamido)- 3,6,9,12,15,18-hexaoxaeicosanoic acid.
The success of the oxidation route to Fmoc-amino-PEG acids and the necessity of 
producing more of the compound made it desirable to re-synthesise 20-(9- 
fluorenylmethyloxycarbonylamido)-3,6,9,12,15,18-hexaoxaeicosanoic acid (21) by this 
new route. It was decided that the synthesis should proceed in much the same way as the 
synthesis of 26-(9-fluorenylmethyloxycarbonylamido)-3,6,9,12,15,18,21,24- 
octaoxahexaeicosanoic acid (46). The synthesis would therefore involve the coupling of 
two PEG-units to give the heptaethylene intermediate. This could either be achieved by 
coupling a hexaethylene glycol derivative with an ethylene glycol derivative or by 
coupling a tetraethylene glycol derivative with a triethylene glycol derivative (Scheme 
55); for the reason of cost, the latter route was chosen.
Scheme 55. -  Alternative routes to heptaethylene intermediate.
1 l-Triphenylmethyloxy-3,6,9-trioxaundecan-l-ol (24), which had previously been 
prepared was converted to the methanesulfonate using the same procedure as for the 
preparation of 8-triphenylmethyloxy-3,6-dioxaoctyl methanesulfonate (31). 8- 
Phenylmethyloxy-3,6-dioxaoctan-l-ol (36) had also already been prepared. The coupling 
reaction was carried out by the same procedure as for the synthesis of 1 - 
triphenylmethyloxy-17-phenylmethyloxy-3,6,9,12,15-pentaoxaheptadecane (37). The
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product, 1 -triphenylmethyloxy-20-phenylmethyloxy-3,6,9,12,15,18-hexaoxaeicosane was 
not purified but was directly deprotected by the same method as compounds (37) and (42) 
to give 20-phenylmethyloxy-3,6,9,12,15,18-hexaoxaeicosan-l-ol. This in turn was 
converted directly to 20-phenylmethyloxy-l-azido-3,6,9,12,15,18-hexaoxaeicosane (47) 
by the usual procedure of mesylation followed by displacement of the methanesulfonate 
group by the azido-anion of sodium azide (Trost et al. 155). Only at this stage was 
purification by column chromatography carried out and the overall yield over these steps 
was 76 % (Scheme 56).
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Scheme 56. -  Synthesis of 20-phenylmethyloxy-l-azido-3,6,9,12,15,18- 
hexaoxaeicosane (47).
115
Reduction of 20-phenylmethyloxy-1 -azido-3,6,9,12,15,18-hexaoxaeicosane (47) 
was accomplished using the procedure adapted from the method published by Foucaud & 
El Guemmout156, with a yield of 97 % (Scheme 57). However instead of purifying 20- 
phenylmethyloxy-3,6,9,12,15,18-hexaoxaeicosylamine (48) by column chromatography, 
purification was achieved by filtration and extraction. To the concentrate of the crude 
reaction was added water and the resulting solution was filtered to remove the solid 
precipitate. The filtrate was then acidified to pH 2 and this solution was partitioned with 
diethyl ether several times. The aqueous solution was then basified to pH 12 by addition 
of sodium bicarbonate and then partitioned with dichloromethane several times to recover 
the product in 97 % yield. By this method of purification absolutely no trace of 
triphenylphosphine or triphenylphosphine oxide could be detected in the isolated product 
by NMR.
Scheme 57. -  Staudinger reduction of 20-phenylmethyloxy-1-azido- 
3,6,9, 12,15,18-hexaoxaeicosane (47).
20-(9-Fluorenylmethyloxycarbonylamido)-3,6,9,12,15,18-hexaoxaeicosan-1 -ol 
(49) was then prepared from 20-phenylmethyloxy-3,6,9,12,15,18-hexaoxaeicosyl-amine 
(48) by dissolving metal reduction followed by Fmoc-protection (the same procedure as 
for the synthesis of compound (45) - synthesis 2) (Scheme 58). The yield for this reaction, 
at 97 % was an improvement over the yield for the synthesis of (45). In eight steps from 
triethylene glycol and tetraethylene glycol, (49) was thus conveniently prepared on a 
large scale (69 mmol = 38 g) in 71 % yield overall with purification by column 
chromatography only being required at two stages.
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BnO 5 O
.NH2 (48)
O
HO
.NH, Not isolated
FmocCI, NaHC03, 
Dioxane/water.
97 % over 2 steps (49) H 0 o .NHFmoc
Scheme 58. -Synthesis of 20-(9-fluorenylmethyloxycarbonylamido)-
3.6.9.12.15.18-hexaoxaeicosan-1 -ol (49).
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The Jones oxidation of (49) to 20-(9-fluorenylmethyloxycarbonylamido)-
3.6.9.12.15.18-hexaoxaeicosanoic acid (21) was carried by the procedure previously 
described and once again (21) was recovered in good yield (71 %)(Scheme 59). Indeed it 
was apparent that despite the difference in the chain lengths of the Fmoc-amino-PEG 
acids, all oxidation steps proceeded in nearly the same yield. The overall yield for the 
synthesis of (21) by the second route was 50 % (Scheme 60), which was almost, double 
the yield obtained via the first route. By the time of the completion of this synthetic route 
Thumshim et al. 147 had published their synthesis. Their overall yield for their 6-step 
synthesis was 33 %.
NHFmoc
NHFmoc
Scheme 59. - Synthesis of 20-(9-fluorenylmethyloxycarbonylamido)-
3,6,9,12,15,18-hexaoxaeicosanoic acid (21).
M s O '
,OTrt (24)
MsO, B 3 N, DCM
B n O
,O T r t
+  B n O
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NaH, DMF
o O T rt
2 OH  
(36)
Not isolated
i) 7FA, DCM, B 3SH
ii) s a t  aq. Na2 C0 3
B n O '
B n O '
Not isolated
i) MsO, EtjN, DCM
ii) NaN3, DMF
N 3 (47) - 76 % yieid over 4 steps from (24)
97%
o.
B n O
HO
97 % over 2 steps (49) HO
(21) HO
,N H , (48)
Na, NH3 , THF
,N H , Not isolated
FmocCI, NaHC03, 
Dioxane/water.
71
' 5 o
Cr03, Acetone, 
.5 M H2904
.N H F m o c
.N H F m o c
Scheme 60. -  Summary of synthetic route to 20-(9-fluorenylmethyloxy-
carbonylamido)- 3,6,9,12,15,18-hexaoxaeicosanoic acid (21).
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2.2.6 Synthesis of ll-(9-fluorenylmethyloxycarbonyl- 
amido)-undecanoic acid.
Following the incorporation of (Z) 16-(9-fluorenylmethyloxycarbonyl- 
amido)-hexadeca-7-enoic acid (14) into a peptide, it was desirable to synthesise a similar 
Fmoc-protected, saturated alkyl chain, amino acid linker. Consequently it was decided 
that the Fmoc-derivative of commercially available 11-aminoundecanoic acid should be 
prepared. An attempt to prepare 1 l-(9-fluorenylmethyloxycarbonylamido)-undecanoic 
acid by directly treating 11-aminoundecanoic acid with fluorenylmethyl chloroformate in 
water/aqueous sodium hydrogencarbonate failed. An inseparable mixture of the Fmoc- 
protected amino acid and the Fmoc-protected di-peptide and tri-peptide were recovered 
(see Scheme 25). Indeed Boumrah et al. 159 had also encountered problems in trying to 
prepare ll-(9-fluorenylmethyloxycarbonylamido)-undecanoic acid (52) directly from 11- 
aminundecanoic acid. They circumvented this problem by preparing it from 11-(9- 
fluorenylmethyloxycarbonylamido)-undecanoic acid benzyl ester (51) (Scheme 61).
H2N
O
1 0  OH
FmocHN
(52)
o
K .
1 0  OH
PhCHjOH, 
HQ gas
6 8 %
Cl h 3n
H* Pti/Q 
7HF
8 8 %
93%
FmocHN
(51)
Dioxane, 
aq. Na2 C03, 
FrnooCI
o
J l.
1 0  OBn
Scheme 61. -  Route to 11 -(9-fluorenylmethyloxycarbonylamido)-undecanoic acid 
by Boumrah et al. 159.
However, the initial benzyl ester formation was inconvenient because it required 
the use of dry hydrochloric acid gas and an alternative was therefore sought. Vinogradov 
et al. 198 had adapted a procedure by Zervas et al. 199 for the preparation of amino acid 
benzyl ester, in order to prepare the toluenesulfonate salt of 11-aminoundecanoic acid
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benzyl ester. The use of toluenesulfonic acid being much less hazardous than the use of 
HC1 gas, this procedure was employed to prepare 11-aminoundecanoic acid benzyl ester 
/7-toluenesulfonate (50). Treatment of (50) with fluorenylmethyl chloroformate in 
dioxane/aqueous sodium bicarbonate gave 1 l-(9-fluorenyl-methyloxycarbonylamido)- 
undecanoic acid benzyl ester (51) in 95 % yield. Benzyl deprotection of (51) to give 11- 
(9-fluorenylmethyloxycarbonylamido)-undecanoic acid (52) was accomplished by the 
procedure of Boumrah et al. 159, the same yield of 88 % being achieved (Scheme 62). 
Thus, over 3 steps (52) was conveniently prepared in an overall yield of 76 %.
O
O ^ S C ^ H ,  
\  PhCHjOH,
Benzene
o
(50) n h 3
+
o
9 Dioxane, 
aq. Na2 C03, 
FmooCI
o
s — o
o
FmocHN
(51)
FmocHN
8 8 %
(52)
Scheme 62. -  Synthesis of 1 l-(9-fluorenylmethyloxycarbonylamido)-undecanoic 
acid (52).
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2.2.7 Peptide synthesis.
2.2.7.1 Solid-phase peptide synthesis (SPPS).
ci
n o 2
P S
1 eq. EtjN, reflux
C b z H N
O H
O
i) HBr, AcOH
ii) BtjN
CbzHN^YHY A ° XY > f
DOC, DMF O
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ii) B3N
P S  C b z H N ^ Y  
O
O H
P S
H 0
HiN" i na ° U '
DOC, DMF C b z H N
N 0 2
P S
C b z H N
TfVgV'°'X>£
O H
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Scheme 63. -  Merrifield’s synthesis of H-Leu-Ala-Gly-Val-OH by SPPS.200
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In 1962, R.B. Merrifield first used nitro-substituted chloromethyl-polystyrene as a
tetrapeptide, H-Leu-Ala-Gly-Val-OH on this resin employing the carbobenzyloxy group 
for transient protection of the a-amine of the amino acids (Scheme 63). This pioneering 
method of peptide synthesis became known as Merrifield solid phase peptide synthesis. 
Since Merrifield’s pioneering work, peptide synthesis has progressed considerably both in 
terms of the chemistry and the technology. Today two main strategies exist for the 
synthesis of peptides on solid-phase, the Boc/Cbz strategy or the Fmoc/dBu strategy. Even 
though both strategies have their merits, a survey by the Association of Biomolecular 
Research Facilities 201 proved the superiority of the Fmoc//Bu strategy. In addition to 
improvements in protecting group strategies (review - Schelhaas & Waldemann ) in 
terms of side-chain and orthogonal protecting groups, as well as coupling 
strategies/reagents (review - Humphrey & Chamberlin 203), there have also been major 
advances in the resins employed for SPPS (review - Fields & Noble 204). Furthermore, 
although peptide synthesis is still carried out on the traditional Merrifield bubbler 200, a 
good deal of it is now carried out on automated peptide synthesisers. The SPPS detailed 
in this section was carried out either on a Merrifield bubbler 200 or on an automated 
peptide synthesiser.
solid support on which to carry out peptide synthesis.200 The author prepared the
Piperidine
+ Piperidine
Base
o
IIc
II
o
Scheme 64. -  Removal of a fluorenylmethoxycarbonyl-group with piperidine.
The protection methodology for both manual and automated SPPS utilised the 
base-labile protecting group, fluorenylmethoxycarbonyl (Fmoc) for a-amino protection. 
The Fmoc group can be rapidly cleaved with the use of mild bases such as piperidine due 
to the highly stabilised nature of the anion produced (Scheme 64) but has excellent acid 
stability. One of the advantages of this protecting group for automated peptide synthesis 
is that the products of deprotection, 9-methylenefluorene and 1 -(fluoren-9-ylmethyl)- 
piperidine are UV active and so the Fmoc removal can be quantitatively monitored. The 
other advantage of the use of this group is that it allows for the utilisation of mild acid- 
cleavable side-chain protection and linkers. The TV-a-Fmoc-amino acid side-chain 
protecting groups used in the synthesis of peptides described in this section include trityl-, 
terf-butyl-, Boc- and Pmc-groups, all of which are acid-labile. In the case of automated 
SPPS, Fmoc deprotection was effected using a 30 % solution of piperidine in 
dimethylformamide whilst for manual SPPS the de-protection solution was 1,8- 
diazabicyclo[5.4.0]undec-7-ene/piperidine in dimethylformamide (1:1:48). Treatment of a 
Fmoc-protected amino acid residue for 10-20 minutes with either of these solutions was 
sufficient in order to achieve efficient deprotection.
Cleavable linker
Fmooglydne
o o-
PEG-spaoer
/  \
/  \
o-
/  \
/  \
Polystyrene support
Figure 2. -  Structure of Fmoc-Glycine NovaSyn TGT resin.
The resin used as the solid support in the peptide syntheses detailed in this section
was Fmoc-Glycine NovaSyn®TGT resin (Fig. 2). This pre-loaded resin from
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Novabiochem™ was chosen as the support for SPPS because of its stability to the 
conditions of peptide synthesis, its excellent swelling properties in the solvents employed 
in the syntheses and because cleavage of the peptide from this resin gave the peptide acid. 
The actual core of this resin is low cross-linked polystyrene, which imparts rigidity to the 
resin. This core is derivatised with 3000-4000 M.W. polyethylene glycol in which the 
PEG chains have been terminally functionalised with an amino group, which imparts 
improved swelling properties in various organic solvents to the resin. The linker between 
the resin core and the pre-loaded Fmoc-glycine residue is Bayer’s 4-carboxytrityl 
linker which can be cleaved with as little as 0.5 % TFA.
As has already been mentioned, a broad range of coupling reagents are 
commercially available for the synthesis of peptides on solid-phase. The choice of 
coupling reagents is very often dependent on the nature of the Fmoc-amino acid being 
coupled to the growing. Often choosing coupling reagents is simply a matter of trail and 
error in SPPS as there would appear to be no general rules governing the choice.
2.2.1.2 SPPS of integrin-targeting peptides.
As all the peptides that were synthesised were integrin-targeting peptides and 
therefore contained the integrin-targeting amino acid sequence -CRRETAWAC-, the 
startegy for the synthesis of the peptides involved initially synthesising the sequence 
-GACRRETAWACG- on the NovaSyn®TGT resin on a large scale (Peptide 1). 
Incorporation of the linker molecules was then carried out as a second step either in a 
Merrifield bubbler (early stage) or in an automated peptide synthesiser (once successful 
coupling protocol had been established). Such a strategy allowed for the use of different 
coupling reagents for the synthesis of the integrin-targeting sequence and the 
incorporation of linker molecules/sixteen lysine ‘tail’.
The synthesis of Peptide 1 by automated SPPS was carried out using the coupling 
reagent 1-hydroxybenzotriazole (HOBt) (Konig & Geiger 206) and N,N- 
diisopropylcarbodiimide (DIPCDI) (Sarantakis et al. 207) (Scheme 65). These reagents are 
now almost standard reagents for automated peptide synthesis and are one of the 
recommended coupling reagent combinations for the automated peptide synthesiser 
(MilliGen 9050Plus PepSynthesiser manual) used to synthesise the peptides detailed in 
this section. With the use of HOBt racemisation is suppressed, as there is no oxazolone 
formation. More importantly, the introduction of A-a-Fmoc-iS'-trityl-L-cysteine into
peptides using base mediated activation is known to result in considerable racemisation 
(Kaiser et a l 20S) and so activation under neutral conditions using for example HOBt and 
DIPCDI is necessary. For this reason the integrin-targeting domain ( 
-GACRRETAWACG-, Peptide 1) was synthesised using HOBt and DIPCDI for the 
activation of the Fmoc-amino acids.
FmocHN
\\
N
\
OH
OA,
H H
FmocHN
Scheme 65. -  DIPCDI/HOBt activation of Fmoc-L-amino acids.
The coupling of an Fmoc-amino acid that is to be introduced into a peptide with 
DIC occurs with the initial formation of an O-acyl isourea derivative, which is an 
activated ester. This ester almost immediately reacts with HOBt to give another activated
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ester that is far less susceptible to racemisation. It is this activated ester which undergoes 
nucleophilic attack by the amino-group of the growing peptide chain and so the next 
Fmoc-amino acid residue is introduced.
H2N
O
FT
N
R'
Resin
O SUooessful ooupling to activated 
Fmooamino add
Unsuccessful 
ooupling to
activated FmocHN
Fmooamino add
R „ . o R'
R"
R esin
O
R"
R’
Resin
Scheme 66. -  ‘Capping’ with A-acetylimidazole.
No matter how effective the coupling reagents may be, 100 % coupling of the 
activated Fmoc-amino acid is very unlikely to occur and so at the end of every coupling 
step there is always a certain percentage of free amine functions of unsuccessfully 
coupled peptides. If the cycle of deprotection and coupling were to be repeated 
immediately, the peptides that failed to couple previously could couple the second time 
giving rise to deletion sequence peptides. These peptides that can differ from the target 
peptide by only one residue are often very difficult to separate from the target peptide by 
HPLC. Therefore, once a coupling cycle was complete, the resin-bound peptide was 
‘capped’ by treating it with a solution of N-acetylimidazole in DMF (Scheme 66) so that 
any peptides that failed to couple to the activated Fmoc-amino acid were acylated. 
Acylation prevents coupling to the next activated Fmoc-amino acid, thus preventing the 
formation of deletion sequences. This also to some extent aids the resolution of failed 
peptide sequences from the target peptide.
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Initially an attempt was made to incorporate Fmoc-amino acid (14) into Peptide 1 
by automated SPPS. This proved unsuccessful as was indicated by UV monitoring of the 
coupling and Fmoc deprotection reactions and was later confirmed by MS analysis of the 
peptide products recovered. The incorporation of compound (14) into Peptide 1 was then 
attempted by manual SPPS on a Merrifield bubbler. However an attempt to incorporate 
(14) into Peptide 1 using the same coupling reagents as for automated peptide synthesis 
(DIC/HOBt in DMF) also proved unsuccessful. This was determined by means of the 
Kaiser test 209 as well as MS analysis (Scheme 67). It was speculated that either the 
coupling reagents were inefficient in mediating the coupling within the timeframe of the 
reaction or the solvent in which the coupling was carried out was unsuitable in terms of 
resin swelling, peptide chain solubility or reagent solubility. Either of these factors could 
influence the coupling of (14) to the peptide; the coupling reagents DIC/HOBt are by no 
means the best coupling reagents with respect to reaction rate and DMF, although a good 
solvent for peptide synthesis does not swell the resin as well as a mixture of DMF and 
DCM. It was however uncertain as to which of these two factors was responsible for 
coupling failure or even if it was both.
firioc—Gly-Ala-Cys-Arg-Arg-Glu-Thr-Ala-Trp-Ala-Cys-Gly—[Resin
Peptide 1
HOB/DIPCDI, 
DMF
Automated SPPS
FmocHN
(14) O
HOB/ DIPCDI, 
DMF 
Manual SPPS
Fmoc-LAA-Gly-Ala-Cys-Arg-Arg-Glu-Thr-Ala-Trp-Ala-Cys-Gly— Resin
Peptide 2
H O
Scheme 67. -  Initial attempts to incorporate (Z) 16-(9-fluorenylmethyloxy- 
carbonylamido)-hexadeca-7-enoic acid (14) into Peptide 1.
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Alternative coupling reagents were then tried, namely 0-(7-azabenzotriazol-l-yl)- 
N,N,N’,N ’-tetramethyluronium hexafluorophosphate (HATU) and l-hydroxy-7- 
azabenzotriazole (HOAt) (Fig. 3) which were recommended as more efficient substitutes 
for DIC and HOBt (Chan & White 210). HO At and HATU have been shown to be superior 
coupling reagents to HOBt and DIPCI in both solid phase and solution phase peptide 
synthesis. Carpino et a l 211,212 had shown that HO At and HATU enhanced coupling yields 
and reduced racemisation in the case of the synthesis of hydrophobic peptides, the 
incorporation of hindered amino acids and segment condensation. This superiority is 
attributed to the increased coupling rates achieved with these reagents due to 
intramolecular base catalysis during aminolysis of HO At esters. In addition to the change 
of coupling reagents, the coupling solvent medium was also changed for the synthesis of 
Peptide 2, a mixture of dichloromethane and dimethylformamide (1:1) being used instead 
of just dimethylformamide. The rationale for this was that addition of dichloromethane 
would increase the solubility of Fmoc-amino acid (14) in the coupling solution and thus 
improve the coupling efficiency, since (14) was not very soluble in DMF alone.
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N N
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N‘ N
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Figure 3. - 0-(7-azabenzotriazol-l-yl)-A,A,A’,A ’-tetramethyluronium 
hexafluorophosphate (HATU), l-hydroxy-7-azabenzotriazole (HOAt) and O- 
(benzotriazol-1 -yl)-jV,N,N',N‘'-tetramethyluronium tetrafluoroborate (TBTU).
For the manual synthesis of Peptide 2 an alternative Fmoc-deprotection method 
was also employed; instead of 30 % piperidine in DMF, 1,8-diazabicyclo [5.4.0]undec-7- 
ene/piperidine/DMF (1:1:48)210. The reason for the choice of this deprotection solution 
was that Wade et al. 213 had shown it to be more effective for the deprotection of difficult 
peptides, particularly peptides containing hydrophobic domains that were prone to 
aggregation. It was speculated that the hydrophobic nature of (14) might also make Fmoc- 
deprotection problematic. Furthermore this deprotection mixture contains a lower
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percentage of piperidine and so the stench is not so strong, a significant factor in manual 
synthesis. The choice of alternative coupling reagents and Fmoc deprotection solution 
proved successful in incorporating Fmoc-amino acid (14) into Peptide 1. The same 
coupling/deprotection conditions were then also used to synthesise the following 
peptides; Peptide 3, Peptide 4 and Peptide 5 (Fig. 4). In the case of Peptide 2, Peptide 3 
and Peptide 4 coupling of the Fmoc-amino acids was determined to have been successful 
by both Kaiser test and MS analysis of cleaved and fully deprotected peptide products. In 
the case of Peptide 5 however it was only possible to confirm incorporation by the Kaiser 
test 209 as the peptide could not be detected by MS analysis.
Fmoc—Lys-LAAGIy-Ala-Cys-Arg-Arg-Glu-TlirAla-Trp-Ala-CysQy—Resin
H
LAA= PeP> < W V PeP R e ' 5 t i d e 3
Rnoc— Lys-HAA^GIy-AlaCys ArgArg Glu-ThrAla-Trp-Ala-CysGly—Resin
h aa7= Pe% ' ^ f ° ^ ^ 0 ^ Pep * * * *
H O
Fmoc-Lys-LAA LAA Gly-Ala-(Vs-Arg-Arg-au-Thr-Ala-Trp-Ala-Cys-Gly-Resin
5I
H
LAA = Pep' N'T % = ^rh sPep R e p H d e 5
Figure 4. -  Peptide 3, Peptide 4 and Peptide 5.
Incorporation of subsequent amino acids into Peptide 3, Peptide 4 and Peptide 5 
was achieved by automated SPPS (MilliGen 9050Plus PepSynthesiser) to give Peptide 6, 
Peptide 7 and Peptide 8 respectively (Fig. 5). However in place of the coupling reagents 
used in the automated synthesis of Peptide 1 (DIC/HOBt), TBTU/HOBt/DIPEA were 
used since from experience these coupling reagents were found to be more efficient.
Additionally, for the synthesis of Peptide 6 and Peptide 8 slight modifications were 
made to the initial coupling cycle of the first Fmoc-amino acid to be incorporated in order 
to in order to try to maximise the efficiency of this first incorporation. Both the Fmoc 
deprotection time and the coupling time of the first amino acid coupling cycle were 
increased in duration as there was a concern that, due to the nature of Peptide 3 and 
Peptide 5 (hydrophobic region at the N-terminus) deprotection or coupling might not go 
to completion within the standard time.
Figure 5. -  Peptide 6, Peptide 7 and Peptide 8.
The synthesis of Peptide 9 was also carried out manually on a Merrifield bubbler 
in order to allow for use of different coupling solvents as well as monitoring of coupling
were coupled sequentially to Peptide 1 using the coupling reagents HOBt and TBTU
(Scheme 68) with diisopropylethylamine. Fmoc-deprotection was carried out with 20 %
H-[ Lys^LAAGIy-Ala-Cys* Arg* Arg-Gl u-Thr Ala-Trp-Ala - Cys Gly-X
Peptide 6
H O
H^Lys^tAA^GIy-Ala-CysArg-ArgGlu-ThrAla-Trp-Ala-CysGly-X
P e p \ P ep Peptide 7HAA7  = N
H O
H-^Lys^AALAAGIy-Ala-CysArgArg-Glu-'Fhr-Ala-Tip-Ala-Cys-Gly-X 
Peptide 8
H O
X = Resin or free carboxylic add
by the Kaiser test 209. Fmoc-aminoundecanoic acid (52) and A-a-Fmoc-e-Boc-L-lysine
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piperidine in dimethylformamide and the coupling medium of dichloromethane/ 
dimethylformamide (1:1) was used as before. The coupling of the Fmoc-amino acids was 
followed by the Kaiser test 209. As this tested negative, a test cleavage/deprotection of the 
Peptide 9 was not carried out. Peptide 10 was then synthesised from Peptide 9 by 
automated SPPS using HOBt and TBTU as the coupling reagents again (Scheme 68).
Fmoc— Gy-Ala-Cys^Aig-Arg-GI u-Thr Ala-Trp-Ala-Cys  ^Gly—Resin
FmocHN
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10
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(HOBt/TBTU)
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o
Scheme 68. -  Synthesis of Peptide 10.
Following the success of the incorporation of (21) (HAA7) into a peptide, it was 
decided that the incorporation of (29) (HAA4) and (46) (HAA9) into peptides should be 
attempted by automated SPPS. The coupling reagents chosen for this were TBTU and 
HOBt and the duration of the deprotection and coupling protocols of the first three Fmoc- 
amino acids to go onto Peptide 1 were extended. Peptide 11 (Fig. 6) was the first to be 
synthesised; monitoring of the coupling and Fmoc deprotection cycles indicated that the
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automated synthesis had been successful. This was confirmed by MS analysis of the 
cleaved/deprotected peptide. Following the success of the automated synthesis of Peptide 
11, Peptide 12 and Peptide 13 (Fig. 6) were synthesised in the same way.
H-^Lys-j— H A A j-G ly -A la -C y s -A rg -A rg -G lu -T h r-A la -T rp -A la -C y sG ly -X
Peptide 11
H -(-L y s -^ H A A r HAAr G ly -A la -C y s -A rg -A rg -G lu -T h r-A la -T rp -A la -C y s -G ly -X
Peptide 12
H -|l_ y s^ H A A £ -G ly -A la -C y s-A rg -A rg -G lu -T h r-A la -T rp -A la -C y s-G ly -X
Peptide 13
HAAg = Pep- N ^ - f ' ° ^ ) ; o ^ PeP
H O
X = Resin or free carboxylicadd
Figure 6. -  Peptide 11, Peptide 12 and Peptide 13.
2 2 .1 3  Peptide cleavage and deprotection.
As the solid support, NovaSyn TGT® was derivatised with Bayer’s 205 extremely 
acid-sensitive 4-carboxytrityl linker, cleavage of the peptide from the resin was effected 
under the deprotection conditions. Thus, treating the fully protected resin-bound peptide 
with 85 % TFA with the addition of the various scavengers and water yielded the fully 
deprotected peptide (Scheme 69).
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H -|-L ys-j^ |x j-^ -G ly -A la -C ys Arg-Arg G lu-Thr-Ala-Trp-Ala-Cys GI5O  ^ ^
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Scheme 69. -  Cleavage/deprotection of the peptide from the solid support.
The use of scavenger reagents is normally essential in the cleavage/ deprotection 
step in order to avoid the reaction of cations generated during this process with the 
peptide. The cations generated during the cleavage/deprotection step i.e. tert-butyl, 
triphenylmethyl etc. are particularly reactive with thiols and under the conditions of 
cleavage/deprotection the resulting thioethers are stable (King et al. 214). The scavengers 
commonly used in the cleavage /deprotection of peptides synthesised by the Fmoc- 
protection strategy on acid-cleavable solid support are phenol, ethanedithiol and 
thioanisole. For most of the peptides, ethanedithiol was replaced with triethylsilane, 
which is equally as effective but odourless.
Substitution of triethylsilane for ethanedithiol turned out to be erroneous however 
for the cleavage/deprotection of Peptide 6. Over the reaction period of 4-6 hours the 
double bond of amino acid residue (14) in Peptide 6 was unexpectedly reduced (Scheme
70) as determined by MS analysis (it was not possible to determine by MS whether 100 % 
reduction had occurred).
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2.5 % Whter
/ \ .G ly -A la -C ys Arg Arg Glu-Thr-Ala-Trp-Ala-Cys Gly-OH
o
Scheme 70. -  Cleavage/deprotection of Peptide 6.
Although there are instances where double bonds can be reduced with 
trifluoroacetic acid and an alkylsilane at room temperature, this reaction was not thought 
to occur with non-conjugated acyclic alkenes. Indeed very few examples of non­
conjugated double bond reduction could be found in the literature, one of the few 
examples being the reduction of methylcyclohexene to methylcyclohexane 215 (Scheme
71).
TFA, B 3S H ,
Z n d 2, Pd(PPh3)4, TFA, B jS H
CHCI3
▼ 1 ▼
9  i f ^ l 0 1
• \ k k  k k
n 1 ^  n
k ^ k ^
0 0
B 3SH,
7FA
Scheme 71. -  Reduction with silanes (hydrosilylation) and trifluoroacetic acid.
135
is desired  are often dissolved in pH 7-8 buffer solutions for the oxidation  reaction e.g.
0.01 M aqueous am m on ium  b icarbonate , 0.2 M a m m on ium  acetate  or 0.01 M phosphate  
buffer “l0.
SH SH
H ^ - L y s ^ -^ -X - j-^ G Iy -A la -C y s A rg A rg -G lu -T h r -A la -T rp -A la -C y s -G ly -O H
Water, 
7 days Atmospheric oxygen
Aq. 0.01 M ammonium 
bicarbonate buffer 
2-3 days
H ^ L y s -^ |-X - j- ^ G Iy -A la -C y s -A rg -A rg -G lu -T h r -A la -T rp -A la -C y s -G ly -O H
S ch em e  72. -  D isu lph ide  bridge  form ation by aerial oxidation.
A t room  tem pera tu re  and  exposure  to a tm ospheric  oxygen  by m eans o f  fairly 
v igo rous  stirring, cyc lisa tion  o f  in tegrin-targeting  peptides w as know n to take up to one 
w eek  (S c h em e  72). In 0 . 0 1 M aqueous  am m on ium  bicarbonate , from  experience  it was 
know n that the cyc lisation  tim e o f  in tegrin-targeting  peptides was reduced  considerably  to 
on ly  2-3 days  (S ch em e  72). T herefo re  initially the cyclisation o f  som e o f  the peptides was 
a ttem p ted  in 0 . 0 1 M a q u eo u s  am m o n iu m  b icarbonate  but it w as observed  that this 
resu lted  in po o r  recovery  o f  the pep tide  by post-cyclisation H PL C  purification. Before  the 
so lu tion  o f  cyc lised  pep tide  in aqueous  am m on ium  bicarbonate  could be concentra ted  in 
vacuo, a large excess  o f  acetic  acid  had to be added in order to avoid the generation  o f  
a m m o n ia  w h ich  w ou ld  react with  the peptide. The residue recovered from concen tra ting  
to d ryness  then  co n ta in ed  both  cyclised  peptide and am m onium  acetate. O n a ttem pting  to 
purify  the cy c lised  pep tide  by H PLC , a considerable  am ount o f  peptide w ould  be carried 
th rough  w ith  the e lu ted  salt. T he  recovery  o f  cyclised peptide was so po o r  that it was 
dec ided  that the  ox ida t ion  o f  the peptide w ould  nevertheless be carried out in w ater  alone 
desp ite  the  longer  reac tion  time. D M S O  oxidation was also tried, fo llow ing  the procedure  
o f  O tak a  et al. 220 bu t the  sam e  problem  o f  poor retention o f  the peptide during  H P L C  was 
e n c o u n te re d  as w ith  the use o f  a m m on ium  bicarbonate  buffer.
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H^-Lys j - j -^ -X - j-^ G Iy -A la -C y s -A rg -A rg -G lu -T h r -A la -T rp -A la -C y s -G ly -O H
SH SH
High dilution
H ^ -L y s j- ^ -X - j^ G ly -A la -C y s -A rg -A r g -G lu -T h r - A la -T r p -A la - C y s G ly -O H
S ---------------------------------------------------------S
Major product
S c h e m e  73. -  O x ida tion  o f  cysteinyl peptides at high dilution results  in a lm ost 
exc lus ive  fo rm ation  o f  in tra-strand disulfide bridges/cyclisation.
SH SH
H ^ -L y s |-^ -X - j-^ G Iy -A la -C y s -A rg -A rg -G lu -T h r -A la -T rp -A la -C y s -G ly -O H
low dilution
H ^ -L y s - j- j^ -X - j-^ G Iy -A la -C y s 'A rg -A rg -G lu -T h r-A la -T rp -A la -C y s -G ly -O H
s — s  s — s
H ^ -L y s ^ j^ -X - j-^ G Iy -A la -C y s -A rg -A rg -G lu -T h r-A la -T rp -A la -C y s -G ly -O H
S — S — P ep
H ^ -L y s ^ - j^ -X - j— G ly -A la -C y s A rg -A rg -G lu -T h r -A la - T rp -A la - C y s G ly - O H
S— S
H ^ L y s ^ ^ X - j — G ly -A la -C y s * A rg -A rg -G lu -T h r -A la -T rp -A la -C y s G ly -O H
S — S — P e p
S c h e m e  74. -  O x ida tion  o f  cysteinyl peptides at low dilution results  in form ation 
o f  intra- an d  in tra -s trand  disulfide bridges.
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In o rder  to achieve peptide cyclisation  alm ost exclusively  (S chem e 73) rather than 
bo th  cyc lisa tion  and  c ross-link ing  (Schem e 74) it was necessary  to carry  out ox idation  at 
a low  concen tra t ion  o f  peptide (circa 0 .025 m g/m l = 0.01 pM ). High dilu tion o f  the 
pep tides  d u r in g  oxidation  ensured  that m ain ly  intra-strand rather than inter-strand 
d isu lp h id e  b r idge  form ation occurred  (Fig. 7). U ltim ately  the form ation o f  d im ers, trimers 
o r  o l ig o m ers  even  at very high dilution could  not be totally e lim inated , but subsequent 
H P L C  purif ica tion  separated  out m ost o f  these m inor peptide impurities.
C y c l isa tio n  o f  peptides was de term ined  to have been successful by M S analysis o f  
the pep tides . S ince  cyclisation resulted in the loss o f  two hydrogens  from the peptide, a 
d if fe rence  o f  2 m ass  units w ould  be expected  betw een cyclised  and  non-cyc lised  peptides. 
T h is  d i f fe ren ce  cou ld  be observed  by m ass spectroscopy and so it w as used  as a m eans o f  
d e te rm in in g  w hen  the cyclisation  reactions were complete. M ass spectroscopy  w as the 
on ly  m eth o d  for de te rm in ing  successful cyclisation since o ther m ethods  such as testing 
for free thiol g roups  by E l lm a n ’s test 223 were ineffective w hen w ork ing  on such small 
scales.
H -(L ys)^A A -G ly-A la-C ys^A rg  A rg G lu -T h r A la-Trp-A la*C ysG ly-O H
H { ly s |^ L A A  L A A d y -A la -C y s  A rg -A rg -G lu -T h r A la-T ip -A la-C y ^G ly -O H
<^A= Pep^ ^ r i ^ r \ Pep
H O
H ^ L y s-)^ H A A p ly -A la-C y sA rg -A ig  a u - T h r  A la-T rp-A la-C ysG ly-O H
HAA7 = - Pep
H o
/ \ 1 1 H ^Lysj^H A A ^G Iy-A la-C ys^A ig A rg -Q u -T h rA la-T rp -A la  CysCSIy-OH
/ \ 1 1 H -|-L ys|^ -H A A ^H A A ^G Iy -A la-C y & A rg * A rg -Q u -'n irA la-T rp -A la-C y sG ly -O H
h a a 4 = P ep - N ^ ^ ° - ^ 0 ^ Y Pep
H O
/ \ 1 1 H -^Lysj^H A A ^G Iy-A la-Cys A ig  A rg G lu -7h rA la-T rp -A la-C ysG ly -O H
HAA, = P ep - N ^ f ° ^ ^ 0 ^ PeP 
H O
/ \ 1 1 H-(— L ysj-^ -A U A  G y -A la  C ys A ig Arg G u -T h rA la -T rp -A la  C y sG y -O H
H
AUA =
O
Figure  7. -  C yclised  in tegrin-targeting  peptides.
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2.2.8 Conclusions.
T h e  successful synthesis o f  the unnatural Fm oc-p ro tec ted  am ino  acids reported  in 
th is  sec t io n  w as further confirmed by their  successful incorporation  into integrin-targeting 
p e p tid e s .  T h e  incorporation o f  the unnatural Fm oc-p ro tec ted  unnatural am ino  acids was 
a c h ie v e d  using  readily available, standard  coup ling  reagents  under s tandard  peptide 
c o u p l in g  conditions . Most noteworthy is the fact that the synthetic  routes to Fm oc-am ino- 
PFXi a c id s  reported  here are convenient, inexpensive  and com para tive ly  high yielding.
C onside rab le  work remains to be done  in term s o f  incorporating  various num bers 
and/ o r  co m b in a t io n s  o f  the unnatural Fm oc-p ro tec ted  am ino  acids into peptides. So far 
o n ly  up  to tw o  unnatural amino acids have been incorporated  sequentia lly  into peptides, 
the  tw o  sequen tia l  residues being identical in both cases. W hat rem ains  to be seen is 
w h e th e r  it will be possible to incorporate tw o  or m ore d iss im ilar  unnatural am ino  acids or 
th ree  o r  m o re  s im ilar  unnatural amino acids sequentially  into a peptide. D ue to the nature 
o f  the  u n n a tu ra l  Fmoc-protected amino acids, this m ay  prove  m ore  challenging.
T h e  incorporation  o f  several s im ilar or d iss im ilar  unnatural am ino  acids 
s e q u e n t ia l ly  into a peptide as a linker be tw een  the ‘h e a d ’ and  the ‘ta i l ’ w ou ld  be o f  
in te res t  bo th  in term s o f  the effect o f  linker length on b iological activ ity  and  the effect o f  
l in k e r  s tru c tu re  on biological activity.
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2.3 Biological testing of LID vectors 
containing integrin-targeting peptides.
F o llow ing  the synthesis o f  the integrin-targeting peptides  con ta in ing  the various 
l inker  a m in o  acids, LID vectors were prepared with these peptides  by Hart and c o ­
w o rk e rs  . In the case o f  all vectors prepared and  tested, Lipofectin  w as em ployed  as the 
lip id  c o m p o n e n t  and p lasm id  DN A contain ing  the gene  encod ing  for luciferase w as used 
as the  nuc le ic  acid  com ponent. In order to produce  LID com plexes  with d iffering  overall 
c ha rge ,  the  am o u n ts  o f  Lipofectin and plasm id D N A  used to p repare  com plexes  were kept 
c o n s ta n t  w h ile  the am oun t  o f  integrin-targeting peptide w as varied. For the purpose  o f  
d irec t  c o m p a r iso n  o f  transfection efficiencies, LID com plexes  w ere  a lso p repared  w ith 
P ep tide  O  (Fig . 8), the original cuPi-integrin-targeting peptide em p loyed  by Hart and co ­
w o rk e rs  for the  prepara tion  o f  LID complexes. A general sum m ary  o f  the p rocedure  
e m p lo y e d  for the  p repara tion  and tesing o f  LID com plexes  d iscussed  here  is g iven  at the 
end  o f  this section.
S---------------------------------------------S
H-(Lys]^GIy-Ala-CysArg-Arg-Glu-ThrAla-Trp-Ala-CysGly-OH
Figure  8. -  S equence  and structure  o f  cupi-in tegrin-targeting Peptide  O.
C ells  w ere  subsequen tly  incubated  with the freshly prepared  com plexes  for a 
g iven  period  a fte r  w hich  they  w ere  lysed in buffer. The resulting suspension  was 
cen tr ifuged  and  the superna tan t  was assayed  for luciferase activity. T he  protein  content in 
sam ples  assayed  for luciferase  activ ity  w as determ ined  and all data  w ere  then expressed  
as the R L U  (re la t ive  light units) s tandard ised  to protein content.
Initially  LID  co m p lex es  con ta in ing  either Peptide 14, Peptide 15, Peptide 16 or 
Peptide  O  w ere  assessed  for their  transfec tion  activities tow ards TF-1 cells  and  the 
transfec tion  results  a re  c o m p ared  in the graph  on the subsequent page  (Fig. 9).
‘ B io logica l testing w as  carr ied  out by  D r S.L. Hart, D r M. W riter  and M s S. B arker  at the 
Institute o f  C hild  H ealth , M o lecu la r  Im m u n o lo g y  Unit, U nivers ity  C ollege  London.
Figure 
9. - 
Transfection 
results 
for Peptide 
14, Peptide 
15 
and 
Peptide 
16.
Luciffi a.se Expression from TF-1 cells incubated with LID complexes composed of pDNA. 
Lipofectin and peptide at peptide pDNA ratios of 1.5:1. 3:1. 5:1 or ‘7:1.
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C om parison  o f  the levels o f  luciferase gene  expression  ach ieved  in TF-1 cells with 
LID  com plexes  p repared  with Peptide 14, Peptide 15, Peptide 16 or Peptide  O  indicated 
that on ly  LID com plexes  con ta in ing  Peptide 16 achieved  com parab le  transfec tion  
e fficiencies to LID com plexes  con ta in ing  Peptide O. LID com plexes  p repared  with a ratio 
o f  Peptide 16 to pD N A  o f  7:1 ach ieved  m arg inally  h igher  levels o f  gene  expression  than 
L ID  com plexes  prepared  with any o f  the three ratios o f  Peptide  O  to pD N A . This  
suggested  that the insertion o f  a hydrophilic  PEG  linker be tw een  the six teen lysine ‘ta i l ’ 
and  the in tegrin-targeting  ‘h e a d ’ o f  Peptide  O  m ight poten tia lly  have  beneficia l effects in 
te rm s o f  the ability o f  the resulting  pep tide  to bind to in tegrins w hen  bound  in LID 
com plexes .  The  insertion o f  l ipophilic, as well as lipophilic and conform ationa lly  
cons tra ined  linkers betw een the six teen lysine ‘ta i l ’ and the in tegrin-targeting  ‘h e a d ’ o f  
Pep tide  O  appeared  to have a negative  effect in term s o f  the ability o f  the resulting  
pep tides  to b ind  to integrins w hen bound  in LID  com plexes. This  certa in ly  appeared  to be 
the case  w hen  either Peptide 14 or Peptide 15 in LID  com plexes  rep laced  Peptide O  in 
L ID  com plexes .
I \ 1 1H—^-Lys—j^AHAGIy-AIa-CysArg-Arg-Qu-ThrAla-Trp-Ala-CysGly—OH
AHA =
F igure  10. -  Structure and sequence  o f  Peptide H.
T h e se  p re lim inary  results for transfection with LID  com plexes  con ta in ing  Peptide 
14, Peptide 15 or Peptide 16 instigated the synthesis  o f  o ther  suitably p ro tec ted  linker 
a m ino  ac ids . H ydrophilic  linker am ino acids were prepared that were e ither  longer  or 
shorte r  than  the hydrophilic  linker in Peptide 16 and these were ‘in se r ted ’ into Peptide O 
at the sa m e  posit ion  as the linker in Peptide 16. In the case o f  l ipophilic  l inker am ino  
acids, s ince  a pep tide  had  already  been synthesised and  bio logica lly  tes ted  that had a 6- 
a m in o h e x an o ic  ac id  linker inserted betw een the sixteen lysine tail and  the head  group  o f  
P ep tide  O , P ep tide  H (Fig. 10), it was decided to synthesise  a peptide  con ta in ing  an 11- 
a m in o u n d e ca n o ic  ac id  linker. For  this purpose 1 1-Fm oc-am inoundecano ic  acid  was
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synthesised which was effectively intermediate in length between 6 -aminohexanoic acid 
and the linker amino acids in Peptide 14 and Peptide 15. The ease of large scale 
preparation of 11-Fmoc-aminoundecanoic acid meant also that if necessary the amino 
acid could be ‘inserted’ into Peptide O one, two, three or more times if desired.
The peptides prepared with these various linker amino acids, Peptide 17, Peptide 
18, Peptide 19 and Peptide 20 were used along with Lipofectin and plasmid DNA 
encoding for luciferase to prepare LID complexes. Complexes were prepared with fixed 
amounts of Lipofectin and plasmid DNA but the amount of peptide used was varied so 
that complexes were prepared in which the ratio of peptide to pDNA was either 3:1 or 
7:1. As before, LID complexes were also prepared with Peptide O in order that a direct 
comparison might be made of the transfection activities of the various complexes with 
those of complexes prepared with Peptide O. Two cell types, N2a and AJ3.1 were 
incubated with the various freshly prepared LID complexes for a given period after which 
they were lysed in buffer. The resulting suspension was centrifuged and the supernatant 
was assayed for luciferase activity. The protein content in samples assayed for luciferase 
activity was determined and all data were then expressed as the RLU (relative light units) 
standardised to protein content. The results of transfection with the various complexes are 
shown in the two graphs on the subsequent two pages (Fig. 11 & 12).
In view of the previous results of biological testing of Peptide 14, Peptide 15 and 
Peptide 16 in LID complexes, the levels of luciferase gene expression achieved in N2a 
and AJ3.1 cells with LID complexes prepared with Peptide 17, Peptide 18, Peptide 19 
or Peptide 20 compared with LID complexes prepared with Peptide O were unexpected. 
The highest levels of gene expression were generally achieved with LID complexes 
prepared w ith Peptide 20 and were comparable with the levels achieved with complexes 
prepared with Peptide O. Out of the LID complexes prepared with peptide containing the 
hydrophilic linkers, only LID complexes containing Peptide 19 achieved any significant 
levels of gene expression in both cell types, but these level were far below those achieved 
with LID complexes prepared with Peptide O.
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Figure 11.- Transfection results for Peptide 17, Peptide 18, Peptide 19 and 
Peptide 20.
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Peptide 20.
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The fact that in N2a cells the level of gene expression achieved with LID 
complexes containing Peptide 20 were almost twice that achieved with LID complexes 
containing Peptide O, but in AJ3.1 cells the level of gene expression achieved with LID 
vectors containing Peptide 20 was approximately equal to that achieved with LID 
complexes containing Peptide O suggested that in order to obtain more meaningful and/or 
reliable results the transfection experiments would need to be carried out several times. 
Averages of the levels of gene expression could then be determined and the standard 
deviation within the levels could be calculated and used as an indication of the reliability 
of reproducing the experiments.
One of the few conclusions that could be drawn from the results obtained was that 
the transfection experiments would have to be repeated several times under identical 
conditions before any firm conclusions could be drawn from the levels of gene expression 
achieved with the various LID complexes. Furthermore it was evident that biological 
testing of LID complexes prepared with Peptide O or all the other peptides would need to 
be carried out simultaneously, and by one individual in such a way all parameters were 
kept constant in order to obtain meaningful results.
Experimental procedure.
Transfections - Lipopolyplex formulations were prepared by mixing the 
components in the following order: 50 pi of Lipofectin (InVitrogen Ltd, Paisley, U. K.;
30 pg/ml in OptiMEM), 70 pi peptide (at between 0.029mg/ml and 0.1 mg/ml in 
OptiMEM, according to peptide charge ratio used), with 50 pi of the luciferase reporter 
plasmid pCILux at (40 pg/ml in OptiMEM). Plasmid pCILux was prepared by subcloning 
a luciferase gene from pGL3 Control (Life Technologies, Paisley, U. K.) into the 
eukaryotic expression vector pCI (Promega, Southampton, U. K.). The complex was 
mixed by pipetting briefly before diluting in OptiMEM to a final volume o f 1.57 ml.
The complete growth medium was removed from cells (TF-1, N2a or AJ3.1 cells) 
plated at 2 x 104 cells /well overnight in 96-well plates and 200 pi of complex (0.25 pg of 
plasmid DNA) added to each well, leaving minimal time between preparing the complex 
and adding to the cells. All transfections were carried out in 6  wells each. The cells were 
incubated with the complexes for 4 hours before replacing with normal media for 24 to 48 
hours, after which reporter gene expression was analysed by luciferase assay (Promega, 
Southampton, UK).
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Luciferase assays - Cells (TF-1, N2a or AJ3.1 cells) were washed twice with PBS 
before the addition of 100 |al of 1 x Reporter Lysis Buffer (Promega, Southampton, UK) 
to the cells for 20 min at 4°C before freezing at -20°C for at least 30 min followed by 
thaw ing at room temperature (±20°C). Twenty microlitres of the lysate at room 
temperature was transferred to a white polystyrene 96-well plate (Porvair Sciences Ltd, 
Shepperton, U. K.) and the luciferase activity was measured using the Luciferase Assay 
System (Promega) and a Lucy-1 Luminometer (Anthos Ltd., Salzburg, Austria). The 
amount of protein present in each transfection lysate was determined with the Bio-Rad 
protein assay reagent by the manufacturer’s instructions, adding 2 0  pi from the luciferase 
test to 200 pi of the reagent diluted 1 in 5 and incubating at room temperature for 10 min 
before comparing the OD.vx, to a range of BSA standards. Luciferase activity was 
expressed as Relative Light Units (RLU) per milligram (mg) of protein (RLU/mg).
2.4 Reagents and techniques
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2.4.1 Analytical thin layer chromatography.
Analytical TLC was performed on Merck silica gel 6 OF254 coated aluminium 
sheets. The developed chromatograms were visualised by irradiation with a UV lamp in 
the case of UV sensitive compounds. Alternatively TLC plates were developed with 
potassium permanganate solution, /;-anisaldehyde dip, ninhydrin dip, phosphomolybdic 
acid dip or bromocreosol blue dip. Compounds possessing a thiol group were visualised 
as bright yellow spots using Ellman’s reagent.
2.4.2 Normal phase column chromatography.
Chromatography columns were packed with silica suspended in eluent to the 
desired height {c. 150 mm). The silica once loaded into the column, was left to settle for 
at least four hours and then covered with a layer of sand (c. 10 mm). The material to 
undergo chromatography was applied in a small volume of the eluent. Chromatography 
was air pressure driven and performed using BDH™ ‘Silica for Chromatography’.
2.4.3 Reverse phase column chromatography.
Reverse phase silica was initially suspended in water and de-gassed for about one 
hour prior to loading into the column. Once loaded, the silica was weighed down with 
glass balls on a circle of filter paper. The material to undergo chromatography was 
applied as an emulsion in water containing the minimal amount of acetonitrile required to 
initially dissolve the material. Chromatography was air pressure driven and performed 
using Merck Silanised Silicagel 60.
2.4.4 HPLC purification of peptides.
HPLC purification of peptides was carried out on a Vydac™ ‘Protein & Peptide 
C IS ’ 218TP reverse phase HPLC column (40 x 250 mm). Analytical HPLC of peptides 
was carried out on a Vydac™ ‘Protein & Peptide C l8 ’ 218TP reverse phase HPLC 
column (2.1 x 250 mm).UV monitoring of HPLC was at 215 nm. The solvents used for 
elution were water and acetonitrile, both with 0 .1  % trifluoroacetic acid added as the ion 
pairing reagent and both solvents were thoroughly de-gassed (oxygen free) with helium.
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HPLC was earned out either on a Waters 600E with Waters 486 UV detector or on a 
Varian ProStar 210 with Varian ProStar 320 UV detector.
2.4.5 IR Spectroscopy.
Infrared spectra were recorded on a Shimadzu FT-IR 8700. Samples were either 
applied to sodium chloride discs if oils or ground into a powder with potassium bromide 
and then pressed into a disc if solids.
2.4.6 Mass spectroscopy.
+ve or -ve Electrospray mass spectra were recorded on a Micromass Quattro LC. 
+ve and -v e  fast atom bombardment or electrospray were recorded on a Thermo Finnigan 
MAT 900XP or on a VG ZAB 2SE.
2.4.7 NM R spectroscopy.
'H (300 MHz) and "C  NMR (75 MHz) spectra were recorded on a Bruker 
AMX300 spectrometer (unless otherwise stated) at ambient temperature, using residual 
isotopic solvent as an internal reference. Coupling constants (J) are reported in Hz. I3C 
NMR were proton decoupled and DEPT or COSY experiments were used for assignment. 
The follow ing abbreviations were used to describe the NMR signals: s, singlet; d, 
doublet; t, triplet; q, quadruplet; qt, quintuplet m, multiplet; dd, doublet of doublets; dt, 
doublets o f triplets, br s, broad singlet. For the I3C NMR o = ortho, m= meta, p  = para, i = 
ipso. A star (*) next to C or H indicate proton or carbon signals of functionalities e.g. 
protecting groups.
2.4.8 Solvents.
Solvents were purchased from British Drug Houses (BDH)™ unless otherwise 
stated. Anhydrous solvents were obtained in the following manners;
Dichloromethane - refluxed and distilled over calcium hydride immediately 
before use.
H IPER SO LV  ACV-dimethylformamide (DMF) - purchased from BDH™ and 
used directly from bottle.
Tetrahydrofuran - refluxed and distilled from sodium wire before use.
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Methanol, acetic acid, acetone, water, toluene, chloroform, ethyl acetate, 
diethyl ether, acetonitrile, hexane, propan-2-ol and dioxane - used directly from 
bottle.
2.4.9 Reagents.
/V-Acetylimidazole - purchased from Lancaster™ and used direct.
Amino acid derivatives -  all Fmoc-amino acid derivatives not synthesised were 
purchased from Novabiochem™ and were stored at 0°C.
11-Aminoundecanoic acid - purchased from BDH™ and used direct 
Ammonia -  distilled from sodium metal immediately prior to use i.e. directly into 
reaction.
Ammonium chloride - purchased from Aldrich™ and used direct.
0-(7-Azabenzotriazol-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate -
purchased from Aldrich™ stored at 0°C and used direct.
2-(lH-BenzotriazoM-yl)-l,l,3,3-tetramethyluronium tetrafluoroborate - purchased 
from Applied Biosystems™ and used direct.
Benzyl alcohol - purchased from Aldrich™ and used direct.
Benzyl bromide/chloride - purchased from Avocado™ and used direct.
Boron trifluoride etherate - purchased from Aldrich™ and used direct.
Bromobenzene - purchased from Lancaster™ and used direct.
Bromoacetic acid, 6-bromohexanoic acid -  purchased from Avocado™ and used direct.
8-Bromooctanoic acid - purchased from Aldrich™ and used direct. 
ferf-Butanol -  purchased from Lancaster™ and used direct.
n-Butvl lithium in hexane - purchased from Lancaster™ stored at 0°C and used direct 
from bottle.
Chromium trioxide - purchased from Lancaster™ and used direct.
l,8-Diazabicyclo|5.4.0|undec-7-ene - purchased from Fluka™ and used direct. 
Dichloroacetic acid - purchased from Aldrich™ and used direct. 
A^/V-Diisopropylcarbodiimide, /V,A-dicyclohexylcarbodiimide -  purchased from 
Avocado™ and used direct.
Dimethylaminopyridine - purchased from Aldrich™ and used direct. 
A^V-Diisopropylethylamine - purchased from Aldrich™ as anhydrous and used direct.
9-Fluorenylmethyl chloroformate - purchased from Avocado™ and used direct.
Ethyl diazoacetate - purchased from Aldrich™ and used direct.
Hexaethylene glycol - purchased from Aldrich™ and used direct.
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Hexamethylphosphoramide - purchased from Aldrich™ and used direct.
Hydrochloric acid -  purchased from BDH™.
l-Hydroxy-7-azabenzotriazole - purchased from Aldrich™ and used direct.
1-Hydroxybenzotriazole - purchased from Aldrich™ and used direct.
Lindlar's catalyst - purchased from Lancaster™.
Lithium acetylide ethylenediamine - purchased from Lancaster™ and used direct. 
Methanesulphonvl chloride -  purchased from Avocado™, distilled over phosphorus 
pentoxide and stored under argon.
Af-Methylmorpholine - purchased from Avocado™, distilled from calcium hydride 
before use and stored under argon.
NovaSyn Glycine-TGT resin - purchased from Novabiochem™ and stored at +4°C.
1,8-Octanediol - purchased from Aldrich™ and used direct.
Palladium on carbon - purchased from Lancaster™.
Phenol - purchased from Aldrich™ and used direct.
Piperidine - purchased from Avocado™, refluxed and distilled from calcium hydride 
before use.
Pyridine - purchased from Avocado™, refluxed and distilled from calcium hydride 
before use.
Pyrrole -  purchased from Lancaster™, distilled over calcium hydride and stored under 
argon at 0°C.
Tetraethylene glycol - purchased from Avocado™ and used direct.
Thioanisole - purchased from Aldrich™ and used direct.
4-Toluenesulfonic acid monohydrate - purchased from Avocado™ and used direct. 
Triethylamine - purchased from Avocado™, refluxed and distilled from calcium hydride 
before use.
Triethylene glycol - purchased from Avocado™ and used direct.
Triethylsilane - purchased from Avocado™ and used direct.
Trifluoroacetic acid - purchased from Avocado™ and used direct.
Triphenylmethyl chloride - purchased from Aldrich™ and used direct. 
Triphenylphosphine purchased from Aldrich™ stored under vacuum over phosphorus 
pentoxide for twenty-four hours prior to use.
Sodium azide, sodium iodide -  purchased from Lancaster™ and used direct.
Sodium hydride in mineral oil - purchased from Avocado™ and used direct (not 
washed).
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Sodium hydrogencarbonate, sodium carbonate, potassium carbonate, sodium 
hydroxide, potassium hydroxide, sodium thiosulfate - purchased from BDH™.
2.4.10 Reagents for visualisation.
/7-anisaldehyde dip -  To ethanol (2325 ml) were added in succession concentrated 
sulphuric acid (87.5 ml), glacial acetic acid (25 ml) and/7-anisaldehyde (6.25 ml). 
Compounds containing an aromatic acid-labile group were seen as bright orange spots on 
the TLC plates.
Ellman’s reagent -  Tris-(hydroxymethyl)-aminomethane was dissolved in water to give 
a concentration o f 0.5 M, and concentrated hydrochloric acid was added until pH 7.4 was 
reached. 0.1% (w/v) 5,5'-dithiobis-2-nitrobenzoic acid was added to 1:1 ethanol/0.5 M 
tris-(hydroxymethyl)-aminomethane hydrochloride to give Ellman’s reagent. Compounds 
containing a thiol group were seen as bright yellow spots on the TLC plates.
Kaiser test -  The following solutions were prepared; 5.0 g of ninhydrin in 100 ml of 
ethanol, 80.0 g o f phenol in 20.0 ml ethanol and 2.0 ml of 0.001 M aqueous potassium 
cyanide in 98.0 ml o f pyridine. To a few beads of resin previously washed with several 
volumes of ethanol are added two drops of each of the aforementioned solutions. The 
beads/mixture are then heated to 120°C for 4-6 minutes. A blue coloured beads indicates 
a positive amine test.
Ninhydrin dip -  A solution of 5 % ninhydrin in ethanol was prepared. Compounds 
containing a free amine group appeared as a blue spot on a white background. 
Phosphomolybdic acid dip - Phosphomolybdic acid (5 g) was dissolved in ethanol (100 
ml) and conc. sulphuric acid (5 ml) was added. Compounds containing non-aromatic 
double or triple bond appeared as a blue spot on a yellow background.
Potassium permanganate dip -  To potassium permanganate (0.2 g) in water (40 ml) 
was added sodium bicarbonate (1.0 g). All organic compounds appeared as a brown- 
yellow spot on a pink background.
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2.5 Experimental.
The experimental section is divided into two section; the first section details the 
synthesis o f the two Fmoc-amino acids, whilst the second section details peptide 
synthesis carried out.
(1) 9-Phenyl-xanthen-9-ol.149
OH
A solution of bromobenzene (21.06 ml, 200 mmol) in dry diethyl ether (60 ml) 
was prepared. A few drops o f this solution was added to dried magnesium turnings (4.74 
g, 195 mmol) in dry diethyl ether (60 ml), which was then heated to initiate the reaction. 
Once the reaction was initiated, the bromobenzene solution was added at such a rate so as 
to ensure that the reaction mixture maintained a steady reflux. Once all the bromobenzene 
had been added, xanthone (23.5 g, 120 mmol) was added. The reaction mixture was 
heated to reflux for a further three hours.
The reaction mixture was cooled to room temperature and the grey precipitate that 
formed was collected and washed with diethyl ether. This precipitate was dissolved in the 
minimum volume of concentrated hydrochloric acid giving a bright orange solution.
Water (1 L) was added to this solution, which was then repeatedly partitioned with 500 
ml volumes of dichloromethane until the aqueous solution had almost completely 
discharged its orange colour. The dichloromethane solution was partitioned with saturated 
aqueous sodium hydrogencarbonate, saturated aqueous sodium chloride, dried over 
anhydrous magnesium sulphate and concentrated in vacuo. The recovered solid was 
recrystallised from toluene and hexane (1:1) overnight, to give 25.39 g (77.5 %) of pale 
yellow crystals.
MP.: 158-160°C (Lit. 160-162°C)
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'H NMR (CDCh) 6 : 2.68 (1H, s, -OH), 7.05-7.45 (13H, m, H aromatic).
"C  NMR (CDCh) 6: 70.88 (1C, *C9), 116.82 (2C, *C4 & *C5), 123.96 (2C, *C2 
& *C7), 126.64 (2C. *C15 & *C13), 127.14 (1C, * 0 4 ) ,  127.65 (2C, *C8 a & *C9a), 
128.37 (2C. *C12 & *C I6 ), 129.42 (2C, *CI & *C8  or *C3 & *C'6 ), 129.45 (2C, *C1 & 
*C8  or *C3 & *C6 ). 148.39 (1C, *C11), 150.14 (2C, *C4a & *CI0a).
IR v /cm ' 1 (KBr): 3549 (st„ O-H stretch), 3041 (wk„ Aryl-H stretch), 2343 (wk„ 
aromatic overtone & combination band), 1601, 1570, 1475, 1445 (st., C=C aromatic 
stretch), 1312, 1290 (st., O-H bend), 1242, 1026 (md., C-O stretch).
MS m/z (+ve Ion FAB): 275 (M +H \ 6 .6  %), 274 (M \ 9.8 %), 257 ([C|yH,30 ] \  
1 0 0 %), 197 ([C13H9O 2]*, 67.5% ), 181 ([C,3H80 ] \  1.7%).
HRMS (FAB, NOB A matrix): Measured mass - 274.0980. Actual mass for M" - 
274.0994.
Analysis CiyHuO:: Calculated - C-83.20, H-5.14. Found - C-83.14, H-5.10.
To 1,8-octanediol (5.96 g, 40 mmol) in toluene (350 ml) was added hydrobromic 
acid (5.25 ml, 48 % aq. solution). The reaction mixture was heated to reflux for 24 hours 
after which time a further quantity of hydrobromic acid was added (1.5 ml). The reaction 
mixture was again left to reflux for 24 hours. The reaction mixture was cooled to room 
temperature and diethyl ether was added (250 ml). The aqueous hydrobromic acid layer 
was separated from the organic layer, the organic phase was partitioned with sat. aq. 
NaH C03 (100 ml), then 0.1 M phosphate buffer pH 7 (100 ml). The aqueous phase was 
back-extracted with diethyl ether ( 1 0 0  ml), the organic solutions were combined, dried 
over anhydrous MgSC>4 and concentrated in vacuo to give a yellow oil (8.56 g). This oil
(2) 8-Brom o-octan-l-ol.224
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was purified by N.P.S.G. chromatography, eluting with hexane/diethyl ether (50:50) to 
give 8.29 g (39.64 mmol, 99 %) of a pale yellow oil.
'H NMR (CDCIi) 6 : 1.33-1.59 (10H, m. BrCH;CH2(CH;)5CH;OH), 1.86 (2H, m, 
BrCH:CH:(CH2)<CH:OH). 3.40 (2H, t, J  = 6 .8  Hz. BrCH:(CH2)sCH2CH2OH), 3.63 (2 H, 
t, J  = 6 .6  Hz. BrCH2(CH2 )5CH2CH2OH).
"C  NMR (CDCIi) 5: 26.02, 28.46, 29.08, 29.58, 33.09, (6C, 
BrCH2CH 2 (CH 2 )2 CH2OH), 33.17 (1C, C7), 34.27 (1C. C8). 63.31 (1C, C l).
1R v /cm ' 1 (NaCl): 3331 (st., O-H stretch), 2930, 2855 (st., C-H stretch), 1464,
1437 (med., C-H deformation), 1057 (st., C -0 stretch), 644 (C-Br).
MS m/z (+ve Ion FAB): 211 (M-HC [8lBr], 40 %), 209 (M+H* [™Br], 42 %), 193 
([C«Hi5 8 lBr]', 19.8%). 191 ([C8H |5 7, Br]’, 23 %), 111 ([C8HI5] \ 44 %), 81 (8 lBr, 15%), 
79 (7l'Br, 17 %), 69 ([C5H9] \  100 %), 55 ([C4H7]', 82 %), 41 ([CjH,]", 53 %), 29 
([C2H5] ', 15%).
HRMS (FAB, NOBA matrix): Measured mass - 209.0550. Actual mass for M+H+ 
-209.0541.
(3) l-Bromo-8-(9-phenyl-xanthen-9-yloxy)-octane.
Br
To 8 -brom o-1-octanol (2) (5.41 g, 25.88 mmol) and 9-phenyl-xanthen-9-ol (1) 
(7.10 g, 25.88 mmol) was added glacial ethanoic acid (75 ml). Once complete dissolution 
had occurred, the solution was concentrated in vacuo. A further volume of glacial
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ethanoic acid (75 ml) was added, and again the resulting solution was concentrated in 
vacuo. This was repeated a further five times. Once all the glacial ethanoic acid had been 
removed for the final time, the remaining oil was re-dissolved in hexane (250 ml). This 
solution was partitioned with sat. aq. NaHC0 3  (100 ml) and sat. aq. NaCl (100 ml), the 
aqueous phase being back-extracted with hexane (100 ml). The organic solutions were 
combined, dried over anhydrous MgS0 4  and concentrated in vacuo to give 12.04 g (100 
%) of a yellow oil.
'H NMR (CDC13) 8 : 1.20-1.42 (8 H, m, BrCH2CH2(CH2)4CH2CH2OPx), 1.51 (2H, 
m, BrCH2CH2(CH2)4CH2CH2OPx), 1.84 (2H, m, BrCH2CH2(CH2)4CH2CH2OPx), 2.96 
(2H, t, J  = 6.2 Hz, BrCH2CH2(CH2)4CH2CH2OPx), 3.40 (2H, t, J  = 6 .8  Hz, 
BrCH2CH2(CH2)4CH2CH2OPx), 7.01-7.41 (13H, m, aromatic).
,3C NMR (CDCI3) 8 : 26.52, 28.50, 29.06, 29.47 (4C, 
BrCH2CH2(CH2)4CH2CH2OPx), 30.23 (1C, Cl),  33.2 (1C, C2), 34.31 (1C, C l), 63.35 
(1C, C8 ), 75.47 (1C, *C9), 116.54, 123.69, 124.22, 126.8, 126.85, 128.14, 129.22,
129.97, 149.89, 151.72 (18C, aromatic).
IR v /cm ' 1 (NaCl): 3033 (wk., Aryl-H stretch), 2932, 2855 (st., C-H stretch), 1603, 
1574, 1477, 1448 (st., C=C aromatic stretch), 1240 (med., aromatic), 1070, 1031 (st., C-0 
stretch).
MS m/z (+ve Ion FAB, NOBA matrix): 465 (M+H+[79Br], 0.7 %), 275 
([C ,9H ,502]+, 11.6 %), 257 ([C ,9H ,30 ] +, 100 %), 197 ([C ,3H 90 2]+, 62.8 %), 181 
( [C 13H 80 ] +, 13.5%).
Analysis C27H290 2Br: Calculated - C-69.68, H-6.28, Br-17.16. Found - C-69.72, 
H-6.20, Br-17.15.
(4) 6-Bromohexanoic acid tert-butyl ester.225
157
o
To 6 -bromohexanoic acid (2.5 g, 12.81 mmol) in dry dichloromethane (50 ml), at 
0°C under nitrogen was added tert-butyl alcohol (5.5 ml, 6 6  mmol, 5 eq.) followed by 
dimethylaminopyridine (0.156 g, 1.28 mmol, 0.1 eq.). After five minutes, 
dicyclohexylcarbodiimide (2.90 g, 14.08 mmol, 1.1 eq.) was added to this solution at 0°C. 
The solution was then left to warm to room temperature and stir for 12 hours.
After 12 hours the reaction was filtered and then partitioned with water (50 ml). 
The organic fraction was dried over anhydrous M gS0 4  and concentrated in vacuo. The 
remaining residue was purified by normal phase silica gel chromatography, eluting with 
hexane/ethyl acetate (90:10) to give 2.51 g (78 %) of a clear oil.
‘H NMR (CDC13) 6 : 1.45 (9H, s, -C(CH3)3), 1.46 (2H, m, 
Br(CH 2 )2 CH2 (CH2 )2COOC(CH3)3), 1.62 (2H, dt, J H2-h 3  = 7.3 Hz, J H3 -h 4  = 7.1 Hz, 
Br(CH 2 )3 CH2 CH2COOC(CH3)3), 1. 8 8  (2H, dt, J H4 -h5 = 7.1 Hz, J H5-h6 = 7.1 Hz, 
BrCH 2 CH2 (CH 2 )3COOC(CH3)3), 2.23 (2H, t, J = 7.3 Hz, Br(CH 2 )4 CH 2 COOC(CH3)3),
3.41 (2H, t , J =  6 . 8  Hz, BrCH 2 (CH 2 )4 COOC(CH3)3).
13C NMR (CDC13) 6 : 24.61 (1C, C3), 27.98, 32.83, 33.84 (3C, C4, C5 and C 6 ), 
28.49 (3C, -C(CH3)3), 35.70 (1C, C2), 80.51 (1C, -C(CH3)3), 173.20 (1C, C=0).
IR v /cm ' 1 (NaCl): 2977, 2936 (st., C-H stretch), 1728 (st., C = 0 stretch), 1456 
(med., C-H deformation), 1393 (wk., tert-butyl C-H stretch), 1367 (st., /er/-butyl C-H 
stretch), 1256, 1155 (st., C-O stretch).
MS m/z (+ve Ion FAB): 253 (M+H+[8 lBr], 15.4 %), 251 (M+H+[7 9 Br], 17.6 %), 
197 ([C6H l2 0 2 8 lBr]+, 34.1 %), 195 ([C6 Hi20 2 7 9 Br]+, 35.7 %), 179 ([C 6H ,0O 8 lBr]+, 14.3 
%), 177 ([C 6 H 10O 7 9 Br]+, 15.1 %), 115 ([C6 H n 0 2]+, 5.7 %), 57 ([C4 H9]+, 100 %), 41 
([C3 H5]+, 33.6 %).
(5) 6-Iodohexanoic acid tert-butyl ester.154
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To 6-bromohexanoic acid tert-butyl ester (4) (2.30 g, 9.2 mmol) in dry acetone 
(400 ml), under nitrogen, was added sodium iodide (41 g, 275 mmol, 30 eq.). The 
reaction mixture was left to stir in darkness, at room temperature for six days after which 
time, it was filtered, the separated solid being washed with diethyl ether which was added 
to the filtrate. The filtrate was concentrated in vacuo and then re-dissolved in diethyl ether 
(250 ml). This solution was partitioned with 5% aqueous sodium thiosulfate (100 ml) and 
saturated aqueous sodium chloride (100 ml). The aqueous phase was back-extracted with 
diethyl ether (150 ml). The organic solutions were combined, dried over anhydrous 
MgSC>4 and concentrated in vacuo to give a yellow oil. This oil was purified by N.P.S.G. 
chromatography, eluting with hexane/ethyl acetate (90:10) to give 2.53 g (93 %) of a 
yellow oil.
'H NMR (CDC13) 8: 1.39-1.49 (2H, m, I(CH2)2CCH2(CH2)2COOC(CH3)3), 1.45 
(9H, s, -C(CH3)3 ), 1.62 (2H, d t ,  = 7.3 Hz, JH3. H4 = 7.2 Hz, 
I(CH2)3CH 2 CH2COOC(CH 3)3 ), 1.84 (2H, d t ,  J H4-h5 = 7.2 Hz, J h s - h s  = 7.0 Hz, 
ICH2CH2 (CH2 )3COOC(CH 3 )3 ), 2.22 (2H, t ,  J = 7.3 Hz, I(CH2)4CH2 COOC(CH 3 )3 ), 3.19 
(2H, t,J =  7.0 Hz, lCH2(CH2)4 COOC(CH3)3 ).
I3C NMR (CDC13) 8: 6.89 (1C, C6), 24.39 (1C, C3), 28.51 (3C, -C(CH3)3), 30.30 
(1C, C4), 33.57 (1C, C5), 35.69 (1C, C2), 80.50 (1C, -C(CH3)3), 173.18 (1C, C=0).
IR v /cm '1 (NaCl): 2977,2933 (st., C-H stretch), 1729 (st., C = 0  stretch), 1456 
(med., C-H deformation), 1392 (wk., /er/-butyl C-H stretch), 1367 (st., /er/-butyl C-H 
stretch), 1254, 1155 (st., C-O stretch).
MS m/z (+ve Ion FAB): 299 (M+H+, 24 %), 243 ([C6H i20 2I]+, 55 %), 225 
([C6H 10OI]+, 24.5 %), 115 ([C6H ,,0 2]+, 25.5 %), 57 ([C4H9]+, 100 %).
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(6) l-Iodo-8-(9-phenyl-xanthen-9-yloxy)-octane.
To l-bromo-8-(9-phenyl-xanthenyloxy)-octane (3) (12.04 g, 25.88 mmol) in dry 
acetone (500 ml) was added sodium iodide (155.1 g, 1.03 mol, 40 eq.). The reaction was 
left stirring under nitrogen, in darkness and at room temperature for seven days.
After seven days, the reaction mixture was concentrated in vacuo. The remaining 
solid was dissolved in diethyl ether (400 ml) and sat. aq. NaHCC>3 (400 ml). The organic 
phase was then partitioned with 5% aqueous sodium thiosulfate (150 ml) and sat. aq.
NaCl (150 ml). The aqueous solutions were combined and back-extracted with diethyl 
ether (200 ml). The organic solutions were combined, dried over anhydrous MgSC>4 and 
concentrated in vacuo to give a dark yellow oil. This oil was purified by N.P.S.G. 
chromatography, eluting with chloroform (100 %) to give 12.9 g (97 %) of a pale yellow 
oil.
'H NMR (CDCI3) 8 : 1.22-1.41 (8 H, m, I C ^ C ^ C ^ C f y C f t O P x ) ,  1.54 (2H, 
m, ICH2CH2(CH2)4CH2CH20Px), 1.82 (2H, m, ICHiOM CP^CHzCHzOPx), 2.98 (2H, 
t, J=  6.2 Hz, ICH2CH2(CH2)4CH2CH2 0 Px), 3.2 (2H, t , J =  7.0 Hz, 
ICH2CH2(CH2)4CH2CH2OPx), 7.01-7.41 (13H, m, aromatic).
I3C NMR (CDCb) 5: 7.53 (1C, Cl), 26.53, 28.83, 29.46, 30.23, 30.83 (5C, 
ICH2CH2(CH2)5CH2OPx), 33.93 (1C, C2), 63.36 (1C, C8 ), 75.48 (1C, *C9), 116.54, 
123.69, 124.22, 126.8, 126.85, 128.14, 129.22, 129.97, 149.89, 151.72 (18C, aromatic).
1R v /cm ' 1 (NaCl): 3033 (wk., Aryl-H stretch), 2932, 2855 (st., C-H stretch), 1603, 
1574, 1477, 1448 (st., C=C aromatic stretch), 1240 (med., aromatic), 1070, 1032 (st., C-O 
stretch).
MS m/z (+ve Ion FAB, NOBA matrix): 535 (M+Na+, 2.5 %), 513 (M +H \ 1.3 %), 
257 ([C,9H i30 ]+, 100 %), 197 ([C,3H90 2]+, 46.2 %), 181 ([C,3H80 ]+, 6.7 %).
HRMS (FAB, NOBA matrix): Measured mass - 513.1270. Actual mass for M+H+ - 
513.1291.
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(7) l-(9-Phenyl-xanthen-9-yloxy)-dec-9-yne.
To lithium acetylide ethylenediamine (11.51 g, 125 mmol, 40 eq.), under nitrogen 
was added dry tetrahydrofuran (30 ml). This suspension was cooled to -78°C and 
hexamethylphosphoramide (6  ml) was added. A solution of l-iodo-8-(9-phenyl-xanthen-
9-yloxy)-octane (6 ) (12.81 g, 25 mmol) in THF (30 ml) was slowly added to the 
suspension at -78°C. Once all the solution had been added to the suspension, the reaction 
was allowed to warm to room temperature and left stirring overnight.
After 24 hours, the reaction was concentrated in vacuo. The remaining oil was 
dissolved in diethyl ether (350 ml). This solution was filtered and then partitioned with 
5% aq. sodium thiosulfate (150 ml) and sat. aq. NaCl (150 ml). The aqueous solutions 
were combined and back-extracted with diethyl ether (100 ml). The organic solutions 
were combined, dried over anhydrous MgSC>4 and concentrated in vacuo to give a brown 
oil. This oil was purified by N.P.S.G. chromatography, eluting with hexane/chloroform 
(50:50) with a few drops of triethylamine, to give 10.05 g (98 %) of a pale yellow oil.
‘H NMR (CDC13) 5: 1.2-1.56 (12H, m, HC^CCH^CH^CHzOPx), 1.95(1H, t , J  
= 2.6 Hz, HC=CCH2(CH2)6CH2OPx), 2.27 (2H, dt, J = 7.0 Hz and 2.6 Hz, 
HC=CCH2(CH2)6CH2OPx), 2.98 (2H, t , J=  6.3 Hz, H C ^C C H ^C H ^O ^O Px), 7.01-
7.41 (13H, m, aromatic).
I3C NMR (CDCI3) 6 : 18.79 (1C, C8 ), 26.58, 28.86, 29.08, 29.4, 29.56, 30.27 (6 C, 
HC=CCH2(CH2)6CH2OPx), 63.41 (1C, C l), 68.45 (1C, CIO), 75.45 (1C, *C9), 85.14 
(1C, C9), 116.54, 123.69, 124.22, 126.8, 126.85, 128.14, 129.21, 129.97, 149.93, 151.71 
(18C, aromatic).
IR v /cm ' 1 (NaCl): 3304 (st., alkyne C-H stretch), 3034 (wk., Aryl-H stretch), 
2932, 2856 (st., C-H stretch), 2120 (wk., C=C stretch), 1603, 1575, 1478, 1448 (st., C=C 
aromatic stretch), 1240 (med., aromatic), 1070, 1031 (st., C-O stretch).
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MS m/z (+ve Ion FAB, NOBA matrix): 433 (M+Na+, 2.1 %), 411 (M+H+, 1.7 %), 
257 ([C,9H ,30 ] +, 100 %), 197 ([C ,3H902]+, 28.4 %), 181 ([C13H8O f ,  4.7 %).
HRMS (FAB, NOBA matrix): Measured mass - 411.2300. Actual mass for M+H+ - 
411.2324.
(8) 2-Methylprop-2-yl 16-(9-phenyl-xanthen-9-yloxy)- 
hexadeca- 7-ynoate.
To l-(9-phenyl-xanthen-9-yloxy)-dec-9-yne (7) (2.05 g, 5 mmol) in dry THF (30 
ml), under nitrogen, was added HMPA (4 ml). This solution was cooled to -78°C and then 
n-butyl lithium (2.6 ml, 2.5 M, 6.5 mmol, 1.3 eq.) was slowly added. The solution was 
left to stir for 30 minutes after which time iodohexanoic acid tert-butyl ester (1.94 g, 6.5 
mmol, 1.3 eq.) in THF (25 ml) was added dropwise. Once this was complete, the reaction 
was allowed to warm to room temperature and was left to stir for 24 hours.
After 24 hours the reaction was concentrated in vacuo to yield a brown gum. The 
gum was dissolved in diethyl ether (300 ml) and the resulting solution was filtered. The 
filtrate was partitioned with 5% aq. sodium thiosulfate (150 ml) and sat. aq. NaCl (150 
ml). The aqueous solutions were combined and back-extracted with diethyl ether (150 
ml). The organic solutions were combined, dried over anhydrous MgSC>4 and 
concentrated in vacuo to give a brown oil. This oil was purified by N.P.S.G. 
chromatography, eluting with hexane/chloroform (40:60) with a few drops of 
triethylamine, to give 2.03 g (70 %) o f a pale yellow oil.
‘HNM R(CDC13)8 : 1.18-1.68 (18H, m, 
PxOCH2(CH2 )6 CH2 C=CCH 2 (CH2 )3CH2COOC(CH3)3), 1.45 (9H, s, -C(CH3)3), 2.13, 2.16 
(4H, 2 x t, PxO(CH2)7 CH2 C=CCH 2 (CH2)4 COOC(CH3)3), 2.22 (2H, t, J = 7.4 Hz, 
PxO(CH2)8C=C(CH2)4 CH2 COOC(CH3)3), 2.96 (2H, t, J =  6.3 Hz, 
PxOCH2 (CH2 )7C=C(CH2)5COOC(CH3)3), 6.99-7.39 (13H, m, H aromatic).
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,3C NMR (CDCb) 8 : 19.03, 19.15 (2C, C6  and C9), 25.08,26.62, 28.7, 29.24, 
29.47,29.55, 29.61, 30.28 (9C, C3, C4, C5, CIO, Cl 1, C12, C13, C14 and C15), 28.53 
(3C, -C(CH3)3), 35.92 (1C, C2), 63.41 (1C, C16), 75.44 (1C, *C9), 80.28 (1C, C(CH3)3), 
80.31, 80.79 (2C, C l  and C8 ), 116.52, 123.68, 124.25, 126.77, 126.84, 128.13, 129.19, 
129.96, 149.93, 151.71 (18C, aromatic), 173.48 (1C, C=0, Cl).
1R v/cm ' 1 (NaCl): 3034 (wk., Aryl-H stretch), 2931, 2856 (st., C-H stretch), 1733 
(st., C=0 stretch), 1603, 1575, 1478, 1447 (st., C=C aromatic stretch), 1392 (wk., tert- 
butyl C-H stretch), 1367 (st., tert-butyl C-H stretch), 1241, 1155, 1070, 1032 (st., ether or 
ester C-O stretch).
MS m/z (+ve Ion FAB, NOBA matrix): 603 (M +Na\ 4.7 %), 269 ([C,6H2 9 0 3]+, 4 
%), 257 ([Ci9H 130 ]+, 100 %), 197 ([C13H90 2]+, 35.7 %), 181 ([C,3H80 ] \  8 %), 57 
([C4H9] \  66.4 %).
(9) 2-Methylprop-2-yl 16-hydroxy-hexadeca-7-ynoate.
To 2-methylprop-2-yl 16-(9-phenyl-xanthen-9-yloxy)-hexadeca-7-ynoate (8 ) 
(1.39 g, 2.39 mmol) in dichloromethane (50 ml), under nitrogen, was added pyrrole (1.65 
ml, 1.6 g, 23.9 mmol, 10 eq.) followed by dichloroacetic acid (1.25 ml, 1.95 g, 15 mmol). 
This solution was left to stir for 10 minutes at room temperature. After 10 minutes, an 
excess of sat. aq. NaHC03 was added and the reaction was stirred vigorously to ensure 
mixing of aqueous and organic phases. The organic and aqueous phases were separated 
and the aqueous phase was partitioned with dichloromethane (100 ml). The organic 
solutions were combined, partitioned with sat. aq. NaCl (50 ml), dried over anhydrous 
MgSC>4, and concentrated in vacuo to yield a dark brown oil. This oil was purified by 
N.P.S.G. chromatography, using only 60 mm in height of silica and eluting with
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chloroform (100 %) with a few drops of triethylamine, to give 0.77 g (95 %) of a clear 
oil.
!H NMR (CDC13) 5: 1.28-1.68 (18H, m, 
HOCH2(CH2)6CH2C=CCH2(CH2)3CH2COOC(CH3)3), 1.45 (9H, s, -C(CH3)3), 2.14, 2.15 
(4H, 2 x t, HO(CH2)7CH2C=CCH2(CH2)4COOC(CH3)3), 2.22 (2H, t, J  = 7.5 Hz, 
HO(CH2)8C=C(CH2)4CH2COOC(CH3)3), 3.63 (2H, t, J = 6 .6  Hz, 
HOCH2(CH2)7C=C(CH2)5COOC(CH3)3).
13C NMR (CDCI3) 6 : 18.99, 19.09 (2C, C6  and C9), 25.05, 26.07, 28.65, 29.13, 
29.19, 29.46, 29.67, 33.15 (9C, C3, C4, C5, CIO, Cl 1, C12, C13, C14 and C15), 28.48 
(3C, -C(CH3)3), 35.90 ( 1C, C2 ), 63.31 ( 1C, C16), 80.3 ( 1C, C(CH3)3), 80.35, 80.73 (2C, 
C l and C8 ), 173.53 (1C, C=0, Cl).
IR v /cm ' 1 (NaCl): 3419 (broad, O-H stretch), 2931, 2856 (st., C-H stretch), 1732 
(st., C=0 stretch), 1392 (wk., tert-butyl C-H stretch), 1367 (med., tert-butyl C-H stretch),
1159 (st., ester C -0 stretch), 1058 (wk., ester C-O stretch).
MS m/z (+ve Ion FAB, NOBA matrix): 325 (M+H+, 4 %), 269 ([Ci6H2 9 0 3]+, 26.5 
%), 251 ([Ci6H2702]+, 8.3 %), 57 ([C4H9]+, 1 0 0  %).
(10) (Z)-2-Methylprop-2-yl 16-hydroxy-hexadeca-7-enoate.
o
A suspension of Lindlar catalyst (500 mg) in hexane/methanol (90:10, 20 ml) was 
prepared under nitrogen. This suspension was connected to a hydrogenation apparatus 
and exposed to hydrogen at atmospheric pressure, at room temperature until no further 
change in gas volume was detected. 2-Methylprop-2-yl 16-hydroxy-hexadeca-7-ynoate 
(9) (0.73 g, 2.26 mmol) in hexane (10 ml) was then added to this suspension and the 
reaction was left to absorb approximately 58 cm of hydrogen, at room temperature. Once
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this had occurred, the reaction mixture was dissolved in dichloromethane (80 ml) and 
filtered. The filtrate was concentrated in vacuo to yield 0.74 g (100 %) of a yellow oil.
]H NMR (CDCI3) 5: 1.23-1.68 (18H, m, 
HOCH2(CH2)6CH2CH=CHCH2(CH2)3CH2COOC(CH3)3), 1.45 (9H, s, - C ( C H 3) 3), 2 .0 2  
(4H, m, HO(CH2)7CH2CH=CHCH2(CH2)4COOC(CH3)3), 2.22 (2H, t, J=  7.5 Hz, 
H O ( C H 2 ) 8C H = C H ( C H 2)4C H 2C O O C ( C H 3) 3) , 3.65 (2 H, t ,y =  6 .6  Hz, 
H O C H 2 (C H 2 ) 7 C H = C H ( C H 2 ) 5 C O O C ( C H 3)3), 5.37 (2 H, m, 
H O C H 2(C H 2 )7 C H = C H (C H 2 ) 5 C O O C ( C H 3 )3).
,3C NMR (CDCI3) 8 : 25.43, 26.14, 27.45, 27.59, 29.16, 29.55, 29.60, 29.82,
29.89, 30.10, 33.21 (11C, C3, C4, C5, C6 , C9, CIO, Cl 1, C12, C13, C14 and C15), 28.48 
(3C, -C(CH3)3), 35.95 ( 1C, C2 ), 63.31 ( 1C, C16), 80.29 ( 1C, -C(CH3)3), 129.95, 130.42 
(2C, C l  and C8 ), 173.65 (1C, C=0, Cl).
IR v /cm*1 (NaCl): 3383 (broad, O-H stretch), 3004 (med., alkene C-H stretch), 
2927, 2855 (st., C-H stretch), 1732 (st., C=0 stretch), 1392 (wk., tert-butyl C-H stretch), 
1367 (med., ter/-butyl C-H stretch), 1154 (st., ester C -0 stretch), 1057 (wk., ester C-0 
stretch).
MS m/z (+ve Ion FAB, NOBA matrix): 349 (M+Na+, 0.6 %), 327 (M+H+, 5.2 %), 
271 ([Ci6H3i0 3]+, 57.3 %), 253 ([C16H2902]+, 40.4 %), 57 ([C4H9]+, 1 0 0  %).
HRMS (FAB, NOBA matrix): Measured mass -  349.2730. Actual mass for 
M+Na+- 349.2719.
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(11) (Z)-2-Methylprop-2-yl 16-azido-hexadeca-7-enoate.
o
O
To (Z)-2-methylprop-2-yl 16-hydroxy-hexadeca-7-enoate (10) (1.57 g, 4.82 
mmol) in dry dichloromethane/triethylamine (1:1, 40 ml) at 0°C, under nitrogen, was 
slowly added methanesulphonyl chloride (0.45 ml, 0.66 g, 5.78 mmol, 1.2 eq.). Once 
addition was complete, the reaction was left to stir for 2 hours at room temperature. After 
2  hours, an excess of sat. aq. NaHCOs was added and the reaction was stirred vigorously 
for 10 minutes. The reaction was then concentrated in vacuo until only a small volume of 
aqueous solution remained. The remaining concentrate was partitioned with 
dichloromethane (2 x 100 ml). The organic phase was partitioned with sat. aq. NaCl (75 
ml), dried over anhydrous MgSC>4 and concentrated in vacuo to give an oil.
The recovered oil was immediately dissolved in dry dimethylformamide (20 ml) 
and sodium azide (1.25 g, 19.3 mmol, 4 eq.) was added. This solution was left to stir 
under nitrogen, at room temperature for five days. After 5 days, the solution was 
concentrated in vacuo to yield a thick oil, which was dissolved in diethyl ether ( 2 0 0  ml) 
and filtered. The filtrate was partitioned with water (70 ml) and sat. aq. NaCl (70 ml). The 
aqueous solutions were combined and partitioned with diethyl ether (80 ml). The organic 
solutions were combined, dried over MgSC>4 and concentrated in vacuo to yield a pale 
brown oil. This oil was purified by N.P.S.G. chromatography, eluting with chloroform 
(100 %), to give 1.52 g (90 %) of a yellow oil.
'H NMR (CDC13) 6 : 1.21-1.45, 1.58 (14H and 4H, m, 
N3CH2(CH2)6CH2CH=CHCH2(CH2)3CH2COOC(CH3)3), 1.45 (9H, s, -C(CH3)3), 2.02 
(4H, m, N3(CH2)7CH2CH=CHCH2(CH2)4COOC(CH3)3), 2.21 (2H, t, J = 7.6 Hz, 
N3(CH2)8CH=CH(CH2)4CH2COOC(CH3)3), 3.26 (2H, t, J=  6.9 Hz, 
N3CH2(CH2)7CH=CH(CH2)5COOC(CH3)3), 5.37 (2H, m, 
N3CH2(CH2)7CH=CH(CH2)5COOC(CH3)3).
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,3C NMR (CDCI3) 5: 25.41, 27.10, 27.43, 27.57, 29.14, 29.23, 29.50, 29.55,
29.75, 29.8, 30.08 (11C, C3, C4, C5, C6 , C9, CIO, Cl 1, C12, C13, C14 and C15), 28.50 
(3C, -C(CH3)3), 35.96 (1C, C2), 51.88 (1C, C16), 80.25 (1C, -C(CH3)3), 130.0, 130.37 
(2C, C7 and C8 ), 173.57 (1C, C=0, Cl).
IR v /cm ' 1 (NaCl): 3004 (med., alkene C-H stretch), 2929, 2855 (st., C-H stretch), 
2096 (st., N3 stretch), 1732 (st., C=0 stretch), 1457 (med., C-H deformation), 1392 (wk., 
/erf-butyl C-H stretch), 1367 (med., tert-butyl C-H stretch), 1153 (st., ester C-O stretch).
MS m/z (+ve Ion FA B, N O B A  matrix): 324 ([C 2oH38 0 2N ]+, 9.2 %), 296 
([C16H3o02N3] \  12.3 %), 268 ( [C ,6H 3o 0 2N ] \  18 %), 250 ([C 16H 28O N ]+, 4.9%), 57 
([C 4H9]+, 100% ).
HRMS (FAB, NOBA matrix): Measured mass -  374.2760. Actual mass for 
M+Na+ - 374.2783.
(12) (Z)-2-Methylprop-2-yl 16-amino-hexadeca-7-enoate.
o
To (Z)-2-methylprop-2-yl 16-azido-hexadeca-7-enoate (11) (1.28 g, 3.65 mmol) 
in dry THF (40 ml), under nitrogen was added triphenylphosphine (1.43 g, 5.5 mmol, 1.5 
eq.). The solution was left to stir at room temperature for 5 hours, after which time water 
(10 ml) was added and the reaction was left to stir for a further 48 hours.
After 48 hours, the reaction was concentrated in vacuo, re-dissolved in diethyl 
ether/ hexane (1:1, 60 ml) and filtered. The filtrate was concentrated in vacuo to yield an 
oil, which was purified by N.P.S.G. chromatography, eluting with a gradient of 
chloroform and triethylamine (99:1 to 90:10), to give 1.11 g (93 %) of a pale yellow oil.
1H NMR (CDCI3) 5: 1.24-1.66 (18H, m, 
H2NCH2(CH2)6CH2CH=CHCH2(CH2)3CH2COOC(CH3)3), 1.45 (9H, s, -C(CH3)3), 2.02
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(4H, m, H2N(CH2)7CH2CH=CHCH2(CH2)4COOC(CH3)3), 2.21 (2H, t , J  = 7.5 Hz, 
H2N(CH2)8CH=CH(CH2)4CH2COOC(CH3)3), 2.69 (2H, t, J  = 6.9 Hz, 
H 2N C H 2 ( C H 2 )7 C H = C H ( C H 2 ) 5 C O O C ( C H 3 ) 3), 5.37 (2 H, m, 
H2NCH2(CH2)7CH=CH(CH2)5COOC(CH3)3).
13C NMR (CDC13) 6 : 25.39, 27.27, 27.42, 27.59, 29.13, 29.63, 29.79, 29.85,
29.89, 30.12 (11C, C3, C4, C5, C6 , C9, CIO, Cl 1, C12, C13, C14 and C15), 28.50 (3C, - 
C(CH3)3), 35.95 ( 1C, C2 ), 42.62 ( 1C, C16), 80.24 ( 1C, -C(CH3)3), 129.95, 130.44 (2 C,
C7 and C8 ), 173.57 (1C, C=0, Cl).
IR v /cm ' 1 (NaCl): 3004 (med., alkene C-H stretch), 2926, 2855 (st., C-H stretch), 
1733 (st., C=0 stretch), 1464 (med., C-H deformation), 1392 (wk., ter/-butyl C-H 
stretch), 1367 (med., tert-butyl C-H stretch), 1152 (med., ester C-O stretch).
MS m/z (+ve Ion FAB, NOBA matrix): 326 (M+H+, 55.9 %), 270 ([C i6H3202N]+,
87.2 %), 57 ([C4H9f , 1 0 0  %).
HRMS (FAB, NOBA matrix): Measured mass -  326.3040. Actual mass for M+H+ 
- 326.3059.
(13) (Z)-2-Methylprop-2-yl 16-(9-fluorenylmethyloxy- 
carbonylamido)-hexadeca- 7-enoate.
o
o
o
O
To (Z)-2-methylprop-2-yl 16-amino-hexadeca-7-enoate (12) (0.46 g, 1.415 mmol) 
in dry THF (20 ml), under nitrogen, at 0°C was added A-methylmorpholine (0.32 ml, 
0.286 g, 2.83 mmol, 2 eq.). This solution was left to stir for 10 minutes and then
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fluorenylmethyl chloroformate (0.73 g, 2.83 mmol, 2 eq.) in dry THF (15 ml) was slowly 
added. Once addition was complete, the reaction was stirred for a further hour at 0°C and 
then left to stir at room temperature overnight.
After 24 hours, the reaction was concentrated in vacuo, re-dissolved in 
dichloromethane (150 ml) and filtered. The filtrate was partitioned with 5% aq. potassium 
hydrogensulphate (70 ml) and sat. aq. NaCl (70 ml). The aqueous solutions were back- 
extracted with dichloromethane (100 ml). The organic solutions were combined, dried 
over anhydrous MgSC>4 and concentrated in vacuo to give a brown solid. This solid was 
purified by N.P.S.G. chromatography, eluting with chloroform (100 %), to give 0.69 g 
(89 %) of a pale brown solid.
!H NMR (CDC13) 5: 1.20-1.66 (18H, m, 
FmocHNCH2(CH2)6CH2CH=CHCH2(CH2)3CH2C0 2 C(CH3)3), 1.45 (9H, s, -C(CH3)3),
2.03 (4H, m, FmocHN(CH2)7CH2CH=CHCH2(CH2)4COOC(CH3)3), 2.21 (2H, t,J =  7.5 
Hz, FmocHN(CH2)8CH=CH(CH2)4CH2COOC(CH3)3), 3.17 (2 H, m, 
FmocHNCH2(CH2)7CH=CH(CH2)5COOC(CH3)3), 4.21 ( 1H, t, J=  6.7 Hz, *H9), 4.40 
(2H, d ,J  = 6 .8  Hz, -NHCOOCH2C,3H9), 4.98 ( 1H, bs, -NH-), 5.37 (2H, m, 
FmocHNCH2(CH2)7CH=CH(CH2)5COOC(CH3)3), 7.31 (2 H, t,J =  7.2 Hz, *H3 and *H6 ), 
7.40 (2H, t, J = 7.3 Hz, *H2 and *H7), 7.61 (2H, d, J = 1A  Hz, *H4 and *H5), 7.77 (2H, 
d ,J  = 7.5 Hz, *H1 and *H8 ).
,3C NMR (CDCI3) 5: 25.45, 27.17, 27.47, 27.63, 29.16, 29.64, 29.69, 29.83,
29.86, 30.13 (11C, C3, C4, C5, C6 , C9, CIO, Cl 1, C12, C13, C14 and C15), 28.50 (3C, - 
C ( C H 3) 3), 35.98 ( 1C, C2 ), 41.53 ( 1C, C16), 47.78 ( 1C, *C9), 66.90 (1C, - 
N H C O O C H 2C 13H 9 ) , 80.24 ( 1C, - C ( C H 3) 3), 120.33, 125.44, 127.4, 128.02 (8 C, *C1, *C2 , 
*C3, *C4, *C5, *C6 , *C7 and *C8 ), 130.02, 130.44 (2C, C7 and C8 ), 141.73, 144.49 
(4C, *C4a, *C4b, *C8 a and *C9a), 156.87 (1C, carbamate C=0), 173.59 (1C, C=0, Cl).
IR v /cm ' 1 (KBr): 3325 (st., N-H stretch), 3005 (wk., alkene C-H stretch), 2926, 
2854 (st., C-H stretch), 1730 (st., ester C=0 stretch), 1689 (st., carbamate C=0 stretch), 
1542 (med., carbamate N-H bend), 1465 (wk., C-H deformation), 1392 (wk., terf-butyl C- 
H stretch), 1367 (wk., tert-butyl C-H stretch), 1266, 1152 (st., ester and carbamate C-0 
stretch).
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MS m/z (+ve Ion FAB, NOBA matrix): 492 ([C3iH4204N]+, 7 %), 270 
([C,6H3202N]+, 9.6 %), 252 ([C,6H3oON]+, 5.8 %), 179 ([Ci4H ,,] \  100 %), 165 ([C13H9]+, 
1 2 %), 57 ([C4H9]+, 44.1 %).
HRMS (FAB, NOBA matrix): Measured mass -  570.3580. Actual mass for 
M+Na+ - 570.3559.
(14) (Z) 16-(9-Fluorenylmethyloxycarbonylamido)- 
hexadeca-7-enoic acid.
To (Z)-2-methylprop-2-yl 16-(9-fluorenylmethyloxycarbonylamido)-hexadeca-7- 
enoate (13) (0.75 g, 1.37 mmol) under nitrogen, at room temperature, was added 
trifluoroacetic acid/water (95:5, 63 ml). To this solution was immediately added 1,3- 
propanedithiol (0.693 ml, 0.747 g, 6.9 mmol, 5 eq.). The reaction was left to stir for 1.5 
hours, after which it was concentrated in vacuo to yield a pale brown solid. The solid was 
purified by N.P.S.G. chromatography, eluting initially with chloroform (100 %), then 
gradually changing to chloroform/methanol/acetic acid (92:6:2), to give 0.64 g (95 %) of 
an off-white solid.
]H NMR (CDC13) 6 : 1.27-1.65 (18H, m, 
FmocHNCH2(CH2)6CH2CH=CHCH2(CH2)3CH2C0 2 H), 2.01 (4H, m, 
FmocHN(CH2)7CH2CH=CHCH2(CH2)4C0 2H), 2.21 (2H, t, J=  4.9 Hz, 
FmocHN(CH2)8CH=CH(CH2)4CH2C0 2 H), 3.17 (2H, m, J = 6.4 Hz, 
FmocHNCH2(CH2)7CH=CH(CH2)5C0 2H), 4.21 (1H, t, J=  6.5 Hz, *H9), 4.40 (2H, d ,J  =
6 .8  Hz, -NHCOOCH2Ci3H9), 4.88 (1H, bs, -NH-), 5.37 (2H, m,
FmocHNCH2(CH2)7CH=CH(CH2)5C0 2H), 7.31 (2H, dt, J=  7.5 Hz and 0.8 Hz, *H3 and 
*H6 ), 7.40 (2H, t, J=  7.4 Hz, *H2 and *H7), 7.61 (2H, d,J =  7.4 Hz, *H4 and *H5), 7.77 
(2H, d,J =  7.5 Hz, *H1 and *H8 ).
O
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,3C NMR (CDCI3) 6 : 25.07, 27.17, 27.39, 27.60, 29.12, 29.62, 29.68, 29.77,
29.83, 30.10, 30.38 (11C, C3, C4, C5, C6 , C9, CIO, Cl 1, C12, C13, C14 and C15), 34.47 
(1C, C2), 41.53 (1C, C l6 ), 47.74 (1C, *C9), 66.90 (1C, -NHCOOCH2Ci3H9), 120.37, 
125.44, 127.44, 128.07 (8 C, ♦Cl, *C2, *C3, *C4, *C5, *C6 , *C7 and *C8 ), 129.95,
130.55 (2C, C l and C8 ), 141.75, 144.44 (4C, *C4a, ♦C4b, *C8 a and *C9a), 156.97 ( 1C, 
carbamate C=0), 179.65 (1C, C=0, Cl).
IR v /cm ' 1 (KBr): 3325 (st., O-H & N-H stretch), 3005 (wk., alkene C-H stretch), 
2926, 2854 (st., C-H stretch), 2600-2400 (wk., O-H stretching), 1730 (st., carboxylic C=0 
stretch), 1689 (st., carbamate C=0 stretch), 1542 (med., carbamate N-H bend), 1465 (wk., 
C-H deformation), 1266, 1152 (st., carbamate & carboxylic C -0 stretch).
MS m/z (+ve Ion FAB, NOBA matrix): 492 (M+H+, 3.2 %), 270 ([C16H320 2N]+, 
10 %), 252 ([Ci6H30ON]+, 5.3 %), 179 ([Ci4H,,]+, 100 %), 165 ([Ci3H9]+, 12 %).
HRMS (FAB, NOBA matrix): Measured mass -  492.3100. Actual mass for M+H+ 
-492.3114.
(15) 1 7-(9-Phenyl-xanthen-9-yloxy)-3,6,9,12,15-pentaoxa- 
heptadecan-l-ol.
To hexaethylene glycol (31.06 g, 110 mmol) was added 9-phenyl-xanthen-9-ol 
(2.74 g, 10 mmol) and 4-toluenesulfonic acid monohydrate (0.152 g, 0.8 mmol). This 
solution was left to stir under nitrogen, at room temperature for 48 hours. After 48 hours, 
triethylamine (0.5 ml, xs) was added and the reaction was left stirring for a further 10 
minutes. The reaction was then concentrated in vacuo to give an oil consisting of product 
in starting material. The product was recovered from the oil by reverse phase silica gel 
chromatography; the oil was loaded onto the R.P. silica gel as an emulsion in 
water/acetonitrile (90:10) and then a gradient was run, water/ acetonitrile (90:10) initially,
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acetonitrile (100 %) finally. Both the product (5.38 g) and hexaethylene glycol (28.23 g) 
were recovered. The product, a yellow oil was further purified by N.P.S.G. 
chromatography, eluting with ethyl acetate/hexane (1:1) to yield 4.04 g (75 %) of a pale 
yellow oil.
'H NMR (CDC13) 8 : 2.83 (1H, bs, HO(CH2CH20 )5CH2CH2OPx), 3.14 (2H, t, 7  = 
5.4 Hz, H0 (CH2CH20 )5CH2CH2 0 Px), 3.53-3.7 (22H, m, H0(CH2CH20 ) 5CH2CH20Px), 
7.01-7.41 (13H, m, H phenylxanthyl).
,3C NMR (CDC13) 5: 62.1 (1C, C l), 63.13 (1C, C17), 70.73, 70.85, 70.9, 70.94, 
70.96, 70.98,71.01,71.04, 73.0 (10C, C2-C16), 75.94 (1C, *C9), 116.62, 123.77, 123.82, 
126.81, 126.88, 128.16, 129.41, 130.0, 149.45, 151.7 (18C, phenylxanthyl).
IR v /cm ' 1 (NaCl): 3386 (st., O-H stretch), 3033 (wk., Aryl-H stretch), 2869 (st., 
C-H stretch), 1603, 1574, 1478, 1448 (st., C=C aromatic stretch), 1320, 1292, 1240 (st., 
O-H bend or aromatic), 1089 (vst., C-O stretch).
MS m/z (+ve Ion FAB): 561 (M +Na\ 4.3 %), 305 ( [C ^ e O v N a f , 1.3 %), 257 
([C19H 130 ]+, 5.7 %).
HRMS (FAB, NOBA matrix): Measured mass -  561.2480. Actual mass for 
M+Na+ - 561.2464.
(16) 1 7-(9-Phenyl-xanthen-9-yloxy)-l-azido-3,6,9,12,15- 
pentaoxaheptadecane.
To 17-(9-phenyl-xanthen-9-yloxy)-3,6,9,12,15-pentaoxaheptadecan-1 -ol (15) 
(5.38 g, 10 mmol) in dry dichloromethane/pyridine (5:4, 90 ml), under nitrogen, at 0°C 
was slowly added methanesulphonyl chloride (0.93 ml, 1.37 g, 12 mmol, 1.2 eq.). Once
172
addition was complete, the reaction was left to warm to room temperature. After 3 hours, 
excess sat. aq. NaHCC>3 was added and the reaction was left to stir for 10 minutes. The 
reaction was then concentrated in vacuo to a fifth of its original volume and to the 
remaining product was immediately added dichloromethane (300 ml). This organic 
solution was partitioned with water (50 ml) and sat. aq. NaCl (100 ml). The aqueous 
solution was back-extracted with dichloromethane (150 ml), the organic solutions were 
combined, dried over anhydrous sodium sulphate and concentrated in vacuo to give an 
orange oil.
The orange oil was dissolved in dimethylformamide (40 ml) and sodium azide 
(2.60 g, 40 mmol, 4 eq.) was added. This solution was left to stir under nitrogen, at room 
temperature for 96 hours. After 96 hours, the reaction was concentrated in vacuo to yield 
a yellow oil, which was re-dissolved in dichloromethane (300 ml). This organic solution 
was partitioned with sat. aq. NaCl (100 ml), the aqueous solution being back-extracted 
with dichloromethane (150 ml). The organic solutions were combined, dried over 
anhydrous Na2S0 4  and concentrated in vacuo to yield a dark yellow oil. This oil was 
purified by N.P.S.G. chromatography, eluting with hexane/ethyl acetate (1:1) to yield
1.55 g (85 %) of a pale yellow oil.
‘H NMR (CDCI3) 6 : 3.14 (2H, t, J = 5.36 Hz, ^ (C H z C ^ O ^ C ^ C f^ O P x ), 3.35 
(2H, t, J=  5.08 Hz, N3CH2CH2 0 (CH2CH20 )5Px), 3.57-3.66 (20H, m, 
N3CH2CH2(CH2CH2 0 )4CH2CH20 Px), 7.01-7.41 (13H, m, H phenylxanthyl).
,3C NMR (CDCI3) 5: 51.11 (1C, C l), 63.11 (1C, C17), 70.41, 70.85, 70.92, 71.0,
71.03,71.07,71.1 (10C, C2-C16), 75.93 (1C, *C9), 116.62, 123.76, 123.82, 126.81, 
126.88, 128.16, 129.41, 130.0, 149.45, 151.69 (18C, phenylxanthyl).
IR v /cm ' 1 (NaCl): 3030 (wk., Aryl-H stretch), 2869 (st., C-H stretch), 2106 (st., - 
N3 stretch), 1603, 1575, 1478, 1449 (st., C=C aromatic stretch), 1315, 1292, 1240 (st., 
aromatic), 1099 (vst., C-O stretch).
MS m/z (+ve Ion FAB): 586 (M+Na+, 100 %), 257 ([C19H 130 ]+, 73 %), 176 
([C8H 180 3N]+, 20 %), 23 (Na+, 72.5 %).
HRMS (FAB, NOBA matrix): Measured mass -  586.2550. Actual mass for 
M+Na+ - 586.2529.
(17) 17-Azido-3,6,9,12,15-pentaoxaheptadecan-l-ol.195
To 17-(9-phenyl-xanthen-9-yloxy)-1 -azido-3,6,9,12,15-pentaoxaheptadecane (16) 
(4.80 g, 8.52 mmol) in water/acetonitrile (9:1, 200 ml), under nitrogen, at room 
temperature was added dichloroacetic acid (5.0 ml, 7.81 g, 60 mmol). After 5 minutes of 
stirring, pyrrole (5.2 ml, 5.36 g, 80 mmol, 10 eq.) was added and the solution was left to 
stir for a further 5 minutes. The solution was then concentrated in vacuo to remove the 
acetonitrile, and filtered to remove the precipitate that had formed. The filtrate was 
further concentrated to half its volume, neutralised with solid NaHCC>3 and finally 
saturated with NaCl. This aqueous solution was partitioned with dichloromethane (4 x 
150 ml). The organic solutions were combined, dried over anhydrous Na2S0 4  and 
concentrated in vacuo to give a dark brown oil. This oil was purified by R.P.S.G. 
chromatography, loading the sample and eluting with water/acetonitrile (95:5), to yield 
2.61 g (99 %) of a pale yellow oil.
NMR (CDC13) 5: 2.44 (1H, bs, ^ C ^ C H z O C I^ C H z O H ), 3.38 (2H, t, J  =
5.1 Hz, N3CH2(CH2 0 CH2)5CH20 H), 3.59-3.76 (22H, m, N3CH2(CH2 0 CH2)5CH2 0 H).
I3C NMR (CDCI3) 5: 51.11 (1C, C l7), 62.15 (1C, C l), 70.40, 70.76, 70.95, 70.99,
71.03, 71.08, 72.93 (10C, C2-C16).
IR v /cm ' 1 (NaCl): 3346 (st., O-H stretch), 2869 (st., C-H stretch), 2104 (st., -N 3 
stretch), 1420 (wk., C-H deformation), 1349, 1300, 1252 (med., O-H bending), 1104 
(vst., C -0 stretch).
MS m/z (+ve Ion FAB): 346 (M+K+, 4 %), 330 (M+Na+, 8 %), 302 
([Ci2H25N0 6Na]+, 17.6 %).
HRMS (FAB, NOBA matrix): Measured mass -  330.1620. Actual mass for 
M+Na+- 330.1641.
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(18) Ethyl 20-azido-3,6,9,12,15,18-hexaoxaicosanoate.
EtO
o
To 17-azido-3,6,9,12,15-pentaoxaheptadecan-l-ol (17) (5.92 g, 19.25 mmol) in 
dry dichloromethane, under nitrogen, at 0°C was added ethyl diazoacetate (5.06 ml, 5.49 
g, 48 mmol, 2.5 eq.). To this was added distilled boron trifluoride etherate (2 drops) and 
the solution was left to stir for 24 hours. After 24 hours, more ethyl diazoacetate (1 ml,
1.08 g, 9.6 mmol, 0.5 eq.) and distilled boron trifluoride etherate (3 drops) was added. 
The solution was then left to stir for a further 72 hours.
After 72 hours, aq. potassium hydroxide (10 ml, 1M) was added and the solution 
was left to stir vigorously for 15 minutes. Dichloromethane (120 ml) was added and the 
organic and aqueous phases were separated. The aqueous solution was saturated with 
NaCl and partitioned with dichloromethane (50 ml). The organic solutions were 
combined, partitioned with sat. aq. NaCl (100 ml), dried over anhydrous Na2SC>4 and 
concentrated in vacuo to yield a yellow oil. This oil was purified by N.P.S.G. 
chromatography, eluting with chloroform/acetonitrile (70:30) to yield 4.1 g (54 %) of a 
pale yellow oil.
*H NMR (CDC13) 8 : 1.28 (3H, t, J = 7.14 Hz, ^CHztCHzOCHz^COzCHzC^), 
3.38 (2H, t, J = 4.9 Hz, ^CHztCHzOCHz^COzEt), 3.65-3.79 (22H, m, 
N3CH2(CH2 0 CH2)5CH2 0 CH2C0 2 Et), 4.14 (2H, s, NaCHztCHzOCHz^CHzOCHzCOzEt), 
4.21 (2H, q, J = 7.1 Hz, NsCHz^HzOCHz^COzCHzC^).
,3C NMR (CDCI3) 8 : 14.58 (1C, -CO2CH2CH3), 51.09 (1C, C20), 61.13 (1C, 
CO2CH2CH3), 69.12, 70.40, 70.98, 71.01, 71.06, 71.08, 71.28 (12C, C2-C19), 170.81 
(1C ,C1,C=0).
IR v /cm ' 1 (NaCl): 2870 (st., C-H stretch), 2104 (st., -N3 stretch), 1751, 1732 (st., 
C=0 stretch), 1450 (wk., C-H deformation), 1286 (med., ester C-O stretch), 1122 (vst., C- 
O stretch).
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MS m/z (+ve Ion FAB): 432 (M+K+, 1.1 %), 416 (M+Na+, 9.1 %), 394 (M+H+,
13.2 %), 366 ([C16H320 8N]+, 9.5 %), 45 ([C2H40 ]+, 100 %).
HRMS (FAB, NOBA matrix): Measured mass -  416.2020. Actual mass for 
M+Na+- 416.2009.
(19) 20-Azido-3,6,9,12,15,18-hexaoxaicosanoic acid.
o
Synthesis 1.
To ethyl 20-azido-3,6,9,12,15,18-hexaoxaicosanoate (18) (4.10 g, 10.43 mmol) in 
methanol/water (2 :1 , 150 ml), under nitrogen, at room temperature, was added lithium 
hydroxide (6.0 g, 0.14 mmol). The solution was left stirring for 24 hours, after which time 
the solution was concentrated in vacuo to remove methanol. The remaining aqueous 
solution was acidified to pH 2 with concentrated hydrochloric acid. This solution was 
partitioned with dichloromethane (3 x 100 ml). The organic solutions were combined, 
dried over anhydrous Na2SC>4 and concentrated in vacuo to yield 3.80 g (99 %) of a 
yellow oil. No purification was necessary.
Synthesis 2.
To 17-azido-3,6,9,12,15-pentaoxaheptadecan-l-ol (17) (1.01 g, 3.29 mmol) in DMF 
(5 ml) was added potassium bromoacetate (1.45 g, 8.2 mmol) and potassium hydroxide 
(1.38 g, 24.6 mmol). The reaction was left to stir at 50°C for 24 hours, after which time 
water (5 ml, 277 mmol) was added and the reaction was left stirring at 50°C for a further 
24 hours.
The reaction was then concentrated in vacuo and re-dissolved in water (150 ml). 
This aqueous solution was first partitioned with dichloromethane (3 x 50 ml), which was 
discarded and then acidified to pH 2 with conc. HC1. The acidified aqueous solution was 
partitioned with dichloromethane (4 x 100 ml), the organic solutions were combined,
dried over anhydrous Na2S0 4  and concentrated in vacuo to yield 0.88 g (73 %) of a 
brown oil. Purification by N.P.S.G. chromatography was not necessary.
'H NMR (CDCI3) 6 : 3.38 (2H, t, J = 5.0 Hz, ^ C ^ C ^ O C H z ^ C C ^ H ), 3.65-3.77 
(22H, m, N3CH2(CH2 0 CH2)5CH2 0 CH2C0 2H), 4.16 (2H, s, 
N3CH2(CH2 0 CH2)5CH2 0 CH2C0 2H).
13C NMR (CDC13) 8 : 51.07 (1C, C20), 69.29, 70.37, 70.74, 70.8, 70.85, 70.91, 
71.0, 71.04, 71.67 (12C, C2-C19), 173.04 (1C, C l, C=0).
IR v /cm ' 1 (NaCl): 3419 (med., C=0 overtones), 2877 (st., C-H stretch), 2534 
(wk., O-H stretch), 2109 (st., -N3 stretch), 1733 (st., C=0 stretch), 1447 (wk., C-H 
deformation), 1119 (st., C-O stretch).
MS m/z (+ve Ion FAB): 404 (M+K+, 2.4 %), 388 (M +Na\ 25.7 %), 366 (M+H+,
3.1 %), 366 ([C|4H30O8N]+, 7.6 %), 45 ([C2H 40]\ 100 %).
HRMS (FAB, NOBA matrix): Measured mass -  388.1710. Actual mass for 
M+Na+- 388.1696.
(20) 20-Amino-3,6,9,12,15,18-hexaoxaicosanoic acid.
o
A suspension of Lindlar catalyst (500 mg) in propan-2-ol (20 ml) was prepared 
under nitrogen. This suspension was connected to a hydrogenation apparatus and exposed 
to hydrogen at atmospheric pressure, at room temperature until no further change in gas 
volume was detected. 20-Azido-3,6,9,12,15,18-hexaoxaicosanoic acid (19) (3.8 g, 10.4 
mmol) in propan-2 -ol ( 1 0  ml) was then added to this suspension and the reaction was left 
stirring under hydrogen, at room temperature until no more hydrogen was absorbed. Once 
no further change in hydrogen absorption had been observed, the reaction mixture was 
dissolved in dichloromethane (80 ml) and filtered. The filtrate was concentrated in vacuo
to yield an orange oil, which on standing under vacuum for several days became an 
orange solid (3.53 g, 100 %).
‘H NMR (CDCI3) 5: 3.04 (2H, t , J=  4.4 Hz, H zN C H itC^O C^^C O zH ), 3.61-
3.73 (22H, m, H z N C ^ C & O C ^ s C & O C ^ O ^ H ) , 3.96 (2H, s, 
H2NCH2(CH20CH2)5CH20CH2C02H).
13C NMR (CDCI3) 6 : 41.04 (1C, C20), 67.12, 69.29, 69.68, 69.82, 70.15, 70.28, 
70.41, 70.53, 70.75, 70.78, 71.91 (12C, C2-C19), 173.04 (1C, C l, C=0).
IR v /cm ' 1 (NaCl): 3400-2100, 1700-1550 (multiple broad bands characteristic of 
zwitterionic group of amino acids; stretch, deformation & vibration o f-N H 3+ & -C 02 ),
1118.6 (st., C-0 stretch).
MS m/z (+ve Ion FAB): 378 (M+K+, 37.5 %), 362 (M+Na+, 31.2 %), 366 (M+H+, 
100 %), 322 ( [ C , 4H 2 8 0 7N ] +, 13.7 %).
HRMS (FAB, NOBA matrix): Measured mass -  340.1990. Actual mass for M+H+ 
-340.1971.
(21) 20-(9-Fluorenylmethyloxycarbonylamido)- 
3,6,9,12,15,18-hexaoxaeicosanoic acid.147
Synthesis 1
To 20-amino-3,6,9,12,15,18-hexaoxaicosanoic acid (20) (1.23 g, 3.6 mmol) in 
dioxane/water (1:1, 60 ml), at 0°C was added sodium bicarbonate (1.09 g, 7.92 mmol, 2.2
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eq.). This solution was left to stir for 10 minutes, after which time fluorenylmethyl 
chloroformate (2.04 g, 7.92 mmol, 2.2 eq.) in dioxane (15 ml) was slowly added. Once 
addition was complete, a further quantity of fluorenylmethyl chloroformate (0.19 g, 0.36 
mmol, 0.2 eq.) and sodium bicarbonate (0.05 g, 0.36 mmol, 0.2 eq.) dissolved in 
water/dioxane (1:1,5 ml) was added every half hour over five hours to the reaction 
stirring at room temperature.
After 5 hours the reaction was then concentrated in vacuo and to the resulting 
solid was added hydrochloric acid (100 ml, 1M). The aqueous solution/emulsion was 
partitioned with dichloromethane (3 x 150 ml), the organic solutions were combined, 
dried over anhydrous Na2SC>4 and concentrated in vacuo to give a yellow residue. This 
residue was purified by N.P.S.G. chromatography, eluting with 
chloroform/methanol/acetic acid (90:10:5) to yield 1.13 g (56 %) of a pale yellow, 
viscous oil.
Synthesis 2
To vigorously stirring 20-(9-fluorenylmethyloxycarbonylamido)-3,6,9,12,15,18- 
hexaoxaeicosan-l-ol (49) (19.17 g, 35.0 mmol) in acetone (500 ml) at 0°C was very 
slowly added chromium trioxide (10.50 g, 105 mmol, 3 eq.) in sulphuric acid (1.5 M, 210 
ml, 315 mmol, 9 eq.). Once addition was complete the reaction was left to warm to room 
temperature and to stir for 24 hours.
After 24 hours water (1000 ml) was added to the reaction along with reverse 
phase silica gel (250 g). The reaction mixture was concentrated in vacuo until the volume 
had decreased by approximately one quarter and more water (500 ml) was added. The 
reaction mixture was once again concentrated in vacuo until no acetone could be detected 
to be present in the mixture. The mixture was then filtered to recover the R.P. silica gel 
which was washed with copious amounts of water until the silica gel was almost 
colourless. The R.P. silica gel was then washed with acetonitrile (4 x 400 ml) and 
chloroform (3 x 300 ml). The organic fractions were combined and concentrated in vacuo 
to give a green oil. This oil was purified by N.P.S.G. chromatography, eluting initially 
with chloroform only, then gradually changing to chloroform/methanol (95:5) and finally 
gradually changing to chloroform/methanol/acetic acid (85:10:5) to yield 14.2 g (71.0 %) 
of a yellow oil.
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'H NMR (CDCI3) 5: 3.38 (2H, m, Fm ocHNCH^CH^CH^CC^H), 3.59-3.62 
(22H, m, FmocHNCH2(CH2 0 CH2)5CH2 0 CH2C0 2H), 4.04 (2H, s, 
FmocHNCH2(CH2OCH2)5CH2OCH2C0 2H), 4.22 (1H, t, J =  6.7 Hz, *H9), 4.42 (2H, d, J  
= 6.7 Hz, -NHCOOCHaCuH,), 5.73 (1H, bs, -NH-), 7.31 (2H, t, J  = 1A  Hz, *H3 and 
*H6 ), 7.41 (2H, t, J = 7.4 Hz, *H2 and «H7), 7.61 (2H, d, J = 7.4 Hz, *H4 and *H5), 7.77 
(2H, d, J  = 7.4 Hz, *H1 and *H8 ).
I3C NMR (CDCI3) 5: 41.01 (1C, C20), 47.49 (1C, *C9), 66.61 (1C, - 
NHCOOCH2Ci3H9), 69.98, 70.02, 70.12, 70.25 (12C, C2-C19), 120.12, 125.25, 127.25, 
127.85 (8 C, *C1, *C2, *C3, *C4, *C5, *C6 , *C7 and *C8 ), 141.50, 144.21 (4C, *C4a, 
*C4b, *C8 a and *C9a), 156.85 (1C, carbamate C=0), 172.84 (1C, C l, C=0).
IR v /cm ' 1 (NaCl): 3333 (st., O-H & N-H stretch), 2871 (st., C-H stretch), 2550 
(wk., O-H stretch), 1717 (st., acid C=0 stretch), 1605 (st., carbamate C=0 stretch), 1538 
(med., carbamate N-H bend), 1450 (wk., C-H deformation), 1252 (st., carbamate C-0 
stretch)., 1109 (st., C-O stretch).
MS m/z (+ve Ion FAB): 584 (M+Na+, 57.5 %), 562 (M+H+, 2.3 %), 179 
([C,4H „]+, 44.6 %), 165 ([C13H9]+, 5.5 %), 23 (Na+, 100 %).
MS m/z (+ve ES): 600 (M+K+, 27 %), 584 (M+Na+, 99 %), 362 
([C,4H2 9 0 8N]+Na+, 3 %), 340 ([Ci4H3o0 8N]+, 2 %).
HRMS (FAB, NOBA matrix): Measured mass -  584.2495. Actual mass for 
M+Na+ - 584.2472.
(22) 1 l-Phenylmethyloxy-3,6,9-trioxaundecan-l-ol.226
To tetraethylene glycol (34.53 ml, 38.84 g, 200 mmol) and tetrabutylammonium 
bromide (0.5 g, cat.) in dry tetrahydrofuran (150 ml) was added cautiously sodium 
hydride (1.20 g, 30 mmol, 60% w/w in mineral oil). After stirring for 20 minutes, benzyl
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chloride (2.30 ml, 2.53 g, 20 mmol) was added to the reaction and the reaction was heated 
to reflux under nitrogen for 24 hours. After 24 hours, the reaction was cooled to room 
temperature and concentrated in vacuo to give an oil. This oil was dissolved in 
dichloromethane (300 ml) and partitioned with sat. aq. NaCl (2 x 200 ml). The organic 
phase was dried over anhydrous sodium sulphate and concentrated in vacuo to give a 
yellow oil. This oil was purified by N.P.S.G. chromatography, eluting initially with 
chloroform and then gradually changing to chloroform/methanol (90:10), to yield 5.68 g 
(99 %) of a pale yellow oil.
!H NMR (CDC13) 6 : 2.94 (1H, bs, -OH), 3.57-3.72 (16H, m, 
H0 (CH2CH2 0 )3CH2CH2 0 CH2C6H5), 4.57 (2H, s, H0 (CH2CH2 0 )3CH2CH2 0 CH2C6H5), 
7.25-7.35 (5H, m, H O ^ ^ C H zO b C H zC H zO O ^H s).
,3C NMR (CDCI3) 5: 62.05 (1C, C l), 69.87, 70.75, 70.97, 71.03, 72.94 (6 C, C2- 
11), 73.60 (1C, -OCH2C6H5), 127.95, 128.10, 128.72, 138.56 (6 C, benzyl).
IR v /cm ' 1 (NaCl): 3362 (vst., O-H stretch), 3062, 3030 (wk., Aryl-H stretch),
2869 (st., C-H stretch), 1959, 1719 (wk., aromatic overtone), 1452, 1350 (med., O-H 
bend), 1276, 1249 (med., C-H bend), 1102 (vst., C-0 stretch).
MS m/z (+ve Ion FAB): 307 (M+Na+, 42 %), 285 (M+H+, 99 %), 195 
([C8H 190 5]+, 10%).
HRMS (+ve ion FAB): Measured mass -  285.1697. Actual mass for M+H+ - 
285.1702.
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(23) ll-Phenylmethyloxy-3,6,9-trioxaundecanoic acid.
HO
To 26-(9-fluorenylmethyloxycarbonylamido)-3,6,9,12,15,18,21,24- 
octaoxahexaeicosan-1-ol (22) (2.84 g, 10 mmol) in aqueous sulphuric acid (75 ml, 1.5 
M), adjusted to pH 1.25 by addition of water and at 0°C was slowly added solid 
chromium (VI) trioxide (3.99 g, 40 mmol). The reaction was left to stir for 24 hours at 
room temperature. After 24 hours, sufficient sodium chloride was added to achieve 
saturation. The aqueous solution was then partitioned with dichloromethane ( 6  x 75 ml). 
The organic fractions were combined, partitioned with sat. aq. NaCl (150 ml), dried over 
anhydrous sodium sulphate and concentrated in vacuo to give a yellow oil. The product 
was isolated from the oil by N.P.S.G. chromatography, eluting with ethyl acetate only to 
yield 2.50 g (84 %) of a pale yellow oil.
’H NMR (CDC13) 5: 3.74-3.89 (12H, m, C eH sC ^O tC ^C ^O ^C H zO ^H ), 4.20 
(2H, s, C6H5CH2 0 (CH2CH2 0 )3CH2CC>2H), 4.57 (2H, s, 
C 6H 5 C H 2 0 ( C H 2 C H 2 0 ) 3 C H 2 C 0 2H ) ,  7.32-7.40 (5H, m, 
C6H5CH2 0 (CH2CH2 0 )3CH2C0 2H).
13C NMR (CDCI3) 8 : 69.18, 69.78, 70.72, 70.88, 71.07, 71.52,71.60 (7C, 
C6H5CH20(CH2CH20)3CH2C02H), 73.68 (1C, C6H5CH20(CH2CH20)3CH2C02H),
128.13, 128.77, 138.34 (6 C, CsHsCT^CKCHjCHzO^O^CC^H), 173.02 (1C, 
C6H5CH2 0 (CH2CH2 0 )3CH2C0 2H).
IR v /cm ' 1 (NaCl): 3438 (st., O-H stretch), 3031 (wk., Aryl-H stretch), 2873 (st., 
C-H stretch), 1962 (wk., aromatic overtone), 1734 (st., C=0 stretch), 1452, 1351 (med., 
O-H bend), 1248, 1206 (med., C-H bend), 1109 (vst., C-0 stretch).
MS m/z (ES +ve): 321 ([M+Na]+, 100 %), 316 ([M+H20 ]+, 95 %), 299 ([M+H]+,
18% ).
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HRMS (FAB, NOBA matrix): Measured mass -  321.2470. Actual mass for 
M+Na+- 321.2461.
(24) ll-Triphenylmethyloxy-3,6,9-trioxaundecan-l-ol.195
To tetraethylene glycol (213.65 g, 1.1 mol) and triethylamine (20.24 g, 27.8 ml, 
2 0 0  mmol) in dry dichloromethane (1500 ml) was added dropwise triphenylmethyl 
chloride (27.88 g, 100 mmol) in dry dichloromethane (500 ml). This solution was left to 
stir under argon, at room temperature for 24 hours. After 24 hours, the reaction was 
concentrated in vacuo to give a yellow oil. This oil was then re-dissolved in 
dichloromethane (1000 ml), partitioned with sat. aq. NaHCC>3 (500 ml), water (3 x 400 
ml) and finally sat. aq. NaCl (500 ml). The organic layer was separated, dried over 
anhydrous sodium sulphate and concentrated in vacuo to give a yellow oil. The recovered 
product, 42.2 g of yellow oil (95 % from triphenylmethyl chloride) was used without 
further purification.
'H NMR (CD3CN) 5: 2.75 (1H, bs, ^H s^C O C ^ C ^ O C H z^ C H zO H ), 3.16 
(2H, t, .7 = 5.1 Hz, (C6H5)3COCH2(CH2 0 CH2)3CH2OH), 3.47-3.63 (14H, m, 
(C6H5)3COCH2(CH20CH2)3CH2OH), 7.25-7.49 (15H, m, 
(C6H5)3C0 CH2(CH20 CH2)3CH2 0 H).
,3C NMR (CD3CN) 5: 60.76 (1C, Cl), 63.17 (1C, Cl 1), 69.87, 69.91, 70.02,
70.04, 70.20, 72.07 (6 C, C2-C10), 86.14 ( 1C, -OC(C6H5)3), 126.77, 127.54, 128.31,
144.03 (18C, -OC(C6H5)3).
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IR v /cm ' 1 (NaCl): 3440 (vst., O-H stretch), 3057 (wk., Aryl-H stretch), 2872 (st., 
C-H stretch), 1597 (wk., C=C aromatic stretch), 1489, 1448 (med., O-H bend or 
aromatic), 1080 (vst., C-O stretch).
MS m/z (+ve ESI): 459 (M +Na\ 99 %), 243 ([C,9Hl5]+, 23 %), 215 
([CgHnOsNaf, 42 %).
HRMS (+ve ESI): Measured mass -  459.21273. Actual mass for M+Na+ - 
459.21420.
(25) ll-Triphenylmethyloxy-l-azido-3,6,9-trioxa-undecane.
To 1 l-triphenylmethyloxy-3,6,9-trioxaundecan-l-ol (24) (21.82 g, 50 mmol) and 
triethylamine (15.33 ml, 11.13 g, 110 mmol, 2.2 eq.) in dry dichloromethane (150 ml), 
under argon at 0°C was added dropwise methanesulfonyl chloride (7.74 ml, 11.45 g, 100 
mmol, 2 eq.) in dry dichloromethane (50 ml). Once addition was complete, the reaction 
was left to stir at room temperature. After three hours another volume of dichloromethane 
( 2 0 0  ml) was added to the reaction and the organic solution was partitioned with sat. aq. 
NaHC0 3  (2 x 200 ml). The organic phase was then partitioned with sat. aq. NaCl (200 
ml), dried over anhydrous sodium sulphate and concentrated in vacuo to give a brown oil. 
This oil was azeotroped several times with toluene to remove water.
The brown oil was dissolved in dimethylformamide (150 ml) and sodium azide 
(13.0 g, 200 mmol) was added. The reaction was left to stir for four days after which time 
it was concentrated in vacuo and then dissolved in dichloromethane (250 ml). This 
organic solution was partitioned with water (2 x 150 ml) followed by sat. aq. NaCl (200 
ml), dried over anhydrous sodium sulphate and concentrated in vacuo to yield a dark 
brown oil. The product was isolated from this oil by N.P.S.G. chromatography, eluting 
initially with chloroform/hexane ( 1 :1), then gradually changing to chloroform only to 
yield 21.0 g (91 %) of a yellow oil.
'H NMR (CDCI3) 8 : 3.25 (2H, t, J = 5.1 Hz, (C sH s^C O Q M C ^O C ^hC H zN j),
3.34 (2H, t, J = 4.8 Hz, ^H s^C O C H ztC H zO C H jbQ L ^) 3.63-3.69 (12H, m, 
(C6H5)3C0CH2(CH20CH2)3CH2 N3), 7.20-7.48 (15H, m, 
(C6H5)3COCH2(CH2OCH2)3CH2 N3).
OC(C6H5)3).
IR v /cm*1 (NaCl): 3059 (wk., Aryl-H stretch), 2870 (st., C-H stretch), 2108 (vst., - 
N3 stretch), 1597 (wk., C=C aromatic stretch), 1489, 1448 (med., aromatic), 1092 (vst., 
C -0 stretch).
MS m/z (+ve Ion FAB): 484 (M+Na+, 98 %), 243 ([(C6H5)3C]+, 63 %).
HRMS (+ve ion FAB): Measured mass -  484.2203. Actual mass for M+Na+ - 
484.2212.
(26) ll-Triphenylmethyloxy-l-amino-3,6,9-trioxaundecane.
To 1 l-triphenylmethyloxy-l-azido-3,6,9-trioxaundecane (25) (21.0 g, 45.5 mmol) 
in tetrahydrofuran (100 ml) was added triphenylphosphine (14.33 g, 54.6 mmol, 1.2 eq.). 
After two hours water (3 ml) was added to the reaction. The reaction was then left to stir 
under argon at room temperature for 24 hours after which time it was concentrated in 
vacuo. To the remaining oil/solid was added diethyl ether (65 ml) and the reaction 
mixture was then filtered and concentrated in vacuo. The product was isolated by 
N.P.S.G. chromatography, eluting initially with a large volume of chloroform and then 
changing to chloroform/methanol/triethylamine (85:10:5) to yield 19.0 g (96 %) of a pale 
yellow oil.
13C NMR (CDCI3) 8:51.10 (1C, C l), 63.78 (1C, C 11), 70.42, 71.10, 71.16, 71.22 
(6 C, C2-C10), 86.98 (1C, -OC(C6H5)3), 127.32, 128.15, 129.15, 144.57 (18C, -
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'H NMR (CDCI3) 5: 2.83 (2H, t, J=  5.2 Hz, ^ H s h C O C ^ C ^ O C ^ ^ C ^ N H z )
3.25 (2H, t, J = 5.2 Hz, (CeHsfcCOOfctC^OCHzfeOfcN^), 3.50 (2H, t,J =  5.2 Hz, 
(C6H5)3C0 (CH2 0 CH2)3CH2CH2NH2), 3.61-3.69 (10H, m, 
(C6H5)3C0CH2(CH20CH2)2CH20CH2CH2 NH2), 7.19-7.49 (15H, m, 
(C6H5)3C0CH2(CH20CH2)3CH2 NH2).
,3C NMR (CDCI3) 6 : 42.15 (1C, C l), 63.79 (1C, Cl 1), 70.75, 71.09, 71.11, 71.14, 
71.22, 73.71 (6 C, C2 -C1 0 ), 87.00 ( 1C, -OC(C6H5)3), 127.32, 128.15, 129.15, 144.55 
(18C, -OC(C6H5)3).
IR v /cm ' 1 (NaCl): 3380 (wk., N-H stretch), 3060 (wk., Aryl-H stretch), 2870 (st., 
C-H stretch), 1600 (wk., C=C aromatic stretch), 1490, 1450 (med., aromatic), 1100 (vst., 
C-0 stretch).
MS m/z (+ve Ion FAB): 436 (M+H+, 14 %), 243 ([(C6H5)3C]+, 99 %).
HRMS (+ve ion FAB): Measured mass -  436.2483. Actual mass for M+H+ - 
436.2487.
(27) ll-Triphenylmethyloxy-l-(9-fluorenylmethyloxy- 
carbonylamido)-3,6,9-trioxaundecane.
H
O
To 11-triphenylmethyloxy-l-amino-3,6 ,9-trioxaundecane (26) (8.7 g, 20 mmol) 
and /V-methylmorpholine (4.4 ml, 4.05 g, 40 mmol) under argon, at 0°C in dry 
dichloromethane (100 ml) was added dropwise 9-fluorenylmethyl chloroformate (9.03 g, 
35 mmol, 1.5 eq.) in dry dichloromethane (40 ml). Once addition was complete, the
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reaction was left to stir at room temperature for 24 hours. After 24 hours more 
dichloromethane ( 1 0 0  ml) was added to the reaction and the resulting solution was 
partitioned with citric acid solution (pH 6 , 150 ml). The organic phase was then 
partitioned with sat. aq. NaCl (200 ml), dried over anhydrous sodium sulphate and 
concentrated in vacuo. The product was isolated by N.P.S.G. chromatography, eluting 
with chloroform only to yield 12.93 g (95 %) of a viscous yellow oil.
'H NMR (CDC13) 5: 3.25 (2H, t, J=  5.2 Hz, 
(C6H5)3COCH2(CH2 0 CH2)3CH2NHCC>2CH2C,3H9), 3.36 (2H, q, J = 4.5 Hz, 
(C6H5)3COCH2(CH20CH2)3CH2NHFmoc), 3.55-3.68 (12H, m,
(C6H5)3C0 CH2(CH2 0 CH2)3CH2 NHFmoc), 4.21 (1H, t, J=  6.7 Hz, Fmoc H9), 4.40 (2H, 
d, J = 6.7 Hz, Fmoc H), 5.40 (1H, bs, -NH-), 7.22-7.49 (15H, m, Fmoc & trityl), 7.59 
(2H, d, Fmoc H4 & H5), 7.77 (2H, d, J=  7.40 Hz, Fmoc HI & H8 ).
13C NMR (CDCI3) 6 : 41.38 (1C, Cl), 47.74 (1C, Fmoc C9), 63.77 (1C, Cl 1), 
66.99 (1C, Fmoc -CH2-), 70.46, 70.82, 71.07, 71.12, 71.24 (6 C, C2-C10), 87.01 (1C, - 
OC(C6H5)3), 120.34, 125.49, 127.44, 128.05 (8 C, Fm ocCl-C 8 ), 127.35, 128.16, 129.16 
(15C, trityl), 141.74, 144.47 (4C, Fmoc C4a, C4b, C8 a & C9a), 144.56 (3C, trityl),
156.92 (1C, carbamate C=0).
IR v /cm ' 1 (NaCl): 3350 (med., N-H stretch), 3060 (wk., Aryl-H stretch), 2860 (st., 
C-H stretch), 1700 (st., carbamate C=0 stretch), 1570-1460 (med., carbamate N-H bend 
& C-C aromatic stretch), 1100 (st., C -0 stretch).
MS m/z (+ve ESI): 697 (M+K+, 19 %), 681 (M+Na+, 99 %).
HRMS (+ve ESI): Measured mass -  680.29881. Actual mass for M+Na+ - 680.29826.
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(28) 77-(9-Fluorenylmethyloxycarbonylamido)-3,6,9- 
trioxaundecan-l-ol.
H 
O
11 -Triphenylmethyloxy-1 -(9-fluorenylmethyloxycarbonylamido)-3,6,9- 
trioxaundecane (27) (12.93 g, 19 mmol) was dissolved in a solution of dichloromethane, 
trifluoroacetic acid and triethylsilane (100 ml, 8:1:1). The reaction was left to stir at room 
temperature under argon for one hour. After one hour water (100 ml) was added to the 
reaction and the resulting mixture was adjusted to pH 7 with sat. aq. NaHCC>3 whilst 
being vigorously stirred. The two layers were partitioned and the aqueous solution was 
partitioned with another volume of dichloromethane (100 ml). The organic fractions were 
combined, dried over anhydrous sodium sulphate and concentrated in vacuo. The product 
was isolated by N.P.S.G. chromatography, eluting initially with a large volume of 
chloroform and then gradually changing the eluent to ethyl acetate only to yield 7.56 g 
(94 %) of a yellow oil.
'H NMR (CDCb) 5: 3.40 (2H, bs, HOCH^C^OCH^CFLNHFmoc), 3.57-3.74 
(14H, m, HOCH2(CH2 0 CH2)3CH2NHFmoc), 4.21 (1H, t ,J  = 6 .6  Hz, Fmoc H9), 4.42 
(2H, d, J  = 6 .6  Hz, Fmoc H), 4.76, 6.06 (1H & 1H, bs, -NH- & -OH), 7.30 (2H, t, J  = 7.4 
Hz, *H3 and *H6 ), 7.39 (2H, t,J =  7.4 Hz, *H2 and *H7), 7.61 (2H, d, J=  7.4 Hz, *H4 
and *H5), 7.76 (2H, d ,./=  7.4 Hz, *H1 and *H8 ).
13C NMR ( C D C I 3) 8 : 41.43 (1C, C 11), 47.76 (1C, Fmoc C9), 61.72(1C,C1),
67.08 (1C, Fmoc -CH2-), 70.10, 70.37, 71.50, 71.26, 72.46 (6 C, C2-C10), 120.18, 125.37, 
127.35, 127.94 (8 C, Fmoc C1-C8), 141.61, 144.27 (4C, Fmoc C4a, C4b, C8 a & C9a), 
157.64 (1C, carbamate C=0).
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IR v /cm ' 1 (NaCl): 3324 (st., N-H & O-H stretch), 3067,3041, 3020 (wk., Aryl-H 
stretch), 2882 (st., C-H stretch), 1672 (st., carbamate C=0 stretch), 1535 (med., 
carbamate N-H bend), 1451 (st., C=C aromatic stretch), 1100 (st., C-O stretch).
MS m/z (+ve Ion FAB): 454 (M +K\ 92 %), 438 (M+Na+, 99 %), 179 ([C,4Hn]+,
34 %).
HRMS (+ve ion FAB): Measured mass -  438.1886. Actual mass for M+Na+ - 
438.1893.
(29) ll-(9-Fluorenylmethyloxycarbonylamido)-3,6,9- 
trioxaundecanoic acid.
To vigorously stirring 1 l-(9-fluorenylmethyloxycarbonylamido)-3,6,9- 
trioxaundecan-l-ol (28) (4.15 g, 10 mmol) in acetone (100 ml) at 0°C was very slowly 
added chromium trioxide (3.0 g, 30.0 mmol, 3 eq.) in sulphuric acid (1.5 M, 60.0 ml, 90 
mmol, 9 eq.). Once addition was complete the reaction was left to warm to room 
temperature and to stir for 24 hours.
After 24 hours water (300 ml) was added to the reaction along with reverse phase 
silica gel (100 g). The reaction mixture was concentrated in vacuo until the volume had 
decreased by approximately one quarter and more water (100 ml) was added. The 
reaction mixture was once again concentrated in vacuo until no acetone could be detected 
to be present in the mixture. The mixture was then filtered to recover the R.P. silica gel, 
which was washed with copious amounts of water until the silica gel was almost 
colourless. The R.P. silica gel was then washed with acetonitrile (4 x 200 ml) and 
chloroform (3  x 150 ml). The organic fractions were combined and concentrated in vacuo
to give a pale green oil. The product was isolated by N.P.S.G. chromatography, eluting 
initially with chloroform only, then gradually changing to chloroform/methanol (95:5) 
and finally gradually changing to chloroform/methanol/ acetic acid (80:5:5) to yield 2.93 
g (6 8 .2  %) of a yellow oil.
'H NMR (CDC13) 8 : 3.39 (2H, m, H O ^C H zO C H ^Q kN H Fm oc), 3.54-3.71 
(10H, m, H 0 2CCH20CH 2(CH20CH 2)2CH2NHFmoc), 4.12 (2H, s, 
H 0 2CCH2(OCH2CH2)3NHFmoc),4.21 (1H, t,J =  6.7 Hz, *H9), 4.39 (2H, d , J=  6.7 Hz, 
H0 2C(CH20 CH2)3CH2NHC0 CH2C 13H9), 5.70 ( 1H, bs, -NH-), 7.30 (2 H, t, J =  7.4 Hz, 
*H3 & *H6 ), 7.38 (2H, t, J =  7.4 Hz, *H2 & *H7), 7.59 (2H, d ,J =  7.4 Hz, *H4 & *H5),
7.74 (2H, d ,7 =  7.4 Hz, *H1 & *H8 ).
,3C NMR (CDCI3) 8 : 41.26 (1C, Cl 1), 47.66 (1C, *C9), 67.09 (1C, - 
NHCOCH2C,3H9), 69.08 (1C, C2), 70.44, 70.61, 70.84, 71.46 (16C, C2-C25), 120.32, 
125.48, 127.45, 128.05 (8 C, *C1, *C2, *C3, *C4, *C5, *C6 , *C7 and *C8 ), 141.70, 
144.39 (4C, *C4a, *C4b, *C8 a and *C9a), 157.26 (1C, carbamate C=0), 173.12 (1C, 
C=0).
IR v /cm*1 (NaCl): 3336 (st., carboxylic O-H stretch), 3060 (wk., Aryl-H stretch), 
2880 (st., C-H stretch), 1715, 1700 (vst., carbamate C=0 stretch & carboxylic acid C=0 
stretch), 1611 (st., carbamate N-H bend), 1450 (st., carboxylic O-H bend), 1251 (st., 
carbamate & carboxylic C-O stretch), 1106 (vst., C-0 stretch).
MS m/z (+ve ES): 452 (M+Na+, 99 %), 430 (M+H+, 3 %).
HRMS (+ve ESI): Measured mass -  452.16899. Actual mass for M+Na+ - 
452.16797.
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(30) 8-Triphenylmethyloxy-3,6-dioxaoctan-l-ol.227
To triethylene glycol (90.10 g, 600 mmol) and triethylamine (6.07 g, 8.36 ml, 60 
mmol) in dry dichloromethane (500 ml) was added dropwise triphenylmethyl chloride 
(6.07 g, 30 mmol) in dry dichloromethane (150 ml). This solution was left to stir under 
nitrogen at room temperature and after 24 hours the reaction was concentrated in vacuo to 
give a yellow oil. This oil was then re-dissolved in dichloromethane (400 ml), partitioned 
with sat. aq. NaHCC>3 (200 ml), water (4 x 250 ml) and finally sat. aq. NaCl (250 ml). The 
organic layer was separated, dried over anhydrous sodium sulphate and concentrated in 
vacuo to give a yellow oil. This oil was purified by N.P.S.G. chromatography, eluting 
initially with chloroform and then gradually changing to chloroform/methanol (98:2), to 
yield 12.04 g (100 %) of a pale yellow oil.
‘H NMR (CDC13) 5: 2.35 (1H, bs, (C eH s^ C O C ^tC ^ O C ^ h C ^O H ), 3.25 (2H, 
t,J =  5.09 Hz, (C6H5)3C0 CH2(CH2 0 CH2)2CH20 H), 3.58-3.71 (10H, m, 
(C6H5)3C0CH2(CH20CH2)2CH20H), 7.18-7.47 (15H, m, 
(C6H5)3C0 CH2(CH2 0 CH2)2CH20 H).
13C NMR (CDC13) 6 : 62.21 (1C, C l), 63.74 (1C, C8 ), 70.95, 71.14, 71.24, 72.98 
(4C, C2-C7), 87.08 (1C, -OC(C6H5)3), 127.37, 128.18, 129.14, 144.52 (18C, - 
OC(C6H5)3).
IR v /cm ' 1 (NaCl): 3440 (vst., O-H stretch), 3057 (wk., Aryl-H stretch), 2872 (st., 
C-H stretch), 1597 (wk., C=C aromatic stretch), 1489, 1448 (med., O-H bend or 
aromatic), 1080 (vst., C-O stretch).
MS m/z (+ve Ion FAB): 415 (M+Na+, 25 %).
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HRMS (+ve ion FAB): Measured mass -  415.1876. Actual mass for M+Na+ - 
415.1885.
(31) 8-Triphenylmethyloxy-3,6-dioxaoctyl 
methanesulfonate.228
To 8-triphenylmethyloxy-3,6-dioxaoctan-l-ol (30) (12.0 g, 30 mmol) and 
triethylamine (9.1 g, 12.5 ml, 90 mmol) in dry dichloromethane ( 100 ml) under nitrogen 
at 0°C was slowly added methanesulphonyl chloride (5.80 ml, 8.59 g, 75 mmol, 2.5 eq.) 
in dry dichloromethane (40 ml). Once addition was complete, the reaction was left to 
warm to room temperature. After 2.5 hours, excess sat. aq. NaHC0 3  was added and the 
reaction was left to stir for 10 minutes. Additional dichloromethane (200 ml) was added, 
the aqueous and organic layers were separated and the organic solution was partitioned 
with sat. aq. NaCl (100 ml). The aqueous solution was back-extracted with 
dichloromethane (150 ml), the organic solutions were combined, dried over anhydrous 
sodium sulphate and concentrated in vacuo to give an orange oil. The oil was then 
azeotroped several times with dry toluene to remove water. This oil became a red solid 
(14.1 g, 99.8 %) after several hours under high vacuum. The product was used without 
further purification.
*H NMR (CDCI3 ) 5: 2.94 (3H, s, C^SC^CH zC^CK C^hO CH zCH zO CtCsH sb),
3.25 (2H, t,J =  5.1 Hz, C ^SC ^C ^C H zC K C H zhO C H z^O C tC eH s^), 3.64-3.76 (6 H, 
m, CH3S03CH2CH20(CH2)20CH2CH20C(C6H5)3), 3.78 (2H, m, 
CH3S03CH2CH20(CH2)20CH2CH2 0C(C6H5)3), 4.35 (2H, m, 
CH3S03CH2CH20(CH2)20CH2 CH20C(C6H5)3), 7.20-7.48 (15H, m, 
CH3S03CH2CH20(CH2)20CH2CH20C(C6H5)3).
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13C NMR (CDCI3) 5: 38.03 (1C, -0 S 0 2CH3), 63.76 (1C, C8 ), 69.50, 69.65 (2C, 
CH3S03CH2CH20(CH2)20CH2CH20C(C6H5)3), 71.15, 71.2 (3C, 
CH3S03CH2CH20(CH2)20CH2CH20C(C6H5)3), 87.04 ( 1C, -OC(C6H5)3), 127.41, 128.19,
129.13, 144.49 (18C,-OC(C6H5)3).
(32) 8-Triphenylmethyloxy-l-azido-3,6-dioxaoctane.
To 8-triphenylmethyloxy-3,6-dioxaoctyl methanesulfonate (29) (14.1 g, 30 mmol) 
in dry dimethylformamide (150 ml) was added sodium azide (5.85 g, 90 mmol, 3 eq.). 
This solution was left to stir for 72 hours after which time it was concentrated in vacuo. 
The product was dissolved in dichloromethane (250 ml) and partitioned with aq. sat. 
NaHCC>3 (2 x 200 ml) followed by aq. sat. NaCl (250 ml). The aqueous layer was back- 
extracted with dichloromethane (150 ml), the organic phases were combined, dried over 
anhydrous sodium sulphate and concentrated in vacuo to give a brown oil. This was 
purified by N.P.S.G. chromatography, eluting initially with ethyl acetate/hexane (85:15) 
and then gradually changing to ethyl acetate/hexane (80:20), to yield 10.6 g (84.7 %) of a 
pale yellow oil.
'H NMR (CDCI3) 5: 3.25 (2H, t, J  = 5.2 Hz, (CsHs^COCTMC^OCfyfeCfyNj),
3.35 (2H, t,J =  5.1 Hz, (CsHs^COCHjCCHzOQ^CHzNj), 3.65-3.67 (8 H, m, 
(C6H5)3C0CH2(CH20CH2)2CH2N3), 7.18-7.41 (15H, m, 
(C6H5)3COCH2(CH2 0 CH2)2CH2N3).
I3C NMR (CDCls) 8 : 51.18 (1C, Cl), 63.80 (1C, C8 ), 70.50, 71.23, 71.31 (4C, 
C2-C7), 87.02 (1C, -OC(C6H5)3), 127.35,128.16, 129.16, 144.56 (18C, -OC(C6H5)3).
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IR v /cm' 1 (NaCl): 3058 (wk., Aryl-H stretch), 2870 (st., C-H stretch), 2108 (vst., 
N3 stretch), 1596, 1490, 1448 (med., C=C aromatic stretch), 1124, 1081 (vst., C-O 
stretch).
MS m/z (+ve Ion FAB): 440 (M+Na+, 50 %), 243 ([(C6H5)3C]+, 100 %).
HRMS (+ve ion FAB, NOBA matrix): Measured mass -  440.1965. Actual mass 
for M+Na+- 440.1950.
(33) 8-Triphenylmethyloxy-l-amino-3,6-ethoxaoctane.229
To 8-triphenylmethyloxy-l-azido-3,6-dioxaoctane (32) (10.8 g, 25.8 mmol) in 
tetrahydrofuran (40 ml) was added at once triphenylphosphine (7.47 g, 28.5 mmol, 1.1 
eq.). This solution was left to stir under argon at room temperature for 2 hours before the 
addition of water (1.4 ml). The solution was then left to stir under argon at room 
temperature for 48 hours. After 50 hours the reaction was concentrated in vacuo, then 
dissolved in diethyl ether (100 ml) and filtered. The filtrate was concentrated in vacuo to 
give a mixture of solid and oil. This oil was purified by N.P.S.G. chromatography, eluting 
initially with a lot of chloroform and then finally eluting with chloroform/triethylamine 
(95:5) to yield 9.12 g (91 %) of a yellow oil.
!H NMR (CDCI3) 6 : 2.85 (2H, t, J = 5.2 Hz, 
(C6H5)3C0 CH2(CH2 0 CH2)2CH2NH2), 3.25 (2H, t, J=  5.2 Hz, 
(C6H5)3COCH2(CH2OCH2)2CH2NH2), 3.52 (2H, t, J=  5.2 Hz, 
(C6H5)3C0(CH20CH2)2CH2CH2NH2), 3.63-3.68 (6 H, m, (C6H5)3CO 
CH2CH20CH2CH20CH2CH2NH2), 7.18-7.44 (15H, m, 
(C6H5)3COCH2(CH2OCH2)2CH2NH2).
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,3C NMR (CDCI3) 5: 42.22 (1C, C l), 63.80 (1C, C8 ), 70.86, 71.12, 71.19 (3C, 
C4-C7), 73.83 ( 1C, C2 ), 87.01 ( 1C, -OC(C6H5)3), 127.34, 128.15, 129.14, 144.56 (18C, - 
OC(C6H5)3).
IR v /cm ' 1 (NaCl): 3379 (wk., N-H stretch), 3057 (wk., Aryl-H stretch), 2868 (st., 
C-H stretch), 1597 (wk., N-H bend), 1489, 1448 (med., C=C aromatic stretch), 1082 (vst., 
C -0 stretch).
MS m/z (+ve Ion FAB): 392 (M +H\ 14 %), 243 ([(C6H5)3C]+, 100 %).
HRMS (+ve ion FAB, NOBA matrix): Measured mass -  392.2239. Actual mass 
for M+H+ - 392.2226.
(34) N,N-Dibenzyl-8-triphenylmethyloxy-3,6-dioxa-l- 
octanamine.
To 8 -triphenylmethyloxy-1 -amino-3,6 -dioxaoctane (33) (9.12 g, 23.3 mmol) in 
dimethylformamide (100 ml) was added anhydrous potassium carbonate (8.05 g, 58.2 
mmol, 2.5 eq.) and benzyl chloride (6.71 ml, 7.37 g, 58.2 mmol, 2.5 eq.). The reaction, 
under argon was heated to 90°C for 48 hours. After 48 hours the reaction was 
concentrated in vacuo and then dissolved in water (150 ml) and dichloromethane (200 
ml). The organic phase was partitioned with sat. aq. NaCl (200 ml), dried over anhydrous 
sodium sulphate and concentrated in vacuo to give a dark red oil. This oil was purified by 
N.P.S.G. chromatography, eluting only with chloroform to yield 10.57 g (79.5 %) of a 
brown oil.
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*H NMR ( C D C I 3 )  8 : 2.68 (2H, t, J = 5.6 Hz, 
(C6H5)3COCH2(CH2OCH2)2CH2N(CH2C6H5)2), 3.25 (2H, t, 
(C6H5)3COCH2(CH20CH2)2CH2N(CH2C6H5)2), 3.56-3.67 (12H, m, 
(C6H5)3COCH2(CH20CH2)2CH2N(CH2C6H5)2), 7.24-7.49 (25H, m, 
(C 6 H 5 )3 C O C H 2 (C H 2 0 C H 2 )2 C H 2 N (C H 2 C 6H 5)2 ).
13C NMR (CDC13) 8 : 53.20 (1C, C l), 58.37 (2C, -N(CH2C6H5)2), 63.81 (1C, C8 ), 
65.73, 70.87, 71.14, 71.21 (4C, C2-C7), 87.01 ( 1C, -OC(C6H5)3), 127.21, 127.33, 128.15, 
128.71, 128.96, 129.17 (25C, trityl & benzyl), 140.22 (2C, benzyl), 144.60 (3C, trityl).
IR v /cm*1 (NaCl): 3060 (wk., Aryl-H stretch), 2872 (st., C-H stretch), 1493, 1448 
(med., C=C aromatic stretch), 1080 (vst., C-0 stretch).
MS m/z (+ve Ion FAB): 570 (M+, 25 %), 243 ([(C6H5)3C]+, 100 %).
HRMS (+ve ion FAB, NOBA matrix): Measured mass -  572.3141. Actual mass 
for M+H+ - 572.3165.
(35) 8-N,N-Dibenzylamino-3,6-dioxaoctan-l-oL
/V,/V-Dibenzyl-8-triphenylmethyloxy-3,6-dioxa-l-octanamine (34) (10.57 g, 18.5 
mmol) was dissolved in a solution of dichloromethane, trifluoroacetic acid and 
triethylsilane (100 ml, 80:10:10). The reaction was left to stir at room temperature under 
argon for one hour. After one hour sat. aq. Na2CC>3 was slowly added to the reaction with 
vigorous stirring until the reaction reached pH 12. The two layers were partitioned and 
the aqueous fraction was back-extracted with dichloromethane (2  x 100 ml). The organic 
fractions were combined, dried over anhydrous sodium sulphate and concentrated in
H° ^ o
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vacuo to give a brown oil. The product was isolated from this oil by N.P.S.G. 
chromatography, eluting initially with chloroform and then gradually changing the eluent 
to chloroform/methanol (9:1) to yield 5.75 g (94.3 %) of a pale brown oil.
'H NMR (CDCI3) 6 : 2.47 (1H, bs, H O C ^C H zO C H zh C H zN tC f^H s^), 3.20 
(2H, t, J  = 4.2 Hz, H0 CH2(CH2 0 CH2)2CH2N(CH2C6H5)2), 3.58-3.73 (8 H, m, 
H0 CH2(CH2 0 CH2)2CH2N(CH2C6H5)2), 3.91 (2H, t, J = 4.2 Hz, 
HOCH2(CH2OCH2)2CH2N(CH2C6H5)2), 4.37 (4H, s, 
H0CH2(CH20CH2)2CH2N(CH2C6H5)2), 7.39-7.48 (10H, m, 
HOCH2(CH20CH2)2CH2N(CH2C6H5)2).
13C NMR (CDCI3) 6 : 50.65 (1C, C8 ), 57.78 (2C, -N(CH2C6H5)2), 61.82 (1C, Cl), 
66.33 (1C, C7), 70.48, 70.70 (2C, C4 & C5), 72.75 (1C, C2), 129.47, 130.27, 131.74, 
138.45 (12C, benzyl).
IR v /cm*1 (NaCl): 3383 (vst., O-H stretch), 2878 (st., C-H stretch), 1454, 1417 
(med., C=C aromatic stretch), 1352 (st., C-N stretch), 1070 (vst., C -0 stretch).
MS m/z (+ve Ion FAB): 352 (M+Na+, 9 %), 330 (M+H+, 78 %), 238 
([C,3H2o0 3N]+, 11 %), 150 ([C 6 H 1603N ]+, 12 %), 91 ([C 7H 7]+, 98 %).
HRMS (+ve ion FAB, NOBA matrix): Measured mass -  330.2062. Actual mass 
for M+H+ - 330.2069.
(36) 8-Phenylmethyloxy-3,6-dioxaoctan-l-oI.230
To triethylene glycol (30.0 g, 200 mmol) and tetrabutylammonium bromide (0.5 
g, cat.) in dry tetrahydrofuran (150 ml) was added cautiously sodium hydride (1.20 g, 30 
mmol, 60% w/w in mineral oil). After stirring for 20 minutes, benzyl chloride (2.53 g, 20 
mmol) was added to the reaction and the reaction was heated to reflux under nitrogen.
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After 24 hours, the reaction was cooled to room temperature and concentrated in vacuo to 
give an oil. This oil was dissolved in dichloromethane (300 ml) and partitioned with sat. 
aq. NaCl (2 x 200 ml). The organic phase was dried over anhydrous sodium sulphate and 
concentrated in vacuo to give a yellow oil. This was purified by N.P.S.G. 
chromatography, eluting initially with chloroform and then gradually changing to 
chloroform/methanol (90:10), to yield 4.94 g (99 %) of a pale yellow oil.
‘H NMR (CDCI3) 5: 2.74 (1H, t, C eH sC H zO C ^C ^O C H j^C ^O H ), 3.60-3.70 
(12H, m, C6H5CH2 0 CH2(CH2 0 CH2)2CH2 0 H), 4.57 (2H, s, 
C6H5CH20CH2(CH20CH2)2CH20H), 7.25-7.35 (5H, m, 
C6H5CH20CH2(CH20CH2)2CH20H.)
I3C NMR (CDCI3) 5: 62.1 (1C, Cl), 69.82, 70.79, 71.01, 71.07 (4C, C4-C8),
72.94 (1C, C2), 73.65 (1C, -OCH2C6H5), 128.0, 128.13, 128.74, 138.61 (6 C, benzyl)
IR v /cm ' 1 (NaCl): 3449 (st., O-H stretch), 3030 (wk., Aryl-H stretch), 2868 (st., 
C-H stretch), 1454 (wk., C-H deformation), 1350, 1294, 1248 (med., O-H bending), 1099 
(vst., C -0 stretch).
MS m/z (+ve Ion FAB): 263 (M+Na+, 4 %), 241 (M+H+, 99 %), 91 ([C7H7]+, 100
%).
HRMS (+ve ion FAB): Measured mass -  241.1442. Actual mass for M+H+ - 
241.1440.
(37) 1-Triphenylmethyloxy-l 7-phenylmethyloxy- 
3,6,9,12,15-pentaoxaheptadecane.
To 8-phenylmethyloxy-3,6-dioxaoctan-l-ol (36) (4.94 g, 20 mmol) and 8 - 
triphenylmethyloxy-3,6-dioxaoctyl methanesulfonate (31) (9.88 g, 21 mmol) in dry
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dimethylformamide (50 ml) under argon was added sodium hydride (2.4 g, 60 mmol, 3 
eq., 60% w/w in mineral oil). This solution was left to stir at room temperature. After 5 
days the reaction was concentrated in vacuo and then re-dissolved in diethyl ether ( 2 0 0  
ml) and water (200 ml). The organic phase was then partitioned with aq. sat. NaCl with a 
little NaHCC>3 (200 ml), dried over anhydrous sodium sulphate and concentrated in vacuo 
to give a viscous dark brown oil. This oil was purified by N.P.S.G. chromatography, 
eluting initially with chloroform and then gradually changing to chloroform/methanol 
(98:2), to yield 9.11 g (74.1 %) of an orange oil.
'H NMR (CDC13) 6 : 3.25 (2H, t, J=  5.2 Hz, 
C6H5CH20CH2(CH20CH2)5CH20C(C6H5)3), 3.64-3.69 (22H, m, 
C6H5CH2 0 CH2(CH2 0 CH2)5CH2 0 C(C6H5)3), 4.57 (2H, s, 
C6H5CH20CH2(CH20CH2)5CH20C(C6H5)3), 7.20-7.52 (20H, m, 
C6H5CH20CH2(CH20CH2)5CH20C(C6H5)3).
13C NMR (CDCI3) 6 : 63.78 (1C, Cl), 69.91, 71.03, 71.07, 71.10, 71.21 (11C, C2- 
C17), 73.65 ( 1C, -OCH2C6H5), 86.98 ( 1C, -OC(C6H5)3), 127.31, 127.96, 128.12, 128.15, 
128.74, 129.15 (20C, trityl & benzyl), 138.76 (1C, benzyl), 144.58 (3C, trityl).
IR v /cm ' 1 (NaCl): 3030 (wk., Aryl-H stretch), 2869 (st., C-H stretch), 1600, 1570, 
1480, 1450 (med., C=C aromatic stretch), 1109 (vst., C-0 stretch).
MS m/z (+ve Ion FAB): 637 (M+Na+, 0.6 %), 613 ([C38H4 5 0 7]+, 1.25 %), 243 
([CI9H15]+, 1 0 0 %).
HRMS (+ve ion FAB, NOBA matrix): Measured mass -  637.3148. Actual mass 
for M+Na+- 637.3141.
199
(38) 17-Phenylmethyloxy-3,6,9,12,15-pentaoxa- 
heptadecan-l-ol.195
To 1 -triphenylmethyloxy-17-phenylmethyloxy-3,6,9,12,15-pentaoxaheptadecane 
(37) (9.11 g, 14.82 mmol) was added a solution made up of dichloromethane, 
triethylsilane and trifluoroacetic acid (100 ml, 80:10:10). The reaction was left to stir at 
room temperature for 1 hour. After one hour sat. aq. Na2C0 3 was slowly added to the 
reaction with vigorous stirring until the reaction reached pH 12. The two layers were 
partitioned and the aqueous fraction was back-extracted several times with 
dichloromethane ( 6  x 100 ml). The organic fractions were combined, dried over 
anhydrous sodium sulphate and concentrated in vacuo to give a yellow solid/oil. This oil 
was re-dissolved in water ( 1 0 0  ml) and the aqueous solution was partitioned twice with 
hexane ( 2  x 100 ml). The aqueous solution was then concentrated in vacuo to give a 
yellow oil. The resulting oil was azeotroped with anhydrous acetonitrile until 5.51 g (99 
%) of oil was recovered which required no further purification.
'H NMR (CD2C12) 5: 3.62-3.79 (22H, m, C eH sC H zO C ^C H zO C ^sC ^O H ), 
4.60 (2H, s, C6H5CH2 0 CH2(CH2 0 CH2)5CH20 H), 7.29-7.38 (5H, m, 
C6H5CH20CH2(CH20CH2)5CH2OH).
I3C NMR (CD2CI2) 5: 60.90 (1C, Cl), 69.13, 69.79, 69.82, 69.93, 70.10, 70.14, 
70.24, 70.46 (10C, C4-C17), 72.08 (1C, C2), 73.86 (1C, -OCH2C6H5), 127.57, 127.68, 
128.30, 138.11 (6 C, benzyl).
IR v /cm 1 (NaCl): 3474 (st., O-H stretch), 3030 (wk., Aryl-H stretch), 2868 (st., 
C-H stretch), 1454, 1348 (med., O-H bend), 1109 (vst., C -0 stretch).
MS m/z (+ve Ion FAB): 395 (M+Na+, 5 %), 373 ([Ci9H33 0 7]+, 16 %).
HRMS (+ve ion FAB, NOBA matrix): Measured mass -  395.2051. Actual mass 
for M+Na+ - 395.2046.
(39) 26-Dibenzylamino-l-phenylmethyloxy- 
3,6,9,12,15,18,21,24-octaoxahexaeicosane.
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To 8--/V,A-dibenzylamino-3,6-dioxaoctan-l-ol (36) (5.06 g, 15.4 mmol) in dry 
dichloromethane (100 ml), under argon was added triethylamine (6.55 ml, 4.76 g, 47 
mmol, 3 eq.). The solution was cooled to 0°C and methanesulfonyl chloride (2.38 ml, 
3.52 g, 31 mmol, 2 eq.) in dry dichloromethane (25 ml) was added dropwise. Once 
addition was complete, the reaction was left to stir for two hours at room temperature. 
After two hours, more dichloromethane (100 ml) was added and the solution was 
partitioned with sat. aq. NaHC0 3  (200 ml). The aqueous layer was back-extracted with 
dichloromethane ( 1 0 0  ml), the organic fractions were combined, partitioned with sat. aq. 
NaCl (200 ml), dried over anhydrous sodium sulphate and concentrated in vacuo. The 
brown oil recovered was azeotroped several times with dry toluene to remove water.
To the brown oil {circa 15.4 mmol) was added dry tetrahydrofuran (50 ml) 
followed by 17-phenylmethyloxy-3,6,9,12,15-pentaoxaheptadecan-l-ol (38) (5.50 g, 14.8 
mmol) and sodium hydride (1.20 g, 30 mmol, 60 % in mineral oil). The reaction was left 
to stir for six days under argon at room temperature. After six days, the reaction was 
concentrated in vacuo and to the remaining oil was added water (100 ml). The aqueous 
phase was partitioned with dichloromethane (4 x 200 ml), the organic fractions were then 
combined, partitioned with sat. aq. NaCl (200 ml), dried over anhydrous sodium sulphate 
and concentrated in vacuo to give a dark red oil. The product was isolated from the oil by 
N.P.S.G. chromatography, eluting initially with ethyl acetate/hexane (1:1), then gradually 
changing to ethyl acetate only and finally changing the eluent to ethyl acetate/methanol 
(98:2). 6.45 g of a brown oil (64 %) were recovered.
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*H NMR ( C D 3C N )  6 : 2.72 (2H, t, J=  6.2 Hz, 
C6H5CH20CH2(CH20CH2)8CH2N(CH2C6H5)2), 3.51-3.69 (34H, m, 
C6H5CH2 0 CH2(CH2 0 CH2)8CH2N(CH2C6H5)2), 3.64 (4H, s, 
C6H5CH2 0 CH2(CH2OCH2)8CH2N(CH2C6H5)2), 4.57 (2H, s, 
C6H5CH20CH2(CH20CH2)8CH2N(CH2C6H5)2), 7.29-7.46 (15H, m, 
C 6 H 5 C H 2 0 C H 2 (C H 2 0 C H 2 ) 8 C H 2 N (C H 2C 6H 5)2).
,3C NMR (CD3CN) 6 : 52.17 (1C, Cl), 58.02 (2C, -N(CH2C6H5)2), 68.77, 69.14, 
69.67, 69.81 (17C, C2-C26), 72.18 (1C, -OCH2C6H5), 126.52, 127.09, 127.31, 127.83, 
127.94, 128.43, 138.45 (18C, O- & A-benzyl).
IR v /cm ' 1 (NaCl): 3061 (wk., Aryl-H stretch), 2868 (st., C-H stretch), 1495, 1452 
(med., C=C aromatic stretch), 1107 (vst., C-0 stretch).
MS m/z (+ve Ion FAB): 684 (M+H+, 45 %), 594 ([C32H52 0 9N]+, 7 %), 504 
([C25H4609N]+, 9 %), 91 ([C7H7]+, 99 %).
HRMS (+ve ESI): Measured mass -  706.3935. Actual mass for M+Na+ - 
706.3925.
(40) 26-Phenylmethyloxy-l -amino-3,6,9,12,15,18,21,24- 
octaoxahexaeicosane.
To 26-phenylmethyloxy-1 -azido-3,6,9,12,15,18,21,24-octaoxahexaeicosane (40) 
(5.29 g, 10 mmol) in tetrahydrofuran (50 ml) was added triphenylphosphine (2.89 g, 11 
mmol, 1.1 eq.). The reaction was left to stir for two hours at room temperature before 
water (0.8 ml, 44 mmol, 4.4 eq.) was added. The reaction was then left to stir at room 
temperature.
202
After 48 hours the reaction mixture was concentrated in vacuo, re-dissolved in 
toluene (100 ml) and then concentrated in vacuo once more. The product was isolated 
from the resulting oil/solid by N.P.S.G. chromatography, eluting initially with copious 
amounts of chloroform and then gradually changing to
chloroform/methanol/triethylamine (90:5:5) to yield 4.86 g (96.5 %) of a pale yellow oil.
‘H NMR (DMSO) 5: 2.67 (2H, t, J = 5.8 Hz, 
C6H5CH2 0 CH2(CH2 0 CH2)8CH2NH2), 3.38 (2H, t, J=  5.8 Hz, 
C6H5CH20(CH2CH20)8CH2CH2NH2), 3.49-3.61 (32H, m, 
C6H5CH2 0 (CH2CH2 0 )8CH2CH2NH2), 4.51 (2H, s,
C6H5CH20CH2(CH20CH2)8CH2NH2), 7.27-7.39 (5H, m, 
C6H5CH20CH2(CH20CH2)8CH2NH2).
,3C NMR (DMSO) 6 : 42.19 (1C, Cl), 70.05, 70.50, 70.70 (16C, C4-C26), 72.94 
(1C, C2), 73.78 (1C, -OCH2C6H5), 128.24, 128.35, 129.09, 139.41 (7C, benzyl).
IR v /cm*1 (NaCl): 3269 (med., N-H stretch), 3050 (wk., Aryl-H stretch), 2869 (st., 
C-H stretch), 1601 (med., N-H bend), 1452 (med., C=C aromatic stretch), 1252 (med., C- 
O & C-N stretch), 1106 (vst., C -0 stretch).
MS m/z (+ve ES): 526 (M+Na+, 8 %), 504 (M+H+, 99 %), 524 ([C18H4o09N]+, 13
%).
HRMS (+ve ESI): Measured mass -  504.3164. Actual mass for M+H+ - 504.3167.
(41) 26-Hydroxyl-l-amino-3,6,9,12,15,18,21,24- 
octaoxahexaeicosane.
To a solution of 26-phenylmethyloxy-l-azido-3,6,9,12,15,18,21,23- 
octaoxahexaeicosane (44) (14.04 g, 26.5 mmol) in ethanol (100 ml) was added palladium
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on carbon (2 g, 10 % on carbon). The solution was then degassed under vacuum with 
stirring for 30 minutes. After 30 minutes the solution was placed under a hydrogen 
atmosphere (1 atm.) and heated to 50°C.
After 24 hours, more palladium on carbon (2 g, 10 % on carbon) was added to the 
reaction and the reaction was then left stirring under the hydrogen atmosphere for a 
further 24 hours.
After 2 days, Raney Nickel slurry in water (4 ml) and acetic acid (2.07 ml, 1.98 g, 
33.13 mmol, 1.25 eq.) were added to the reaction and the reaction was then left to stir 
under the hydrogen atmosphere for a further 5 days.
After a total of one week, the reaction mixture was filtered through a pad of 
Celite, the Celite pad being washed five times with ethanol (5 x 50 ml). The filtrate was 
concentrated in vacuo and then toluene was added (100 ml). The solution was again 
concentrated in vacuo, re-dissolved in triethylamine (50 ml) and then concentrated in 
vacuo to give 11.8 g (>100 %) of a dark blue oil. The product was isolated from this oil 
by N.P.S.G. chromatography, eluting with chloroform and methanol saturated with 
ammonia (80:20). After column chromatography the product was re-dissolved in water 
and freeze-dried to yield 4.44 g (40 %) of a colourless oil.
!H NMR (CD3OD) 5: 3.13 (2H, t, J = 5.1 Hz, H O C ^ C ^ O C ^ g Q ^ N H z ) , 
3.52-3.68 (32H, m, H O C ^C ^O C ^g C H zN H z), 3.73 (2H, t, J = 5.1 Hz, 
HOCH2(CH2OCH2)gCH2NH2).
,3C NMR (CD3OD) 5: 40.67 (1C, Cl), 62.11 (1C, C26), 67.94, 70.83, 71.06, 71.2, 
71.32, 71.37, 71.53, 73.57 (16C, C2-C25).
IR v /cm ' 1 (NaCl): 3397 (vst., O-H & N-H stretch), 2871 (st., C-H stretch), 1650 
(med., N-H bend), 1452, 1350 (med., O-H bend), 1250, 1106 (st., C -0 stretch).
MS m/z (+ve ES): 414 (M+H+, 99 %).
HRMS (+ve ES): Measured mass -  414.2695. Actual mass for M+H+ - 414.2697.
(42) 1-T riphenylmethyloxy-26-phenylmethyloxy-
3,6,9,12,15,18,21,24-octaoxahexaeicosane.195
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To 17-phenylmethyloxy-3,6,9,12,15-pentaoxaheptadecan-l-ol (38) (16.38 g, 43.9 
mmol) in dry dimethylformamide (250 ml) was added 8-triphenylmethyloxy-3,6- 
dioxaoctyl methanesulfonate (31) (28.23 g, 60 mmol, 1.35 eq.) and sodium hydride (4.0 
g, 100 mmol, 2.3 eq., 60% w/w in mineral oil). The reaction was left to stir for four days 
at room temperature after which time it was concentrated in vacuo. The reaction mixture 
was re-dissolved in diethyl ether (400 ml) and cooled in an ice bath to 0°C. Water was 
then slowly added until hydrogen was no longer evolved. The organic phase was then 
partitioned twice with aq. sat. NaCl with a little NaHCC>3 (2 x 300 ml), dried over 
anhydrous sodium sulphate and concentrated in vacuo to give a viscous dark brown oil. 
The product was isolated by N.P.S.G. chromatography, eluting with ethyl acetate only to 
yield 24.2 g (75.0 %) of a yellow oil.
'H NMR (CDC13) 6 : 3.24 (2H, t , J  = 5.2 Hz, 
C6H5CH20CH2(CH20CH2)8CH20C(C6H5)3), 3.57-3.69 (34H, m, 
C6H5CH20 CH2(CH2 0 CH2)8CH2 0 C(C6H5)3), 4.56 (2H, s, 
C6H5CH20CH2(CH20CH2)8CH20C(C6H5)3), 7.21-7.48 (20H, m, 
C6H5CH20CH2(CH20CH2)8CH20C(C6H5)3).
13C NMR (CDCI3) 6 : 63.38 (1C, Cl), 69.51, 70.60, 70.67, 70.81 (17C, C2-C26), 
73.24 (1C, -OCH2C6H5), 86.57 ( 1C, -OC(C6H5)3), 126.91, 127.56, 127.74, 128.39, 128.74 
(20C, trityl & benzyl), 138.36 (1C, benzyl), 144.18 (3C, trityl).
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IR v /cm ' 1 (NaCl): 3058, 3031 (wk., Aryl-H stretch), 2868 (st., C-H stretch), 1962 
(wk., aromatic), 1596 (wk., aryl C-C stretch), 1489, 1449 (med., C=C aromatic stretch),
1105 (vst., C -0 stretch).
MS m/z (+ve Ion FAB): 769 (M+Na+, 75 %), 243 ([(C6H5)3C]+, 39 %).
HRMS (+ve ion FAB): Measured mass -  769.3929. Actual mass for M+Na+ - 
769.3922.
(43) 26-Phenylmethyloxy-3,6,9,12,15,18,21,24- 
octaoxahexaeicosan-l-ol.195
To 1 -triphenylmethyloxy-26-phenylmethyloxy-3,6,9,12,15,18,21,24- 
octaoxahexaeicosane (42) (24.0 g, 32.1 mmol) was added a solution of trifluoroacetic 
acid (20 ml) and triethylsilane (20 ml) in dichloromethane (160 ml). The reaction was left 
to stir at room temperature for 1 hour. After one hour sat. aq. Na2C0 3 was slowly added 
to the reaction with vigorous stirring until the reaction reached pH 12. The two layers 
were partitioned and the aqueous fraction was back-extracted several times with 
dichloromethane ( 9  x 100 ml). The organic fractions were combined, dried over 
anhydrous sodium sulphate and concentrated in vacuo to give a yellow solid/oil. This oil 
was re-dissolved in water ( 2 0 0  ml) and the aqueous solution was partitioned twice with 
hexane (2 x 200 ml). The aqueous solution was then concentrated in vacuo to give a 
yellow oil. The resulting opaque oil was azeotroped with anhydrous acetonitrile until 16.2 
g (99.9 %) of a colourless oil was obtained.
!H NMR (CDC13) 5: 3.57-3.73 (36H, m, CeHsCHzOC^C^OCHz^CHzOH),
4.55 (2H, s, C6H5CH2 0 CH2(CH2 0 CH2)8CH20 H), 7.21-7.33 (5H, m, 
C6H5CH20CH2(CH20CH2)8CH20H).
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13C NMR (CDCI3) 5: 61.57 (1C, Cl), 69.46, 70.19, 70.44, 70.46, 70.55, 70.62 
(16C, C4-C26), 72.38 (1C, C2), 73.22 (1C, -OCH2C6H5), 127.55, 127.69, 128.32, 138.30 
(7C, benzyl).
IR v /cm ' 1 (NaCl): 3332 (vst., O-H stretch), 3030 (wk., Aryl-H stretch), 2869 (st., 
C-H stretch), 1455 (med., C=C aromatic stretch), 1104 (vst., C-O stretch).
MS m/z (+ve ESI): 543 (M+K+, 3 %), 527 (M+Na+, 99 %).
HRMS (+ve ESI): Measured mass -  527.2850. Actual mass for M+Na+ - 
527.2826.
(44) 26-Phenylmethyloxy-l-azido-3,6,9,12,15,18,21,24- 
octaoxahexaeicosane.
To 26-phenylmethyloxy-3,6,9,12,15,18,21,24-octaoxahexaeicosan-l-ol (43) (16.2 
g, 32.1 mmol) and triethylamine (11.33 g, 15.6 ml, 112 mmol) in dry dichloromethane ( 
200 ml), under nitrogen, at 0°C was slowly added methanesulphonyl chloride (7.43 ml, 
10.99 g, 96 mmol, 3 eq.) in dry dichloromethane (75 ml). Once addition was complete, 
the reaction was left to warm to room temperature. After 4 hours, excess sat. aq. NaHC0 3  
was added and the reaction was left to stir for 10 minutes. Additional dichloromethane 
(300 ml) was added, the aqueous and organic layers were separated and the organic 
solution was partitioned with sat. aq. NaCl (250 ml). The aqueous solution was back- 
extracted with dichloromethane (2 x 250 ml), the organic solutions were combined, dried 
over anhydrous sodium sulphate and concentrated in vacuo to give an orange oil. The oil 
was then azeotroped several times with dry toluene to remove water. This oil became a 
red solid after several hours under high vacuum.
This red solid was re-dissolved in dry dimethylformamide (200 ml) and sodium 
azide (10.4 g, 160 mmol, 5 eq.) was added. The reaction was left to stir for 72 hours at 
room temperature, under argon. After 72 hours the reaction was concentrated in vacuo, 
xylene (250 ml) was then added and the reaction was once again concentrated in vacuo. 
The reaction mixture was triturated with diethyl ether (750 ml) and filtered, the filtrate 
being concentrated in vacuo to give an orange oil. The product was isolated by N.P.S.G. 
chromatography, eluting initially with ethyl acetate and then gradually changing to ethyl 
acetate/methanol (95:5) to yield 14.4 g (85.0 %) of a yellow oil.
'H NMR (CDCI3) 5: 3.36 (2H, t, J=  5.1 Hz, C eH sC ^O C ^tC H zO C ^g C ^N j), 
3.58-3.70 (34H, m, C6H5CH20CH2(CH20CH2)8CH2N3), 4.55 (2H, s, 
C6H5CH20CH2(CH20CH2)8CH2N3), 7.21-7.33 (5H, m, 
C6H5CH20CH2(CH20CH2)8CH2N3).
13C NMR (CDCI3) 6: 50.70 (1C, C l), 69.48, 70.0, 70.59, 70.65 (17C, C2-C26),
73.22 (1C, -OCH2C6H5), 127.54, 127.69, 128.32, 138.33 (7C, benzyl).
IR v /cm'1 (NaCl): 3020 (wk., Aryl-H stretch), 2866 (st., C-H stretch), 2106 (st., 
azide stretch), 1454 (med., C=C aromatic stretch), 1105 (vst., C-O stretch).
MS m/z (+ve ES): 568 (M+K+, 2 %), 552 (M+Na+, 99 %), 524 
([C25H4309N]+Na+, 3 %).
HRMS (+ve ion FAB): Measured mass -  552.2906. Actual mass for M+Na+ - 
552.2897.
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(45) 26-(9-Fluorenylmethyloxycarbonylamido)- 
3, 6, 9,12,15,18,21,24-octaoxahexaeicosan-l-ol.
O
Synthesis 1
To 26-hydroxyl-1 -amino-3,6,9,12,15,18,21,24-octaoxahexaeicosane (41) (6.42 
mmol from previous step) and sodium hydrogencarbonate (1.08 g, 12.84 mmol, 2.0 eq.) 
stirring in acetone/water (30 ml), at 0°C was added fluorenylmethyl chloroformate (3.32 
g, 12.84 mmol, 2.0 eq.) in acetone (20 ml). Once addition was complete, the reaction was 
allowed to warm to room temperature and left to stir for 6 hours.
After 6 hours the reaction was concentrated in vacuo to remove acetone. The 
remaining aqueous solution was adjusted to pH 6 by addition of solid citric acid. The 
resulting solution was then partitioned three times with dichloromethane (3 x 100 ml). 
The organic fractions were combined, dried over anhydrous sodium sulphate and then 
concentrated in vacuo to give a yellow oil. This oil was purified by N.P.S.G. 
chromatography, eluting initially with ethyl acetate and then gradually changing to ethyl 
acetate/methanol (4:1) to yield 1.50 g (36.8 %) of a yellow oil.
Synthesis 2
A solution of 26-phenylmethyloxy-l-amino-3,6,9,12,15,18,21,24- 
octaoxahexaeicosane (40) (5.51 g, 10.94 mmol) in dry diethyl ether (50 ml) under argon 
was cooled to -78°C. Into this solution was condensed ammonia until the volume of the 
solution had almost doubled (c. 100 ml). To the solution under argon at -78°C were 
added sodium pellets until a dark blue colour persisted. The reaction was allowed to 
warm to from -78°C to -30°C and then cooled back to -78°C. Methanol was then slowly
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added to the reaction at -78°C under argon until the solution was no longer blue in colour. 
The reaction was then allowed to warm to room temperature and once most of the 
ammonia had evaporated, the reaction was concentrated in vacuo and then kept under 
high vacuum for 24 hours.
To the remaining residue was then added water (100 ml) and the pH was adjusted 
to 4 with concentrated hydrochloric acid. The pH of the solution was then adjusted to 7 
by addition of solid sodium hydrogencarbonate. Once the solution had been neutralised, 
sodium hydrogencarbonate (1.38 g, 16.41 mmol, 1.5 eq.) was again added followed by 
water (50 ml) and dioxane (100 ml). To this solution cooled to 0°C was slowly added 
fluorenylmethyl chloroformate (4.25 g, 16.41 mmol, 1.5 eq.) in dioxane (50 ml). Once 
addition was complete the reaction was allowed to warm to room temperature and left to 
stir for 6 hours.
After 6 hours the solution was acidified to pH 6 by addition of solid citric acid and 
then concentrated in vacuo to remove dioxane. The remaining aqueous solution was 
partitioned three times with chloroform (3 x 250 ml). The organic fractions were 
combined, dried over anhydrous sodium sulphate and concentrated in vacuo to give a 
yellow oil. This oil was purified by N.P.S.G. chromatography, eluting with ethyl 
acetate/methanol (4:1) to yield 6.1 g (87.7 %) of a yellow oil.
!H NMR (CDCI3) 6 : 2.71 (1H, bs, -OH), 3.39 (2H, m, 
HOCH2(CH20CH2)8CH2NHCOCH2Ci3H9), 3.55-3.73 (34H, m, 
H0 CH2(CH2 0 CH2)8CH2NHC0 CH2Ci3H9), 4.22 (1H, t,J =  6 .8  Hz, *H9), 4.41 (2H, d, J  
= 6 .8  Hz, H0 CH2(CH2 0 CH2)8CH2NHC0 CH2Ci3H9), 5.50 (1H, bs, -NH-), 7.31 (2H, t, J  
= 7.4 Hz, *H3 & *H6 ), 7.39 (2H, t, J = 7.4 Hz, *H2 & *H7), 7.61 (2H, d, J = 7.4 Hz, *H4 
& *H5), 7.76 (2H, d, J=  7.4 Hz, *H1 & *H8 ).
13C NMR (CDCI3) 6: 40.96 (1C, C26), 47.31 (1C, *C9), 61.72 (1C, C l), 66.55 
(1C, -NHCOCH2Ci3H9), 70.06, 70.35, 70.57 (15C, C4-C25), 72.55 (1C, C2), 119.94, 
125.08, 127.04, 127.65 (8C, ♦Cl, *C2, *C3, *C4, *C5, *C6, *C7 and *C8), 141.32,
144.04 (4C, *C4a, *C4b, *C8a and *C9a), 156.56 (1C, carbamate C=0).
IR v /cm'1 (NaCl): 3325 (st., O-H & N-H stretch), 3066, 3041, 3020 (wk., Aryl-H 
stretch), 2883 (st., C-H stretch), 1672 (vst., carbamate C=0 stretch & N-H bend), 1452 
(med., C=C aromatic stretch), 1346 (med., carbamate C-Ostretch), 1105 (vst., C-O 
stretch).
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MS m/z (+ve ion FAB): 658 (M+Na+, 8 %), 636 (M+H+, 32 %), 414 
([C,8H4o0 9N]+, 21 %), 179 ([C14Hn]+, 68 %).
HRMS (+ve ion FAB): Measured mass -  636.3380. Actual mass for M+H+ - 
636.3384.
(46) 26-(9-Fluorenylmethyloxycarbonylamido)-
3,6,9,12,15,18,21,24-octaoxahexaeicosanoic acid.
To vigorously stirring 26-(9-fluorenylmethyloxycarbonylamido)- 
3,6,9,12,15,18,21,24-octaoxahexaeicosan-l-ol (45) (6.10 g, 9.60 mmol) in acetone (125 
ml) at 0°C was very slowly added chromium trioxide (2.878 g, 28.8 mmol, 3 eq.) in 
sulphuric acid (1.5 M, 57.6 ml, 86.4 mmol, 9 eq.). Once addition was complete the 
reaction was left to warm to room temperature and to stir for 24 hours.
After 24 hours water (400 ml) was added to the reaction along with reverse phase 
silica gel (120 g). The reaction mixture was concentrated in vacuo until the volume had 
decreased by approximately one quarter and more water (100 ml) was added. The 
reaction mixture was once again concentrated in vacuo to remove acetone. The mixture 
was then filtered to recover the R.P. silica gel, which was washed with copious amounts 
of water until the silica gel was almost colourless. The R.P. silica gel was then washed 
with acetonitrile (4 x 200 ml) and chloroform (3 x 150 ml). The organic fractions were 
combined and concentrated in vacuo to give a pale green oil. The product was isolated by 
N.P.S.G. chromatography, eluting initially with chloroform only, then gradually changing 
to chloroform/methanol (95:5) and finally gradually changing to 
chloroform/methanol/acetic acid (80:15:5) to yield 4.38 g (70.0 %) of a yellow oil.
O
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*H NMR (CDCI3) 6 : 3.38 (2H, m, H0 2C(CH2 0 CH2)8CH2NHCOCH2C 13H9), 3.54- 
3.73 (30H, m, H0 2 CCH2 0 CH2(CH2 0 CH2)7CH2NHC0 CH2Ci3H9), 4.14 (2H, s, 
H0 2CCH2(OCH2CH2)8NHCOCH2Ci3H9 ) ,4 .2 1  (1H, t , J=  6.9 Hz, *H9), 4.39 (2H, d, J  = 
6.9 Hz, H0 2 C(CH2OCH2)8CH2NHCOCH2C,3H9), 5.54 (1H, bs, -NH-), 7.31 (2H, t, J  =
7.4 Hz, *H3 & *H6 ), 7.38 (2H, t, J = 7.4 Hz, *H2 & *H7), 7.59 (2H, d, J =  7.4 Hz, *H4 
& *H5), 7.74 (2H, d, J =  1A  Hz, *H1 & *H8 ).
,3C NMR (CDCI3) 6 : 40.94 (1C, C26), 47.27 (1C, *C9), 66.59 (1C, - 
NHCOCH2C,3H9), 70.05, 70.33, 70.49, 70.58, 71.11 (16C, C2-C25), 119.94, 125.09, 
127.05, 127.66 (8 C, *C1, *C2, *C3, *C4, *C5, *C6 , *C7 and *C8), 141.30, 144.00 (4C, 
*C4a, *C4b, *C8 a and *C9a), 156.65 (1C, carbamate C=0), 171.64 (1C, C=0).
IR v /cm*1 (NaCl): 3336 (st., carboxylic O-H stretch), 3060 (wk., Aryl-H stretch), 
2881 (st., C-H stretch), 1714, 1700 (vst., carbamate C=0 stretch & carboxylic acid C=0 
stretch), 1600 (st., carbamate N-H bend), 1451 (st., carboxylic O-H bend), 1251 (st., 
carbamate & carboxylic C-0 stretch), 1106 (vst., C-0 stretch).
MS m/z (+ve ES): 672 (M+Na+, 2 %), 650 (M+H+, 99 %), 428 ([Ci8H380,oN]+, 4
%).
HRMS (+ve ESI): Measured mass -  672.2998. Actual mass for M+Na+ - 
672.2990.
(47) 20-Phenylmethyloxy-l -azido-3,6,9,12,15,18-hexaoxa- 
eicosane.
To 1 l-triphenylmethyloxy-3,6,9-trioxaundecan-l-ol (24) (43.65 g, 100 mmol) and 
triethylamine (30.66 ml, 22.26 g, 220 mmol, 2.2 eq.) in dry dichloromethane (250 ml), 
under argon at 0°C was added dropwise methanesulfonyl chloride (15.48 ml, 22.91 g, 200
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mmol, 2 eq.) in dry dichloromethane (100 ml). Once addition was complete, the reaction 
was left to stir at room temperature. After five hours another volume of dichloromethane 
(250 ml) was added to the reaction and the organic solution was partitioned with sat. aq. 
NaHCOs (2 x 300 ml). The organic phase was then partitioned with sat. aq. NaCl (400 
ml), dried over anhydrous sodium sulphate and concentrated in vacuo to give a brown oil. 
This oil was azeotroped several times with toluene to remove water and then placed under 
high vacuum until the oil became an orange solid.
To the orange solid, under argon was added 8-phenylmethyloxy-3,6-dioxaoctan-l- 
ol (36) (28.34 g, 100 mmol) in dry dimethylformamide (200 ml) followed by sodium 
hydride (12.0 g, 300 mmol, 3 eq., 60% w/w in mineral oil). The reaction was left to stir 
for 5 days at room temperature. After 5 days the reaction was concentrated in vacuo and 
then re-dissolved in diethyl ether (1000 ml) and water (500 ml). The organic phase was 
then partitioned with aq. sat. NaCl with a little NaHCC>3 (500 ml), dried over anhydrous 
sodium sulphate and concentrated in vacuo to give a brown oil.
To this brown oil was added a solution made up of dichloromethane, triethylsilane 
and trifluoroacetic acid (300 ml, 80:10:10). The reaction was left to stir at room 
temperature for 2 hours. After one hour sat. aq. Na2CC>3 was slowly added to the reaction 
with vigorous stirring until the reaction reached pH 12. The two layers were partitioned 
and the aqueous fraction was back-extracted several times with dichloromethane (9  x 1 0 0  
ml). The organic fractions were combined, dried over anhydrous sodium sulphate and 
concentrated in vacuo to give a yellow solid/oil. This oil was re-dissolved in water (200 
ml) and the aqueous solution was partitioned twice with hexane (2 x 200 ml). The 
aqueous solution was then concentrated in vacuo to give a pale yellow oil. The resulting 
oil was azeotroped with anhydrous acetonitrile several times.
To this oil and triethylamine (30.66 ml, 22.26 g, 220 mmol, 2.2 eq.) in dry 
dichloromethane (250 ml), under argon at 0°C was added dropwise methanesulfonyl 
chloride (15.48 ml, 22.91 g, 200 mmol, 2 eq.) in dry dichloromethane (75 ml). Once 
addition was complete, the reaction was left to stir for five hours at room temperature. 
After five hours another volume of dichloromethane (300 ml) was added to the reaction 
and the organic solution was partitioned with sat. aq. NaHC0 3  (2 x 300 ml). The organic 
phase was then partitioned with sat. aq. NaCl (300 ml), dried over anhydrous sodium 
sulphate and concentrated in vacuo to give a brown oil. This oil was azeotroped several 
times with toluene to remove water.
The brown oil was dissolved in dimethylformamide (150 ml) and sodium azide 
(32.51 g, 500 mmol, 5 eq.) was added. The reaction was left to stir for four days after
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which time it was concentrated in vacuo and then re-dissolved in diethyl ether ( 1 0 0 0  ml). 
The ethereal solution was filtered and the filtrate was concentrated in vacuo to give a 
brown oil. This oil was purified by N.P.S.G. chromatography, eluting with diethyl ether 
only to yield 33.39 g (75.6 %) of a yellow oil.
NMR (CDC13) 6 : 3.37 (2H, t, J = 5.1 Hz, C6H5CH2 0 (CH2CH2 0 )6CH2CH2N3), 
3.60-3.69 (26H, m, C fiH sCH zO tC ^C ^O ^CI^CH z^), 4.56 (2H, s, 
C6H5CH20(CH2CH20)6CH2CH2N3), 7.22-7.35 (5H, m, -OCH2C6H5).
13C NMR (CDCI3) 5: 50.66 (1C, Cl), 69.43, 70.03, 70.57, 70.59, 70.64, 70.68 
(13C, C2-C20), 73.21 (1C, -OCH2C6H5), 127.58, 127.73, 128.35, 138.37 (7C, benzyl).
IR v /cm' 1 (NaCl): 3010 (wk., Aryl-H stretch), 2867 (st., C-H stretch), 2106 (st., 
azide stretch), 1453 (med., C=C aromatic stretch), 1104 (vst., C -0 stretch).
MS m/z (+ve ES): 464 (M+Na+, 99.9 %), 436 ([C2iH3 5 0 7N]+Na+, 4 %).
HRMS (+ve ion FAB): Measured mass -  442.2566. Actual mass for M+H+ - 
442.2553.
(48) 20-Phenylmethyloxy-3,6,9,12,15,18-hexaoxa- 
eicosylamine.
To 20-phenylmethyloxy-l-azido-3,6,9,12,15,18-hexaoxaeicosane (47) (32.70 g, 
74.06 mmol) in tetrahydrofuran (200 ml) was added triphenylphosphine (23.32 g, 8 8 .8 8  
mmol, 1.2 eq.). The solution was left to stir for 3 hours at room temperature before the 
addition of water (5.4 g, 296 mmol, 4 eq.). The reaction was then left to stir at room 
temperature for 48 hours.
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After 48 hours the reaction was concentrated in vacuo and to the remaining oil 
was added water (500 ml). The reaction was then filtered to remove the precipitate, the 
precipitate being washed twice with water (2  x 150 ml). The filtrate was combined and 
acidified to pH 2 with concentrated hydrochloric acid. This solution was partitioned four 
times with diethyl ether (4 x 300 ml). The aqueous solution was then adjusted to pH 11 
by addition of solid Na2C0 3  and also saturated with NaCl. The resulting solution was 
partitioned four times with dichloromethane (4 x 300 ml). The organic fractions were 
combined, dried over anhydrous sodium sulphate and concentrated in vacuo to yield 
29.77 g (96.8 %) of a colourless oil, which required no further purification.
*H NMR (DMSO) 8 : 2.65 (2H, t, J = 5.8 Hz, 
C6H5CH2 0 CH2(CH2OCH2)6CH2NH2), 3.36 (2H, t,J =  5.8 Hz, 
C6H5CH20(CH2CH20)6CH2CH2NH2), 3.49-3.61 (24H, m, 
C6H5CH2 0 (CH2CH2 0 )6CH2CH2NH2), 4.51 (2H, s,
C6H5CH20CH2(CH20CH2)6CH2NH2), 7.27-7.39 (5H, m, 
C6H5CH20CH2(CH20CH2)6CH2NH2).
13C NMR (DMSO) 8 : 42.33 (1C, Cl), 70.06, 70.52, 70.72 (12C, C4-C20), 72.96 
(1C, C2), 74.08 (1C, -OCH2C6H5), 128.28, 128.40, 129.14, 139.42 (7C, benzyl).
IR v / c m 1 (NaCl): 3377, 3313 (wk., N-H stretch), 3086, 3062, 3028 (wk., Aryl-H 
stretch), 2865 (st., C-H stretch), 1959, 1886 (wk., aromatic overtones), 1583 (med., N-H 
bend), 1454 (med., C=C aromatic stretch), 1106 (vst., C-0 stretch).
MS m/z (+ve ES): 438 (M+Na+, 12 %), 416 (M+H+, 99 %), 524 ([C7H7]+, 13 %).
HRMS (+ve ESI): Measured mass -  416.2639. Actual mass for M+H+ - 416.2642.
(49) 20-(9-Fluorenylmethyloxycarbonylamido)- 
3,6,9,12,15,18-hexaoxaeicosan-l-ol.
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BY °
o
A solution of 20-phenylmethyloxy-l-amino-3,6,9,12,15,18-hexaoxaeicosane (48) 
(29.76 g, 71.6 mmol) in dry diethyl ether (200 ml) under argon was cooled to -78°C. Into 
this solution was condensed ammonia until the volume of the solution had almost doubled 
(c. 400 ml). To the solution under argon at -78°C were added sodium pellets until a dark 
blue colour persisted. The reaction was allowed to warm to from -78°C to -30°C over 30 
minutes and then cooled back to -78°C. A saturated methanolic solution of ammonium 
chloride was slowly added to the reaction at -78°C under argon until the solution was no 
longer blue in colour. The reaction was then allowed to warm to room temperature and 
once most of the ammonia had evaporated, the reaction was concentrated in vacuo. To the 
remaining residue was added water (400 ml) and the pH was adjusted to 4 with 
concentrated hydrochloric acid. The pH of the solution was then adjusted to 7 by addition 
of solid sodium hydrogencarbonate. Once the solution had been neutralised, sodium 
hydrogencarbonate (9.02 g, 107.4 mmol, 1.5 eq.) was again added followed by dioxane 
(200 ml). To this solution, cooled to 0°C was slowly added fluorenylmethyl 
chloroformate (27.78 g, 107.4 mmol, 1.5 eq.) in dioxane (250 ml). Once addition was 
complete the reaction was allowed to warm to room temperature and left to stir for 24 
hours.
After 24 hours the solution was acidified to pH 6 by addition of solid citric acid 
and then concentrated in vacuo to remove dioxane. The remaining aqueous solution was 
partitioned three times with chloroform (3 x 350 ml). The organic fractions were 
combined, dried over anhydrous sodium sulphate and concentrated in vacuo to give a 
yellow oil. This oil was purified by N.P.S.G. chromatography, eluting initially with ethyl 
acetate only and then gradually changing to ethyl acetate/methanol (4:1) to yield 38.04 g 
(97.0 %) of a yellow oil.
'H NMR (CDCI3) 5: 2.88 (1H, bs, -OH), 3.39 (2H, q, J = 5.2 Hz, 
HOCH2(CH20CH2)6CH2NHCOCH2Ci3H9), 3.55-3.63 (34H, m, 
HOCH2(CH2 0 CH2)6CH2NHFmoc), 3.70 (2H, m, HOC^CH zO CHz^C^N HFm oc),
4.22 (1H, t, J = 6.9 Hz, *H9), 4.41 (2H, d, J = 6.9 Hz,
H0 CH2(CH2 0 CH2)6CH2NHC0 CH2C 13H9), 5.57 (1H, t, J = 5.2 Hz, NH), 7.31 (2H, t, J  =
7.4 Hz, *H3 & *H6 ), 7.39 (2H, t,J =  7.4 Hz, *H2 & *H7), 7.61 (2H, d,J =  7.4 Hz, *H4 
& *H5), 7.76 (2H, d, J = 7.4 Hz, *H1 & *H8 ).
13C NMR (CDCI3) 6 : 40.95 (1C, C20), 47.30 (1C, *C9), 61.71 (1C, Cl), 66.54 
(1C, -NHCOCH2C 13H9), 70.09, 70.34, 70.57 (11C, C4-C19), 72.56 (1C, C2), 119.96, 
125.10, 127.06, 127.65 (8 C, *C1, *C2, *C3, *C4, *C5, *C6 , *C1 and *C8 ), 141.32,
144.04 (4C, *C4a, *C4b, *C8 a and *C9a), 156.59 (1C, carbamate C=0).
IR v /cm*1 (NaCl): 3326 (st., O-H & N-H stretch), 3041, 3020 (wk., Aryl-H 
stretch), 2884 (st., C-H stretch), 1672 (vst., carbamate C=0 stretch & N-H bend), 1452 
(med., C=C aromatic stretch), 1346 (med., carbamate C-Ostretch), 1105 (vst., C-0 
stretch).
MS m/z (+ve ES): 548 (M+H+, 9 %), 178 ([Ci4Hn ]+, 35 %).
HRMS (FAB, NOBA matrix): Measured mass -  548.2868. Actual mass for M+H+ 
- 548.2859.
(50) 11-Aminoundecanoic acid benzyl ester p - 
toluenesulfonate.198
o
To 11-aminoundecanoic acid (10.05 g, 50.0 mmol) in benzene (500 ml) was 
addedp-toluenesulfonic acid monohydrate (10.46 g, 55.0 mmol, 1.1 eq.) and benzyl
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alcohol (150 ml, large excess). The reaction was then heated to reflux under argon and the 
liberated water, being trapped by aid of a Dean and Stark receiver was removed 
azeotropically. The reaction was refluxed for 5 hours after which time no more water was 
distilled off.
The reaction was then allowed to cool to room temperature. Diethyl ether (500 ml) 
was slowly added to the reaction at room temperature and the resulting solution was left 
to stand for 24 hours at 4°C. After 24 hours the crystalline solid that had formed was 
filtered and washed with diethyl ether (3 x 100 ml). The crystalline product was then re­
crystallised from methanol/diethyl ether to yield 21.2 g (91 %) of product.
'H NMR (DMSO) 5: 1.25 (12H, bs, Tos'H3N+CH2CH2(CH2)6CH2CH2C 0 2Bn),
1.55 (4H, m, Tos'H3N+CH2CH2(CH2)6CH2CH2C02Bn), 2.31 (3H, tosyl), 2.36 (2H, t, Jm. 
H3 = 7.3 Hz, Tos H3N+(CH2)9CH2C02Bn), 2.77 (2H, t, J H h - h i o  = 7.4 Hz, Tos' 
H3N+CH2(CH2)9C02Bn), 5.11 (2H, s, T o s '^ N ^ C H ^ o C O ^ H ^ H s), 7.15 (2H, d, J  =
7.7 Hz, tosyl meta-H), 7.34 (5H, m, benzyl), 7.55 (2H, d, J  = 7.7 Hz, tosyl ortho-U), 7.70 
(3H, bs, TosH3N+(CH2)ioC02Bn).
13C NMR (DMSO) 5: 21.71 (1C, O S O ^ H ^ H j) , 25.41 (1C, C3), 26.72, 27.88, 
29.36, 29.42, 29.57, 29.68 (7C, C4-C10), 34.44 (1C, C2), 39.87 (1C, Cl 1), 66.21 (1C, - 
OCH2C6H5), 126.44 (2C, tosyl), 128.83, 128.90, 129.07, 129.34, 137.27, 138.83 (9C, 
toysl & benzyl), 146.26 (1C, toysl), 173.69 (1C, C=0).
IR v /cm'1 (KBr): 3065 (st., N-H stretch), 2921, 2849 (st., C-H stretch), 1735 (vst., 
C=0 stretch), 1610 (med., N-H bend), 1474 (st., C-H bend & C=C stretch), 1185 (vst., C- 
H stretch, C-N stretch, S=0 stretch & C-O stretch).
MS m/z (+ve ES): 486 (M+Na+, 2 %), 292 ([Ci8H3o 0 2N ]+, 99.9 %).
HRMS (+ve ESI): Measured mass -  292.2283. Actual mass for (C isH3oN 0 2)+ - 
292.2271.
Analysis: hygroscopic compound.
(51) 1 l-(9-Fluorenylmethyloxycarbonylamido)- 
undecanoic acid benzyl ester.159
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To 11-aminoundecanoic acid benzyl ester/?-toluenesulfonate (50) (11.59 g, 25.0 
mmol) and sodium carbonate (3.31 g, 31.25 mmol, 1.25 eq.) in dioxane/water (2:1, 300 
ml) at 0°C was slowly added fluorenylmethyl chloroformate (9.70 g, 37.5 mmol, 1.5 eq.) 
in dioxane (100 ml). Once addition was complete the reaction was allowed to warm to 
room temperature and was left to stir for 7 hours.
After 7 hours the reaction was concentrated in vacuo to remove dioxane. The 
remaining solid/solution was partitioned twice with dichloromethane (2 x 200 ml). The 
organic fractions were combined and partitioned with sat. aq. NaCl (100 ml) adjusted to 
pH 5 with citric acid. The organic solution was then dried over anhydrous magnesium 
sulphate and concentrated in vacuo to give a yellow solid. The product was recovered 
from this solid by column chromatography eluting with chloroform/ethyl acetate (95:5) to 
yield 12.2 g (95 %) of a white solid.
‘H NMR (CDC13) 8 : 1.29 (12H, m, F m o c H N C ^ C ^ C J ^ C ^ C ^ C C ^ B n ) , 1.51 
(2H, m, Fm0 cHNCH2CH2(CH2)8CO2Bn), 1.66 (2H, m, FmocHN(CH2)8CH2CH2C0 2 Bn),
2.37 (2H, t, J H2-H3 = 7.5 Hz, FmocHN(CH2)9CH2C02Bn), 3.19 (2H, m, 
FmocHNCH2(CH2)9C02Bn), 4.23 (1H, t, J = 6 .8  Hz, *H9), 4.41 (2H, d, J = 6 .8  Hz, - 
NHCOOCH2C13H9), 4.77 (1H, bs, -NH-), 7.32-7.79 (13H, m, benzyl & Fmoc).
,3C NMR (CDCI3) 8 : 25.26, 27.03, 29.41, 29.51, 29.55, 29.66, 29.75, 30.30 (8 C, 
C3-C10), 34.64 (1C, C2), 41.43 (1C, Cl 1), 47.66 (1C, *C9), 66.37 (1C,
OCH2C6H5), 66.80 (1C, -NHCOOCH2C13H9), 120.27, 125.35, 127.32, 127.96 (8 C, *C1, 
*C2, *C3, *C4, *C5, *C6 , *C7 and *C8 ), 128.47, 128.85, 136.48 (5C, benzyl), 141.65,
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144.37 (4C, *C4a, *C4b, *C8a and *C9a), 156.73 (1C, carbamate C=0), 173.97 (1C, 
C=0,C1).
IR v /cm'1 (KBr): 3299 (med., N-H stretch), 2912, 2848 (st., C-H stretch), 1729 
(st., ester C=0), 1692 (st., carbamate C=0), 1521, 1470, 1450 (med., aromatic C=C 
stretch & aliphatic C-H bend), 1277, 1229, 1139 (med., C-N, C-0 & S=0 stretch).
MS m/z (+ve Ion FAB): 514 (M+H+, 95 %), 292 ([Ci8H3o02N]+, 71 %).
HRMS (+ve ion FAB): Measured mass -  514.2949. Actual mass for M+H+ - 
514.2957.
Analysis: hygroscopic compound.
(52) 1 l-(9-Fluorenylmethyloxycarbonylamido)- 
undecanoic acid.159
o  o
To 1 l-(9-fluorenylmethyloxycarbonylamido)-undecanoic acid benzyl ester (16) 
(5.14 g, 10.0 mmol) in tetrahydrofuran (80 ml) was added palladium on carbon (10 %,
100 mg). This reaction mixture was first de-gassed by stirring under vacuum and was 
then placed under a hydrogen atmosphere (standard atmospheric pressure). The reaction 
was left stirring under the hydrogen atmosphere until 241 cm of hydrogen had been 
absorbed by the reaction. The reaction was then filtered through a bed of Celite, the Celite 
bed being washed thrice with tetrahydrofuran (3 x 50 ml). The filtrate was concentrated in 
vacuo and a white solid was recovered. This white solid was re-crystallised from ethyl 
acetate to yield 3.70 g (87.8 %) of white crystals.
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‘H NMR (DMSO) 8: 1.25 (12H, m, Fm ocH N C ^C ^CH h^C ^CH zC C^H ), 
1.41-53 (2H, m, FmocHNC^CIiKCHz^C^CHzCCbH), 2.20 (2H, t, J H2-h3 = 7.3 Hz, 
FmocHN(CH2)9CH2C02H), 2.99 (2H, m, FmocHNCH2(CH2)9C 0 2H), 4.23 (1H, t, J=  6.7 
Hz, *H9), 4.32 (2H, d, J = 6.7 Hz, -NHCOOCH2Cl3H9), 4.41 (1H, bs, -NH-), 7.34 (2H, 
dt, J = 1A  Hz and 1.1 Hz, *H3 and *H6), 7.43 (2H, t, J = 1A  Hz, *H2 and *H7), 7.71 
(2H, d, J = 7.4 Hz, *H4 and *H5), 7.90 (2H, d, J = 7.4 Hz, *H1 and *H8).
,3C NMR (DMSO) 8: 25.58, 27.15, 29.56, 29.66, 29.72, 29.82, 29.90, 30.29 (8C, 
C3-C10), 34.94 (1C, C2), 41.14 (1C, Cl 1), 47.75 (1C, *C9), 66.08 (1C, - 
NHCOOCH2Ci3H9), 121.00, 126.06, 127.92, 128.49 (8C, *C1, *C2, *C3, *C4, *C5, *C6, 
*C7 and *C8), 141.68, 144.88 (4C, *C4a, *C4b, *C8a and *C9a), 157.00 (1C, carbamate 
C=0), 175.54 (1C, C=0, Cl).
IR v /cm'1 (KBr): 3346 (st., O-H & N-H stretch), 3018 (med., aromatic C-H 
stretch), 2925, 2850 (st., aliphatic C-H stretch), 1949, 1913 (wk., aromatic overtone 
bands), 1688 (vst., acid & carbamate C O  stretch), 1528, 1464, 1450 (st., aromatic C O  
stretch, aliphatic C-H bend & C-O-H bend), 1279, 1239, 1140 (med., C-N, S O  & C-0 
stretch).
MS m/z (+ve Ion FAB): 446 (M+Na+, 99.9 %), 202 ([C,iH24 0 2N]+, 10 %).
HRMS (+ve ESI): Measured mass -  446.22930. Actual mass for M+Na+ - 
446.23018.
Analysis: hygroscopic compound.
2.6 Solid-Phase Peptide Synthesis
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Solid-phase peptide synthesis was carried out either manually on a Merrifield 
Bubbler or automatically on a peptide synthesiser module (MilliGen 9050Plus 
PepSynthesiser). All reagents used for either manual or automatic synthesis were 
purchased from commercial suppliers, with the exception of the two Fmoc-protected 
amino acids whose synthesis has been described earlier. HIPERSOLV® DMF of HPLC 
grade was used straight from the bottle, whilst dichloromethane and piperidine were 
freshly distilled over calcium hydride before use. All peptide syntheses were carried out 
under nitrogen.
The solid support used for SPPS was a NovaSyn-TGT resin pre-loaded with N-a- 
Fmoc-glycine. All SPPS reactions were carried out at room temperature.
2.6.1 Automated peptide synthesis.
The procedure for setting up and carrying out the synthesis of a peptide on the 
MilliGen 9050Plus PepSynthesiser peptide synthesiser module is described as follows.
1. The desired peptide sequence was entered into the programme.
2. The chemistry of each amino acid that was used in the synthesis of the peptide 
was selected.
3. The support substitution and quantity of support was entered.
4. A protocol for the inclusion of each Fmoc-protected amino acid into the peptide 
was chosen.
5. A list of the necessary resources for the peptide synthesis was automatically 
calculated using the data entered in the previous steps.
6. The peptide synthesiser was loaded with the required quantity of reagents as 
detailed on the resource list, and primed ready to commence synthesis.
7. Synthesis was initiated.
Before commencing a SPPS, the resin was pre-swelled in DMF for a minimum of 
20 minutes prior to loading into the reaction column. The substitution of the resin used 
was the same for all peptide syntheses carried out i.e. 0.220 meq/g. The protocol for the
2 2 2
inclusion of Fmoc-protected amino acids was also the same for all peptide syntheses 
carried out, however the variables of the protocol were altered for the inclusion of certain 
Fmoc-protected amino acids. For every Fmoc-amino acid inclusion, a four-fold excess of 
reagent (Fmoc-amino acid and coupling reagents) was used with respect to the quantity of 
resin-bound Fmoc-amino acid.
The table below (Table 1) details a standard Fmoc-amino acid coupling protocol. 
The three main features of such a protocol are; removal of the Fmoc protection with the 
de-block solution, addition of the next Fmoc-amino acid along with coupling reagents, 
and finally capping of any unreacted amino-groups with the auxiliary reagent.
Flow(ml/min). Time (sec). Reagent.
5 15 DMF wash
5 60 De-block
1.5 300 De-block
Dissolve A.A
5 420 DMF wash
5 A.A. injection
5 900 A.A. recycle
5 900 A.A. recycle
5 240 DMF wash
5 120 Aux. wash
0 180 Aux. wash
50 240 DMF wash
Table 1. - A standard Fmoc-amino acid coupling protocol.
The various reagent solutions that are detailed in the table above were made to the 
same concentrations for every peptide synthesis carried out. The table on the subsequent 
page (Table 2) lists the concentrations of these various reagents and washing solutions. 
The reagent solutions were prepared according to specifications for the MilliGen 
9050Plus PepSynthesiser, with the exception of the de-block solution.
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Reagent/Solution. Concentration.
De-block reagent 30 % Piperidine in DMF.
Coupling reagent 1 0.6 M DIPCI in DMF (A l) or
0.6M TBTU & 0.6 M HOBt in DMF (Bl).
Coupling reagent 2 0.6 M HOBt in DMF (A2) or 1.0 M DIPEA (B2).
Auxiliary wash. 0.3 M NAI in DMF.
Wash solution DMF/DCM (3:2)
Table 2. -  Reagent solutions.
The incorporation of subsequent Fmoc-amino acids into the peptide was 
determined by U.V. monitoring of the coupling reaction and the Fmoc deprotection. 
During the coupling reaction, the decrease in Fmoc protected species in solution as a 
result of incorporation into the growing peptide was quantitatively assessed. Likewise, the 
increase in dibenzofulvene/dibenzofulvene adduct in solution because of Fmoc 
deprotection was also quantitatively assessed. The success of amino acid incorporation 
could therefore be determined visually on a bar chart.
Flow (ml/min). Time (sec). Reagent.
5 15 DMF wash
5 60 De-block
1.5 300 De-block
5 420 DMF wash
5 360 Wash solution
Table 3. -  Final protocol.
The final cycle of a peptide synthesis, the ‘End’ protocol involved removing the 
terminal Fmoc-group with the de-block solution and washing the resin-bound peptide 
with the ‘Wash’ solution (‘Solvent exchange’). However, in the case of the synthesis of a 
peptide that was then to be used in further syntheses, the ‘End’ protocol did not include 
terminal Fmoc-group removal, only ‘Solvent exchange’. The cycle that includes Fmoc- 
group removal is detailed in the table above (Table 3). The other cycle is identical except 
that it does not involve de-block solution addition.
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2.6.2 Peptide-resin cleavage and peptide deprotection.
(General procedure.)
To the dry resin-bound peptide (0.110 mmol) in a Merrifield bubbler was added a 
solution (10 ml) consisting of trifluoroacetic acid (85 %), thioanisole (5 %), phenol (5 %), 
water (2.5 %) and triethylsilane (2.5 %). The resin-bound peptide in the solution was left 
to agitate for 10 minutes by bubbling with a stream of nitrogen. After 10 minutes, the 
solution was drained into a flask. Another volume of the solution (10 ml) was then added 
to the resin-bound peptide and again bubbling with N2 was re-commenced for 10 minutes. 
The solution was drained into the flask and the above procedure was repeated four more 
times. Once this was complete, the contents of the flask were left to stir at room 
temperature, under nitrogen for 6 hours.
After 6 hours, the solution was concentrated in vacuo and, to the residue that 
remained was added diethyl ether/hexane (1:1, 50 ml). The organic solution was carefully 
decanted to retain the solid precipitate that had formed, which was then dried under 
vacuum. The solid was then re-dissolved in water, de-gassed under vacuum and freeze- 
dried.
Peptide 1.
Rnoc—Gly-Ala-Cys-Aig-Arg-Qu-Hii^Ala-Trp-Ala-Cys-gy—[Resin|
• Coupling solutions A1 and A2 used.
• Fmoc-L-Cys(Trt)-OH protocol altered; recycle times were extended by 5 minutes 
each.
• Alternative ‘End’ protocol selected; solvent exchange only, no final de-block.
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Peptide 2.
FmocLAA-Gy-AlaCysArgArg-Glu-Thr Ala-Trp-AlaCysGly— Resin
P e p
H O
Peptide 1 (0.37 g, 0.055 mmol) was pre-swelled with DMF on a Merrifield 
Bubbler under nitrogen. The DMF was removed, l,8-diazabicyclo[5.4.0]undec-7- 
ene/piperidine/DMF (1:1:48, 8 ml) was added to cover the resin-bound peptide and the 
reaction was agitated by nitrogen bubbling over 10 minutes. After 10 minutes, the 
deprotection solution was removed and the resin-bound peptide was washed with DMF (2 
x 10 ml). A further quantity of l,8-diazabicyclo[5.4.0]undec-7-ene/piperidine/DMF 
(1:1:48, 8 ml) was again added and bubbling was re-commenced for 10 minutes, followed 
by washing with DMF.
This procedure was repeated a further three times. After the final deprotection, the 
resin-bound peptide was thoroughly washed with DMF (50 ml). (Z) 16-(9- 
fluorenylmethyloxycarbonylamido)-hexadeca-7-enoic acid (14)(0.108 g, 0.22 mmol), O- 
(7-azabenzotriazol-1 -yl)-A,A, A ’,7V’-tetramethyluronium hexafluorophosphate (0.083 g, 
0.22 mmol) and l-hydroxy-7-azabenzotriazole (0.029 g, 0.22 mmol) were dissolved in 
the minimum quantity of DMF/DCM (5 ml, 1:1). To this solution was added N,N- 
diisopropylethylamine (0.096 ml, 0.0711 g, 0.55 mmol) and the resulting solution was 
immediately added to the resin-bound peptide. The reaction was agitated by bubbling 
with N2 for two hours.
After two hours, the reagent solution was removed and the resin-bound peptide 
was washed with DMF, dichloromethane, and diethyl ether, then dried under vacuum. A 
small quantity of the resin-bound peptide (-30 mg) was cleaved/deprotected. Diethyl 
ether/hexane was however not added to the residue recovered when the 
cleavage/deprotection solution was concentrated in vacuo.
The residue was then purified by preparative reverse phase HPLC, using the 
solvent gradient profile given below (Table 4). Both water and acetonitrile contained 0.1
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% trifluoroacetic acid. The retention time of the product was approximately 55 minutes 
(H20/MeCN, 36:64).
Time (min) % Water % Acetonitrile
0 90 10
40 40 60
60 0 100
Table 4. - Solvent gradients (flow -  15 ml/min).
This peptide product that was recovered was analysed by mass spectroscopy and 
was found to contain Peptide 2 (see MS data below). The product less the terminal Fmoc 
group was also found to be present in the residue as determined by MS.
MS m/z (+ve ES): Measured mass - 1754 (878, [M+2H+]/2). Actual mass -
1754.1.
Peptide 3.
Fmoc—Lys-LAAGIyAla-Cys^Arg-ArgGlu-Thr-Ala-Trp-Ala-CysGly—Resin
H O
Peptide 2 (0.37 g, 0.055 mmol) was pre-swelled with DMF on a Merrifield 
Bubbler under nitrogen. The DMF was removed, l,8-diazabicyclo[5.4.0]undec-7- 
ene/piperidine/DMF (1:1:48, 8 ml) was added to cover the resin-bound peptide and the 
reaction was agitated by nitrogen bubbling over 10 minutes. After 10 minutes, the 
deprotection solution was removed and the resin-bound peptide was washed with DMF (2 
x 10 ml). A further quantity of l,8-diazabicyclo[5.4.0]undec-7-ene/piperidine/DMF
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(1:1:48, 8 ml) was again added and bubbling was re-commenced for 10 minutes, followed 
by washing with DMF.
This procedure was repeated a further three times. After the final deprotection, the 
resin-bound peptide was thoroughly washed with DMF (50 ml). Fmoc-Lysine(Boc)-OH 
(0.103 g, 0.22 mmol), HATU (0.083 g, 022 mmol) and HO At (0.029 g, 0.22 mmol) were 
dissolved in the minimum quantity of DMF (5 ml). To this solution was added N,N- 
diisopropylethylamine (0.096 ml, 0.0711 g, 0.55 mmol) and the resulting solution was 
immediately added to the resin-bound peptide. The reaction was agitated by bubbling 
with N2 for 1.5 hours.
After 1.5 hours, the reagent solution was removed and the resin-bound peptide 
was washed with DMF, dichloromethane, diethyl ether, then stored under argon at 0°C.
Peptide 4.
Fttioc— Lys-HAAjGlyAlaCysArgArgGlirlhr A laT rpA laC ysG y-R esin
H O
Peptide 1 (0.37 g, 0.055 mmol) was pre-swelled with DMF on a Merrifield 
Bubbler under nitrogen. The DMF was removed, l,8-diazabicyclo[5.4.0]undec-7- 
ene/piperidine/DMF (1:1:48, 8 ml) was added to cover the resin-bound peptide and the 
reaction was agitated by nitrogen bubbling over 10 minutes. After 10 minutes, the 
deprotection solution was removed and the resin-bound peptide was washed with DMF (2 
x 10 ml). A further quantity of l,8-diazabicyclo[5.4.0]undec-7-ene/piperidine/DMF 
(1:1:48, 8 ml) was again added and bubbling was re-commenced for 10 minutes, followed 
by washing with DMF. This procedure was repeated a further three times. After the final 
deprotection, the resin-bound peptide was thoroughly washed with DMF (50 ml). 20-(9- 
Fluorenylmethyloxycarbonylamido)- 3,6,9,12,15,18-hexaoxoeicosanoic acid (21 )(0.123 
g, 0.22 mmol), HATU (0.083 g, 0.22 mmol) and HO At (0.029 g, 0.22 mmol) were
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dissolved in the minimum quantity of DMF (5 ml). To this solution was added N,N- 
diisopropylethylamine (0.096 ml, 0.0711 g, 0.55 mmol) and the resulting solution was 
immediately added to the resin-bound peptide. The reaction was agitated by bubbling 
with N2 for one hour.
After one hour, the reagent solution was removed and the resin-bound peptide was 
washed with DMF (2 x 20 ml). l,8-diazabicyclo[5.4.0]undec-7-ene/piperidine/DMF 
(1:1:48, 8 ml) was added to cover the resin-bound peptide and the reaction was agitated 
by nitrogen bubbling over 10 minutes. After 10 minutes, the deprotection solution was 
removed and the resin-bound peptide was washed with DMF ( 2 x 10  ml). A further 
quantity of l,8-diazabicyclo[5.4.0]undec-7-ene/piperidine/DMF (1:1:48, 8 ml) was again 
added and bubbling was re-commenced for 10 minutes, followed by washing with DMF. 
This procedure was repeated a further three times. After the final deprotection, the resin- 
bound peptide was thoroughly washed with DMF (50 ml). Fmoc-Lysine(Boc)-OH (0.103 
g, 0.22 mmol), HATU (0.083 g, 0.22 mmol) and HOAt (0.029 g, 0.22 mmol) were 
dissolved in the minimum quantity of DMF (5 ml). To this solution was added N,N- 
diisopropylethylamine (0.096 ml, 0.0711 g, 0.55 mmol) and the resulting solution was 
immediately added to the resin-bound peptide. The reaction was agitated by bubbling 
with N2 for one hour.
After one hour, the reagent solution was removed and the resin-bound peptide was 
washed with DMF, dichloromethane, and diethyl ether, then dried under vacuum. A small 
quantity of the resin-bound peptide (-40 mg) was cleaved/deprotected by the standard 
procedure. The residue recovered from cleavage/deprotection was analysed by mass 
spectroscopy and was found to contain almost exclusively the desired product, Peptide 4 
(see MS data below).
MS m/z (+ve ES): Measured mass -  1953.01 (652.1 [M+3H+]/3, 977.4 
[M+2H+]/2). Calculated mass -  1952.24.
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Peptide 5.
FhrxxrLys^LAALAAGIy-Ala-Cys-Arg-Arg-Glu-ThrAla-Trp-Ala-Cy^Gly
H O
Peptide 5 was prepared in the same manner as Peptide 4, (Z) 16-(9- 
fluorenylmethyloxycarbonylamido)-hexadeca-7-enoic acid (14) being used in place of 20- 
(9-fluorenylmethyloxycarbonylamido)- 3,6,9,12,15,18-hexaoxoeicosanoic acid (21).
Following incorporation of (14) and L-lysine into the Peptide 1, a small quantity 
of the resin-bound peptide (-30 mg) was cleaved/deprotected. However, the deprotection 
was not carried out by the standard procedure. The scavenger, triethylsilane was in this 
case replaced by 1,2-ethanedithiol. The deprotection time was also shortened from six 
hours to four hours. Diethyl ether/hexane was not added to the residue recovered when 
the cleavage/deprotection solution was concentrated in vacuo. The residue recovered 
from cleavage/deprotection was analysed by MS but it was not possible to determine 
whether the residue contained the desired peptide.
The residue was then purified by preparative reverse phase HPLC, using the 
solvent gradient profile given below (Table 5). Both water and acetonitrile contained 0.1 
% trifluoroacetic acid.
-Resin
Time (min) % Water % Acetonitrile
0 90 10
30 50 50
60 0 100
Table 5. - Solvent gradients (flow -  15 ml/min).
Although the HPLC data suggested that several peptides had been isolated, MS 
analysis of the products recovered from HPLC purification could not confirm that one of 
the products that had been recovered was the desired peptide.
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Peptide 6.
H-[lys^LAAGIy-Ala-CysArg-Arg-Glu-'nirAla-Tip-Ala-CysGly-X
H O
X = Resin or free carboxylic add
• Coupling solutions B 1 and B2 used.
• First Fmoc-L-Lys(Boc)-OH protocol altered; de-block time extended by 5 
minutes and recycle times extended by 10 minutes.
The peptide was cleaved from the resin and deprotected. However, once the 
cleavage solution was concentrated in vacuo, the residue was not washed with diethyl 
ether/hexane. The residue was analysed by MS and was found to contain the desired 
peptide as well as large amount of the desired peptide but with one Boc group still 
remaining. The residue was therefore re-dissolved in a solution of TFA (37 ml), TES (1 
ml) and water (2 ml). The solution was left to stir for 1 hour under nitrogen, at room 
temperature. The solution was then concentrated in vacuo once again. MS analysis 
showed that there was no peptide with one Boc group remaining. The residue was then re­
dissolved in water, de-gassed under vacuum and freeze-dried.
The residue was purified by preparative reverse phase HPLC, using the solvent 
gradient profile given below (Table 6). Both water and acetonitrile contained 0.1 % 
trifluoroacetic acid. The retention time of the product was approximately 20 minutes 
(H20/MeCN, 75:25).
Time (min) % Water % Acetonitrile
0 90 10
35 50 50
50 0 100
Table 6. - Solvent gradients (flow -  15 ml/min).
MS analysis of the peptide recovered from HPLC purification however indicated 
that a peptide had been recovered that was two mass units greater than the desired 
peptide.
MS m/z (+ve ES): Measured mass -  3585.74 (449.4 [M+8H+]/8, 513.4 
[M+7H+]/7, 598.5 [M+6H+]/6, 718.0 [M+5H+]/5). Calculated mass -  3582.69.
Peptide 7.
H^Lys^HAA^-Gly-Ala-CysAiTj-Arg-Glu-'rhrAla-Trp-Ala-CysGly-X
H O
X = Resin or free carboxylicadd
• Coupling solutions B 1 and B2 used.
• First Fmoc-L-Lys(Boc)-OH protocol altered; de-block time extended by 5 
minutes and recycle times extended by 10 minutes.
The peptide was cleaved from the resin and deprotected by the standard 
procedure. The residue was analysed by MS and was found to contain the desired peptide. 
The residue was then re-dissolved in water, de-gassed under vacuum and freeze-dried.
Time (min) % Water % Acetonitrile
0 95 5
30 75 25
40 0 100
Table 7. - Solvent gradients (flow -  15 ml/min).
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The residue was then purified by preparative reverse phase HPLC, using the 
solvent gradient profile given below (Table 7). Both water and acetonitrile contained 0.1 
% trifluoroacetic acid. The retention time of the product was approximately 20 minutes 
(H20/MeCN, 83:17).
MS analysis of the peptide recovered from HPLC purification showed that the 
Peptide 7 had been purified and recovered.
MS m/z (+ve ES): Measured mass -  3652.56 (457.6 [M+8H+]/8, 522.8 
[M+7H+]/7, 609.7 [M+6H+]/6, 731.6 [M+5H+]/5). Calculated mass -  3652.61.
Peptide 8.
H—(-Lys|^j_AALAAGIyAla-CysArgArgGlu-Thr-Ala-Trp-Ala-Cys(3ly-X
“ A -  ’’• " ' N ' r t r — H s|f-P' C
H O
X = Resin or free carboxylic add
• Coupling solutions B 1 and B2 used.
• First Fmoc-L-Lys(Boc)-OH protocol altered; de-block time extended by 5 
minutes and recycle times extended by 10 minutes.
The peptide was cleaved from the resin and deprotected. However, the 
deprotection was not carried out by the standard procedure. The scavenger, triethylsilane 
was in this case replaced by 1,2-ethanedithiol. The deprotection time was also shortened 
from six hours to four hours. Diethyl ether/hexane was not added to the residue recovered 
when the cleavage/deprotection solution was concentrated in vacuo. The residue was 
analysed by MS and was found to contain the desired peptide. The residue was then re­
dissolved in water, de-gassed under vacuum and freeze-dried.
The residue was then purified by preparative reverse phase HPLC, using the 
solvent gradient profile given below (Table 8). Both water and acetonitrile contained 0.1 
% trifluoroacetic acid. The retention time of the product was approximately 23 minutes 
(H20/MeCN, 64:36).
Time (min) % Water % Acetonitrile
0 95 5
10 70 30
35 55 45
40 0 100
Table 8. - Solvent gradients (flow -  15 ml/min).
MS analysis of the products recovered from HPLC purification showed that the 
Peptide 8 had been purified and recovered.
MS m/z (+ve ES): Measured mass -  3834.06 (480.2 [M+8H+]/8, 548.7 
[M+7H+]/7, 639.9 [M+6H+]/6, 767.7 [M+5H+]/5). Calculated mass -  3834.13.
Peptide 9.
ftnoc— Lys-Lys-AUA-Gy-Ala-Cys-Aig-Aig-Glu-'nirAla-Tip-Ala-CysGy—Resin
Peptide 1 (0.10 mmol) was pre-swelled with DMF on a Merrifleld Bubbler under 
nitrogen. The DMF was removed, piperidine/DMF (1:4, 10 ml) was added to cover the 
resin-bound peptide and the reaction was agitated by nitrogen bubbling over 10 minutes.
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After 10 minutes, the deprotection solution was removed and the resin-bound peptide was 
washed with DMF (2 x 10 ml). A further quantity of piperidine/DMF (1:4, 10 ml) was 
again added and bubbling was re-commenced for 10 minutes, followed by washing with 
DMF (6 x 10 ml).
11 -(9-Fluorenylmethyloxycarbonylamido)-undecanoic acid (17)(0.211 g, 0.50 
mmol), TBTU (0.16 g, 0.50 mmol) and HOBt (0.08 g, 0.50 mmol) were dissolved in the 
minimum quantity of DMF/DCM (1:1, 7.5 ml). To this solution was added N,N- 
diisopropylethylamine (0.175 ml, 0.129 g, 1.0 mmol) and the resulting solution was 
immediately added to the resin-bound peptide. The reaction was agitated by bubbling 
with N2 for one hour.
After one hour, the reagent solution was removed and the resin-bound peptide was 
washed with DMF (4 x 10 ml). Piperidine/DMF (1:4, 10 ml) was added to cover the 
resin-bound peptide and the reaction was agitated by nitrogen bubbling over 10 minutes. 
After 10 minutes, the deprotection solution was removed and the resin-bound peptide was 
washed with DMF (2x10  ml). A further quantity of piperidine/DMF (1:4, 10 ml) was 
again added and bubbling was re-commenced for 10 minutes, followed by washing with 
DMF (6 x 10 ml). Fmoc-Lysine(Boc)-OH (0.234 g, 0.50 mmol), TBTU (0.16 g, 0.40 
mmol) and HOBt (0.08 g, 0.50 mmol) were dissolved in the minimum quantity of 
DMF/DCM (1:1, 7.5 ml). To this solution was added A,A-diisopropylethylamine (0.175 
ml, 0.129 g, 1.0 mmol) and the resulting solution was immediately added to the resin- 
bound peptide. The reaction was agitated by bubbling with N2 for one hour.
After one hour, the reagent solution was removed and the resin-bound peptide was 
washed with DMF ( 4x 10  ml). Piperidine/DMF (1:4, 10 ml) was added to cover the 
resin-bound peptide and the reaction was agitated by nitrogen bubbling over 10 minutes. 
After 10 minutes, the deprotection solution was removed and the resin-bound peptide was 
washed with DMF ( 2x 10  ml). A further quantity of piperidine/DMF (1:4, 10 ml) was 
again added and bubbling was re-commenced for 10 minutes, followed by washing with 
DMF (6 x 10 ml). Fmoc-Lysine(Boc)-OH (0.234 g, 0.50 mmol), TBTU (0.16 g, 0.50 
mmol) and HOBt (0.08 g, 0.50 mmol) were dissolved in the minimum quantity of 
DMF/DCM (1:1, 7.5 ml). To this solution was added A/A-diisopropylethylamine (0.175 
ml, 0.129 g, 1.0 mmol) and the resulting solution was immediately added to the resin- 
bound peptide. The reaction was agitated by bubbling with N2 for one hour. After one 
hour, the reagent solution was removed and the resin-bound peptide was washed with 
DMF, dichloromethane, and diethyl ether, then dried under vacuum.
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Monitoring of the three amino acid couplings by means of the Kaiser test showed 
that the coupling of 1 l-(9-fluorenylmethyloxycarbonylamido)-undecanoic acid (52) and 
both Fmoc-lysine(Boc)-OH had been successful. No test cleavage/deprotection was 
carried out to determine coupling success by MS analysis.
Peptide 10.
H—(-Lys-^AUA-Gly-Ala-CysArg-Art|-Glu-'nirAla-Trp-Ala-Cy^Gly—X
AUA = P ep
N
O
P ep
X = Resin or free carboxylic add
• Coupling solutions B1 and B2 used.
• First Fmoc-L-Lys(Boc)-OH protocol altered; de-block time extended by 5 
minutes and recycle times extended by 10 minutes.
The peptide was cleaved from the resin and deprotected by the standard 
procedure. The residue was analysed by MS and was found to contain the desired peptide. 
The residue was then re-dissolved in water, de-gassed under vacuum and freeze-dried.
Time (min) % Water % Acetonitrile
0 90 10
40 75 25
Table 9. - Solvent gradients (flow -  15 ml/min).
The residue was purified by preparative reverse phase HPLC, using the solvent 
gradient profile given below (Table 9). Both water and acetonitrile contained 0.1 %
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trifluoroacetic acid. The retention time of the product was approximately 30 minutes 
(H20/MeCN, 79:21).
MS analysis of the peptide recovered from HPLC purification showed that Peptide 
10 had been purified and recovered.
MS m/z (+ve ES): Measured mass -  3516.44 (503.34 [M+7H+]/7, 587.14 
[M+6H+]/6, 704.25 [M+5H+]/5, 880.08 [M+4H+]/4). Calculated mass -  3514.53.
Peptide 11.
H-^LysjnHAAjGly-Ala-Cy^Arg-Arg-Glu-ThrAla-Trp-Ala-CysGly-X
H O
X = Resin or free carboxylicadd
• Coupling solutions B 1 and B2 used.
• HAA (11 -(9-fluorenylmethyloxycarbonylamido)-3,6,9-trioxaundecanoic acid 
(29)) protocol altered; Fmoc deprotection time extended by 10 minutes recycle 
time extended by 10 minutes.
• Two Fmoc-L-Lys(Boc)-OH protocols following HAA attachment cycle; 
deprotection times extended by 5 minutes and recycle times extended by 10 
minutes.
The peptide was cleaved from the resin and deprotected by the standard 
procedure. The residue was analysed by MS and was found to contain the desired peptide. 
The residue was then re-dissolved in water, de-gassed under vacuum and freeze-dried.
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The residue was purified by preparative reverse phase HPLC, using the solvent 
gradient profile given below (Table 10). Both water and acetonitrile contained 0.1 % 
trifluoroacetic acid. The retention time of the product was approximately 27 minutes 
(H20/MeCN, 81:19).
Time (min) % Water % Acetonitrile
0 95 5
30 80 20
Table 10. - Solvent gradients (flow -  15 ml/min).
MS analysis of the peptide recovered from HPLC purification showed that the 
Peptide 11 had been purified and recovered.
MS m/z (+ve ES): Measured mass -  3518.80 (503.76 [M+7H+]/7, 587.45 
[M+6H+]/6, 704.69 [M+5H+]/5, 880.70 [M+4H+/4, 1174.04 [M+3H+/3). Calculated mass 
-3520.40.
Peptide 12.
H-^-Lysj^-HAA^-HAA^GIy-Ala-CysArg-Arg-Glu-'FlirAla-Trp-Ala-CysGly-X
X = Resin or free carboxylie add
• Coupling solutions B 1 and B2 used.
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• HAA (11 -(9-fluorenylmethyloxycarbonylamido)-3,6,9-trioxaundecanoic acid 
(29)) protocols altered; both Fmoc deprotection times extended by 10 minutes 
and recycle times extended by 10 minutes.
• Two Fmoc-L-Lys(Boc)-OH protocols following second HAA attachment cycle; 
deprotection times extended by 5 minutes and recycle times extended by 10 
minutes.
The peptide was cleaved from the resin and deprotected by the standard 
procedure. The residue was analysed by MS and was found to contain the desired peptide. 
The residue was then re-dissolved in water, de-gassed under vacuum and freeze-dried.
The residue was purified by preparative reverse phase HPLC, using the solvent 
gradient profile given below (Table 11). Both water and acetonitrile contained 0.1 % 
trifluoroacetic acid. The retention time of the product was approximately 28 minutes 
(H20/MeCN, 81:19).
Time (min) % Water % Acetonitrile
0 95 5
30 80 20
Table 11.- Solvent gradients (flow -  15 ml/min).
MS analysis of the peptide recovered from HPLC purification showed that Peptide 
12 had been purified and recovered.
MS m/z (+ve ES): Measured mass -  3708.78 (464.72 [M+8H+]/8, 530.86 
[M+7H+]/7, 619.14 [M+6H+]/6, 742.75 [M+5H+]/5, 928.05 [M+4H+/4). Calculated mass 
-  3709.05.
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Peptide 13.
H^Lys^HAA^Qy-Ala-CysArg-Arg-Qu-Thr-Ala-Trp-Ala-CysGly-X
HAAg = P eP \
P ep
H O
X = Resin or free carboxylicaad
• Coupling solutions B1 and B2 used.
• HAA (26-(9-fluorenylmethyloxycarbonylamido)-3,6,9,12,15,18,21,24- 
octaoxahexaeicosanoic acid (46)) protocol altered; Fmoc deprotection time 
extended by 10 minutes and recycle time extended by 10 minutes.
• Two Fmoc-L-Lys(Boc)-OH protocols following HAA attachment cycle; 
deprotection times extended by 5 minutes and recycle times extended by 10 
minutes.
The peptide was cleaved from the resin and deprotected by the standard 
procedure. The residue was analysed by MS and was found to contain the desired peptide. 
The residue was then re-dissolved in water, de-gassed under vacuum and freeze-dried.
The residue was purified by preparative reverse phase HPLC, using the solvent 
gradient profile given below (Table 12). Both water and acetonitrile contained 0.1 % 
trifluoroacetic acid. The retention time of the product was approximately 36 minutes 
(H2Q/MeCN, 81:19).
Time (min) % Water % Acetonitrile
0 90 10
40 80 20
Table 12. - Solvent gradients (flow -  15 ml/min).
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MS analysis of the peptide recovered from HPLC purification showed that Peptide 
13 had been purified and recovered.
MS m/z (+ve ES): Measured mass -  3742.71 (535.85 [M+7H+]/7, 624.83 
[M+6H+]/6, 749.40 [M+5H+]/5, 936.49 [M+4H+/4). Calculated mass -  3740.71.
Peptide 14.
H-[lys|^-AA-Gly-Ala-CV^Arg-Arg-au-ThrAla-Trp-Ala-Cy&Gly-OH
H O
Peptide 6* (peptide recovered which was two mass units greater) was dissolved in 
de-gassed water/acetonitrile (2:1) to make a final concentration o f -0.025 mg/ml. The 
solution was left to stir at room temperature exposed to the atmosphere for one week. 
After one week the reaction was concentrated in vacuo, the remaining residue was re­
dissolved in de-gassed water and freeze-dried.
The residue was then purified by preparative reverse phase HPLC, using the 
solvent gradient profile given below (Table 13). Both water and acetonitrile contained 0.1 
% trifluoroacetic acid. The retention time of the product was approximately 22 minutes 
(H20/MeCN, 73:27).
Time (min) % Water % Acetonitrile
0 95 5
35 50 50
40 0 100
Table 13. - Solvent gradients (flow -  15 ml/min).
MS analysis of the peptide recovered from HPLC purification showed that the 
Peptide 6 had been successfully oxidised.
MS m/z (+ve ES): Measured mass -  3584.00 (449.4 [M+8H+]/8, 513.4 
[M+7H+]/7, 598.5 [M+6H+]/6, 718.0 [M+5H+]/5). Calculated mass -  3581.67.
Peptide 15.
H^tys^HAAply-Ala-CysArg-ArgGlu-'nirAla-Trp-Ala-CysGly-OH
haa7= Pep- N ^ f  - pep
H
Peptide 7 was cyclised in the same manner as for the preparation of Peptide 14. 
Following cyclisation, the product was purified by preparative reverse phase HPLC, using 
the solvent gradient profile given below (Table 14). Both water and acetonitrile contained 
0.1 % trifluoroacetic acid. The retention time of the product was approximately 22 
minutes (H20/MeCN, 81:19).
Time (min) % Water % Acetonitrile
0 95 5
30 75 25
40 0 100
Table 14. - Solvent gradients (flow -  15 ml/min).
MS analysis of the peptide recovered from HPLC purification showed that the 
Peptide 7 had been successfully oxidised.
MS m/z (+ve ES): Measured mass -  3651.01 (457.4 [M+8H+]/8, 522.6 
[M+7H+]/7, 609.5 [M+6H+]/6, 731.1 [M+5H+]/5). Calculated mass -  3650.60.
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Peptide 16.
H^Lys^-AALAAGIy-Ala-C^s-Arg-Arg-Glu-'rhr-Ala-Trp-Ala-Cys-Gly-OH
p*','N 'H r = 4 ^ f p"
H O
Peptide 8 was cyclised in the same manner as for the preparation of Peptide 14. 
Following cyclisation, the product was purified by preparative reverse phase HPLC, using 
the solvent gradient profile given below (Table 15). Both water and acetonitrile contained 
0.1 % trifluoroacetic acid. The retention time of the product was approximately 24 
minutes (H20/MeCN, 63:37).
Time (min) % Water % Acetonitrile
0 95 5
10 70 30
35 55 45
40 0 100
Table 15. - Solvent gradients (flow -  15 ml/min).
MS analysis of the peptide recovered from HPLC purification showed that Peptide 
8 had been successfully oxidised.
MS m/z (+ve ES): Measured mass -  3831.80 (480.1 [M+8H+]/8, 548.4
[M+7H+]/7, 639.6 [M+6H+]/6, 767.4 [M+5H+]/5). Calculated mass -  3832.10.
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Peptide 17.
s---------------------------s
H-^tysj^HAA^ Gy-Ala-Cys Arg-Aig-G u-Thr Ala-Trp-Ala-CysGly-OH
Peptide 11 was cyclised in the same manner as for the preparation of Peptide 14. 
Following cyclisation, the product was purified by preparative reverse phase HPLC, using 
the solvent gradient profile given below (Table 16). Both water and acetonitrile contained 
0.1 % trifluoroacetic acid. The retention time of the product was approximately 29 
minutes (H2 0 /MeCN, 80:20).
Time (min) % Water % Acetonitrile
0 95 5
30 80 20
Table 16. - Solvent gradients (flow -  15 ml/min).
MS analysis of the peptide recovered from HPLC purification showed that Peptide 
11 had been successfully oxidised.
MS m/z (+ve ES): Measured mass -  3515.75 (704.12 [M+5H+]/5, 879.89
[M+4H+/4, 1172.92 [M+3H+/3). Calculated mass -  3518.38.
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Peptide 18.
s---------------------------s
/ \ 1 1 H^Lys-j^HAA^HAAjGy-Ala-tysArtj-Arg-Glu-'nirAla-Trp-Ala-CysGly-OH
H O
Peptide 12 was cyclised in the same manner as for the preparation of Peptide 14. 
Following cyclisation, the product was purified by preparative reverse phase HPLC, using 
the solvent gradient profile given below (Table 17). Both water and acetonitrile contained 
0.1 % trifluoroacetic acid.. The retention time of the product was approximately 29 
minutes (H20/MeCN, 80:20).
Time (min) % Water % Acetonitrile
0 95 5
30 80 20
Table 17. - Solvent gradients (flow -  15 ml/min).
MS analysis of the peptide recovered from HPLC purification showed that Peptide 
12 had been successfully oxidised.
MS m/z (+ve ES): Measured mass -  3705.12 (464.11 [M+8H+]/8, 530.40 
[M+7H+]/7, 618.63 [M+6H+]/6, 742.02 [M+5H+]/5, 927.18 [M+4H+/4). Calculated mass 
-  3707.60.
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Peptide 19.
H-|Lys^HAA^GIy-Ala-CysArg-Aig-Glu-"nirAla-Trp-Ala-CysGly-OH
HAAg = - Pep
Peptide 13 was cyclised in the same manner as for the preparation of Peptide 14. 
Following cyclisation, the product was purified by preparative reverse phase HPLC, using 
the solvent gradient profile given below (Table 18). Both water and acetonitrile contained 
0.1 % trifluoroacetic acid. The retention time of the product was approximately 29 
minutes (H20/MeCN, 83:17).
Time (min) % Water % Acetonitrile
0 90 10
5 85 15
40 80 20
Table 18. - Solvent gradients (flow -  15 ml/min).
MS analysis of the peptide recovered from HPLC purification showed that Peptide 
13 had been successfully oxidised.
MS m/z (+ve ES): Measured mass -  3740.26 (468.56 [M+8H+]/8, 535.34
[M+7H+]/7, 624.37 [M+6H+]/6, 748.98 [M+5H+]/5). Calculated mass -  3738.69.
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Peptide 20.
/ \ 1 1 H—p ly s —J^AUAGIy-Ala-CysAiTj-Arg-Glu-7hrAla-Trp-Ala-CysGly—OH
AUA = P ep
N
O
P ep
Peptide 9 was cyclised in the same manner as for the preparation of Peptide 14. 
Following cyclisation, the product was purified by preparative reverse phase HPLC, using 
the solvent gradient profile given below (Table 19). Both water and acetonitrile contained 
0.1 % trifluoroacetic acid. The retention time of the product was approximately 37 
minutes (H2 0 /MeCN, 80:20).
Time (min) % Water % Acetonitrile
0 90 10
5 83 17
40 80 20
Table 19. - Solvent gradients (flow -  15 ml/min).
MS analysis of the peptide recovered from HPLC purification showed that Peptide 
9 had been successfully oxidised.
MS m/z (+ve ES): Measured mass -  3513.89 (503.00 [M+7H+]/7, 586.66 
[M+6H+]/6, 703.74 [M+5H+]/5). Calculated mass -  3512.51.
Chap
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3.1 Project aims.
Efficient condensation, protection and transport of nucleic acids are essential to 
the success of non-viral gene therapy. Many classes of compounds have been shown to be 
capable of condensing and protecting nucleic acids such a polypeptides, 
polyamidoamines, polyethylenimines (random polymer) and other polyamines (ordered 
or random structures). One of these classes of compounds, polyethylenimine has even 
been implicated in the intracellular transport of nucleic acids. Possibly the most 
interesting of these four classes are polyethylenimines and other polyamines. These 
compounds are stable to enzymatic degradation (proteases) since they contain no ester or 
amide linkages and PEI has been shown to possess buffering properties that are very 
beneficial in terms of transfection efficiency. A great deal of attention has been given to 
the development of polyethylenimine as a transfection agent, alone, as a conjugate or 
used in conjunction with other transfection agents. However few efforts have been 
focused towards the development of other polyamines as transfection agents. 
Consequently the aim of the work reported here was to synthesise a variety of 
polypropylenimines that could then be coupled to receptor-targeting peptides to form 
polypropylenimine-peptide conjugates. These conjugates would then be assessed for their 
ability to condense DNA as well as mediate gene transfer into target cells.
The low molecular weight triamine, spermidine has been shown to efficiently
231condense nucleic acids and protect them from enzymatic degradation . DNA- 
spermidine complexes formed above 90 % charge neutralisation have been viewed by 
electron microscopy and classical structures of DNA condensates have been clearly 
observed.232 Furthermore it has been shown that the DNA in these complexes formed is 
completely protected from degradation even by pancreatic DNase 1, a nuclease with a 
relatively broad substrate specificity 232. Early attempts to study the binding to DNA of 
several spermidine analogues of structure H2N(CH2)3NH(CH2)xNH2, where X = 5 to 8 
were made by Srivenugopal et al. 233. The authors used a microcentrifuge assay to 
monitor DNA aggregation and sedimentation induced by polyamine binding. The authors 
observed that much lower concentrations of spermidine and H2N(CH2)3NH(CH2)sNH2 
were required to achieve 100 % sedimentation of DNA. This indicated that these two 
molecules had a much higher affinity for DNA than the other analogues.
Binding (not condensation) of a range of low molecular weight polyamines was 
also investigated by Stewart & Gray 234 by means of ethidium bromide displacement and 
it was shown that binding of polyamines did not just vary with the number of amine 
functions but also with the spacing between the amine functions. Yoshikawa & 
Yoshikawa 235 showed that even certain diaminoalkanes were capable of inducing 
compaction of a single double-stranded DNA chain. However it was clear from this study 
that only 1,3 -diam inopropane and 1,5-diaminopentane were capable of inducing 
compaction and not methylenediamine, 1,2-diaminoethane, 1,4-diaminobutane or 1,6- 
diaminohexane, which suggested that there was a relationship between the ability to 
compact DNA and the distance between amino functions in diamines.
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237Figure 1. -  Polyamines tested for transfection activity by Thomas et al.
Further studies to elucidate the relationship between the number of amine 
functions per molecule and the ability of the polyamines to condense DNA were carried 
out by Saminathan et a l 236. The authors showed that the efficacy of polyamines to
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induce DNA compaction followed the order pentamines > tetramines > triamines.
Another publication by several of those who had contributed to the study of 
Saminathan et al. examined the facilitation of cellular uptake of triplex-forming 
oligonucleotides (TFO) by polyamines (structures -  Fig. 1). The authors measured the
-i'j
levels of polyamine-mediated [ P]-labelled TFO uptake by MCF-7 cells for the various 
polyamines in the series (Fig. 1). The results showed that polyamines in which amine 
functions were separated by 4 carbon atoms (4-4-4 and 4-4-4-4) were relatively poor 
transfection agents. Bis-ethylation of the terminal ends of the polyamines was also not 
beneficial in terms of transfection efficiency. The highest transfection levels were 
obtained with the polyamine 3-4-3-4-3 but polyamine 3-3-3-3 was also highly efficient.
A further study 238 on the some of the polyamines synthesised by Thomas et al.
237, namely 3-3-3, 3-4-3, 3-3-3-3, 3-3-3-3-3 and 3-4-3-4-3, showed that polyamine 
3-3-3-3 possessed the highest binding affinity to plasmid DNA. Moreover, the resulting 
polyamine/pDNA toroids that were observed to form with 3-3-3-3 had the smallest outer 
diameter compared to the other three polyamines in the series (117 nm as compared to 
118 nm, 168 nm and 191 nm). These results indicate that there exists some sort of 
relationship between the DNA-binding affinity of these polyamines and the amine 
spacing within them as well as the number of amine functions per molecule, but the exact 
nature of this ‘structure-activity’ relationship is far from clear and requires a great deal 
more investigation.
The ‘proton sponge effect’ of polyethylenimine has received much attention since 
the high transfection efficiency of PEI/pDNA complexes was noticed and attributed to the 
pH buffering ability of PEI. The endosomolytic activity of PEI is believed to be in part 
responsible for the high levels of transfection observed. The acid-base properties of PEI 
have been studied by Suh et a l 239 who observed that upon titration of PEI with a strong 
acid, as the number of positive centres in PEI molecules increased, protonation of 
subsequent amines was electrostatically suppressed. The authors also showed that the 
same effect occurred in smaller polyamines such as 7V-(2-(2-(2-aminoethylamino)- 
ethylamino)-ethyl)-ethane-1,2-diamine or 7/-(2-(2-aminoethylamino)-ethyl)-ethane-1,2- 
diamine; the pK of an amine is reduced to 3.3-3.5 when two ammonium cations are 
located at two y-positions to the un-protonated amino nitrogen atom. The low 
molecular weight amine, A-(2-(2-aminoethylamino)-ethyl)-ethane-1,2-diamine can in 
effect be compared to the repeating units of PEI. The acid-base properties of PEI/pDNA 
complexes however have not been investigated and conclusions about the buffering 
ability of PEI when used as a gene transfer agent cannot be drawn from the work of Suh
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et al. . The buffering role of PEI within endolysosomes has been investigated indirectly 
(Kichler et al. 240, Szoka et al. 241) and although no such investigation has been carried out 
on any other polyamines, it could be envisaged that there exist other polyamines that 
might also have a buffering capability that would endow them with endosomolytic 
activity.
NH
NH
NH
NH
NH
Figure 2. -  DAB 16, third generation polypropylenimine dendrimer, one of five 
dendrimers on which Kabanov et al. 242 carried out potentiometric titrations and one of 
five dendrimers tested for in vitro transfection by Zinselmeyer et al. 246.
Although no studies comparing the acid-base properties of polypropylenimines, 
polybutylenimines, polyhexylenimines etc. with the acid-base properties of 
polyethylenimines can be found in literature, some studies on the acid-base properties of 
polypropylenimine starburst dendrimers have been published. Kabanov et al. 242 
investigated the polyelectrolyte behaviour of several generations (G1-G5) of 1,4- 
diaminobutane (DAB) polypropylenimine starburst dendrimers (Fig. 2 -  3rd generation 
DAB 16) in aqueous solution. To summarise the authors’ conclusions, they stated that 
potentiometric titrations of the DAB dendrimers showed that the presence of two types of 
amine groups with different basicities and electrostatic interactions of the protonated
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am ine groups are im portant factors in the peculiarities o f  the ionisation o f  the 
dendrim ers.242 The authors also rem arked that there was a considerable difference 
betw een the ionisation characteristics o f  the sm aller dendrim er (G 1-G 3) and the 
ionisation characteristics o f  the two larger dendrim ers (G4 and G5). An investigation o f  
the acid-base properties o f  starburst DAB dendrim ers was also carried out by van 
D uijvenbode et al. 243.
le.Bjun
Figure 3. -  Fluorescence microscopy images of (a) DAPI-labelled T4dC 
bacteriophage DNA, (b) T4dC DNA + DAB 32 (N/P = 1:1), (c) T4dC + DAB 32 (N/P =
1:1) and (d) T4dC DNA + DAB 32 (N/P = 2:1). (Reproduced from Kabanov 245)
Another study on DAB starburst dendrimers was carried out by Kabanov 244 
but this publication was exclusively concerned with investigating the interactions of DAB 
dendrimers with ‘flexible’ linear polyanions (poly-(sodium acrylate), polyacrylic acid, 
poly-(sodium styrenesulfonate)) and so is of little relevance to the application of DAB 
dendrimers for gene transfer. However, in a subsequent publication Kabanov et al. 245
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presented the results of investigations into the complexation of the same DAB 
polypropylenimine dendrimers (G1-G5) with DNA (salmon sperm native DNA -  300-500 
bp and bacteriophage T4dC native DNA -  166 kbp). The authors formed complexes of 
DAB dendrimers G 1 to G5 with salmon sperm DNA at various N/P charge ratios and 
then performed circular dichroism spectroscopic measurements on the resulting 
complexes. The spectra that they obtained were according to the authors very similar to 
the CD spectra of DNA incorporated into medium-sized bacteriophage particles which 
are considered to be characteristic of a highly wound (condensed) DNA double helix. The 
authors also stated that, using fluorescence microscopy they were able to observe the 
transition of 4,6-diamidino-2-phenylindole-labelled (DAPI) bacteriophage T4dC DNA 
from the extended coil conformation to small compact particles upon the addition of DAB 
dendrimer at a N/P > 1 (Fig. 3). The authors proposed that these results strongly indicated 
that DAB starburst dendrimers were capable of condensing DNA.
Although the application of polyethylenimine for gene transfer has been 
extensively investigated, few reports of the use of polypropylenimine as a gene transfer 
agent can be found in literature. Indeed one of the first investigations into the use of 
polypropylenimines as gene transfer agents was undertaken only recently by Zinselmeyer 
et al. 246 who purchased five generations of commercially available starburst 
polypropylenimine dendrimers (Sigma-Aldrich). The dendrimers DAB 4, DAB 8 , DAB 
16 (Fig. 2), DAB 32 and DAB 64, which are all based on a core of 1,4-diaminobutane, 
were assessed for their ability to bind to DNA and deliver pCMVSport /?-galactosidase 
into A431 cells (human epidermoid carcinoma cell line) as well as for their cytotoxicity. 
The authors showed that the dendrimers DAB 8 , DAB 16, DAB 32 and DAB 64 were 
able to exclude ethidium bromide from binding to DNA but the dendrimer DAB 4 was 
not. The authors proposed that this was an indication of the ability of dendrimers DAB 8 
to DAB 64 to condense DNA but no other evidence was provided in support of this. The 
cytotoxicity of the dendrimers compared to the cationic lipid DOTAP and the order of 
cytotoxicity against A431 cells was determined to be DAB 4 < DAB 8  < DOTAP < DAB 
16 < DAB 32 < DAB 64. The authors proposed that the cytotoxicity of the higher 
generation dendrimers was due to binding to cellular anions and consequent disruption of 
cellular processes. They believed that DAB 4 and DAB 8 were less toxic because they 
contained a limited number of anion binding sites whereas in the larger dendrimers even 
after DNA binding had reached ‘completion’, anionic binding sites were still available. It 
could be envisaged that as the dendrimers are approximately spherical in shape and DNA 
is a relatively rigid, rod-like chain, effectively the dendrimer would have to distort to a
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certain degree to bind to the DNA. In the case of the larger dendrimers, this might then 
leave another part of the dendrimer in a conformation that would be unsuitable for 
binding to rigid, rod-like DNA. It might be this part of the larger dendrimers that cannot 
bind to DNA and so remains free to bind to other cellular anions, causing the dendrimer 
to be cytotoxic.
Assessment of the transfection efficiency of the dendrimers revealed that the 
transfection activity decreased in the order DAB 8 > DAB 16 > DAB 4 > DAB 32 > DAB 
64, with the efficiency of DAB 8 and DAB 16 being comparable under certain conditions 
to DOTAP (Fig. 4). The decrease in activity was believed by the authors to be due to the 
increasing toxicity with increasing dendrimer size since administration of higher doses of 
DAB/pDNA complexes in the case of larger dendrimers (DAB 16, DAB 32, DAB 64) 
resulted in greater cytotoxicity but the opposite was observed for the smaller dendrimers 
(DAB 4, DAB 8 ). Indeed the authors commented that at low DAB/pDNA doses DAB 16 
appeared to be almost twice as efficient as DAB 8 , DAB 16 achieving transfection levels 
equal to that of DOTAP.
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Figure 4. -  Comparison of transfection levels achieved with complexes of DAB 
dendrimers and pDNA with that of DOTAP/pDNA complexes (high doses of complex). 
(Reproduced from Zinselmeyer et al. 246)
Although the study of Zinselmeyer et a l 246 was one of the first to compare the 
transfection efficiencies of consecutive generations of polypropylenimine dendrimers, in
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an earlier study by Gebhart & Kabanov 247 the transfection efficiency of DAB 64 had 
been evaluated and compared to other transfection agents. However, in this study 247 
DAB 64 was the only polypropylenimine dendrimer to be tested and furthermore it was 
compared to vectors that were known to possess exceptionally high transfection 
efficiency (50 kDa PEI, 25 kDa PEI, Superfect™, Lipofectin®, LipofectAMINE™,
(R)CeLLFECTIN ). The poor transfection of DAB 64 led the authors to perhaps erroneously 
conclude that transfection with DAB dendrimers was not worth investigating further.
Very recently Zinselmeyer et a l 248 published their results on the delivery of antisense 
oligonucleotides targeting DNA encoding for the epidermal growth factor receptor 
protein by generation 2 and 3 polypropylenimines (DAB 8  and DAB 16). Although the 
authors showed that the DAB dendrimers could effectively deliver antisense 
oligonucleotides into A431 cells, they drew no other conclusions and so the study has not 
made any significant contribution to knowledge of the mode of action of these 
transfection agents.
Although little can be concluded about the potential endosomolytic properties of 
polypropylenimines from the work of Kabanov et al. 242,244,245 or van Duijvenbode et a l 
243, the results of Zinselmeyer et al. 246,248 suggest that transfection mediated by 
polypropylenimine polymers is worth further investigation. However, it is also apparent 
from the work of Zinselmeyer et al. 246,248 that perhaps polypropylenimine starburst 
dendrimer are not the only types of polypropylenimines worth investigating further and 
that other structures might be of interest. Indeed it could be suggested that sterically 
crowded and highly constrained structures such as the DAB dendrimers that have been 
tested by Zinselmeyer et a l 246,248 might not be the most suitable dendrimers for binding 
to such a structurally rigid molecule as DNA. Less crowding within the dendrimers and 
greater conformational freedom would allow the ‘limbs’ of the dendrimers to adapt to the 
conformation of the DNA better. This in turn might result in dendrimers with greater 
binding affinity for DNA and fewer or no anion binding sites in dendrimer/DNA 
complexes. The geometry of dendrimers might not only influence their DNA-binding 
affinity but also their buffering capability. Whilst starburst polypropylenimine dendrimers 
contain only primary and tertiary amine functions and linear polypropylenimines contain 
only primary and secondary amine functions, polypropylenimines could be designed and 
synthesised that contain all three types of amine function. These polypropylenimines, 
although highly ordered unlike commercially available branched polyethylenimine (a 
random polymer), would contain 1°, 2° and 3° amines, which are also found in branched 
polyethylenimines. Furthermore, in view of the growing success of the incorporation of
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targeting ligands into non-viral gene delivery vehicles ’ ’ , the possibility of
attaching targeting ligands to polypropylenimines might be quite attractive.
The intention for the work reported here was to synthesise conjugates bearing 
polypropylenimine functions of various geometries, linear (Fig. 5), starburst (Fig. 5 & 6 ) 
and structures that are intermediate between the two (Fig. 6 ). The preparation of a series 
of conjugates would then allow for a systematic evaluation of their DNA-binding 
properties as well as their activities as transfection agents possibly leading to the 
determination of a structure-activity relationship. In effect, the synthesis of these 
conjugates would not only require a suitable synthetic route to the desired polyamine 
structures, but would also require that the resulting polyamines be suitable for coupling to 
a peptide or peptides either on or off solid support.
Linear polypropylenimine-peptide oonjugate
NH
I
P e p t i d e
NHNH
P e p t i d e
NHNH
NH
NH
Starburst
polypropylenimine-peptide
oonjugate
P e p t i d e
NH
NH
Figure 5. -  Examples of structures of target linear or starburst polypropylenimine- 
peptide conjugates.
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NH NH
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Starburst/1 i near-combi nation
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conjugates Pep t ide
HN NH
NH
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Figure 6 . - Structures of target polypropylenimine-peptide conjugates.
The formation of conjugates composed of polyamines and peptides can very often 
be limited in terms of the functional groups that can be used to mediate the coupling or
coupling conditions as peptides, depending on their amino acid residue composition, can 
be unstable to many reaction conditions. The preparation of polyethylenimine-peptide 
conjugates from un-protected PEI and un-protected peptides has been previously 
described in literature 254. Coupling was achieved by means of a disulphide linkage, 
coupling via amide bonds clearly not being an option since both peptide and PEI 
contained free 1° or 2 ° amines and the peptide contained various other free functionalities. 
The method involved derivatising a certain percentage of the amine functions of PEI by 
treating with a given number of equivalents of succinimidyl 3-(2-pyridyldithio)- 
propionate and then reducing with dithiothreitol. The thiol-derivatised PEI was then 
reacted with the thiol-bearing peptide (cysteine residue) under oxidative conditions to 
give the peptide-PEI conjugate coupled via a disulphide bridge. Although this method 
was reasonably effective, it resulted in a fairly heterogeneous population of conjugates. 
The conjugates were purified first by size exclusion chromatography and then by reverse 
phase HPLC and even then the authors could only describe the purity as reasonable. 
Similar methods to this can also be found in literature that only differ in terms of the 
functional groups through which the polyamine and peptide are linked.
An alternative to such a strategy is to protect all the amine functions except those 
that are to be coupled to the peptide(s) as well as use protected peptide(s) and then couple 
the two components to give the conjugate. This strategy not only allows for the use of a 
wider range of coupling methods or conditions but is also more likely to give a 
homogeneous population of polyamine-peptide conjugates i.e. the presence of exactly 
three free amine functions in the polyamine will result in conjugates in which the 
polyamine/peptide ratio should be exactly 1:3. Attachment of the polypropylenimines 
could be achieved in various ways but perhaps the simplest and most compatible with 
solid-phase peptide synthesis would be via amide bond formation. Peptide synthesis by 
the standard Fmoc/rBu solid-phase strategy on a resin with a very acid labile linker allows 
for the generation of a resin-bound, side-chain protected, free amine peptide or a side- 
chain protected, free amine/free carboxyl peptide. These side-chain protected, resin- 
bound or free peptides can then be coupled via their A-terminal free amine functions. 
Coupling of the polypropylenimines to the A-terminus of free or resin-bound peptides 
would require that the polypropylenimines have free carboxyl groups and that all the 
amine functions are protected in order to prevent cross coupling of polyamines. The 
strategy is summarised in the schematic diagrams below (Scheme 1 & 2).
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Scheme 1. -  Strategy for coupling polyamine to peptide on solid support -  one 
peptide coupled to one polyamine molecule.
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Scheme 2. - Strategy for coupling polyamine to peptide off solid support -  
multiple peptides coupled to one polyamine molecule.
The deprotection of the protecting groups employed on the polyamine would have 
to be compatible with the functional groups of the peptides since after the coupling step 
the protecting groups will need to be removed in the presence of the peptide. This 
criterion greatly limits the selection of the polyamine protecting groups. Not only must 
the deprotection conditions be compatible with the peptide side-chain functional groups 
but also the protecting group must be stable to the peptide/polyamine coupling conditions 
and the conditions of the steps in the synthesis of the polyamine. Clearly if the amine 
functions of the polyamine are supposed to be protected while another function, X is 
supposed to be free for coupling to peptides, this requires a strategy in which the function 
X is either not affected by the amine protection step or is revealed/inserted/generated after 
the amine protection step in a way that does not affect the protected amines (Scheme 3).
Poly a mine
V - L r i i _—  Polyamine —
M /  \ I I
NProNPro NPro
NProNPro NPro
ProN—  Polyamine
NProNPro NPro
NProNPro NPro
H N NH2  NH2  NH2  NProNPro NPro l
H2 N—  Polyamine — X ProN—  Polyamine — X ■#>
H2 N nh 2  nh 2  nh 2
Coupling to 
peptide
ProN NProNPro NPro
Scheme 3. -  Alternative routes to A-protected, functionalised polyamines.
Whatever protecting group strategy and coupling strategy are employed, ideally it 
should be possible to prepare any of the polypropylenimine dendrimer-peptide conjugates 
by the same strategies in order to facilitate the preparation of a small library of 
polypropylenimine-peptide conjugates. The preparation of a small library of these 
conjugates would then allow for a comparative assessment of their DNA-binding 
affinities and their transfection activities.
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3.2 Synthesis of Boc-protected 
polypropylenimine carboxylic acids.
3.2.1 Design of polypropylenimine carboxylic acids.
The core of all the polypropylenimine dendrimers was envisaged to be an amino 
acid as this would allow for straightforward coupling of all dendrimers to the N-terminus 
of peptides. If the fully protected peptide were still on the solid support, coupling of 
dendrimer to peptide would be carried out using standard solid-phase coupling reagents, 
the N-protected, free carboxyl dendrimer and coupling reagents being added to the resin- 
bound peptide (Scheme 4).
SC Pro ProN
P olyam in eProN
N P roN P ro NPro
H2N —  P ep tid e +
ProN
N P roN P ro NPro
Standard solid-phase 
coupling conditions
_  N P roN P ro  NPro  
ProN I I |\  1 1 L O SC P ro
p roN —  P o ly a m in e
ProN I TT L
N P roN P ro  NPro
H
N —  P ep tid e
Pro = protecting group
SCFYo = side-chain protection
Scheme 4. -  Coupling of a single dendrimer molecules to a single resin-bound 
peptide.
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It was also envisaged that it might become desirable to couple several peptides to 
one dendrimer molecule. For this, the preparation of the activated ester of the TV-protected 
dendrimer would be required beforehand, followed by addition of the side-chain protected 
peptide (Scheme 5).
ProN,
P r o N -
ProN
° ^ 0H N P r o N P r o ^
P olyam ine
OH
NProNPro^:^
CT OH
Formation of 
activated ester
Pro = protecting group 
SCPro = side-chain protection 
AE= activated ester
ProN,
P r o N —  
/
ProN
NProNPro
° ^ ae
AE
NProNPrq^i^
SC P ro
1
P olyam ine + h 2n — P e p t id e
O
OH
if
SC Pro
N P r o N P r o T OHProN
SC Pro
ProN
N —
ProN
OH
N—
OH
P ep tid e
P ep tid e
P ep t id e
Po lyam in e
SC P ro
Scheme 5. -  Formation of activated ester of dendrimer followed by coupling to 
multiple peptides.
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The synthesis of dendrimers could be attempted via several different routes. One 
route would commence from the desired amino acid core with attachment of successive 
3-aminopropyl units to the amino function in the presence of the free carboxylic acid 
(Scheme 6  -  route A). An alternative to this route would be to start from an O-protected 
amino alcohol, the dendrimer structure being formed initially followed by de-protection 
of the hydroxyl group and oxidation to the corresponding carboxylic acid (Scheme 6  -  
route B). A third route would commence from a protected amine that, once the dendrimer 
structure had been achieved, would be deprotected and then reacted with an electrophile 
bearing the desired carboxylic acid function either as the free acid or protected (Scheme 7 
-  route C).
Route A
o R O
Route B
R R
R= polypropylenimine functions 
Pr= protecting groupR O
Scheme 6. -  Routes A and B to amino acid core polypropylenimine dendrimers.
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H2N
N
R \  / P r
N
OH
N
NH
I
R
I
R= polypropylenimine functions 
R* = protecting group
Scheme 7. -  Route C to amino acid core polypropylenimine dendrimers.
3.2.2 Construction of polypropylenimine structures.
In order to determine which approach would be the most convenient for 
preparation of the carboxyl-functionalised polypropylenimines, it was necessary first to 
consider the various methods for constructing the polypropylenimine structures. The 
repeat unit of the polypropylenimines is 3-aminopropyl and obviously there are many 
different ways to introduce this unit onto a primary or secondary amine. However as the 
intention was to prepare a series of polypropylenimines with specific geometries, it was 
essential that addition of 3-aminopropyl units could be carefully controlled (Scheme 8 ). If 
it were desirable to synthesise a linear polypropylenimine, it would be essential that 
addition of only one 3-aminopropyl unit to every free primary amine function occurred. 
Not only would there be the requirement of a precise stoichiometry for the addition but 
also a reasonably high yield as the procedure would be highly iterative in order to 
produce larger polypropylenimines. Likewise, if the aim was to generate a highly 
branched polypropylenimine, the addition of two 3-aminopropyl units to every primary 
amine would need to be controlled and the addition would need to proceed in high yield. 
The same would apply for the preparation of dendrimers with geometries that were 
intermediate between linear and branched.
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i—s  Addition of two 3-aminopropyl 
units to every terminal 1 ° amine 
i—s  Addition of one 3-aminopropyl 
unit to every terminal 1 ° amine
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Scheme 8 . -  Controlled addition of 3-aminopropyl units to terminal 1° amines.
An inability to control to a high degree the addition of either one or two 3- 
aminopropyl units to every terminal primary amine would make it very difficult to obtain 
the desired geometry for the various polypropylenimines. Even if the desired compound 
were to be the major product of the reaction, the removal of by-products in which only a 
small fraction of the terminal amines have undergone incorrect addition would be
difficult. The difficulty in removing by-products from the desired product would increase 
with increasing size of the polypropylenimine functions.
A large number of synthons exist for the preparation of polypropylenimines as a 
result of the biological importance of trimethylene-bridged polyamines. In some cases the 
addition of 3-aminopropyl units to primary or secondary amines has involved the use of 
electrophiles such as bromides, iodides, mesylates or tosylates bearing either protected 
amine functions or functional groups that are precursors to amines. Examples of some of 
these synthons are shown below (Scheme 9).
NPro
H2N' NH,
PrN' N'
H
NPr
Deprotection
X = Br, I, OTs, OMs
h 2n ' N'
H
‘NH.
H2N' NH.
Reduction
X = B\ I, OMs, OTs
Y = CN, CHjNa, CHjNOj H2N' NH.
Scheme 9. -  Synthons used to prepare trimethylene-bridged polyamines.
Alternatives to the synthons already mentioned (Scheme 9) include aldehydes or 
carboxylic acid derivatives bearing either protected amine functions or functional groups 
that are precursors to amines. The use of these two synthons results in the initial 
formation of an imine or an amide respectively, which can then be reduced to the 
secondary amines. The free primary amine can then either be generated from the 
protected amine or amine precursor during reduction of the imine or amide or in a 
separate step (Scheme 10). However, clearly the use of these synthons is limited to the 
addition of one 3-aminopropyl unit to every primary amine.
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The aforementioned methods for adding 3-aminopropyl units to primary amines, 
although effective, generally require preparation of the electrophiles. Some of the 
electrophiles are commercially available such as A-(3-bromopropyl)-phthalimide and 3- 
bromopropionitrile but are relatively expensive. This is a significant factor in the choice 
of synthon when ever-increasing quantities may be required for the synthesis of 
subsequent dendrimer generations. Another consideration when choosing the synthon is 
its steric bulk, which is a major factor when preparing highly branched dendrimers. As 
polyamine dendrimers increase in size, the steric crowding within them increases and 
consequently it becomes increasingly difficult to insert the next 3-aminoalkyl units. The 
use of synthons that bear amines masked with protecting groups can therefore be 
unsuitable for the synthesis of highly branched polyamine dendrimers for the reason that 
protecting groups tend to be bulky.
Scheme 1 1 .-  Effect of steric crowding in higher generation dendrimers.
An example would be the use of l-bromo-3-(dibenzylamino)-propane, the bulk of 
the benzyl protecting groups being large enough to hinder or prevent addition of the 
second l-bromo-3-(dibenzylamino)-propane to an already sterically crowded primary
4equiv
amine (Scheme 11). Whilst for lower generations of dendrimers addition of two 3- 
aminpropyl units onto each terminal amine would not be problematic, for higher 
generations steric crowding would make the addition of two 3-aminopropyl units onto 
each terminal amine impossible. For this reason the use of synthons that have very small 
steric bulk is preferential and out of the various synthons that bear amine precursor 
functions, one of the least bulky are those of general formula XCH2CH2CN. Various 
compounds of this general formula are commercially available such as 3-hydroxy- 
propionitrile, 3-chloropropionitrile or 3-bromopropionitrile. The latter two compounds are 
very expensive and so not suited for highly repetitive synthesis. 3-Hydroxy-propionitrile 
is inexpensive but the mesyl or tosyl derivative of this compound would have to be 
prepared and both these derivatives undergo elimination during their preparation to give 
acrylonitrile (Scheme 12). 3-Chloropropionitrile and 3-bromopropionitrile also readily 
eliminate under basic conditions to give acrylonitrile (Scheme 12).
Scheme 12. -  Elimination under basic conditions to give acrylonitrile.
Acrylonitrile is commercially available as well as inexpensive and the Michael 
addition of amines to acrylonitrile has been studied extensively. The addition of 3- 
aminopropyl units onto primary or secondary amines by reaction with acrylonitrile 
followed by reduction was reported as early as 1944 254. It was Vogtle et al. 255 who first 
proposed that this synthon might be of particular use in preparing polypropylenimine 
dendrimers. The authors showed that it was possible to prepare polypropylenimine 
dendrimers by divergent synthesis from a benzylamine core with addition of acrylonitrile 
in the presence of acetic acid followed by borohydride reduction in methanol in the 
presence of cobalt (II) (Scheme 13). The sequence of dendrimers prepared by the authors 
was however very limited as successive yields were low. Probably the reason why the
authors obtained such low yields was because of the increasing difficulty of extracting 
higher generations of polypropylenimines from aqueous solution. After work-up of the 
borohydride reaction with hydrochloric acid followed by addition of ammonia, the 
authors recovered the product from aqueous solution by repeated chloroform extraction.
0 0 (1 1 ), NaBH4, 
MeOH  ► 
76%
Go(ll), NaBH4, 
MeOH
35%
6 6 % Acrylonitrile, Acetic add
n h 2 n h 2 n h 2 n h 2
N N N N
Scheme 13. -  1st and 2nd generation polypropylenimines synthesised by Vogtle et
a l
The problem of extracting polypropylenimines from aqueous solution requires 
serious consideration when planning the synthetic route to these compounds. The 
avoidance of procedures that require aqueous work-up to recover the product can often be 
essential. Since the preparation of what Vogtle et a l 255 called large molecular cavities, 
various other methods for preparing polypropylenimines have been devised. Acrylonitrile 
was still used for the cyanoethylation of amines but the reduction of nitrile groups to 
primary amines was preferentially achieved using catalytic hydrogenation. The catalyst 
commonly employed for the reduction of nitriles is Raney nickel, although rhodium is 
just as effective but its cost is prohibitive. Platinum on the contrary was reported to be 
ineffective for the hydrogenation of nitriles 254. Clearly the use of catalytic hydrogenation
‘JCC
would not have been an option for Vogtle et a l because of their choice of benzylamine
as their dendrimer core. Catalytic hydrogenation of nitrile groups is however not 
straightforward as in the presence of only catalyst and hydrogen formation of mixtures of 
primary, secondary and tertiary amines occurs (Scheme 14).
Raney nickel 
catalyst
NH.
N
. NH
__ ( /R  = N NH
NH
NH
Scheme 14. -  Formation of primary, secondary and tertiary amines.
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Catalytic hydrogenation was successfully employed by Womer & Miilhaupt
yen
and Meijer & de Brabander-van den Berg in the synthesis of polypropylenimine 
dendrimers, using acrylonitrile as the synthon for bis-cyanoethylation of terminal amines. 
Both groups of authors carried out the hydrogenation of nitriles in solutions of hydroxide
'yen
in alcohol/water and recovered the desired products in good yields (67 -  86 % ) despite
having to extract the dendrimers from aqueous solutions after hydrogenation because of 
the use of sodium hydroxide in the reaction mixture. The presence of a large excess of 
hydroxide in the reaction mixture was however essential to prevent the formation of 
secondary and tertiary as well as primary amines (Scheme 15). A far more convenient 
alternative to the use of sodium hydroxide to avoid secondary and tertiary amine 
formation, is the use of ammonia. Adkins & Schwoegler 258 showed as early as 1939 that 
hydrogenation of nitriles with Raney nickel in the presence of a large excess of ammonia 
resulted in almost exclusive formation of primary amines (Scheme 15). When ammonia is 
used in place of hydroxide, once hydrogenation is complete, the product can be recovered
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by simply filtering to remove the catalyst and concentrating in vacuo which can be very 
advantageous if the product is highly water-soluble.
Raney nickel 
catalyst
OH
R
- <
n h 2
R— = N
+ H,
NH 2
n h 2
R
NH 2
Scheme 15. -  Inhibition of secondary and tertiary amine formation during 
hydrogenation of nitriles by hydroxide or ammonia.
Successive reaction with acrylonitrile followed by hydrogenation under optimal 
conditions is clearly a very convenient method for extending polypropylenimines with 3- 
aminopropyl units. This method has yet another advantage however as the Michael 
addition of a primary amine to acrylonitrile can be controlled by the stoichiometric ratios 
of the two reactants to produce either mono- or di-substituted cyanoethylamines. The 
ability to control the addition of primary amines to acrylonitrile was first realised by
9 < QHoffmann & Jacobi who patented their procedures for mono- and di-cyanoethylation. 
The addition of amines, both primary and secondary as well as ammonia to acrylonitrile 
was investigated more extensively by Whitmore et al. 254 who observed that mono- or di- 
cyanoethylation occurred depending on the conditions not just the stoichiometry. They 
also observed that conditions required to achieve either mono- or di-cyanoethylation of 
different primary or secondary amines were not the same i.e. piperidine added to 
acrylonitrile without heating whilst the addition of methylamine to acrylonitrile required 
heating for several hours. Notably, the authors also ascertained that attempting to heat any 
of the 2-cyanoethylamines they had prepared to temperatures close to their boiling points 
resulted in rapid disproportionation to acrylonitrile and amine.
Several hundred procedures for mono- and di-cyanoethylation of amines can be 
found in the literature today as a result of the necessity to determine the optimal 
conditions that are specific to particular amines. Reaction conditions can vary 
tremendously not just between mono- and di-substitution. Piperidine for example was 
reported to react with acrylonitrile so vigorously that the reaction had to be cooled during 
addition of acrylonitrile whereas di-(2-ethylhexyl)-amine had to be heated with 
acrylonitrile at 100°C for 360 hours 254. Holcomb & Hamilton 260 reported that they 
heated /i-di-pentylamine with acrylonitrile to 50°C for 24 hours with thorough stirring in
Oft 1order to recover the product in 90 % yield. Montana et al. prepared a series of mono- 
cyanoethylated sulfonamides by refluxing primary amines with one equivalent of 
acrylonitrile in toluene and then treating the mono-cyanoethylated product with 3,4- 
dimethoxyphenylsulfonyl chloride. Vogtle et al. on the other hand achieved multiple 
di-cyanoethylation of primary amines by heating at reflux polypropylenimines with a 
large excess of acrylonitrile and acetic acid. A brief survey of the literature rapidly 
reveals that the conditions for Michael addition of amines to acrylonitrile vary 
considerably for different amines and even for the same amines different procedures can 
be employed.
As was mentioned earlier, it was envisaged that in order to attach the 
polypropylenimine structures to the A-terminus of peptides the target structures would 
need to possess a free carboxylic acid group and all the primary and secondary amines 
within the structure would have to be protected. Only acid sensitive protecting groups 
could be employed since groups removed by base hydrolysis or nucleophiles would be 
incompatible with either the synthesis of the polypropylenimines or the peptide function 
of the polypropylenimine-peptide conjugate. Protecting groups that could be removed by 
hydrogenolysis were also unsuitable because of the presence of two thiol functions in the 
peptide that would be conjugated to the polypropylenimine; palladium would be poisoned 
by the thiols whilst hydrogenation with Raney nickel would remove the thiol groups. 
However the fact that higher generation polypropylenimines would be sterically crowded 
at the termini meant that the use of acid-labile protecting groups would be restricted to 
those that were not bulky. The use of such groups as trityl or its derivatives was not 
considered as it is most likely that protection of all the terminal amines of a highly 
branched dendrimer would never be successful. The most suitable protecting group for 
protection of the amine function was clearly the tert-butoxycarbonyl group as this group 
would be conveniently removed during peptide de-protection and was not excessively
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bulky. An example of the structure of one of the target polypropylenimine carboxylic 
acids is shown below (Figure 7).
Figure 7. -  An example of one of the target polypropylenimine carboxylic acids.
using acrylonitrile for mono-cyanoethylation of primary amines and hydrogenation in the 
presence of Raney nickel and ammonia (Scheme 16). The authors used N-(3- 
am inopropy l)-l,3 -p ropaned iam ine  as the starting material for their synthesis and Boc 
protected the central secondary amine using the procedure of Xu et al. 263. Xu et a l 264 
had found that it was possible to trifluoroacetylate primary amines in the presence of 
secondary amines with a very high degree of selectivity (>98 %). Garrett et al. 262 treated 
A - ( 3 - a m i n o p r o p y l ) - l ,3 - p r o p a n e d i a m i n e  with 2 equivalents of ethyltrifluoroacetate and 
then treated the resulting bis-(3-trifluoroacetamidopropyl)-amine (1) with di-ter/-butyl 
dicarbonate. The trifluoroacetyl protecting groups were then removed with ammonia and
l,l-dimethylethyl-A,A-di-(3-aminopropyl)-carbamate (3) was treated with 2.5 equivalents 
of acrylonitrile to obtain l,l-dimethylethyl-A,//-di-(3-(2-cyanoethylamino)-propyl)- 
carbamate. Hydrogenation of the nitriles was carried out by the method of Adkins & 
Schwoegler 258 and was followed by the global protection of free amines with di-benzyl- 
di-carbonate to give l,l-dimethylethyl-7V^Ar-di-(3-(A-phenylemthyloxycarbonyl)-Ar-(3- 
(phenylmethyloxycarbonylamino)-propyl)-amino)-propyl)-carbamate. Removal of the 
Boc protecting group with trifluoroacetic acid then allowed the authors to couple bromo- 
N-{2-( 1,1 -dimethylethoxycarbonylamino)-ethyl)-hexanamide to di-(3-(7V- 
phenylmethoxycarbonyl)-7V-(3-(phenylmethoxycarbonylamino)-propyl)-amino)-propyl)-
O
’yf/y
Garrett et al. had previously prepared a compound with a similar structure
amine.
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Scheme 16. - Synthesis of Ar-(2-(l,l-dimethylethoxycarbonylamino)-ethyl-6-(di- 
(3-(A^-phenylmethoxycarbonyl)-7V-(3-(phenylmethoxycarbonylamino)-propyl)-amino)- 
propyl)-amino)-hexanamide by Garrett et al. 262.
The synthetic strategy of Garrett et al. 262 appeared suitable for the synthesis of the 
series of polypropylenimine carboxylic acids. It was envisaged that initially various 
polypropylenimines would be prepared much in the same way as the aforementioned 
authors had prepared their target compound with a bromoalkyl acid benzyl ester being 
used in place of bromo-./V-(2-( 1,1-dimethylethoxycarbonylamino)-ethyl)-hexanamide in 
the final step. Removal of the benzyloxycarbonyl protecting groups and the benzyl ester 
protecting group by hydrogenolysis could then be followed by Boc protection to give the 
target compounds. Mukheijee et a l  264 had previously shown that addition of 
triethylenetetramine to acrylonitrile occurred preferentially via the terminal primary 
amines rather than the secondary amines (Scheme 17). Their results indicated that even 
di-cyanoethylation of primary amines was possible in the presence of secondary amines. 
This suggested that it would be possible to selectively cyanoethylate at the terminal 
primary amines of polypropylenimines without having to protect secondary amines. The 
possibility of being able to mono- and di-cyanoethylate selectively at primary amines in 
the presence of secondary amines would simplify the synthesis of linear 
polypropylenimines and polypropylenimines that had geometries intermediate between 
linear and highly branched.
Scheme 17. -  Mono-, di- and tri-cyanoethylated triethylenetetramines prepared by 
Mukheijee et al. 264.
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3.2.3 Route to Boc-protected polypropylenimine carboxylic 
acids.
l,l-Dimethylethyl-Ar,A^-di-(3-aminopropyl)-carbamate (3) was prepared by the 
method of Garrett et al. 262 in 92 % yield over the three steps. The final step in the 
preparation of (3) was however modified slightly since treatment with aqueous ammonia 
on methanol proved less than satisfactory in removing the trifluoroacetyl groups. In 
addition to treatment with ammonia, after concentration in vacuo to remove methanol, to 
the remaining aqueous solution was added sodium hydroxide until the pH reached 12. 
After leaving the aqueous solution to stand for a while only then was extraction with 
dichloromethane attempted. This resulted in complete deprotection of the considerable 
quantity of mono-trifluoracetylated compound that remained after treatment with 
ammonia. Mono-cyanoethylation of (3) was then attempted using the procedure described 
by Garrett et al. but this was found to be equally as unsatisfactory; the authors had 
only achieved a 30 % yield for this reaction also (Scheme 18).
2.1 eq.
NH
MeOH, rt, 48 hrs 
Yield = -3 0 %
MeCN, 48 hrs 
Yield = -5 0  %
MeCN, KjCO,
48 hrs, 55°C 
Yield = 80 %
Scheme 18. -  Conditions for mono-cyanoethylation of 1,1 -dimethylethyl-A,A-di- 
(3-aminopropyl)-carbamate (3).
Upon changing the solvent from methanol to acetonitrile an improvement was 
observed in the yield (~50 %) (Scheme 18). Addition of 1 equivalent of potassium 
carbonate to the reaction mixture of acrylonitrile and (3) in acetonitrile followed by 
heating at 55°C for 24 hours further improved the yield to 80 % (Scheme 18).
Remarkably the product, l,l-dimethylethyl-A^A^-bis-(3-(2-cyanoethylamino)-propyl)- 
carbamate (4) required no further purification as it appeared that by careful extraction by­
products were not recovered from the aqueous layer. Di-cyanoethylation of (3) with 
slightly in excess of 4 equivalents of acrylonitrile under the conditions employed by
'yfsy
Garrett et al. to achieve mono-cyanoethylation failed to produce any of the desired 
compounds. Di-cyanoethylation of (3) was also attempted under the same conditions as 
for the preparation of (4) but this also failed. A procedure used by van Duijvenbode et a l 
265 to prepare A W V ’,V ’-tetracyanoethylpropyl-l,2-ethylenediamine was then adapted, 
van Duijvenbode et al. had prepared this product in 94 % yield by heating 1 equivalent 
of ethylenediamine with 5 equivalents of acrylonitrile in water to 80°C.
H,Nf v  ' N '  v  'NH - +
0 ^ 0
X .
N
25 eq.
(3)
8 6 % HjO, MeCN (3:2) 
KjjCO  ^55°C
N, .N
N' N'
0 ^ 0
X
N‘
N
(5)
N
Scheme 19. -  Synthesis of l,l-dimethylethyl-7V,A-bis-(3,3-bis-(2- 
cyanoethylamino)-propyl)-carbamate (5).
Initial attempts to prepare l,l-dimethylethyl-V,7V-bis-(3,3-bis-(2- 
cyanoethylamino)-propyl)-carbamate (5) by the procedure for preparing N,N,N’,N ’- 
tetracyanoethylpropyl-l,2-ethylenediamine gave the product in only ~15 % yield. Various 
other conditions were tried such as heating at 80°C for up to 48 hours, adding potassium 
carbonate to the reaction as well as adding acetonitrile to the reaction as a co-solvent in 
various proportions. Nevertheless the product was still only recovered in at best 50 % 
yield and significant amount of mono- and mono/di-cyanoethylated products were
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recovered. Increasing the amount of acrylonitrile added to the reaction to 25 equivalents 
and carrying out the reaction in aqueous potassium carbonate/acetonitrile as well as 
maintaining the reaction at 55°C for the duration of the reaction (24 hrs) significantly 
improved the yield to 8 6  % (Scheme 19). However, under these conditions very vigorous 
stirring was found to be essential to the success of this reaction as when the reaction was 
stirred mildly so that two phases could be distinguished, none of the desired product was 
recovered.
N.
(4)
N
0 ^ 0
X
89 % mass 
recovery
Raney Ni, Hj 
MeOH, NH3  
5 days
.N
H2N'
(6)
N'
CT^OX
‘NH, H2N' N'
0 ^ 0X
NH.
Scheme 20. -  Hydrogenation of 1,1-dimethylethyl-A, A-bis-(3-(2- 
cyanoethylamino)-propyl)-carbamate (4).
Compounds (4) and (5) were then hydrogenated under the same conditions as 
were employed by Adkins & Schwoegler for the hydrogenation of nitriles. A solution 
of either (4) or (5) in methanol was saturated with ammonia and Raney nickel was added. 
Hydrogenation was carried out at 180 psi., at 50°C and it was found by trial and error that 
the reaction reached completion in five days, as determined by disappearance of starting 
material. l,l-Dimethylethyl-A,A-bis-(3-(3-aminopropyl)-aminopropyl)-carbamate (6 ) and 
1,1 -dimethylethyl-TV, A-bis-(3,3-bis-(3-aminopropyl)-aminopropyl)-carbamate (7) were 
recovered after hydrogenation but it was evident that some by-products had formed as a 
result of acrylonitrile elimination (Schemes 20 & 21). Although the integration values of 
proton signals in the NMR of compounds (6 ) and (7) seemed correct, the mass spectra 
of (6 ) and (7) clearly showed several by products. It was impossible to estimate what was
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the percentage of (6 ) or (7) in the products recovered from hydrogenation. Purification of
(6 ) and (7) was found to be impossible either by crystallisation as amine salts or by 
column chromatography. The crude compounds therefore had to be used in subsequent 
reaction. Elimination of acrylonitrile from the starting material resulting in the formation 
of products with lower molecular weights was one of the reasons why yields of less than 
100 % were obtained. The other reason was because some of the reaction mixture 
(starting material or product) was lost on pressurising and de-pressurising the Parr 
hydrogenator, which was inevitable.
(5)
N N
84 % mass 
recovery
Raney Ni, IT, 
MeOH, NH3  
5 days
+
Scheme 21. -  Hydrogenation of l,l-dimethylethyl-A^,7y-bis-(3,3-bis-(2- 
cyanoethylamino)-propyl)-carbamate (5).
The Cbz-protection of (6 ) and (7) was initially attempted with benzyl 
chloroformate. Garrett et al. 262 achieved the protection of the free amines of 1,1-
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dimethylethyl-./V,Af-bis-(3-(3-aminopropyl)-aminopropyl)-carbamate (6 ) with dibenzyl 
dicarbonate but the high cost of this compound prohibited its use. Several attempts to 
prepare 1,1 -dimethylethyl-Ar,Ar-di-(3-(A^-phenylemthyloxycarbonyl)-A^-(3- 
(phenylmethyloxycarbonylamino)-propyl)-amino)-propyl)-carbamate by treating a 
solution of (6 ) and triethylamine in dichloromethane with an excess of benzyl 
chloroformate were all unsuccessful (Scheme 22). Partially Cbz-protected products were 
recovered despite efforts to vary the rate of addition, the reaction temperature and the 
solvent (tetrahydrofuran and chloroform). Cbz-protection of (6 ) was also attempted in 
water/tetrahydrofuran and water/dioxane mixtures using sodium hydrogencarbonate, 
sodium carbonate and sodium hydroxide as base (Scheme 22), but still the desired 
product was not isolated. An attempt was made to prepare dibenzyl dicarbonate from 
benzyl chloroformate according to the procedure published by Plusquellec et al. and 
then treat a solution of (6 ) and triethylamine in dichloromethane with the product isolated 
from this reaction, but this also failed to give the desired product. Attempts to Cbz-protect
(7) were equally as fruitless and so benzyl protection of (6 ) and (7) was opted for in place 
of Cbz-protection.
Scheme 22. - Attempts to prepare l,l-dimethylethyl-A,7V-di-(3-(7V- 
phenylemthyloxycarbonyl)-7V-(3-(phenylmethyloxycarbonylamino)-propyl)-amino)- 
propyl)-carbamate.
PhCHjOCOCI, 
HjO/THF or HjO/Dioxane, 
NaOH or Na2C03 or NaHC03
or
PhCHjOCOCI, B3N, 
v DCM or 7HF or CHQ3.
Benzyl protection of (6 ) was initially attempted by treating (6 ) with 6  equivalents 
of benzyl bromide and 6  equivalents of potassium carbonate in dimethylformamide at 
room temperature. After one week still none of the desired product could be detected and 
upon work-up of the reaction a mixture of mono-, di- and tri-benzylated products was 
recovered, as determined by mass spectroscopy. Changing the solvent from 
dimethylformamide to ethanol and again treating (6 ) with 6  equivalents of benzyl 
bromide and 6  equivalents of potassium carbonate finally furnished 1,1 -dimethylethyl- 
A,A-bis-(3-(benzyl-(3-(dibenzylamino)-propyl)-amino)-propyl)-carbamate (8 ) but only in 
22 % yield. Even after addition of 8 equivalents of benzyl bromide and 10 equivalents of 
potassium hydroxide to (6 ) in ethanol every 48 hours for eight days, (8 ) was only isolated 
in 50 % yield (Scheme 23). All attempts to benzyl protect (8 ) were unsuccessful and so it 
was decided that this synthetic route to polypropylenimine carboxylic acids would be 
abandoned. That Garrett et a l chose to use the expensive reagent dibenzyl dicarbonate 
indicated that the authors may also have encountered problems whilst attempting to 
protect the free amines of l,l-dimethylethyl-A,Ar-bis-(3-(3-aminopropyl)-aminopropyl)- 
carbamate (6 ) and for this reason resorted to its use.
(6)
5 0 %
N
0 hrs - BhB* ( 8  eq), 
KOH (10 eq), BOH 
48 hrs - BnBr ( 8  eq), 
KOH (10 eq)
96 hrs - BiB* ( 8  eq), 
KOH (10 eq)
144 hrs - BiB* ( 8  eq), 
KOH (10 eq)
(8)
Scheme 23. -  Synthesis of l,l-dimethylethyl-7V,7V-bis-(3-(benzyl-(3- 
(dibenzylamino)-propyl)-amino)-propyl)-carbamate (8 ).
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Scheme 24. -  Synthesis of antitumour dendritic imides; a) acrylonitrile, methanol; 
b) H2, Raney Ni, 1.4 M NaOH, EtOH; c) TFA, CH2CI2/C6H5OCH3 (1:1); d) aromatic 
anhydride, EtOH. X = 1,8-naphthalimide, 3-amino- 1,8-naphthalimide, 3-nitro-l,8- 
naphthalimide or 2,3-diphenylmaleimide (B ra^a  et a l ).
The hydrogenation of the nitrile functions of (4) and (5) as well as subsequent 
protection of the amine functions generated was very unsatisfactory and so an alternative 
route was required for the synthesis of Boc-protected polypropylenimine carboxylic
9 f\lacids. In a recent publication by Bra*.a et al. , the authors had described the 
preparation of DNA-intercalating antitumour dendritic imides, the dendrimer structures
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being polypropylenimines. The target structures had been synthesised by cyanoethylation 
of the termini of dendrimer precursors, deprotecting the central amine function and then 
reacting the free amine with 1,8-naphthalic anhydride to give the imide. Once the imide 
had been formed, the nitriles were hydrogenated to give the target structures (Scheme 24).
It was envisaged that this approach could be applied to the synthesis of Boc- 
protected polypropylenimine carboxylic acids. The synthesis of highly branched 
polypropylenimines in which all but the terminal amines are tertiary amines would be 
straightforward but the synthesis of linear polypropylenimines and linear/branched 
polypropylenimines would be more complicated as secondary amines would have to be 
protected prior to Boc de-protection. At this stage it was decided that the preparation of 
first generation dendrimers would be attempted in order to determine whether the route 
was feasible. Before the Boc deprotection of l,l-dimethylethyl-Af,A-bis-(3-(2- 
cyanoethylamino)-propyl)-carbamate (4) could be carried out the two secondary amines 
had to be protected and as the intention was to reduce the nitrile functions by 
hydrogenation after the coupling of the central amine with a haloalkanoic ester, the Cbz- 
protecting group was chosen. Cbz protection of (4) was easily achieved by treating (4) 
with 4 equivalents of sodium hydrogencarbonate in tetrahydrofuran/water with 3 
equivalents of benzyl chloroformate in tetrahydrofuran, 1,1 -dimethylethyl-A, Ar-bis-(3- 
(benzyloxycarbonyl-(2-cyanoethyl)amino)-propyl)-carbamate (9) being formed in 88 % 
yield (Scheme 25).
(4)
H A  H
\  PhCHjOCOa, THF, 
88  % \  HjO, NaHOOj
(9)
Scheme 25. -  Preparation of l,l-dimethylethyl-7V, A-bis-(3-(benzyloxycarbonyl- 
(2-cyanoethyl)amino)-propyl)-carbamate (9).
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Scheme 26. -  Formation of terf-butylacetamides during Boc deprotection of 1,1- 
dimethylethyl-/V,/V-bis-(3,3-bis-(2-cyanoethylamino)-propyl)-carbamate (5) with 
trifluoroacetic acid/dichloromethane and triethylsilane.
Cleavage of the /ert-butoxycarbonyl group of compounds (5) and (9) was initially 
carried out using trifluoroacetic acid/dichloromethane (1:1) and triethylsilane as the 
cation scavenger. Despite the addition of a large excess of triethylsilane, significant 
amount of side products were formed, namely various tert-butyl amides (Scheme 26). 
Triethylsilane was replaced by other cation scavengers such as thioanisole,
'Jf.Q
dimethylsulfide, butanethiol and benzenethiol , which were added to the deprotection 
reaction in large excess but still tert-buty\ amide formation was observed. The addition of 
large quantities of such malodorous scavengers to the deprotection reactions was however 
not practical. Instead /ert-butoxycarbonyl cleavage was attempted using a mixture of
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trifluoroacetic acid/acetonitrile (1:1) and 6 equivalents of triethylsilane for good measure. 
Under these conditions (5) and (9) were cleanly deprotected to bis-(3,3-bis-(2- 
cyanoethylamino)-propyl)-amine (10) and bis-(3-(benzyloxycarbonyl-(2-cyanoethyl)- 
amino)-propyl)-amine (11) respectively (Scheme 27). Purification of (11) was carried out 
by column chromatography but in the case of (10) it was found that leaving the crude 
product recovered after aqueous base work-up under very high vacuum for several days 
removed all traces of A-ter/-butylacetamide.
1ST v  ' N '  v  ' N
0 ^ 0  0 ^ 0 , cr^o
X
(9)
1) 7FA/MeCN (1:1), B3SH
2) NaHCOj aq.
Scheme 27. -  Boc deprotection of l,l-dimethylethyl-7V,A-bis-(3,3-bis-(2- 
cyanoethylamino)-propyl)-carbamate (5) and 1,1-dimethylethyl-A, A-bis-(3- 
(benzyloxycarbonyl-(2-cyanoethyl)amino)-propyl)-carbamate (9).
As a result of the necessity to carry out the Boc deprotection in a vast excess of 
acetonitrile with respect to the starting material, large amounts of trifluoroacetic acid had 
to be used in order to maintain the concentration at the required level. This was less than 
satisfactory both in terms of cost and handling. Boc deprotection was consequently 
attempted using 1.5 M hydrochloric acid in acetonitrile/water (3:1) with an excess of 
triethylsilane. This deprotection procedure was tested on 1,1 -dimethylethyl-A,A-bis-(3- 
((3-(bis-(2-cyanoethyl)-amino)-propyl)-(2-cyanoethyl)amino)-propyl)-carbamate (12) and
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after purification by column chromatography to remove terf-butylacetamide, bis-(3-((3- 
(bis-(2-cyanoethyl)-amino)-propyl)-(2-cyanoethyl)amino)-propyl)-amine (13) was 
recovered in 96 % yield (Scheme 28). This procedure was therefore equally as effective 
as the procedure involving trifluoroacetic acid but was considerably more economical.
(12)N
N
1)1.5 MHO, HjO/MeCN (1:3)
2) NaHC03 aq
N N N N
Scheme 28. -  Boc deprotection of l,l-dimethylethyl-A,7V-bis-(3-((3-(bis-(2- 
cyanoethyl)-amino)-propyl)-(2-cyanoethyl)amino)-propyl)-carbamate (12) with 
hydrochloric acid in water/acetonitrile.
For the next step of coupling (10), (11) or (13) to an haloalkanoic acid, 6- 
bromohexanoic acid and 11-bromoundecanoic acid were chosen. Protection of the 
carboxyl functions of 6-bromohexanoic acid and 11-bromoundecanoic acid as esters was 
preferable prior to the coupling step and the benzyl protecting group was chosen for this 
purpose. Although coupling of (10), (11) or (13) to 6-bromohexanoic acid or 11- 
bromoundecanoic acid could be achieved without protecting the carboxyl groups, the 
reaction conditions would be much harsher than those that would be employed for the 
coupling of the benzyl ester derivatives. Typically the use of strong base and heating 
would be required which could result in elimination of acrylonitrile from (10), (11) or 
(13) and furthermore a brief survey of literature revealed that coupling of amines to
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haloalkanoic acids generally proceeded in low yield. The intention was that after coupling 
of (10), (11) or (13) to benzyl 6-bromohexanoate or benzyl 11-bromoundecanoate, which 
both were prepared following a procedure by Neises et al. 269, subsequent hydrogenation 
of the nitrile groups would also result in simultaneous benzyl deprotection. Thus there 
would be no need for a separate deprotection step that would elongate the synthesis. 
According to Greene & Wuts 171 the stability of benzyl esters towards primary and 
secondary amines was ‘marginal’ i.e. dependent on the exact conditions and so the 
coupling reaction was initially attempted with (10) and benzyl 11-bromoundecanoate (14) 
(Scheme 29).
N, (10)
N'
Br
N N
6 6 %
DMF, 35°C
(14)
O
N
(15)
Scheme 29. -  Coupling of bis-(3,3-bis-(2-cyanoethylamino)-propyl)-amine (10) 
and benzyl 11-bromoundecanoate (14).
As 1 l-(bis-(3-(bis-(2-cyanoethyl)-amino)-propyl))-aminoundecanoic acid benzyl 
ester (15) was prepared in reasonable yield by coupling (10) and (14), (11) was then 
coupled with benzyl 11-bromoundecanoate (14) and benzyl 6-bromohexanoate (16), and 
(13) was coupled with benzyl 6-bromohexanoate (16). 1 l-(Bis-(3-(benzyloxycarbonyl-(2- 
cyanoethyl)-amino)-propyl))-aminoundecanoic acid benzyl ester (17) and 6-(bis-(3- 
(benzyloxycarbonyl-(2-cyanoethyl)-amino)-propyl))-aminohexanoic acid benzyl ester 
(18) were prepared in 60-65 % yield (Scheme 30). Further optimisation of the reaction 
conditions resulted in 6-(bis-(3-((3-(bis-(2-cyanoethyl)-amino)-propyl)-(2- 
cyanoethyl)amino)-propyl))-aminohexanoic acid benzyl ester (19) being prepared in 87 % 
yield (Scheme 31).
K2C03, w ,
DMF, 35°C
O OBn
K ^ ,  Kl, 
DMF, 35°C
Scheme 30. -  Synthesis of 1 l-(bis-(3-(benzyloxycarbonyl-(2-cyanoethyl)-amino)- 
propyl))-aminoundecanoic acid benzyl ester (17) and 6-(bis-(3-(benzyloxycarbonyl-(2- 
cyanoethyl)-amino)-propyl))-aminohexanoic acid benzyl ester (18).
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Scheme 31. - Synthesis of 6-(Bis-(3-((3-(bis-(2-cyanoethyl)-amino)-propyl)-(2- 
cyanoethyl)amino)-propyl))-aminohexanoic acid benzyl ester (19).
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One of the other major advantages of coupling (10), (11) and (13) with 
bromoalkanoic acid benzyl esters was that the extraction and purification by column 
chromatography of the products was facile, which would not have been the case had the 
carboxyl been a free acid. The reduction of the nitrile functions of compounds (15), (17), 
(18) and (19) could then be carried out by hydrogenation but because the four compounds 
were benzyl esters, the procedure of Adkins & Schwoegler in which a large excess of
'JCfL
ammonia was employed was unsuitable. The procedure of Womer & Mulhaupt 
(hydrogen, Raney nickel and 1.4 M sodium hydroxide in ethanol/water (95:5)) could have 
been employed instead, as base hydrolysis would result in the formation of the free acid 
just as hydrogenolysis would. The product generated by this procedure would have to be 
treated with di-ter/-butyl dicarbonate directly, as extraction from aqueous solution would 
be impossible.
Scheme 32. -  One-pot hydrogenation/Boc-protection of nitriles carried out by 
Lenz et al. 270; triethylamine (10 eq.), di-tert-butyl dicarbonate (3 eq.) and 10 % Pd/C 
were added to a solution of the glycopyranosylcyanides in ethanol/tetrahydrofuran (5:3) 
and then the mixture was stirred for 6 hours under hydrogen at atmospheric pressure.
NPhth NHBocNPhth
NPhth NPhth
73%
NPhth NPhth NHBoc
NPhth NHBocNPhth
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Recently however Lenz et a l 270 had published a more convenient one-pot
procedure for the reduction of nitriles and subsequent Boc-protection of the resulting 
amines. The authors reported that they had succeeded in converting the nitrile function of 
glycopyranosylcyanides into a Boc-amine function in good yield (73-97 %) by stirring the 
cyanides with palladium on carbon, di-ter/-butyl dicarbonate and triethylamine in 
tetrahydrofuran/ethanol under a hydrogen atmosphere (Scheme 32). According to the 
authors, this simultaneous reduction/Boc-protection procedure prevented the formation of 
imine side-products.
O OBn
Scheme 33. -  Synthesis of 11 -(N,N- bis-(3-(bis-(3-(ter/-butoxycarbonylamino)- 
propyl)-amino)-propyl))-aminoundecanoic acid benzyl ester (20).
adapted for the reduction/Boc-protection of compounds (15), (17), (18) or (19). Palladium 
on carbon was however substituted with Raney nickel and the reaction was carried out at 
a much higher pressure of hydrogen. Compound (15) was reduced/Boc-protected under 
similar conditions; Raney nickel, compound (15), 2.5 equivalents of di-/er/-butyl 
dicarbonate and 25 equivalents of triethylamine in isopropanol were initially 
hydrogenated for five days at room temperature (~15°C). MS analysis of the reaction 
mixture showed that the reaction had not gone to completion (unreduced nitrile groups 
still present) within this time and so the reaction was hydrogenated for a further five days. 
After ten days the crude reaction was analysed by mass spectroscopy and was found to 
contain almost exclusively 1 Bis-(3-(bis-(3-(ter/-butoxycarbonylamino)-propyl)-
amino)-propyl))-aminoundecanoic acid benzyl ester (20) (Scheme 33). The benzyl ester
Raney Ni, H>, Boc>0, B3 N, 
PrO H, 10 days, 15°C
NHBoc NHBoc
NHBocBocHN 5
97fiIt was envisaged that the same one-pot strategy employed by Lenz et al. could be
had clearly withstood hydrogenation which was surprising as benzyl esters had previously 
been cleaved by hydrogenolysis with Raney nickel under very similar conditions 
271,272,273 jn(jeeci Hashimoto et al. 274 had described the rapid (0.5 hrs) cleavage of benzyl 
esters under very similar conditions to those employed (Raney Ni, ethanol, triethylamine, 
RT). Hydrogenation of (15) was intentionally carried out at a low temperature (~15°C) so 
as to avoid acrylonitrile elimination, which had been observed to take place during the 
hydrogenation of compounds (4) and (5) at 50°C. Although this had the negative effect of 
almost doubling the reaction time, the lack of side-products formed as a result of 
elimination was very beneficial in terms of the purification of (20) by column 
chromatography. That the benzyl ester had not been cleaved was quite fortuitous as 
purification of the product could be achieved by normal phase column chromatography.
770The method of Lenz et a l seemed to be very effective in terms of preventing the 
formation of side-products. As the benzyl protecting group of (15)/(20) had not been 
removed during hydrogenation in the presence of Raney nickel, it was necessary to 
remove the group subsequently. The benzyl deprotection of (20) was initially attempted 
by catalytic hydrogenation using palladium on carbon and hydrogen at atmospheric 
pressure but after several days of stirring in tetrahydrofuran under these conditions, 
remarkably (20) was recovered in 100 % yield. Removal of the benzyl group from (20) 
was also attempted by catalytic transfer hydrogenation with cyclohexene according to the
'ync
procedure of Anantharamaiah & Sivanandaiah as well as 1,4-cyclohexadiene
according to the procedure of Felix et al. 276 (Scheme 34).
NH Bo c NHBo c
Fd1C, 1,4-cydohexadiene
BocHN NHBoc
(21)OBn
NHBocNHBoc
Rd/C, cydohexene
BocHN NHBoc
OH
Scheme 34. -  Attempted benzyl deprotection of (20) by catalytic transfer 
hydrogenation.
Failure to cleave the benzyl ester of (20) by hydrogenolysis meant that base 
hydrolysis had to be employed. Base hydrolysis was initially attempted according to the 
procedure described by Huffman et a l 277; a solution of (20) in aqueous sodium 
hydrogencarbonate/tetrahydrofuran was adjusted to pH 10.5 by addition of saturated 
aqueous sodium carbonate solution and then left to stir for 24 hours at room temperature. 
Hydrolysis under these conditions however failed to occur and so hydrolysis was 
attempted at higher pH; to a solution of (20) in water/tetrahydrofuran was added an 
excess of sodium hydroxide (pH 12) and the reaction was left to stir at room temperature 
for 24 hours. Under these conditions hydrolysis again failed to occur and it appeared that 
the starting material ‘oiled-out’ upon addition of sodium hydroxide. Varying the ratio of 
water to tetrahydrofuran as well as replacing tetrahydrofuran with dioxane had no effect, 
the starting material being recovered every time.
NH B oc  NH Bo c
BocHN NHBo c
OBn
(20)
\  (CH^CO/HjO, 
9 2 % \ K 2C03,pH11
HjO/THF or Dioxane, 
NaOH, pH 12
(21)
NHBo c NHBoc
BocHN NHBoc
OH
Scheme 35. -  Preparation of N,N- bis-(3-(bis-(3-(ter/-butoxycarbonylamino)- 
propyl)-amino)-propyl)-undecanoic acid (21).
Finally benzyl deprotection was attempted using sodium carbonate in 
acetone/water as it was found that (20) neither did ‘oil-out’ from this solvent mixture nor
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did the solution become opaque upon addition of solid sodium carbonate. The reaction 
was adjusted to pH 11 by addition of solid potassium carbonate, left to stir at room 
temperature for 24 hours and after this time it was found that (20) was completely 
hydrolysed, N,N- bis-(3-(bis-(3-(ter/-butoxycarbonylamino)-propyl)-amino)-propyl)- 
undecanoic acid (21) being recovered in 92 % yield (Scheme 35).
At this point the reduction/Boc-protection of compounds (17), (18) and (19) 
became impossible due to a mechanical failure of the Parr hydrogenator in which all the 
hydrogenation reactions previously described had been carried out. In view of the fact 
that hydrogenation at high pressures would no longer be possible, an alternative reduction 
method had to be found. One alternative was to use a procedure recently published by 
Caddick et a l 278. The authors had devised a protocol for one-pot nitrile reduction and 
Boc-protection of the resulting amine using nickel (II) chloride hexahydrate, sodium 
borohydride and di-terf-butyl dicarbonate in methanol. This protocol had been applied to 
the reduction/Boc-protection of a variety of mono-nitriles with varying degrees of 
success. However, even if this protocol was effective for the reduction/Boc-protection of 
compounds (17), (18) and (19), an effective procedure for the reduction of nitrile groups 
without immediate Boc-protection would be required in order to prepare higher 
generation dendrimers.
Although the reduction of mono- and di-nitriles with cobalt (II) chloride had been 
shown to be highly efficient as well as devoid of secondary/ or tertiary amine formation
77Q 78fi 781 7^c’ ’ , Vogtle et al using this protocol had not succeeded in preparing dendrimers
larger than (7) because of problems associated with work-up/extraction of water-soluble,
787metal-complexing polyamines. Furthermore, Caddick et a l had previously claimed 
that in their hands transition metal-assisted sodium borohydride reduction of nitriles had 
led to extensive formation of secondary amines. An alternative method for nitrile 
reduction was therefore required that would avoid the need for aqueous work­
up/extraction after the reduction step and would not result in the formation of secondary 
amines. The use of borane-dimethylsulphide was one such alternative according to Brown
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et a l who had described the reduction of pivalonitrile to neopentylamine without the 
need for aqueous work-up.
787In their publication, Brown et a l described an improved procedure for borane- 
dimethyl sulphide reduction of nitriles. They showed that a variety of alkanenitriles could 
be reduced to the corresponding alkylamines by refluxing with one equivalent of borane- 
dimethyl sulphide in tetrahydrofuran and recovered in good yield (88-61 %). The authors 
described two work-up procedures for the reactions; the first involved adding aqueous
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hydrochloric acid to the reaction, heating to reflux, allowing to cool to room temperature, 
adding sodium hydroxide and then extracting the product with ether. The second 
procedure involved cooling the reaction to 0°C, adding methanolic hydrogen chloride, 
bringing the reaction to reflux again and distilling off the methyl borate as well as 
methanol and tetrahydrofuran which then resulted in the isolation of the amine
“JO A
hydrochloride. Hettich & Schneider , in preparing cobalt (III) polyamine complexes 
used the latter procedure to prepare tris-(3-aminopropyl)-amine from tris-(2-cyanoethyl)- 
amine in good yield (Scheme 36).
N
.NH.
r.l\L
N‘
N
1) 1.0 M BH3 -THF
2) MeOH-HO 
 *
3) Amberlyst A26
91 %
h 2n . .N.
NH,
Scheme 36. -  Synthesis of tris-(3-aminopropyl)-amine, Hettich & Schneider 284
Reduction of nitriles with borane-dimethyl sulphide was only intended as 
impromptu alternative to hydrogenation because of the unexpected failure of the Parr 
hydrogenator and so when considering the protecting group strategy, it was intended that 
borane-dimethyl sulphide reduction could be effectively replaced by hydrogenation. A 
protecting group was therefore required for the central amine of the polypropylenimines 
that was stable to borane-dimethyl sulphide reduction, hydrogenation using Raney nickel 
under various conditions, nucleophiles as well as acid (di-cyanoethylation of primary 
amines had been reported to occur in high yield in the presence of acetic acid). One such 
protecting group was /?-toluenesulfonamide group, which is remarkably robust and so can 
withstand the conditions mentioned but can be cleaved by, among other methods, 
dissolving metal reduction. According to Greene & Wuts m , the cleavage ofp- 
toluenesulfonamides by dissolving metal reduction could be carried out in the presence of 
terf-butoxycarbonyl protecting groups and indeed several procedures had been published 
in which this had been achieved 285’286’287# instead of l,l-dimethylethyl-A,A-bis-(3- 
aminopropyl)-carbamate (3), 7V,Ar-bis-(3-aminopropyl)-toluenesulfonamide (23) was 
therefore prepared.
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The preparation of (23) (Scheme 37) was achieved using a similar procedures to 
the preparation of (3); previously prepared 7V,iV-bis-(3-trifluoroacetamidopropyl)amine (1) 
was treated with p-toluenesulfonyl chloride in the presence of triethylamine (Greene & 
Wuts m ) to give Af,7V-bis-(3-trifluoroacetamidopropyl)-toluenesulfonamide (22). In view 
of the problems encountered with removing the trifluoroacetamide protecting groups from 
(2) with ammonia, an alternative procedure was sought. Treatment of (22) with potassium 
carbonate in methanol/water followed by extraction resulted in poor recovery of the 
product, as did treatment of (22) with AMBERLITE IRA420 289 in methanol followed by 
filtration and concentration in vacuo. A particularly effective method for large-scale 
deprotection of (22) was found to be treatment with hydrazine monohydrate in ethanol 
followed by removal of ethanol and extraction with toluene to give (23) in 95 % yield.
O
J LF-C N'
3 H A *H
O
+ Cl— s- ^ //
(1)
h 2n
h 2n -
96 % XBgN, DCM
o
X
N‘
0 = S = 0
95% HjNNHj ,
BOH, 80°C
O
o (23)
A ,
H
(22)
Scheme 37. -  Preparation of A,A-bis-(3-aminopropyl)-toluenesulfonamide (23).
Mono-cyanoethylation and di-cyanoethylation of the primary amines of (23) with 
acrylonitrile was then carried out. The use of /?-toluenesulfonamide as the protecting 
group of the central nitrogen now allowed for the use of the procedure of Vogtle et a l 255 
to achieve di-cyanoethylation. Indeed, refluxing (23) with 2 equivalents of acetic acid per
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amine function in a large excess of acrylonitrile for 72 hours eventually gave N,N-bis-(3- 
(bis-(2-cyanoethyl)-amino)-propyl)-toluenesulfonamide (24) in 99 % yield (Scheme 38). 
Not only was there an improvement in yield compared to di-cyanoethylation under 
conditions described for the synthesis of (5), but also the reproducibility of this procedure 
was superior.
Scheme 38. -  Synthesis ofV,V-bis-(3-(bis-(2-cyanoethyl)-amino)-propyl)- 
toluenesulfonamide (24) according to the procedure of Vogtle et a l  255.
0 = S = 0
(23) AcOH 2 eq./amine
o=s=o
(23)
HjO/O^CN,
2 . 1  eq.
H o=s=o H
(25)
Scheme 39. -  Synthesis ofV,V-bis-(3-(2-cyanoethylamino)-propyl)- 
toluenesulfonamide (25).
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The procedure for mono-cyanoethylation of primary amines was also improved 
upon. It was found that vigorously stirring a solution of (23), 2.1 equivalents of 
acrylonitrile and 2 equivalents of potassium carbonate in water/acetonitrile at 55°C for 48 
hours in a sealed tube rather than in a pressure equalised system resulted in recovery of 
A^A^-bis-(3-(2-cyanoethylamino)-propyl)-toluenesulfonamide (25) in 95 % yield (Scheme 
39). Again this procedure was far more reproducible than the procedure employed for the 
synthesis of (4).
Reduction of the two nitrile functions of (25) was initially carried out according to 
the procedure detailed by Brown et al. with the exception that the reaction time was 
extended to several hours. Borane-dimethyl sulphide (1 equivalent per nitrile) was added 
to a refluxing solution of (25) in tetrahydrofuran and after 6 hours the reaction was cooled 
to room temperature and hydrochloric acid was added. The reaction was then heated to 
reflux for 30 minutes, then cooled to 0°C and sodium hydroxide was added. After 
removal of tetrahydrofuran and addition of more water, the aqueous solution was 
extracted with dichloromethane to recover the crude product. Analysis of the crude 
material by MS showed that it contained a mixture of products (Scheme 40) which had 
been formed either as a result of incomplete reduction or as a result of acrylonitrile 
elimination.
(25) Tosyl
1)THF, reflux- 
Bh .^SMej 1  eq./nitrile
2 ) + HO aq., reflux
H
Tosyl
Scheme 40. -  Borane-mediated reduction of Ar,A^-bis-(3-(2-cyanoethylamino)- 
propyl)-toluenesulfonamide (25) according to procedure published by Brown et al. 283.
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In order to avoid elimination of acrylonitrile and to ensure that nitrile reduction 
went to completion, the reduction procedure was altered. It was clear from the initial 
attempt to reduce (25) that one equivalent of borane-dimethyl sulphide per nitrile was for 
some reason insufficient. This was unexpected since in theory 2/3 equivalent of borane (2 
hydrides) should have been required for complete reduction. However, similarly Brown et 
al. obtained their lowest yield for the reduction of adiponitrile to 1,6-diaminohexane 
despite using 1.1 equivalents (cf. only 1 equivalent for mononitriles). Hettich & Schneider
9RAon the other hand used 5.9 equivalents of borane-dimethyl sulphide per molecule of 
tris-(2-cyanoethyl)-amine (1.96 equivalents per nitrile function) and recovered the desired 
product in very good yield. The number of equivalents of borane-dimethyl sulphide was 
therefore increased to 2 equivalents per nitrile function for the reduction of (25). 
Furthermore, instead of heating the solution of (25) in tetrahydrofuran to reflux and then 
adding borane-dimethyl sulphide, borane-dimethyl sulphide was added to a solution of
(25) in tetrahydrofuran at room temperature and the reaction was left to stir for 3 hours at 
room temperature. After three hours the reaction was heated to 55°C and left stirring for 3 
days. After three days the reaction was worked-up in the same manner as described by 
Brown et al. . Analysis of the crude material recovered from the reaction showed that it 
contained almost exclusively 7V,/V-bis-(3-(3-aminopropyl)-amino-propyl)- 
toluenesulfonamide (Scheme 41).
(25) H Tosyl
H
1 ) 2  eq/nitrile
THF, RT- 55°C 
\  2) + HCI aq., reflux
(26) h 2N 2
Tosyl
Scheme 41. -  Improved procedure for the reduction of compound (25).
Purification of A,/V-bis-(3-(3-aminopropyl)-amino-propyl)-toluenesulfonamide
(26) was not possible although analysis of the crude product indicated that it contained 
only minor amounts of impurities. The mono-cyanoethylation of the terminal primary
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amines of this compound was therefore attempted directly. As was mentioned earlier, 
according to Mukheijee et al. 264 treatment of a polyamine bearing both primary and 
secondary amines with acrylonitrile resulted in mono-cyanoethylation of the primary 
amines only. With this in mind, (26) was treated with acrylonitrile by the same method as 
for the preparation of (25). Analysis of the products of the reaction between 1 equivalent 
of (26) and 2.1 equivalents of acrylonitrile showed three products to be present in 
approximately equal amounts (25-30 %). These three products were separated by column 
chromatography and their structures were determined (Scheme 42).
(26)
2 . 1  eq,
N
Hp/CHjCN,
25-30 %
25-30 %
25-30 %
Scheme 42. -  Reaction of A,A-bis-(3-(3-aminopropyl)-amino-propyl)- 
toluenesulfonamide (26) with 2.1 equivalents of acrylonitrile.
It was clear from the ratio of the three products that were recovered that mono- 
cyanoethylation of A,7V-bis-(3-(3-aminopropyl)-amino-propyl)-toluenesulfonamide (26) 
did not occur selectively at the terminal primary amines. Selectivity was presumably 
dependent on either the structure of the polyamine or the reaction conditions or both. 
Indeed, Poppelsdorf & Myerly 290 had shown that treatment of jV-methy 1-1,2- 
diaminoethane with acrylonitrile under conditions that were very similar to those
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described by Mukheijee et al. 264, resulted in the formation of 3-((2-aminoethyl)- 
methylamino)-propionitrile and 3-(2-methylaminoethylamino)-propionitrile in a ratio of 
95:5 (Scheme 43). Rosini et al. 291 on the other hand reported that treatment of 1 
equivalent of Ar,A^-bis-(6-aminohexyl)-octane-1,8-diamine in methanol with 1 equivalent 
of acrylonitrile resulted in the formation of a mixture of products. From this mixture the 
author recovered 3-(6-(8-(6-aminohexylamino)-octylamino)-hexylamino)-propionitrile in 
17 % yield and 3-((6-aminohexyl)-(8-(6-aminohexylamino)-octyl)-amino)-propionitrile in 
15 % yield (Scheme 43).
95 % 5 %
1 eq, MeOH
H
N NH
6 8
17%
N
15%
Scheme 43. -  Reactions of N-methyl-1,2-diaminoethane and N,7V-bis-(6- 
aminohexyl)-octane-1,8-diamine with 1 equivalent of acrylonitrile.
Failure to selectively mono-cyanoethylate the primary amine functions of (26) 
over the secondary amine functions meant that the secondary amine functions had to be 
protected prior to reduction of the nitrile groups. The use of tert-butoxycarbonyl 
protection was thought to be suitable for this purpose, as Boc protecting groups are 
known to be stable to borane-dimethyl sulphide although this has only been 
experimentally proven at temperatures of 25°C and lower. Ar,A^-bis-(3-(2- 
cyanoethylamino)-propyl)-toluenesulfonamide (25) was therefore treated with di-tert-
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butyl dicarbonate and TV, 7V-Bis-(3-(ter/-butoxycarbonyl-(2-cyanoethyl)-amino)-propyl)- 
toluenesulfonamide (27) was recovered in excellent yield (99. 9 %) (Scheme 44).
B 3N,
THF
(27)
Scheme 44. -  Synthesis of A-Bis-(3-(tert-butoxycarbonyl-(2-cyanoethyl)- 
amino)-propyl)-toluenesulfonamide (27).
The reduction of (27) with borane-dimethyl sulphide was not straightforward 
however since the reduction procedure normally involves addition of hydrochloric acid or 
methanolic hydrogen chloride to the reaction at the later stage in order to destroy excess 
borane and hydrolyse the borazine derivative that has formed. Both the necessity to use 2 
equivalents of borane-dmimethyl sulphide per nitrile function of (27) and the fact that a 
solution of borane-dimethyl sulphide will nearly always be partially decomposed makes it 
impossible to know how much hydrogen chloride must be added to a borane-mediated 
reduction and for this reason it was decided to modify the procedure. As with the 
reduction of (25), 2 equivalents of borane-dimethyl sulphide per nitrile function were 
added to a solution of (27) in tetrahydrofuran at 40°C. After stirring for several hours the 
reaction was heated to 55°C and left for 3 days. After 3 days the reaction was cooled to 
0°C and a large excess of methanol was added in order to destroy excess borane. The 
reaction was then heated to reflux for several hours after which time it was concentrated 
in vacuo. Analysis of the crude product showed that it contained almost exclusively N,N- 
bis-(3-(ter/-butoxycarbonyl-(3-aminopropyl)-amino)-propyl)-toluenesulfonamide (28)
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which was mono-cyanoethylated directly employing the procedure described for the 
preparation of (25) (Scheme 45).
N,
N'
0 ^ 0X
,N
N' N'
Tosyl QX 0
X <27>
1 ) B H v S M e„  THF 
2) MeOH
HoN' N'
0 ^ 0X
‘IjT ^  'N '  
Tosyl
NH,
(28)
N.
68 % yield over 2 steps
N'
0 ^ 0X
N 2.1 eq. 
MeCN/K^O
N '  ^  'N  
Tosyl X Q
X
-N
(29)
Scheme 45. -  Preparation of 7V,A-bis-(3-(tert-butoxycarbonyl-(3-(2- 
cyanoethylamino)-propyl)-amino)-propyl)-toluenesulfonamide (29).
Despite the fact that the standard work-up of the borane reduction was not carried 
out, mono-cyanoethylation of crude (28) with acrylonitrile was quite effective and N,N- 
bis-(3-(ter/-butoxycarbonyl-(3-(2-cyanoethylamino)-propyl)-amino)-propyl)- 
toluenesulfonamide (29) was recovered in 68 % yield over two steps after purification. As 
compound (29) was successfully prepared by this method, the same procedure was 
employed for the preparation of AX-bis-(3-(ter/-butoxycarbonyl-(3-(ter/-butoxycarbonyl- 
(3-(2-cyanoethylamino)-propyl)-amino)-propyl)-amino)-propyl)-toluenesulfonamide (32). 
Protection of the two free amine functions of (29) with di-ter/-butyl dicarbonate was 
followed by borane-mediated reduction of the two nitrile functions of N,N-bis-(3-(tert- 
butoxycarbonyl-(3-(ter/-butoxycarbonyl-(2-cyanoethyl)-amino)-propyl)-amino)-propyl)- 
toluenesulfonamide (30) under identical conditions as for the preparation of (28). Crude
vV,A-bis-(3-(tert-butoxycarbonyl-(3-(ter/-butoxycarbonyl-(3-aminopropyl)-amino)-
propyl)-amino)-propyl)-toluenesulfonamide (31) was then treated with 2.1 equivalents of
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acrylonitrile under standard conditions to give (32) in 76 % yield over two steps from 
(30) after purification (Scheme 46).
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Scheme 46. -  Synthesis of AfX-bis-(3-(ter/-butoxycarbonyl-(3-(te/T- 
butoxycarbonyl-(3-(2-cyanoethylamino)-propyl)-amino)-propyl)-amino)-propyl)- 
toluenesulfonamide (32).
In order to obtain the fully Boc-protected polyamine-tosylamides, (29) and (32) 
were then reduced and under the conditions previously described (borane-dimethyl
sulphide then methanol) and treated with di-/er/-butyl dicarbonate directly. Reduction of 
the nitrile functions of (29) with 2 equivalents of borane-dimethyl sulphide per nitrile 
followed by work-up/quenching with methanol resulted in isolation of crude N,N-bis-(3- 
(/ert-butoxycarbonyl-(3-(3-aminopropyl)-aminopropyl)-amino)-propyl)- 
toluenesulfonamide (33) as confirmed by MS. Initial attempts to Boc-protect (33) in 
tetrahydrofuran and triethylamine with di-terf-butyl dicarbonate were unsuccessful as 
Af,Af-bis-(3-(terf-butoxycarbonyl-(3-(terf-butoxycarbonyl-(3-(ter/-butoxycarbonylamino)- 
propyl)-amino)-propyl)-amino)-propyl)-toluenesulfonamide (34) was recovered in only 
-30 % yield. Attempts to Boc-protect (33) under standard aqueous Boc protection 
conditions (tetrahydrofuran/water, potassium carbonate) were also less than satisfactory 
with (34) being recovered in -45 % yield.
N. .N
NT v  'NT ^  'N' 
o \  ° - f °  o"l o ,
X  Xi X (29)
1) BHj.SMej, THF
2) MeOH
H2N‘ N'
^  0=S=0 _O O I 0  0X
N'
X
NH,
X (33)
BoCjO, MeOH, ^ C 0 3
o
O N
> k  "
N '  v  ' N '  v  'IjT v  'NT v  'N '
xW xW 0=S=0 xX~ ^  ^  • 0  0 ,  o  o  ,X X0 0 0 0X X
65 % yield over 2 steps
o
. XN O ,HX
(34)
Scheme 47. -  Preparation of 7V,vV-bis-(3-(/er/-butoxycarbonyl-(3-(tert- 
butoxycarbonyl-(3-(/er/-butoxycarbonylamino)-propyl)-amino)-propyl)-amino)-propyl)- 
toluenesulfonamide (34).
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Boc protection was finally attempted in methanol with potassium carbonate and 
di-terf-butyl dicarbonate according to a procedure described by Einhom et al. . The 
authors had devised a procedure for Boc-protecting amines from their salts by sonicating 
the amine hydrochlorides in ethanol or methanol with di-tert-butyl dicarbonate and base 
(sodium hydrogencarbonate was used by the authors but they stated that sodium 
carbonate was suitable also). Although sonication was suggested to be the best means for 
‘mixing’ the reaction, stirring was also said to be effective but resulted in much more 
prolonged reaction times. Prolonged stirring of the reaction mixture (3-4 days) rather than 
sonication produced (34) in 65 % yield over two steps (Scheme 47).
N, x- N
> T  v  ' N '  v  'N  N N'
/ k .  / k .  0 = S = 00 0 0 0 I 0 ^ 0 , 0 ^ 0 ,X X A X X
1) BHj.SMe* IMF
2) MeOH
(32)
(35)
BoCjO, MeOH, K,C03
HN" v  ' N '  v  ' N '  v  'N  ^  N ^  N" v  ' N '  v  ' N '  v  'NH
0 = S  = 0  x l s  ^
O O 0  0  0  0  O O I 0 ^ 0  y 0 ^ 0 ,  0 ^ 0 ,  0 ^ 0 ,x x x x  A x x x x
30 % yield over 2 steps (36)
Scheme 48. -  Preparation of A, A-bis-(3-(ter/-butoxycarbonyl-(3-(ter/- 
butoxycarbonyl-(3-(ter/-butoxycarbonyl-(3-(ter/-butoxycarbonylamino)-propyl)-amino)- 
propyl)-amino)-propyl)-amino)-propyl)-toluenesulfonamide (36).
Reduction of (32) to A,A-bis-(3-(ter/-butoxycarbonyl-(3-(tert-butoxycarbonyl-(3- 
(3-aminopropyl)-amino)-propyl)-amino)-propyl)-amino)-propyl)-toluenesulfonamide (35) 
under standard conditions proceeded smoothly as determined by MS analysis of the 
crude. Boc-protection was carried out according to the aforementioned procedure for 
conversion of (33) to (34) but this led to the isolation of A,7V-bis-(3-(tert-butoxycarbonyl-
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(3-(tert-butoxycarbonyl-(3-(ter/-butoxycarbonyl-(3-(tert-butoxycarbonylamino)-propyl)- 
amino)-propyl)-amino)-propyl)-amino)-propyl)-toluenesulfonamide (36) in only 30 % 
over two steps (Scheme 48). However due to a lack of time this procedure was only 
carried out once and so there was not the possibility to optimise the conditions.
Scheme 49. -  Reduction of A, A-bis-(3-(bis-(2-cyanoethyl)-amino)-propyl)- 
toluenesulfonamide (24).
Reduction of the four nitrile functions of (24) was initially attempted using the 
same procedure as for the reduction of (27), (29) and (30). To compound (24) in 
tetrahydrofuran at room temperature was added 8 equivalents of borane-dimethyl 
sulphide (2 equivalents per nitrile) and after stirring for several hours the reaction was 
then heated to 60°C for 3 days. After three days the reaction was quenched with a large 
excess of methanol and then concentrated in vacuo. MS analysis of the crude reaction 
mixture showed it to contain several products in addition to the desired product, N,N-bis- 
(3-(bis-(3-aminopropyl)-amino)-propyl)-toluenesulfonamide (37). These side-products 
were determined to be due to incomplete reduction of (24) i.e. not all the nitrile functions 
had been reduced. The reaction was repeated using 8 equivalents of borane-dimethyl 
sulphide but instead of being left at 60°C for 3 days, the reaction time was extended to 6 
days. After 6 days the reaction was worked-up by the usual procedure and again MS 
analysis showed the reaction to be incomplete. This suggested that an even greater excess 
of borane-dimethyl sulphide needed to be added and so the reaction was repeated using 
10 equivalents of borane-dimethyl sulphide (2.5 equivalents per nitrile), the reaction time
1) 10 eq. BK.SMe^THF 
\ 2 )  MeOH
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being 3 days (Scheme 49). MS analysis of the crude material recovered from the reaction 
showed it to contain almost exclusively Af,Af-bis-(3-(bis-(3-aminopropyl)-amino)-propyl)- 
toluenesulfonamide (37).
o=s=o
NHBoc
73%  
BoqO, MeOH,
W ,
BocHN
o=s=o
34%
N 200 eq., 
AcOH 12 eq.
N
NHBoc
N (38)
NHBoc
o=s=o
Scheme 50. -  Preparation of 7V,jV-bis-(3-(bis-(3-/er/-butoxycarbonylamino- 
propyl)-amino)-propyl)-toluenesulfonamide (38) and Ar,ALbis-(3-(bis-(3-(bis-(2- 
cyanoethyl)-amino)-propyl)-amino)-propyl)-toluenesulfonamide (39).
Compound (37) was subsequently Boc-protected for the purpose of preparing the 
first generation dendrimeric polypropylenimine or di-cyanoethylated at all the terminal 
amine functions in order to prepare the second generation dendrimeric 
polypropylenimine. Stirring (37) in triethylamine and tetrahydrofuran with 6 equivalents 
of di-terf-butyl dicarbonate for 4 days gave 7V,A^-bis-(3-(bis-(3-/er/-butoxycarbonylamino- 
propyl)-amino)-propyl)-toluenesulfonamide (38) in good yield (73 %) (Scheme 50) and 
so the procedure of Einhom et al. 292 was not employed. The isolation of (38) required 
two purification steps however; initially column chromatography was performed with a 
mixture of chloroform and piperidine and the crude product recovered from this column 
was then purified again by column chromatography eluting with a mixture of chloroform,
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methanol and triethylamine. The first column was found to be necessary in order to 
achieve separation of product from impurities with the second column.
The poly-cyanoethylation of (37) with acrylonitrile (Scheme 50) was carried out 
under the conditions described by Vogtle et a l 255. Compound (37) was refluxed with a 
mixture of 12 equivalents of acetic acid (2 equivalents per amine function as used by 
Vogtle et a l 255) and a very large excess of acrylonitrile for 3 days. After 3 days the 
reaction was worked-up in the same way as for the synthesis of (24) and analysed by MS. 
MS analysis showed the desired compound to be present but purification was of (39) was 
problematic. It was found that the same protocol for purifying (38) had to be used to 
purify (39). An initial purification by column chromatography eluting with chloroform 
and piperidine was necessary in order to achieve separation by column chromatography 
eluting with chloroform, methanol and triethylamine. Even then N, V-bis-(3-(bis-(3-(bis- 
(2-cyanoethyl)-amino)-propyl)-amino)-propyl)-toluenesulfonamide (39) was recovered in 
poor yield (34 %) because of mixing of product and impurities during chromatography.
The reduction of V,V-bis-(3-(bis-(3-(bis-(2-cyanoethyl)-amino)-propyl)-amino)- 
propyl)-toluenesulfonamide (39) was carried out using the same protocol as for the 
reduction of (24)(Scheme 51). MS analysis of the crude material recovered from the 
reduction of (39) showed that the desired product, V,V-bis-(3-(bis-(3-(bis-(3- 
aminopropyl)-amino)-propyl)-amino)-propyl)-toluenesulfonamide (40) was present. The 
crude (40) was not purified but was Boc-protected directly, initially employing the 
procedure for the Boc protection of (37). This procedure proved to be unsatisfactory, as 
after 10 days of stirring (40) with di-/er/-butyl dicarbonate in triethylamine and 
tetrahydrofuran, the desired product could still not be detected in the reaction by MS. 
After 15 days stirring at room temperature the reaction was finally worked-up and TLC as 
well as MS analysis of the crude material recovered showed that only partially Boc- 
protected products had been formed. Boc protection of (40) was then attempted according
909to the protocol of Einhom et a l since this protocol had been shown to be superior to 
the THF/TEA/B0 C2O protocol for the Boc protection of (33). Compound (40) was 
therefore stirred with di-tert-butyl dicarbonate and potassium carbonate in methanol for 
several days (Scheme 51). Monitoring of the reaction by MS failed to determine whether 
any product had formed and TLC analysis of the reaction was equally as uninformative. 
Consequently after five days the reaction was terminated and the material recovered was 
purified by column chromatography. As for (38) and (39), it was necessary to perform 
two column chromatography runs, the first with chloroform and piperidine, the second 
with chloroform, methanol and triethylamine. However for the purification of V,V-Bis-(3-
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(bis-(3-(bis-(3-(ter/-butoxycarbonylamino)-propyl)-amino)-propyl)-amino)-propyl)- 
toluenesulfonamide (41) it was necessary to run a third column eluting with a less polar 
mixture of chloroform, methanol and triethylamine in order to obtain the pure product. 
Although it would have been desirable to devise a more convenient method for purifying 
(41), a lack of time prevented this.
.N N.
N.
N' N'
.N
N' N'
o=s=o
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N' N'
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1) 20 eq. BK.SMe, 7HF 
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Scheme 51. -  Preparation of A,A-Bis-(3-(bis-(3-(bis-(3-(ter/- 
butoxycarbonylamino)-propyl)-amino)-propyl)-amino)-propyl)-toluenesulfonamide (41).
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The next step in the syntheses of the various Boc-protected polypropylenimine 
carboxylic acids was to remove the /?-toluenesulfonamide protecting group in order that 
the central secondary amines of the various structures might be coupled to the 
bromoalkanoic acid benzyl esters. Various protocols have been developed for the removal
acidic conditions which of course would have been unsuitable in this case. Several 
protocols have also been described in literature for the removal of these protecting groups 
by dissolving metal reduction using either lithium or sodium, which have been reported to 
be compatible with the di-te/Y-butoxycarbonyl protecting group 171. Out of the various 
compatible protocols for removal of this protecting group, dissolving metal reduction was 
one of the most convenient and so was the first procedure to be tried.
NHBo c NHBoc
Scheme 52. -  Deprotection of N,N- bis-(3-(bis-(3-tert-butoxycarbonylamino- 
propyl)-amino)-propyl)-toluenesulfonamide (38) by dissolving metal reduction.
The/?-toluenesulfonamide deprotection of N,N- bis-(3-(bis-(3-ter/- 
butoxycarbonylamino-propyl)-amino)-propyl)-toluenesulfonamide (38) was the first to be 
attempted. Deprotection was carried out using sodium in liquid ammonia and 
tetrahydrofuran according to the procedure described by Schultz et a l 293. Addition of 
solid sodium to (38) in tetrahydrofuran and liquid ammonia until a blue colour persisted 
for 20 minutes was followed by quenching of the reaction with solid ammonium chloride.
of p-toluenesulfonamide groups m , many of which involve cleavage under strongly
BocHI NHBoc
\ 1 )  Na, NHj, THF, -78°C 
23 % \  2 ) sa t aq. NaHC03
NHBoc NHBoc
BocHN NHBoc
293The reaction was then worked-up according to the described procedure and analysed 
by MS. MS analysis revealed a mixture of five products, (3-((3-(3-(bis-(3-/er/- 
butoxycarbonylamino-propyl)-amino)-propylamino)-propyl)-(3-teAY- 
butoxycarbonylamino-propyl)-amino)-propyl)-carbamic acid tert-butyl ester (42) and 
compounds in which between 1 and 4 Boc groups had been removed as well as the p- 
toluenesulfonamide group. The desired product, (42) was eventually isolated by column 
chromatography in only 10 % yield. The reaction was repeated using the same conditions 
with the exception that sodium was added more carefully and only enough was added so 
that the reaction remained light blue in colour. After stirring for 3 hours at -78°C, the 
reaction was quenched with saturated aqueous sodium hydrogencarbonate and then 
worked-up. MS analysis again showed that various side-products were present in the 
crude material recovered from the reaction. Compound (42) was isolated from this crude 
material by column chromatography in only 23 % yield (Scheme 52). Various other 
dissolving metal reduction protocols were applied to the /?-toluenesulfonamide 
deprotection of (38) such as sodium/naphthalene in diethyl ether 294, sodium in isopropyl 
alcohol and lithium in ammonia . None of these methods were any more suitable for 
the deprotection of (38) since, in every case, removal of Boc groups occurred extensively.
N H B o c  NHBoc
NHB ocBocHN
1) 3-4 eq. Na, NH3 , 
THF, -78°C
2) sa t aq. NaHC03
t
NHBoc  NHBo c  NHBoc  NHBoc
NHBocNHBo cBocHN
37 % 22 % of (38) recovered 33 %
Scheme 53. -  Deprotection of (38) by dissolving metal reduction using only 3-4
equivalents of sodium metal.
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Attempts to avoid Boc deprotection during p-toluenesulfonyl deprotection of (38) 
by adding only the amount of sodium that was required to effect p-toluenesulfonamide 
cleavage i.e. 2-4 equivalents of sodium rather than adding sodium until a blue colour 
persisted were also unsuccessful. Indeed it seemed that Boc deprotection by dissolving 
metal reduction was almost as effective as tosyl deprotection by dissolving metal 
reduction since a product was isolated that was missing a Boc group but was still tosyl- 
protected (Scheme 53).
| ft o  Mg 10 eq, MeOH, ft
"  / V o A nh' I o  Sonication 20-120 mins ' i
R R
R= Ph, Bh, Ala, -CHjC^NHTroc, -C^CHjNHZ 
Ar= - C ^ C ^ ,  - C ^ ,  -C ^ N O ^ , -CBH3 Me3 -2,4,6
(») CN
N B o c/
Tosyl
X = SMejj, SPhj, aC4Hg
Mg 10 eq, MeOH,
Sonication 40 mins
CN
NHBo c
(in)
Bo cHN
Tosyl
Mg 28 eq, MeOH, 
Reflux, 6 hrs
Scheme 54. -  Cleavage of arenesulfonamides by magnesium reduction; (I)
Ragnarsson et a l 298, (II) Matthews et a l . (III) Matsubara et al299 297
An alternative to /7-toluenesulfonyl deprotection by dissolving metal reduction 
was required and one such alternative was cleavage by magnesium reduction. Ragnarsson
7QO
et a l had reported a mild and efficient cleavage of arenesulfonamides by magnesium. 
The procedure involved sonicating the arenesulfonamides with 5-10 equivalents of 
magnesium powder in methanol for up to 2 hours, working-up with very dilute 
hydrochloric acid, adjusting the pH by addition of base and then extracting. This protocol
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had been employed by the authors for the deprotection of a variety of Boc-protected 
arenesulfonamides in which the Boc group was located on the same nitrogen atom as the 
arenesulfonyl group and yields obtained were excellent (95-100 %) (Scheme 54-(I)). This 
procedure was also employed by Matthews et al. 299 for the /?-toluenesulfonyl 
deprotection of Boc-protected precursors to sila-substituted /?-amino acids (Scheme 54- 
(II)), again in very good yields (81-98 %).
Deprotection of (38) was consequently attempted by sonication with magnesium 
powder in methanol. Compound (38) was dissolved in dry methanol, 10 equivalents of 
magnesium powder were added and the reaction was sonicated. Monitoring the reaction 
was carried out by TLC and the reaction was terminated once all the starting material had 
disappeared. The reaction was then worked-up according to the procedure of Ragnarsson 
et a l 298 and the crude material was analysed by MS and TLC. Both MS and TLC 
analysis showed that the crude material contained a variety of products formed as a result 
of either Boc or p-toluenesulfonyl deprotection or both. The reaction was repeated but the 
work-up was altered to check whether Boc deprotection had been caused by addition of 
hydrochloric acid. Instead of using hydrochloric acid for the work-up, acetic acid was 
used. This however did not make any difference to the outcome of the reaction as Boc 
deprotection was still observed to occur along with p-toluenesulfonyl deprotection.
2Q7
Matsubara et al. had also used magnesium reduction to remove a p- 
toluenesulfonyl group in the presence of a terf-butoxycarbonyl group but instead of 
sonicating in methanol they refluxed the /7-toluenesulfonamide with magnesium in 
methanol (Scheme 54-(III)). The authors succeeded in deprotecting a /?-toluenesulfonyl 
group in the presence of a Boc group on another nitrogen atom and obtained the desired 
product in reasonable yield (78 %). In view of this, the procedure of Matsubara et al. 297 
was also applied to the /7-toluenesulfonyl deprotection of (38) but still the same level of 
Boc deprotection was observed under these conditions as with sonicating with 
magnesium in methanol.
Photolytic cleavage of the /7-toluenesulfonamide group was also attempted in 
desperation. Abad et al. 300 had shown that various /7-toluenesulfonamides could be 
deprotected by irradiating a solution of the /7-toluenesulfonamide in diethyl ether with 
light from a mercury lamp. The authors reported that photolytic cleavage under these 
conditions gave the corresponding free amines in 85-90 % yield. Yuan et al. 301 used the 
same procedure to deprotect (4-(octadecyloxy)-3-(S)-((/?-toluenesulfonyl)-amido)-but-l- 
yl)-phosphocholine but they recovered (3-(S )-amino-4-(octadecyloxy)but-l-yl)- 
phosphocholine in only 43 % yield. They had attempted to cleave the p-
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toluenesulfonamide group by various other means such as with sodium/ammonia, Red-Al, 
aluminium amalgam and sodium amalgam but all these methods had failed to give the 
desired product. Nevertheless photolytic cleavage of (38) was carried out according to the 
procedure described by Abad et al. 30°; (38) was dissolved in ether and the solution was 
de-oxygenated by bubbling argon through it. The solution, under argon was then 
irradiated for several hours, progress of the reaction being monitored by TLC. Once all 
the starting material had disappeared the reaction was worked up and the crude material 
was analysed by MS and TLC. The crude material was found to contain numerous 
products, none of which could be identified, and so this deprotection procedure was 
abandoned.
The last resort for the cleavage of the /?-toluenesulfonamide groups of (34), (36), 
(38) and (41) was electrochemical reduction. This was a last recourse since equipment 
was required for electrochemical reduction that is not normally found in a synthetic 
organic chemistry laboratory. A survey of literature revealed that although relatively little 
had been published on the removal of /?-toluenesulfonyl groups by electrochemical 
reduction when compared to dissolving metal reduction, nevertheless several 
comprehensive investigations had been carried out on the reduction of arylsulfonamides. 
Homer & Neumann 302 were the first to discover that p-toluenesulfonamides could be 
reduced to free amines at a mercury cathode in methanol in the presence of 
tetramethylammonium chloride in good yield (55-98 %). The authors however did not 
employ controlled potential electrolysis and so there was no selectivity for reduction ofp- 
toluenesulfonamides only.
Following on from this early work, Cottrell & Mann carried out extensive 
studies on the electrochemical reduction of primary, secondary and tertiary 
arylsulfonamides. The authors examined the reductions of these arylsulfonamides by 
applying cyclic voltammetry, electron spin resonance spectroscopy and large-scale 
electrolysis with chemical product identification. In contrast to Homer & Neumann 302, 
the authors carried out their reactions in acetonitrile with tetraethylammonium bromide in 
order that they could investigate the effects of the absence or presence of proton donors 
on the reactions. Cottrell & Mann used cyclic voltammetry to establish the peak 
potentials of several 1°, 2° and 3° arylsulfonamides (Table 1). The cyclic voltammograms 
of all the arylsulfonamides showed one irreversible reduction step in the range -2.8 to 
-3.0 V (against silver/silver nitrate reference electrode).
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Compound Peak potential/ -E p, V
1) p-Toluenesulfonamide 2.97
2) Benzenesulfonamide 2.82
3) N-Methyl-p-toluenesulfonamide 2.91
4) N-Propyl-p-toluenesulfonamide 2.87
5) N,N-Diethyl-p-toluenesulfonamide 2.93
6) N,N-Dimethyl-p-toluenesulfonamide 2.85
Table 1. -  Cyclic voltammetric peak potentials; voltammetry at mercury plated 
platinum wire, sweep rate lOV/sec, compound concentration 5-10 mM in TEAB/MeCN, 
potential measured against Ag/AgNC>3 (0.10M) reference electrode. (Cottrell & Mann 303)
Once the voltammetric peak potentials had been ascertained, the authors carried 
out large-scale potential electrolysis of the arylsulfonamides, the progress of the 
reductions being monitored by observation of the current-time behavior. The authors 
quantitatively analysed the reaction products and also determined the number of electrons 
required per molecule for reductive cleavage (Table 2).
SM Reaction potential V N
% SM
Product analysis 
% Amine % Sulfinate
(1) -2.80 0.95±0.02 51±2 n.d. 52±10
(2) -2.80 0.96±0.02 n.d. n.d. n.d.
(3) -2.80 0.97±0.02 n.d. 45±10 n.d.
(4) -2.80 1.96±0.04 0±2 100±2 n.d.
(5) -2.80 1.96±0.04 0±2 94±2 96±10
(6) -2.80 1.94±0.04 n.d. 97±5 n.d.
Table 2. -  Quantitative results of constant potential arylsulfonamide reduction; 
SM -  starting material (see Table 3), n -  number of electrons per molecule of starting 
material, n.d. -  not determined. (Cottrell & Mann 303)
The results of Cottrell & Mann 303 confirmed that electrochemical reduction of 3° 
arylsulfonamides was particularly efficient. The authors also investigated the effect of 
adding phenol as a proton source to the reaction in three-fold excess to the starting 
material. By carrying out electrochemical reduction with and without phenol and
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comparing the quantitative results they were able to conclude that phenol had no effect on 
the reduction reactions. Based on their observation that the reduction of 1°, 2° and 3° 
arylsulfonamides was a two-electron process and that triethylamine and ethene were 
produced during the reaction, the authors proposed a pathway for the reaction (Scheme 
55).
OOHK + e --e- O-Ho
+ e _ o
N
O
2 -
H
H
+Et4NH
/
:N +  HN
\
+CH3CN
N
O
Acetonitrile + Bhene + Triethylamine
Scheme 55. -  Proposed pathway for electrochemical reduction of 
arylsulfonamides (Cottrell & Mann 303).
This mechanism for the cleavage of arenesulfonamides was not however 
universally accepted. Mairanovsky 304, in a review on electrochemical removal of 
protecting groups in which the author also gave details of his own observations, argued 
that the mechanism proposed by Cottrell & Mann was not convincing. The author, on 
the basis of data obtained from delayed homogenous electron transfer against a standard 
potential gradient, suggested that according to this equation (Scheme 60), the two 
electrons would have to be transferred at exactly the same potential 304. Although a single 
two-electron wave was observed in cyclic voltammograms of arenesulfonamides, the 
author argued that transfer of the two electrons nevertheless occurred at different 
potentials. In the case of electrochemical reduction of arenesulfonamides, the second 
electron transfer potential was less negative than the first and so instead of two one-
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electron waves being observed, one two-electron wave was observed. The author 
proposed an alternative mechanism for reduction of arenesulfonamides in aprotic media 
and as well as a mechanism for electrochemical reduction in protic media (Scheme 56).
Bedrochemical reduction in aprotic 9 0 Ivent
O-HR +e- o + c
Bedrochemical reduction in protic solvent
o
O f +e_
j \ U |o?-~
o
o
o
R
NH
+H* of \ ~ u
OH R
+e-
r y U
' ---- OH R
Scheme 56. -  Mechanisms for electrochemical reduction of arenesulfonamides in 
aprotic and protic solvents proposed by Mairanovsky 304.
Although several other examples of electrochemical deprotection of 
arenesulfonamides could be found in literature (Roemmele & Rapoport 305, Kurzmeier & 
Schmidtchen 306, Schmidtchen et al. 307, Waelchli et al. 308, Fiedler et al. 309), few 
examples could be found in which an arenesulfonamide was cleaved electrolytically in 
the presence of a terf-butoxycarbonyl group. Grehn et al. 310 had shown that it was 
possible to selectively cleave a ‘I0’ toluenesulfonamide of a Boc-protected mixed
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primary-secondary toluenesulfonamides (Scheme 57). However in this example the Boc 
group was located on the same nitrogen atom as the toluenesulfonyl group that was 
selectively removed and the authors believed that the presence of the Boc group on the 
same nitrogen atom did in fact facilitate electrochemical cleavage of the ‘I0’ 
toluenesulfonamide.
0 = S = 0
Boc,0
DMAP
O ^/O tB u 
0 = S = 0  O
Cathodicdeavage
R= methyl or ethyl
o=s=o
H
N^^OtBuT
o
Scheme 57. - Selective cleavage of a ‘1°’ toluenesulfonamide of a Boc-protected
11 nmixed primary-secondary toluenesulfonamide. (Grehn et a l )
A more relevant example of the electrolytic cleavage of a toluenesulfonamide in 
the presence of a tert-butoxycarbonyl group was found in a publication by Bigler et al.
31 *. The authors, en route to (E,E)-A-(3-[15N]-aminopropyl)-3,3'-bis-(4-hydroxyphenyl)- 
N,N1'-(butane-1,4-diyl)-bis-(prop-2-enamide) found it necessary to cleave the 
toluenesulfonyl group from tert-butyl-7V-(8-hydroxy-5-(4-toluenesulfonyl)-5-azaoctyl)- 
carbamate. They chose to cleave the toluenesulfonamide electrolytically although they 
did not give any explanation for their choice of method. The controlled potential 
electrolysis of the /er/-butyl-vV-(8-hydroxy-5-(4-toluenesulfonyl)-5-azaoctyl)-carbamate 
was carried out by the authors according to a procedure by Goulaouic-Dubois et a l.3n 
and the desired product, tert-butyl-A-(4-((3-hydroxypropyl)-amino)-butyl)-carbamate was 
obtained in 98 % yield (Scheme 58).
322
98%
 ~  h o ^ - ^ n ^ ^ NHB0C
Me4N*d-, BOH, H
controlled potential 
electrolysis
Scheme 58. -  Deprotection of ter/-butyl-A-(8-hydroxy-5-(4-toluenesulfonyl)-5- 
azaoctyl)-carbamate by electrochemical reduction (Bigler et al. 3n).
Pt foil anode
>
Anolvte
P c to n ltO f 'O '/
Cclvonot'o i
B
-
- J r
Reference electrode
Nitrogen bubbler 
Cathode
Catholvte
Mercury pool
Figure 8 . -  Depiction o f preparative electrochemical cell used by Roemmele & 
Rapoport 30 5 for the removal of A-arylsulfonyl groups from hydroxy-a-amino acids. 
Anolyte: 0.1 M tetraethylammonium bromide in acetonitrile. Catholyte: N- 
arylsulfonamide and 300 mol % phenol in 0.1 M tetraethylammonium bromide in 
acetonitrile. Cathode: 18-gauge copper wire. Reference electrode: IBM Model 8635246 
electrode, Ag/0.1 M AgNCVCthCN. A -  Princeton Applied Research Model 173 
potentiostat/galvanostat. B -  Fisher-Porter Solv-Seal joint fitted with medium porosity 
glass frit.
The excellent yield obtained by Bigler et al. 311 for their electrochemical 
deprotection suggested that controlled potential electrolysis might be a viable alternative 
for the deprotection of compounds (34), (36), (38) and (41). It was decided that the
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procedure of the aforementioned authors should be attempted first, as this was the only 
procedure in which a toluenesulfonamide bearing a Boc group on another nitrogen atom 
had been deprotected. For the purpose of carrying out preparative electrochemical 
reduction it was necessary to design and set up a three-electrode, divided electrochemical 
cell of suitable dimensions. Bigler et al. 311 had described the electrochemical cell they 
had used but no illustration was provided of the cell and so for the purpose of designing 
the cell, the diagram of the electrochemical cell used by Roemmele & Rapoport 3 05 was 
referred to (Fig. 8 ).
Stainless 
steel ai
Anolyte
Fotentiostat
Argon
Bubbler
Reference electrode 
H g/H gd2
Catholyte
Mercury pool
Porosity # 4  g lass frit
Figure 9. -  Electrochemical cell designed for preparative electrochemical 
reduction of toluenesulfonamides.
The electrochemical cell that was made was dissimilar to that used by Roemmele 
& Rapoport 3 05 in that the two chambers were separated by a porosity #4 frit (fine), and a 
tap was fitted to the bottom of the anolyte chamber. The cell was also a one-piece
construction rather than two-piece linked at the glass frit joint (as in Fig. 8). Furthermore 
in place of the silver (0)/silver (I) IBM electrode, a mercury (0)/mercury (II) chloride 
electrode was employed as the reference electrode, a stainless steel tube (surface area ~ 
60 cm2) was used as the anode and a platinum electrode in a mercury pool (surface area ~ 
20 cm ) was used as the cathode. The approximate volume of each chamber of 
electrochemical cell was ~ 250 cm3 (see Fig. 9 for illustration of cell) and de­
oxygenation/mixing of the catholyte was achieved by running a continuous stream of 
argon through the catholyte.
In order not to waste compounds (34), (36), (38) and (41), the preparation of 
which required several steps, electrochemical reduction using the apparatus illustrated 
above (Fig. 9) was initially attempted on 7V,Af-diethyl-/?-toluenesulfonamide. This was 
easily prepared by adding a 2.5-fold excess of diethylamine to a solution ofp- 
toluenesulfonyl chloride in dichloromethane and then after 24 hours working-up the 
reaction with saturated aqueous sodium carbonate. Using TV, N-diethyl-/?- 
toluenesulfonamide as the starting material, the electrochemical reduction conditions 
were gradually optimised until complete reduction of the starting material was observed. 
The advantages of using jV,jV-diethyl-/?-toluenesulfonamide as the starting material were 
that the reduction reaction was easily followed by TLC and the volatility of the 
diethylamine produced meant that by holding a piece of damp universal indicator paper 
above the reaction, it was possible to determine that reduction was taking place.
\  TEABi MeCN, Phenol, 
73 % \  Bectrolysis-2.5 V
Scheme 59. -  Electrochemical deprotection of N, A M ns-^S^-am ino^-tert- 
butyldiphenylsilyloxy^-methylbutyO-p-toluenesulfonamide by Schmidtchen et al. 307.
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Initially electrochemical reduction of A, 7V-diethyl-/?-toluenesulfonamide was 
attempted under the conditions described by Bigler et al. 311 (tetramethylammonium 
chloride in ethanol). After many attempts to adjust various parameters using these 
conditions, still no electrochemical reduction could be observed to be taking place. 
Electrochemical reduction was also attempted according to the procedures of Cottrell & 
Mann 303, Kurzmeier & Schmidtchen 306, Waelchli et al. 308, Fiedler et al. 309 and 
Goulaouic-Dubois et al. 312 but all proved unsuccessful. Finally the electrochemical 
reduction of N, A-diethyl-p-toluenesulfonamide was attempted according to the procedure 
described by Roemmele & Rapoport 305, which was very similar to the procedure 
described by Schmidtchen et al. 307. Although Roemmele & Rapoport 305 employed 
electrochemical reduction to cleave a 1° arylsulfonamide (A-arylsulfonyl-threonine), 
Schmidtchen et al. on the other hand employed electrochemical reduction to cleave the 
2° arylsulfonamide of A,A-bis-((3S)-3-amino-4-ter/-butyldiphenylsilyloxy-3- 
methylbutyl)-/?-toluenesulfonamide (Scheme 59).
By trial and error, the electrochemical deprotection of N,A-diethyl-/?- 
toluenesulfonamide was eventually achieved under conditions that were very similar to 
those described by the aforementioned authors. The reduction reaction was found to 
proceed optimally in a catholyte 0.01 M solution of tetraethylammonium bromide in 
acetonitrile. The same solution was used in the anodic chamber but additional 
tetraethylammonium bromide had to be added to this chamber (40 equivalents with 
respect to starting material) in order for the reaction to proceed to completion. Phenol had 
to be added to the cathodic chamber as a proton source (25 equivalents with respect to 
starting material) prior to the addition of the starting material otherwise the reaction 
appeared not to proceed at all. Cyclic voltammetry measurements under these conditions 
revealed that a cathode potential o f -2.45 V with respect to the mercury/mercury chloride 
reference electrode was required in order to effect reduction. As described by 
Schmidtchen et al. 307, a drop and subsequent stabilisation in cell current indicated the 
endpoint of the reaction and TLC of the reaction mixture further confirmed this. 
Deprotection of 5.0 mmol of A^A-diethyl-p-toluenesulfonamide under the conditions 
described and in the apparatus described took approximately 6 hours to reach completion.
Once the conditions/procedure for the electrochemical cleavage of A, A-diethyl-/?- 
toluenesulfonamide had been established, the electrochemical deprotection of compounds 
(34), (36), (38) and (41) was attempted. The first compound to be deprotected under the 
conditions described was (38); following pre-electrolysis of the anolyte solution (40 
equivalents of tetraethylammonium bromide in acetonitrile) and the catholyte solution
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(0.01 M tetraethylammonium bromide in acetonitrile and 25 equivalents of phenol) at 
-2.55 V, (38) was added to the cathodic chamber and electrolysed at -2.45 V. The 
reaction was monitored by TLC and MS as well as by observing the change in current 
with time. However after 12 hours a considerable amount of starting material was 
determined to still be present in the cathodic chamber and so electrolysis was continued. 
Electrolysis had to be continued for 72 hours for all the starting material to be consumed 
(2.32 mmol of (38)). The extended reaction time meant that evaporation of acetonitrile 
from the catholyte and anolyte was quite significant and so in order to minimise this the 
reaction was water-cooled to ~ 8°C by means of a cold-finger in both the anodic and 
cathodic chambers. Once the reaction was complete, the catholyte solution was carefully 
transferred from the cathodic chamber whilst ensuring that the anodic chamber was 
drained at the same rate by means of the fitted tap. This was done in order to prevent the 
solution in the anodic chamber from passing into the cathodic chamber due to hydrostatic 
pressure.
NHBoc  NHBoc
BocHN NHBoc
(38)
r, CH3CN, CgHgOH 
C edrolysis; -2.45 V
NHBoc NHBoc
BocHN NHBoc
Scheme 60. -  Electrochemical deprotection of N,N- bis-(3-(bis-(3-tert- 
butoxycarbonylamino-propyl)-amino)-propyl)-toluenesulfonamide (38).
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Initial attempts to work-up the reaction involved concentrating the cathodic 
solution in vacuo until all the acetonitrile was removed, re-dissolving the remaining solid 
in chloroform and partitioning with saturated sodium carbonate. After column 
chromatography (3-((3-(3-(bis-(3-tert-butoxycarbonylamino-propyl)-amino)- 
propylamino)-propyl)-(3-ter/-butoxycarbonylamino-propyl)-amino)-propyl)-carbamic 
acid ter/-butyl ester (42) was recovered in ~ 45 % yield. The work-up procedure was then 
slightly modified and before concentrating the cathodic solution, saturated aqueous 
sodium carbonate was added. Acetonitrile was then removed under vacuum, chloroform 
was added and the remaining solution was adjusted to pH 12 with solid sodium 
hydroxide. This was found to be effective in almost completely removing phenol from the 
organic layer and retaining it in the aqueous layer as the potassium salt, which 
considerably facilitated extraction of the product. Following purification of the crude 
product by column chromatography (42) was recovered in 66 % (Scheme 60), a 
considerable improvement over the yield obtained following dissolving metal reduction.
Scheme 61. -  Electrochemical deprotection of A,7V-bis-(3-(tert-butoxycarbonyl- 
(3-(ter/-butoxycarbonyl-(3-(/ert-butoxycarbonylamino)-propyl)-amino)-propyl)-amino)- 
propyl)-toluenesulfonamide (34).
(34)
7 6  % B4 N*d‘, q -H pH  MeCN,
Bectrolysis: -2.45 V
(43)
Electrochemical deprotection of (34) (Scheme 61) and (36) (Scheme 62) was 
carried out by the same procedure as for the deprotection of (38). The reactions were
monitored by TLC as well as MS and as for (38), the deprotection of (34) and (36) 
reached completion in 72 hours. (3-ter/-Butoxylcarbonylamino-propyl)-(3-teA7- 
butoxycarbonyl-(3-(3-(ter/-butoxycarbonyl-(3-(ter/-butoxycarbonyl-(3-ter/- 
butoxycarbonylamino-propyl)-amino)-propyl)-amino)-propylamino)-propyl)-amino)- 
propyl)-carbamic acid /er/-butyl ester (43) and (3-(tert-butoxycarbonyl-(3-/er/- 
butoxycarbonylamino-propyl)-amino)-propyl)-(3-/ert-butoxycarbonyl-(3-(3-(ter/- 
butoxycarbonyl-(3-(ter/-butoxycarbonyl-(3-(ter/-butoxycarbonyl-(3-ter/- 
butoxycarbonylamino-propyl)-amino)-propyl)-amino)-propyl)-amino)-propylamino)- 
propyl)-amino)-propyl)-carbamic acid tert-butyl ester (44) were recovered in 76 % and 79 
% respectively. Most importantly and in contrast to dissolving metal reduction, during the 
electrochemical deprotection of (34), (36) and (38) no side-products could be detected 
that were the result of Boc-deprotection.
0=S=0
HNT ^  'N
0 ^ 0x x x x
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X  XJ  O,  0 ^ 0 ,  O '  C>
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(36)
79% B^N+CI-, CgHjOK MeCN, 
Electrolysis: -2.45 V
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0 ^ 0  0 ^ 0 . 0 ^ 0 , 0 ^ 0  X X X X
(44)
Scheme 62. -  Electrochemical deprotection of A^X-bis-(3-(/er/-butoxycarbonyl- 
(3-(ter/-butoxycarbonyl-(3-(ter/-butoxycarbonyl-(3-(ter/-butoxycarbonylamino)-propyl)- 
amino)-propyl)-amino)-propyl)-amino)-propyl)-toluenesulfonamide (36).
The extended duration of the deprotection reactions (72 hours) resulted in some of 
the starting material and/or products diffusing from the cathodic chamber into the anodic 
chamber as detected by MS. This accounted for the yields of (42), (43) and (44) being 
less than 100 % and could not be prevented. Attempts to recover product that had crossed
329
to the anodic chamber proved unsuccessful because of the large amount of 
tetraethylammonium bromide present in the anolyte, which complicated the extraction 
process. The only way that this loss could have been minimised would have been to 
design an electrochemical cell in which the surface area of the mercury pool cathode was 
much greater as well as increasing the surface area of the anode correspondingly.
Scheme 63. -  Unsuccessful deprotection of A,A-Bis-(3-(bis-(3-(bis-(3-(ter/- 
butoxycarbonylamino)-propyl)-amino)-propyl)-amino)-propyl)-toluenesulfonamide (41).
Finally the electrochemical deprotection of A,A-bis-(3-(bis-(3-(bis-(3-(ter/- 
butoxycarbonylamino)-propyl)-amino)-propyl)-amino)-propyl)-toluenesulfonamide (41) 
was attempted (Scheme 63). The same method was employed as for the deprotection of 
all the aforementioned p-toluenesulfonamides and the reaction was monitored by TLC 
(disappearance of starting material). Monitoring of the reaction by MS was inconclusive 
as neither the starting material parent ion peak nor the product parent ion peak could be 
observed. Again after 72 hours the complete disappearance of the starting material in the
NHBo cBocHN
NHBocBocHN
2
2
(41)
X B4 N+B“, CHjCN, CbH5OH Bectrolysis; -2.45 V
w
BocHN NHBo c
NHBocBocHN
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catholyte was observed and so electrolysis was terminated and the reaction was worked 
up by the standard procedure. When the crude material recovered following work-up was 
analysed by TLC, multiple products were observed and the desired product could not be 
identified. Separation of the various products by column chromatography proved 
impossible because of mixing of close-running compounds and attempts to identify the 
desired product in the fractions recovered from column chromatography was also 
unsuccessful. Due to a lack of time it was not possible to repeat and optimise the 
electrochemical deprotection of compound (41).
BocHN'
BocHN'
N'
(42)
N' NHBoc Br
NHBo c
O 
10  O 
1.15 eq. (14)
55% 2 eq. ^CO j, 0.15 eq. Kl 
DMF, 40°C, 7 days
BocHN'
BocHN'
N' N' N' NHBoc
NHBoc
(20)
O ^O B n
Scheme 64. -  Synthesis of 1 l-(Ar,Ar-bis-(3-(bis-(3-^-butoxycarbonylamino- 
propyl)-amino)-propyl))-aminoundecanoic acid benzyl ester (20).
Following deprotection of the central nitrogen atoms of (34) and (38), the free 
amine functions of (42) and (43) were coupled to benzyl 11-bromoundecanoate (14). In 
both cases, the coupling reactions were only carried out once due to a lack of time and so 
no optimisation of conditions was possible. Compound (42) was the first to be reacted 
with (14); (42), 1.15 equivalents of (14) and anhydrous potassium carbonate were stirred 
in dimethylformamide at 40°C for one week. After one week, removal of 
dimethylformamide was followed by acidification of the reaction with 0.5 M citric acid, 
the purpose of this being to avoid premature base hydrolysis of the benzyl ester. The 
reaction was then adjusted to pH 9 with saturated aqueous sodium hydrogencarbonate and 
then extracted with chloroform. Following column chromatography, 1 l-(A,Ar-bis-(3-(bis-
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(3-ter/-butoxycarbonylamino-propyl)-amino)-propyl))-aminoundecanoic acid benzyl ester 
(20) was recovered in 55 % yield (Scheme 64).
HN N N v  N ^  N ^  N v  NH
L L L H I I I
(43)
O
1.14 eq. (14)
2.3 eq. K^CO^ 0.15 eq. Kl, DMF,
^  0 30°C, no light, 7 days
u
(45)
Scheme 65. -  Synthesis of 1 l-(N,Af-bis-(3-(tert-butoxycarbonyl-(3-(tert- 
butoxycarbonyl-(3-(/cr/-butoxycarbonylamino)-propyl)-amino)-propyl)-amino)-propyl)- 
aminoundecanoic acid benzyl ester (45).
The procedure for the coupling of (43) and (14) was slightly modified from that 
employed for the coupling of (42) and (14). A greater number of equivalents of 
anhydrous potassium carbonate (2.3 equivalents) were added to (43) and (14) in 
dimethylformamide and the reaction was stirred at only 35°C for one week but in the 
absence of light. The work-up procedure was also altered in that after removing 
dimethylformamide under vacuum, saturated aqueous sodium hydrogencarbonate was 
rapidly added, monitoring of the pH of the reaction mixture showing that the pH almost 
rapidly reached pH 9. The aqueous solution was then extracted with chloroform and the 
crude product was purified by column chromatography to give 1 \-(N,N-bis-(3-(tert- 
butoxycarbonyl-(3-(terr-butoxycarbonyl-(3-(tert-butoxycarbonylamino)-propyl)-amino)- 
propyl)-amino)-propyl)-aminoundecanoic acid benzyl ester (45) in 94 % yield (Scheme
65).
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Cleavage of the benzyl esters of (20) (from (42)) and (45) was not possible due to 
a lack of time. However a procedure for the cleavage of the benzyl ester of (20) (from 
(15)) had already been previously established and it was envisaged that the same 
procedure would have been suitable for the deprotection of (45). Likewise coupling of 
(44) to (14) was also not possible due to a lack of time.
3.2.4 Conclusions.
Attempts to synthesise polypropylenimine carboxylic acids were met with 
reasonable success. Although only one polypropylenimine carboxylic acid was finally 
incorporated into an integrin-targeting peptide, in effect synthetic routes to several other 
polypropylenimine carboxylic acids were established which could then be easily 
incorporated into integrin-targeting peptides. Furthermore it was demonstrated during the 
synthesis of some of the polypropylenimine carboxylic acid benzyl esters that indeed Boc 
protecting groups are not stable to the conditions employed for dissolving metal 
reduction. An alternative method for deprotecting toluenesulfonamides was ultimately 
employed which was confirmed to be suitable for use in the presence of multiple Boc 
groups.
3.3 Reagents
Acrylonitrile -  purchased from Acros™ and distilled to remove stabiliser. 
7V-3-Aminopropyl-l,3-propanediamine -  purchased from Aldrich™ and used direct. 
Ammonia -  distilled from sodium metal immediately prior to use i.e. directly into 
reaction.
Ammonium chloride - purchased from Aldrich™ and used direct.
Aqueous ammonia 33 % - purchased from BDH™ and used direct.
0-(7-AzabenzotriazoI-l-yl)-l,l>3,3-tetramethyluronium hexafluorophosphate -
purchased from Aldrich™ stored at 0°C and used direct.
2-(lH-Benzotriazol-l-yl)-l,l>3,3-tetramethyluronium tetraf]uorofoorate _ purchased 
from Applied Biosystems™ and used direct.
Benzyl alcohol - purchased from Aldrich™ and used direct.
Benzyl bromide/chloride - purchased from Avocado™ and used direct.
Benzyl chloroformate - purchased from Avocado™ and used direct.
Borane dimethylsulphide - purchased from Acros™ and used direct. 
6-Bromohexanoic acid -  purchased from Avocado™ and used direct. 
11-Bromoundecanoic acid - purchased from Aldrich™ and used direct.
Celite® - purchased from Lancaster™ and used direct.
A^V-dicyclohexylcarbodiimide -  purchased from Avocado™ and used direct. 
Dimethylaminopyridine - purchased from Aldrich™ and used direct. 
A,A-Diisopropylethylamine - purchased from Aldrich™ as anhydrous and used direct. 
Di-terf-butyl dicarbonate -  purchased from Avocado™ and used direct.
Ethyl trifluoroacetate - purchased from Lancaster™ and used direct.
Hydrazine monohydrate - purchased from Aldrich™ and used direct.
Hydrochloric acid -  purchased from BDH™.
1-Hydroxybenzotriazole - purchased from Aldrich™ and used direct.
Phenol - purchased from Aldrich™ and used direct.
Piperidine - purchased from Avocado™, refluxed and distilled from calcium hydride 
before use.
Potassium iodide - purchased from Aldrich™ and used direct.
Raney Nickel 50 % slurry in water - purchased from Acros™ and used direct. 
Tetraethylammonium bromide - purchased from Aldrich™ and used direct. 
Thioanisole - purchased from Aldrich™ and used direct.
4-Toluenesulfonyl chloride - purchased from Avocado™ and used direct.
Triethylamine - purchased from Avocado™, refluxed and distilled from calcium hydride 
before use.
Triethylsilane - purchased from Avocado™ and used direct.
Trifluoroacetic acid - purchased from Avocado™ and used direct.
Sodium metal - purchased from Lancaster™ and used direct.
Sodium hydrogencarbonate, sodium carbonate, potassium carbonate, sodium 
hydroxide, potassium hydroxide, potassium hydrogencarbonate - purchased from 
BDH™.
3.4 Experimental.
(1) Bis-(3-trifluoroacetamidopropyl)-amine.
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To A-3-aminopropy 1-1,3-propanediamine (2.8 ml, 2.62 g, 20 mmol) in ethanol (40 
ml) was slowly added ethyl trifluoroacetate (5.0 ml, 5.97 g, 42 mmol, 2.1 eq.). The 
reaction was left to stir for three days under argon at room temperature. After three days, 
the reaction was concentrated in vacuo and then dissolved in ethyl acetate (150 ml). The 
organic solution was partitioned with sat. aq. NaHC0 3 (100 ml) and sat. aq. NaCl (100 
ml). The organic solution was then dried over anhydrous sodium sulphate and 
concentrated in vacuo to yield 6.46 g (100 %) of a white solid that required no further 
purification.
MP: 167-169°C (L it.381: 168-170°C).
'HNM R(CDC13) 5: 1.41 (lH ,b s , -NH-), 1.73 (4H, qn, 7 = 6 .2  Hz, 7  = 6.2 Hz, 
(CF3 OCNCH2 CH2 CH2 )2N), 2.72 (4H, t, 7  = 6.2 Hz, (CF3OCNCH2 CH2 CH2 )2N), 3.45 (4H, 
m, (CF3 OCNCH2 CH2 CH2 )2N), 8.12 (2H, bs, -NH-).
13C NMR (DMSO) 6 : 28.51 (2C, (CF3OCNCH2CH2 CH2 )2N), 38.08 (2C, 
(CF3 OCNCH2 CH2CH2 )2N), 46.84 (2C, CF3 OCNCH2CH2CH2 )2N), 116.33 (2C, JC-f = 288 
Hz, (CF3OCNCH2CH2CH2 )2N), 156.49 (2C, 7c-f = 36 Hz, (CF3 OCNCH2 CH2CH2 )2N).
IR v/cm ' 1 (NaCl): 3331 (st., N-H stretch), 2951 (st., C-H stretch), 1667 (st., amide 
C =0 stretch), 1554 (st., 2° amide N-H bend), 1483 (med., C-H deformation), 1389 (med., 
amide C-N stretch), 1241, 1132 (st., C-N stretch & amide C -0 stretch).
MS m/z (+ve FAB): 324 (M+H+, 99 %), 228 ([C8H 17ON3F3]+, 27 %), 154 
([C6H 17N 3 ]+Na+, 43 %).
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HRMS (FAB, NOB A matrix): Measured mass -  324.1139. Actual mass for M+H+ 
-324.1147.
(2) 14-Dimethylethyl-AyV-bis-(3-((trifluoroacetyl)- 
amino)-propyl)-carbamate.262
To bis-(3-trifluoroacetamidopropyl)amine (1) (6.47 g, 20 mmol) and triethylamine 
(2.78 ml, 2.02 g, 20 mmol) under argon, in dry dichloromethane (100 ml) was added di- 
tert-butyl dicarbonate (4.80 g, 22.0 mmol). The reaction was left to stir at room 
temperature for 48 hours. After 48 hours, the reaction was partitioned with sat. aq. 
NaHCOs (100 ml) and then sat. aq. NaCl (100 ml). The aqueous phases were back- 
extracted with dichloromethane (100 ml), the organic phases were combined, dried over 
anhydrous sodium sulphate and concentrated in vacuo. The product recovered, initially an 
oil, became 8.03 g of a white solid (95 %) after several hours under high vacuum. The 
product required no further purification.
MP: 96-98°C (Lit.381: 96-98°C).
'H NMR (CDC13) 5: 1.48 (9H, s, Boc), 1.77 (4H, m, 
(CF3OCNCH2CH2CH2)2NBoc), 3.27-3.57 (8H, m, (CF3OCNCH2CH2CH2)2NBoc).
13C NMR (CDC13) 5: 27.93 (2C, (CF3OCNCH2CH2CH2 )2NBoc), 28.65 (3C, 
(CF30CNCH2CH2CH2)2NC02C(CH3)3), 36.88 (2C, (CF3OCNCH2CH2CH2 )2NBoc), 
44.52 (2C, CF3OCNCH2CH2CH2)2NBoc), 81.43 (1C, 
(CF30CNCH2CH2CH2)2NC02C(CH3)3), 116.32 (2C, JC-f = 288 Hz, 
(CF3OCNCH2CH2CH2)2NBoc), 157.09 (1C, (CF30CNCH2CH2CH2)2NC02C(CH3)3), 
157.82 (2C, J c-F = 36 Hz, (CF3OCNCH2CH2CH2 )2NBoc).
O O
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IR v /cm"1 (NaCl): 3323 (med., N-H stretch), 2957 (st., C-H stretch), 1714 (st., 
carbamate C =0 stretch), 1662 (st., amide C =0 stretch), 1556 (st., 2° amide N-H bend), 
1483 (med., C-H deformation), 1366 (med., tert-butyl C-H stretch), 1238, 1150 (st., C -0  
& C-N stretch & amide C -0  stretch).
MS m/z (+ve ES): 446 (M +N a\ 40 %), 324 ( [ Q o H ^ ^ F e f ,  100 %). HRMS 
(FAB, NOB A matrix): Measured mass -  424.1679. Actual mass for M+H+ - 424.1671.
(3) l,l-Dimethylethyl-AyV-bis-(3-aminopropyl)- 
carbamate.262
1,1 -Dimethylethyl-A,A-bis-(3-((trifluoroacetyl)-amino)-propyl)-carbamate (2)
(8.0 g, 18.9 mmol) was dissolved in methanol (40 ml) and to this was added aqueous 
ammonia (33 % v/v, 20 ml). This reaction mixture was heated to 60°C in a sealed reaction 
vessel for 20 hours. After 20 hours the reaction was concentrated in vacuo to remove the 
methanol. The remaining aqueous solution was adjusted to pH 12 with sodium hydroxide. 
The aqueous solution was then partitioned with dichloromethane (8 x 40 ml). The organic 
fractions were combined, dried over anhydrous sodium sulphate and concentrated in 
vacuo to yield 4.23 g (97 %) o f a viscous oil. The oil required no further purification.
*H NMR (DMSO) 6: 1.43 (9H, s, Boc), 1.56 (4H, m, Jm.m = 6.6 Hz, J H 2- h i  = 7.1 
Hz, (H2NCH2CH2 CH2 )2NBoc), 2.54 (4H, t, J =  6.6 Hz, (H2NCH2 CH2CH2 )2NBoc), 3.19 
(4H, t, J =  7.1 Hz, (H2NCH 2 CH2CH2 )2NBoc).
13C NMR (DMSO) 6: 28.65 (3C, (H2NCH2CH2CH2)2NC02C(CH3)3), 32.99 
((H2NCH2CH2CH2)2NBoc), 39.69 ((H zN C ^C ^C H z^N B oc), 44.68 
((H2NCH2CH2CH2)2NBoc), 78.67 (1C, (H2NCH2CH2CH2)2NC02C(CH3)3), 155.36 (1C, 
(H2NCH2CH2CH2)2NC02C(CH3)3).
O ^ OY
NH
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IR v /cm'1 (NaCl): 3369, 3300 (med., N-H stretch), 2932 (st., C-H stretch), 1682 
(st., C=0 stretch), 1479 (med., C-H deformation), 1366 (med., /er/-butyl C-H stretch), 
1250, 1165 (st., C-0 & C-N stretch).
MS m/z (+ve ES): 232 (M+H+, 52 %), 132 ([C6H18N3]+, 100 %).
HRMS (+ve Cl): Measured mass -  232.2029. Actual mass for M+H+ - 232.2024.
(4) lJ-Dimethylethyl-A^-bis-O-^-cyanoethylamino)- 
propyl)-carbamate.262
To l,l-dimethylethyl-A/A-bis-(3-aminopropyl)-carbamate (3) (8.30 g, 36 mmol) 
and anhydrous potassium carbonate (5.53 g, 40 mmol) in dry acetonitrile (150 ml) was 
added acrylonitrile (4.98 ml, 4.01 g, 75.6 mmol, 2.1 eq.). The reaction mixture was heated 
to 55°C under argon and in complete darkness for 24 hours. After 24 hours, the reaction 
was concentrated in vacuo and then dissolved in water (200 ml). The aqueous phase was 
partitioned with dichloromethane (1 x 100 ml). The organic fractions were combined and 
partitioned with a solution made up of sat. aq. NaHC03 (150 ml). The aqueous phase was 
back-extracted with dichloromethane (150 ml), the organic phases were combined, dried 
over anhydrous sodium sulphate and concentrated in vacuo to give 9.67 g (80 %) of a 
viscous yellow oil. The product required no further purification.
!H NMR (C6D5CD3) 5: 0.85 (2H, bs, -NH-), 1.43-1.51 (13H, m, 
(NCCH2CH2HNCH2CH2CH2)2NC02C(CH3)3), 1.76 (4H, t, J = 6.6 Hz, 
(NCCH2CH2HNCH2CH2 CH2 )2NBoc), 2.26-2.33 (8H, 2 x t, J =  6.7 Hz & J = 6.6 Hz, 
(NCCH2CH2HNCH2CH2CH2)2NBoc), 3.13 (4H, m,
(NCCH2CH2HNCH2CH2CH2)2NBoc).
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13C NMR (C6D5CD3) 5: 18.85 ((NCCH2CH2HN(CH2)3)2NBoc), 28.88 (3C, 
(NC(CH2)2HN(CH2)3)2N C02C(CH3)3), 29.54 ((NC(CH2)2HNCH2CH2CH2)2NBoc),
45.48, 45.73, 46.79 (6C, (NCCH2CH2HNCH2CH2CH2)2NBoc), 79.19 (1C, 
(NC(CH2)2HN(CH2)3)2N C02C(CH3)3), 119.01 ((NC(CH2)2HN(CH2)3)2NBoc), 155.96 
(1C,(NC(CH2)2HN(CH2)3)2NC02C(CH3)3).
IR v /cm'1 (NaCl): 3315 (med., N-H stretch), 2932, 2835 (st., C-H stretch), 2247 
(wk., C=N stretch), 1682 (st., C=0 stretch), 1479 (med., C-H deformation), 1366 (med., 
tert-b\ity\ C-H stretch), 1248, 1171 (st., C-0 & C-N stretch).
MS m/z (+ve ES): 360 (M+Na+, 4 %), 338 (M+H+, 95 %), 238 ([Ci2H24N5]+, 100
%).
HRMS (FAB, NOBA matrix): Measured mass -  338.2550. Actual mass for M+H+ 
- 338.2556.
(5) l,l-Dimethylethyl-N,N-bis-(3,3-bis-(2- 
cyanoethylamino)-propyl)-carbamate.
To l,l-dimethylethyl-7V,A-bis-(3-aminopropyl)-carbamate (3) (9.24 g, 40.0 mmol) 
and potassium carbonate (11.06 g, 80.0 mmol) in water/acetonitrile (250 ml, 3:2) was 
added acrylonitrile (65.83 ml, 53.06 g, 1.0 mol). The reaction was heated to 55°C for 24 
hours under argon with very vigorous stirring. After 24 hours, the reaction was 
concentrated in vacuo until only the aqueous solution remained. The aqueous solution 
was partitioned with dichloromethane (3 x 150 ml). The organic fractions were combined, 
partitioned with sat. aq. NaCl adjusted to pH 9 with sodium hydrogencarbonate, dried
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over anhydrous sodium sulphate and concentrated in vacuo to give an oil. The product 
was purified by N.P.S.G. chromatography eluting initially with diethyl ether only and 
then gradually changing to ethyl acetate only to yield 15.3 g (86.3 %) of a pale yellow oil.
'H NMR (CD2C12/500MHz) 6: 1.43 (9H, s,
((NC(CH2)2)2N(CH2)3)2N C02C(CH3)3), 1.68 (4H, qn, J = 7.0 Hz, J =  7.1 Hz, 
((NC(CH2)2)2NCH2CH2 CH2)2NBoc), 2.47 (8H, t, J =  6.7 Hz, 
((NCCH2CH2)2N(CH2)3)2NBoc), 2.51 (4H, t, J =  7.0 Hz, 
(NC(CH2)2)2NCH2 CH2CH2)2NBoc), 2.81 (8H, t, J =  6.7 Hz, 
((NCCH2CH2 )2N(CH2)3)2NBoc), 3.22 (4H, m, ((NC(CH2)2)2NCH2CH2CH2 )2NBoc).
13C NMR (CD2C12/500MHz) 5: 17.56 (((NCCH2CH2)2N(CH2)3)2NBoc), 26.67 
(((NC(CH2)2)2NCH2CH2CH2)2NBoc), 28.50 (3C, ((NC(CH2)2)2N(CH2)3)2N C02C(CH3)3), 
45.66 (((NC(CH2)2)2NCH2CH2CH2)2NBoc), 49.73 (4C, ((NCCH2CH2)2N(CH2)3)2NBoc),
51.09 ((NC(CH2)2)2NCH2CH2CH2)2NBoc), 79.32 (1C,
((NC(CH2)2)2N(CH2)3)2N C 02C(CH3)3), 119.17 (((NC(CH2)2)2N(CH2)3)2NBoc), 155.60 
(1C, ((NC(CH2)2)2N(CH2)3)2N C 02C(CH3)3).
IR v /cm'1 (NaCl): 2937, 2837 (st., C-H stretch), 2249 (wk., C=N stretch), 1682 
(st., C=0 stretch), 1470 (med., C-H deformation), 1366 (med., tert-butyl C-H stretch), 
1248, 1159 (st., C-0 & C-N stretch).
MS m/z (+ve ES): 482 (M+K+, 80 %), 466 (M+Na+, 18 %), 444 (M+H+, 99 %), 
344 ([C18H30N7]+, 20 %).
HRMS (+ve ESI): Measured mass -  466.2905. Actual mass for M+Na+ - 
466.2900.
341
(6) l,l-Dimethylethyl-Ar,Ar-bis-(3-(3-aminopropyl)-
262aminopropyl)-carbamate.
l,l-Dimethylethyl-/V,A-bis-(3-(2-cyanoethylamino)-propyl)-carbamate (4) (7.16 
g, 21.2 mmol) was dissolved in methanol (40 ml). This solution was saturated with 
ammonia and then Raney Nickel (50 % w/w, 3 ml) was added. The reaction was treated 
in a Parr hydrogenator with hydrogen gas at 180 psi. at 50°C for five days. After five 
days, the reaction was filtered through a bed of Celite® and the filtrate was concentrated 
in vacuo to give 6.50 g (90.7 %) of a viscous yellow oil. The product could not be 
isolated, as separation from contaminants was not possible.
'H NMR (CDC13) 6 : 1.38-1.43 (15H, m, (H2N(CH2)3HN(CH2)3)2NC02 C(CH3)3), 
1.54-1.65 (8 H, m, (^NCHzCHzC^HNCHzCHzOH^NBoc), 2.52, 2.59 (8 H, 2 x m, 
(H2NCH2 CH2 CH2HNCH2 CH2 CH2 )2NBoc), 2.71 (2H, m, 
(H2NCH2 CH2 CH2HNCH2 CH2 CH2 )2NBoc), 3.17 (4H, m, 
(H2N(CH2)3HNCH2CH2CH2)2NBoc).
13C NMR (CDCI3 ) 6 : 28.79 (3C, (H2N(CH2)3HN(CH2)3)2NC02C(CH3)3), 29.44 
((H2NCH2 CH2CH2 HNCH2CH2 CH2 )2NBoc), 34.11
((H2NCH2CH2CH2HNCH2 CH2 CH2 )2NBoc), 40.85 ((H2NCH2(CH2 )2HN(CH2 )3 )2NBoc), 
45.16 ((H2NCH2 CH2 CH2 HNCH2 CH2 CH2 )2NBoc), 47.61, 48.24 (4C, 
(H2NCH2 CH2CH2HNCH2 CH2 CH2 )2NBoc), 79.59 (1C, 
(H2N(CH2)3HN(CH2)3)2NC02C(CH3)3), 156.03 (1C, 
( H 2N (C H 2 )3 H N (C H 2 )3 )2 N C 0 2 C (C H 3)3).
IR v /cm ' 1 (NaCl): 3296 (med., N-H stretch), 2930, 2864 (st., C-H stretch), 1686 
(st., C=0 stretch), 1479 (med., C-H deformation), 1366 (med., tert-butyl C-H stretch), 
1248, 1169 (st., C-O & C-N stretch).
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MS m/z (+ve ES): 346 (M+H+, 99 %), 246 ([Ci7H39N5]+, 16 %).
HRMS (+ve ES): Measured mass -  346.3181. Actual mass for M+H+ - 346.3176.
(7) l,l-Dimethylethyl-N9N-bis-(393-bis-(3-aminopropyl)- 
aminopropyl)-carbamate.
1,1 -Dimethylethyl-A,Ar-bis-(3,3-bis-(2-cyanoethylamino)-propyl)-carbamate (5) 
(6.10 g, 13.77 mmol) was dissolved in methanol (40 ml). This solution was saturated with 
ammonia and then Raney Nickel (50 % w/w, 3 ml) was added. The reaction was treated 
with hydrogen gas at 180 psi. at 50°C for five days. After five days, the reaction was 
filtered through a bed of Celite® and the filtrate was concentrated in vacuo to give 5.10 g 
(84 % mass recovery) of a viscous yellow oil. The product could not be isolated, as 
separation from contaminants was not possible.
lH NMR (DMSO) 6 : 1.42-1.70 (29H, m, 
((H2NCH2CH2CH2)2NCH2CH2 CH2)2NC02C(CH3)3), 2.32-2.43 (12H, m, 
((H2NCH2 CH2 CH2 )2NCH2 CH2 CH2 )2NBoc), 2.57 (8 H, m, 
((H2NCH2 CH2 CH2)2NCH2 CH2 CH2 )2NBoc), 3.15 (4H, m, 
((H2N(CH2 )3 )2NCH2 CH2 CH2 )2NB0 C).
13C NMR (DMSO) 5: 26.36, 26.65 (((HzNCJ^C^CHzhNCHzO^Cf^N Boc),
29.10 (3C, ((H2N(CH2)3)2N(CH2)3)2NC02C(CH3)3), 31.70 (4C, 
((H2NCH2CH2 CH2)2NCH2 CH2 CH2 )2NBoc), 41.04 (4C,
((H2NCH2 (CH2 )2)2N(CH2 )3 )2NBoc), 46.12 (((H2NCH2 CH2 CH2 )2NCH2 CH2 CH2 )2NBoc), 
51.97 (((H2NCH2 CH2 CH2 )2NCH2 CH2 CH2)2NBoc), 52.23 (4C, 
((H2NCH2 CH2 CH2 )2NCH2 CH2 CH2 )2NBoc), 79.03 (1C, 
((H2N(CH2)3)2N(CH2)3)2NC02C(CH3 )3), 155.52 ( 1 C, 
((H2N(CH2)3)2N(CH2)3)2NC02 C(CH3)3).
NH
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IR v /cm'1 (NaCl): 3290 (med., N-H stretch), 2932, 2804 (st., C-H stretch), 1693, 
1682 (st., C=0 stretch), 1470 (med., C-H deformation), 1366 (med., tert-butyl C-H 
stretch), 1250, 1165 (st., C-0 & C-N stretch).
MS m/z (+ve FAB): 460 (M+H+, 52 %), 360 ([Ci8H4 6N7]+, 14 %).
HRMS (+ve ESI): Measured mass -  460.4335. Actual mass for M+H+ - 460.4333.
(8) 7,7 -Dimethylethyl-N,N-bis-(3-(benzyl-(3- 
(dibenzylamino)-propyl)-amino)-propyl)-carbamate.
To 1,1-dimethylethyl-A,A-bis-(3-(3-aminopropyl)-aminopropyl)-carbamate (6) 
(1.036 g, 3.0 mmol) in ethanol (50 ml) was added benzyl bromide (2.85 ml, 4.10 g, 24.0 
mmol, 8eq.) and potassium hydroxide (1.68 g, 30.0 mmol, 10eq.). The reaction was left to 
stir for 48 hours at room temperature under argon.
After 48 hours a further quantity of benzyl bromide (2.85 ml, 4.10 g, 24.0 mmol, 
8eq.) and potassium hydroxide (1.68 g, 30.0 mmol, lOeq.) were added. The reaction was 
again left to stir at room temperature under argon.
After 4 days a further quantity of benzyl bromide (2.85 ml, 4.10 g, 24.0 mmol, 
8eq.) and potassium hydroxide (1.68 g, 30.0 mmol, lOeq.) were added. The reaction was 
again left to stir at room temperature under argon.
After 6 days a further quantity of benzyl bromide (2.85 ml, 4.10 g, 24.0 mmol, 
8eq.) and potassium hydroxide (1.68 g, 30.0 mmol, lOeq.) were added. The reaction was 
again left to stir at room temperature under argon.
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After a total of 8 days the reaction was concentrated in vacuo and then re­
dissolved in water (150 ml). The aqueous solution was partitioned three times with 
dichloromethane (3 x 150 ml). The organic fractions were then combined and partitioned 
with sat. aq. NaCl adjusted to pH 9 with NaHCC>3 , dried over anhydrous sodium sulphate 
and concentrated in vacuo to give a brown oil. The product was partially purified by 
N.P.S.G. chromatography eluting with ethyl acetate only to give a pale orange oil. This 
oil was further purified by N.P.S.G. chromatography, eluting with diethyl ether only to 
give 1.32 g (49.6 %) of the desired product.
'H NMR (CDC13) 5: 1.43 (9H, s, -C(CH3)3), 1.63 (4H, m, 
((C6H5CH2)2N(CH2)3(C6H5CH2)NCH2CH2CH2)2NBoc), 1.69 (4H, m, 
((C6H5CH2)2NCH2CH2CH2(C6H5CH2)N(CH2)3)2NBoc), 2.34-2.46 (12H, m, 
((C6H5CH2)2NCH2CH2CH2(C6H5CH2)NCH2CH2CH2)2NBoc), 3.06 (4H, m, 
((C6H5CH2 )2N(CH2 )3 (C6H5CH2 )NCH2CH2CH2 )2NBoc), 3.51 (4H, s, 
((C6H5CH2 )2N(CH2 )3 (C6H5CH2)N(CH2)3 )2NBoc), 3.54 (8H, s, 
((C6H5CH2 )2N(CH2 )3 (C6 H5 CH2 )N(CH2 )3 )2NBoc), 7.16-7.38 (30H, m, benzyl).
13C NMR (CDCI3 ) 5: 24.95 
(((C6H5CH2)2NCH2CH2CH2(C6H5CH2)N(CH2)3)2NBoc), 26.64 (2C, 
((C 6 H 5 C H 2 )2 N (C H 2 )3 (C 6 H 5C H 2 )N C H 2 C H 2 C H 2 )2 N B o c ) , 28.92 (3C, -C(CH3)3), 46.05 
( ( ( C 6H 5C H 2)2N ( C H 2) 3( C 6H 5C H 2 ) N C H 2C H 2C H 2) 2N B o c ) ,  51.90, 52.19, 52.50 (6C, 
((C6H5CH2)2NCH2CH2CH2(C6H5CH2)NCH2CH2CH2)2NBoc), 58.81 (4C, 
( ( C 6H 5C H 2) 2N ( C H 2) 3( C 6H 5C H 2) N ( C H 2) 3) 2N B o c ) ,  59.03
(((C 6 H 5 C H 2 )2 N (C H 2 )3 (C 6 H 5C H 2 )N (C H 2 )3 )2 N B o c ) , 79.36 (1C, -C(CH3)3), 127.14, 128.64, 
129.18, 140.27 (36C, benzyl), 155.86 (1C, Boc C=0).
IR v /cm'1 (NaCl): 3084, 3061, 3026 (med., aromatic C-H stretch), 2940, 2798 (st., 
aliphatic C-H stretch), 1947, 1869, 1807 (wk., aromatic overtone bands), 1685 (vst., C=0 
stretch), 1452, 1417 (med., C-H deformation), 1366 (med., tert-butyl C-H stretch), 1247, 
1218, 1155 (med., C-0 & C-N stretch), 755 (vst., aromatic C-H bend).
MS m/z (+ve FAB): 887 (M+H+, 5 %), 795 ( ^ ^ O z N s f ,  4 %), 91 ([C7H7]+, 99 
%), 57 ([C4H9]+, 11 %).
HRMS (+ve ESI): Measured mass -  886.5980. Actual mass for M+H+ - 886.5993.
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(9) l,l-Dimethylethyl-N,N-bis-(3-(benzyloxycarbonyl-(2- 
cyanoethyl)amino)-propyl)-carbamate.
To l,l-dimethylethyl-7V,ALbis-(3-(2-cyanoethylamino)-propyl)-carbamate (4) (6.0 
g, 17.8 mmol) and sodium hydrogencarbonate (5.98 g, 71.2 mmol, 4 eq.) stirring in 
water/dioxane (80 ml, 1:1) at 0°C was added slowly benzyl chloroformate (7.63 ml, 9.11 
g, 53.4 mmol, 3 eq.) in dioxane (40 ml). Once addition was complete the reaction was left 
to warm to room temperature.
After 24 hours, the reaction was concentrated in vacuo to remove dioxane. The 
remaining aqueous phase was partitioned twice with dichloromethane (2 xlOO ml). The 
organic fractions were combined, dried over anhydrous sodium sulphate and concentrated 
in vacuo to give a yellow oil. The product was purified by N.P.S.G. chromatography 
eluting with diethyl ether only to yield 9.50 g (88.0 %) of a yellow oil.
*H NMR (CDC13) 5: 1.42 (9H, s, 
(NC(CH2)2(C6H5 CH202C)N(CH2)3)2NC02C(CH3)3), 1.72 (4H, m, 
(NC(CH2)2(C6H5CH202C)NCH2CH2CH2)2NBoc), 2.57 (4H, m, 
(NCCH2 CH2(C6H5CH202C)N(CH2)3)2NBoc), 3.11 (4H, m, 
(NC(CH2)2(C6H5CH202C)NCH2CH2CH2)2NBoc), 3.29 (4H, m, 
(NC(CH2)2(C6H5CH2 0 2 C)NCH2 CH2 CH2)2NBoc), 3.49 (4H, t, J = 6.9 Hz, 
(NCCH2CH2 (C6 H5CH2 0 2 C)N(CH2 )3 )2NBoc), 5.12 (4H, s, 
(NC(CH2)2(C6H5CH202C)N(CH2)3 )2NBoc), 7.34 (10H, m, 
(NC(CH2)2(C6H5CH2 0 2 C)N(CH2 )3 )2NB0 C).
13C NMR (CDCI3 ) 6 : 17.33, 17.96 ((NCCHzCHztCeHsC^C^CMCHz^NBoc), 
28.15 ((NC(CH2 )2 (C6H5 CH2 0 2 C)NCH2 CH2 CH2)2NBoc), 28.64 (3C, -C(CH3)3), 44.96 
(4C, (NCCH2CH2(C6H5 CH202C)NCH2CH2CH2)2NBoc), 46.64
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((NC(CH2)2(C6H5CH202C)NCH2CH2CH2)2NBoc), 67.88 
((NC(CH2)2(C6H5CH202C)N(CH2)3)2NBoc), 80.08 (1C, -C(CH3)3), 118.79 
((NC(CH2)2(C6H5CH202C)N(CH2)3)2NBoc), 128.32, 128.51, 128.91, 136.51 (12C, 
(NC(CH2)2(C6H5CH202C)N(CH2)3)2NBoc), 155.64 (1C, Boc & Cbz C=0).
IR v /cm'1 (NaCl): 3089, 3064, 3032 (wk., aryl-H stretch), 2972 (st., C-H stretch), 
2249 (wk., C=N stretch), 1683 (st., C=0 stretch), 1495 (med., C-H deformation), 1366 
(med., tert-butyl C-H stretch), 1266, 1142 (st., C-O & C-N stretch).
MS m/z (+ve ES): 644 (M +K\ 3 %), 628 (M+Na+, 99 %), 606 (M +H\ 5 %), 506 
([C28H360 4N5]+, 38 %).
HRMS (+ve ESI): Measured mass -  628.3113. Actual mass for M+Na+ - 
628.3105.
(10) Bis-(3,3-bis-(2-cyanoethylamino)-propyl)-amine.
N N
To 1,1 -dimethylethyl-TV, /V-bis-(3,3-bis-(2-cyanoethylamino)-propyl)-carbamate 
(5) (2.22 g, 5.0 mmol) was added acetonitrile (40 ml) and triethylsilane (4 ml) followed 
by trifluoroacetic acid (40 ml). The solution was left to stir for 4 hours at room 
temperature.
After 4 hours the reaction was concentrated in vacuo, re-dissolved in toluene and 
once again concentrated in vacuo. The remaining oil was re-dissolved in dichloromethane 
(100 ml). The organic solution was partitioned with sat. aq. NaHC03, the aqueous phase 
being back-extracted twice with dichloromethane (2 x 100 ml). The organic fractions 
were combined, dried over anhydrous sodium sulphate and concentrated in vacuo to give 
a yellow oil. The product was purified by N.P.S.G. chromatography eluting with 
chloroform/methanol/water (12:6:1) to yield 1.55 g (90.0 %) of a colourless oil.
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'H NMR (DMSO) 5: 1.76 (4H, m, J  = 6.7 Hz & 7.6 Hz 
((NC(CH2)2 )2NCH2CH2CH2 )2NH), 2.58 (4H, t, J =  6.7 Hz,
(NC(CH2)2 )2NCH2CH2CH2 )2NH), 2.63 (8H, t , J =  6.4 Hz, ( ( N C C H z C ^ ^ C ^ ^ N H ) ,  
2.77 (8H, t , J =  6.4 Hz, ((NCCH2CH2)2N(CH2 )3 )2NBoc), 2.97 (4H, t , J  = 7.6 Hz, 
((NC(CH2)2)2NCH2CH2CH2)2NBoc).
13C NMR (DMSO) 6: 16.29 (4C, ((NCCH2CH2)2N(CH2)3)2NH), 24.31 
(((NC(CH2)2)2NCH2CH2CH2)2NH), 45.87 ( ( (N Q C ^ ^ N C ^ C ^ C H z ^ N H ), 49.08 (4C, 
((NCCH2CH2)2N(CH2)3)2NH), 50.22 ((N Q C H z^N C H zC ^C ^^N H ), 120.73 
(((NC(CH2)2)2N(CH2)3)2NH).
IR v /cm'1 (NaCl): 2948, 2822 (st., C-H stretch), 2249 (st., C=N stretch), 1464, 
1422 (st., C-H deformation), 1250, 1138, 1038 (st., C-N stretch).
MS m/z (+ve ES): 366 (M +Na\ 3 %), 344 (M+H+, 99 %).
HRMS (+ve ESI): Measured mass -  344.2555. Actual mass for M+H+ - 344.2557.
(11) Bis-(3-(benzyloxycarbonyl-(2-cyanoethyl)-amino)- 
propyl)-amine.
To l,l-dimethylethyl-jV,/V-bis-(3-(benzyloxycarbonyl-(2-cyanoethyl)amino)- 
propyl)-carbamate (9) (6.35 g, 10.49 mmol) in acetonitrile (70 ml) and triethylsilane (8 
ml) was added trifluoroacetic acid (50 ml) over two hours. The solution was left to stir for 
a further 2 hours at room temperature.
After 4 hours the reaction was concentrated in vacuo, re-dissolved in toluene and 
once again concentrated in vacuo. The remaining oil was re-dissolved in dichloromethane
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(100 ml). The organic solution was partitioned with sat. aq. NaHCCh, the aqueous phase 
being back-extracted twice with dichloromethane (2 x 100 ml). The organic fractions 
were combined, dried over anhydrous sodium sulphate and concentrated in vacuo to give 
a yellow oil. After 48 hours under high vacuum 5.30 g (99.1 %) of product was recovered 
which required no further purification.
'H NMR (DMSO) 6: 1.69 (4H, m, (NC(CH2)2(Cbz)NCH2CH2CH2)2NH), 2.55 
(4H, m, (NC(CH2)2(Cbz)NCH2CH2CH2 )2NH), 2.79 (4H, t,J =  6.5 Hz, 
(NCCH2 CH2(Cbz)N(CH2)3 )2NH), 3.36 (4H, t, 6.8 Hz, 
(NC(CH2)2(Cbz)NCH2 CH2CH2 )2NH), 3.55 (4H, t, J =  6.5 Hz,
(NCCH2CH2 (Cbz)N(CH2)3 )2NH), 5.14 (4H, s, ( N Q C H z h ^ H s ^ O z C M C ^ ^ N H ) ,  
7.41 (10H, m, (NC(CH2)2(C6H5CH202C)N(CH2)3)2NH).
I3C NMR (DMSO) 5: 16.10, 16.77 ((NCCH2CH2(Cbz)N(CH2 )3 )2NH), 27.25,
28.12 ((NC(CH2)2 (Cbz)NCH2CH2CH2 )2NH), 42.42, 43.15
((NCCH2CH2(Cbz)N(CH2)3 )2NH), 45.01 ((NC(CH2)2(Cbz)NCH2 CH2CH2 )2NH), 46.06 
((NC(CH2)2 (Cbz)NCH2 CH2CH2 )2NH), 66.41 ((N Q C ^ h ^ H sC ^ O zC M C H z^ h N H ), 
118.96 ((NC(CH2)2(Cbz)N(CH2)3 )2NH), 127.48, 127.79, 128.35, 136.68(120, 
(NC(CH2)2(C6H5CH202C)N(CH2)3)2NBoc), 155.79 (1C, Cbz C=0).
IR v /cm'1 (NaCl): 3324 (wk., N-H stretch), 3033 (wk., aryl-H stretch), 2945 (st., 
C-H stretch), 2249 (wk., C=N stretch), 1674 (st., C=0 stretch), 1495 (med., C-H 
deformation), 1215, 1130 (st., C-0 & C-N stretch).
MS m/z (+ve ES): 507 (M+H+, 99 %).
HRMS (+ve ESI): Measured mass -  506.2779. Actual mass for M+H+ - 506.2761.
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(12) l,l-Dimethylethyl-N,N-bis-(3-((3-(bis-(2-cyanoethyl)- 
amino)-propyl)-(2-cyanoethyl)amino)-propyl)-carbamate.
> k
To 1,1 -dimethylethyl-A, A-bis-(3-(3-aminopropyl)-aminopropyl)-carbamate (6 ) 
(6.43 g, 18.6 mmol) and potassium carbonate (5.15 g, 37.2 mmol) in water/acetonitrile 
(200 ml, 3:2) was added acrylonitrile (26.3 ml, 21.22 g, 400.0 mmol). The reaction was 
heated to 55°C for 48 hours under argon with very vigorous stirring. After 48 hours, the 
reaction was concentrated in vacuo until only the aqueous solution remained. The 
aqueous solution was partitioned with dichloromethane (3 x 150 ml). The organic 
fractions were combined, partitioned with sat. aq. NaCl adjusted to pH 9 with sodium 
hydrogencarbonate, dried over anhydrous sodium sulphate and concentrated in vacuo to 
give an oil. The product was purified by N.P.S.G. chromatography eluting initially with 
diethyl ether only and then gradually changing to ethyl acetate only to yield 9.29 g (75.2 
%) of a pale yellow oil.
'H NMR (CDC13) 5: 1.43 (9H, s, 
((NC(CH2)2)2N(CH2)3(NC(CH2)2)N(CH2)3)2NC02C(CH3)3), 1.56-1.98 (8H, m, 
((NC(CH2 )2 )2NCH2CH2 CH2 (NC(CH2 )2 )NCH2 CH2 CH2 )2NBoc), 2.41-2.53, 2.59 (20H & 
4H, m & t, J =  6.9 Hz,
((NCCH2CH2 )2NCH2 CH2 CH2 (NCCH2 CH2 )NCH2 CH2CH2 )2NBoc), 2.72 (4H, t, J =  6.5 
Hz, ((NC(CH2 )2 )2N(CH2 )3 (NCCH2CH2 )N(CH2)3 )2NBoc), 2.83 (8 H, t, J = 6.7 Hz, 
((NCCH2 CH2 )2N(CH2 )3(NC(CH2 )2 )N(CH2 )3 )2NBoc), 3.19 (4H, t,J =  6 . 8  Hz, 
((NC(CH2)2)2N(CH2)3(NC(CH2)2)NCH2CH2CH2)2NB0C).
,3C NMR (CDCI3 ) 5: 16.58 (((NC(CH2 )2 )2N(CH2 )3 (NCCH2 CH2 )N(CH2 )3 )2NBoc),
16.88 (4C, ((NCCH2 CH2 )2N(CH2 )3 (NC(CH2 )2 )N(CH2 )3 )2NBoc), 25.28, 26.12 (4C, 
((NC(CH2 )2 )2NCH2 CH2 CH2 (NC(CH2 )2 )NCH2CH2 CH2 )2NBoc), 28.54 (3C, -C(CH3)3),
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45.59 (((NC(CH2)2)2N(CH2)3(NC(CH2)2)NCH2CH2CH2)2NBoc), 49.27 
(((NC(CH2)2)2N(CH2)3(NCCH2CH2)N(CH2)3)2NBoc), 49.55 (4C, 
((NCCH2CH2)2N(CH2)3(NC(CH2)2)N(CH2)3)2NBoc), 51.01, 51.17 (6C, 
((NC(CH2)2)2NCH2CH2CH2(NC(CH2)2)NCH2CH2CH2)2NBoc), 79.41 (1C, -C(CH3)3),
118.88 (4C, ((NC(CH2)2)2N(CH2)3(NC(CH2)2)N(CH2)3)2NBoc), 119.43 
(((NC(CH2)2 )2N(CH2 )3 (NC(CH2 )2 )N(CH2)3 )2NBoc), 155.50 (1C, Boc).
IR v /cm'1 (NaCl): 2938, 2827 (st., C-H stretch), 2360, 2331, 2249 (st., C=N 
stretch), 1683 (st., C=0 stretch), 1419 (med., C-H deformation), 1366 (med., /er/-butyl C- 
H stretch), 1250, 1164 (st., C-0 & C-N stretch).
MS m/z (+ve ES): 665 (M+H+, 99 %), 554 ( [ C 3o H 5o N i i ] +, 20 %), 333 ([M+2H+]/2,
15%).
HRMS (+ve ESI): Measured mass -  686.4603. Actual mass for M+Na+ - 
686.4588.
(13) Bis-(3-((3-(bis-(2-cyanoethyl)-amino)-propyl)-(2- 
cyanoethyl)amino)-propyl)-amine.
N N N N
To l,l-dimethylethyl-A,A-bis-(3-((3-(bis-(2-cyanoethyl)-amino)-propyl)-(2- 
cyanoethyl)amino)-propyl)-carbamate (12) (4.86 g, 7.32 mmol) in acetonitrile (75 ml) 
and triethylsilane (6ml) was added hydrochloric acid (25 ml, 6 M). The resulting solution 
was left to stir for 4 hours at room temperature.
After 4 hours the pH of the reaction was adjusted to 9 by slow addition of solid 
NaHCC>3 . Once the reaction was at pH 9, it was concentrated in vacuo to remove 
acetonitrile. To the resulting solution was added water (75 ml) followed by solid Na2 C0 3
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in order to adjust the pH to 11. This aqueous solution was partitioned three times with 
dichloromethane (3 x 150 ml). The organic fractions were then combined, dried over 
anhydrous sodium sulphate and concentrated in vacuo to give a yellow oil. The product 
was purified by N.P.S.G. chromatography eluting with chloroform/methanol/ 
triethylamine (96:2:2) to yield 3.95 g (95.8 %) of a colourless oil.
!H NMR (CDCI3 ) 6 : 1.54-1.67 (8 H, m, 
((NC(CH2 )2 )2NCH2CH2 CH2 (NC(CH2 )2 )NCH2 CH2 CH2 )2NH), 2.44-2.65 (24H, m, 
((NCCH2 CH2 )2NCH2 CH2CH2 (NCCH2 CH2 )NCH2 CH2 CH2 )2NH), 2.72 (4H, t, J =  6.5 Hz, 
((NC(CH2 )2 )2N(CH2 )3 (NCCH2CH2 )N(CH2 )3 )2NH), 2.82 (8 H, t, J =  6.7 Hz, 
((NCCH2CH2)2N(CH2)3(NC(CH2)2)N(CH2)3)2NH).
13C NMR (CDCI3 ) 5: 16.87 (((NC(CH2)2 )2N(CH2)3(NCCH2 CH2 )N(CH2 )3)2NH),
17.13 (4C, ((NCCH2CH2)2N(CH2)3(NC(CH2)2)N(CH2)3)2NH), 25.54 
(((NC(CH2)2)2NCH2CH2CH2(NC(CH2)2)NCH2CH2CH2)2NH), 27.56 
(((NC(CH2)2)2NCH2CH2CH2(NC(CH2)2)NCH2CH2CH2)2NH), 48.45 
(((NC(CH2)2)2N(CH2)3(NC(CH2)2)NCH2CH2CH2)2NH), 49.60 
(((NC(CH2)2)2N(CH2)3(NCCH2CH2)N(CH2)3)2NH), 49.79 (4C, 
((NCCH2CH2)2N(CH2)3(NC(CH2)2)N(CH2)3)2NH), 51.23, 51.35, 52.15 (6C, 
((NC(CH2)2)2NCH2CH2CH2(NC(CH2)2)NCH2CH2CH2)2NH), 119.16 (4C, 
((NC(CH2)2)2N(CH2)3(NC(CH2)2)N(CH2)3)2NH), 119.72 
(((NC(CH2)2)2N(CH2)3(NC(CH2)2)N(CH2)3)2NH).
IR v /cm'1 (NaCl): 2948, 2823 (st., C-H stretch), 2247 (st., C=N stretch), 1464, 
1421 (st., C-H deformation), 1251, 1138, 1038 (st., C-N stretch).
MS m/z (+ve ES): 565 (M+H+, 99 %), 283 ([M+2H+]/2, 5 %).
HRMS (+ve ESI): Measured mass -  564.4236. Actual mass for M+H+ - 564.4245.
111
(14) Benzyl 11-bromoundecanoate.
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To 11 -bromoundecanoic acid (26.0 g, 98 mmol), dimethylaminopyridine (1.22 g, 
10 mmol) and benzyl alcohol (11.4 ml, 11.89 g, 110 mmol) in dry dichloromethane, 
under argon, at 0°C was added dicyclohexylcarbodiimide (22.69 g, 110 mmol) at once. 
The reaction was left to stir at room temperature for 20 hours, after which time it was 
concentrated in vacuo. To the reaction was added diethyl ether (150 ml) and the resulting 
solution was filtered. The filtrate was concentrated in vacuo to give a yellow oil/solid.
The product was purified by N.P.S.G. chromatography, eluting with chloroform only to 
yield 32.04 g (92 %) of a pale yellow oil.
*H NMR (CDCI3 ) 6 : 1.28-1.39 (1 OH, m, B rtC H zM C ^sC ^C ^C C ^B n), 1.42 
(2H, m, BrCH2CH2CH2(CH2)7C02 Bn), 1.65 (2H, m, Br(CH2 )8CH2CH2C02Bn), 1.85 (2H, 
m, BrCH2CH2 (CH2 )8 C0 2 Bn), 2.36 (2H, t, 7 H 2 - h 3  = 7.5 Hz, Br(CH2 )9 CH2 C0 2 Bn), 3.40 
(2H, t, J h i i - h i o  = 6.9 Hz, BrCH2 (CH2 )9 C0 2 Bn), 5.12 (2H, s, Br(CH2 )ioC0 2 CH2 C6H5 ),
7.34 (5H, m, Br(CH2 )ioC02CH2 C6H5).
,3C NMR (CDCI3 ) 5: 25.34 (1C, C3), 28.56, 29.12, 29.49, 29.57, 29.70, 29.73 
(6 C, C4-C9), 34.23 (1C, CIO), 34.73 (1C, Cl 1), 35.34 (1C, C2), 66.44 (1C,
CH2C6 H5), 128.54, 128.93, 136.61 (6 C, -CH2C6 H5), 174.00 (1C, C=0).
IR v /cm ' 1 (NaCl): 3065, 3033 (wk., aromatic C-H stretch), 2929, 2854 (st., 
aliphatic C-H stretch), 1739 (vst., C=0 stretch), 1456 (med., C-H bend & aromatic C=C 
stretch), 1250, 1164 (st., ester C-O stretch).
MS m/z (+ve ESI): 379 ([Ci8H2 7 0 2 8 1 BrNa]+, 16 %), 377 ([C,8H2 7 0 2 7 9 BrNa]+, 16
%).
HRMS (+ve ESI): Measured mass -  377.1094. Actual mass for M(7 9 Br)+Na+ - 
377.1086.
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(15) ll-(Bis-(3-(bis-(2-cyanoethyl)-amino)-propyl))- 
aminoundecanoic acid benzyl ester.
To bis-(3,3-bis-(2-cyanoethylamino)-propyl)-amine (10) (1.72 g, 5.0 mmol) in 
dimethylformamide (10 ml) was added 11-bromoundecanoic acid benzyl ester (14) (1.95 
g, 5.50 mmol), anhydrous potassium carbonate (1.04 g, 7.5 mmol) and potassium iodide 
(0.083 g, 0.50 mmol). The reaction was heated to 35°C and left stirring under argon for 
one week.
After one week, the reaction was concentrated in vacuo, re-dissolved in xylene 
and again concentrated in vacuo. To the remaining oil/solid was added dichloromethane 
(50 ml) and sat. aq. NaHCC>3 (50 ml). The organic phase was separated from the aqueous 
phase, which was partitioned twice with dichloromethane (2 x 50 ml). The organic 
fractions were combined, dried over anhydrous sodium sulphate and concentrated in 
vacuo to give a yellow oil. The product was purified by N.P.S.G. chromatography eluting 
with ethyl acetate only to yield 2.05 g (66.4 %) of a yellow oil.
]H NMR (CDC13) 6: 1.29-1.41 (14H, m, 
((NC(CH2)2)2N(CH2)3)2NCH2(CH2)7CH2CH2C02Bn), 1.56-1.67 (6H, m, 
((NC(CH2)2)2NCH2CH2CH2)2N(CH2)8CH2CH2C02Bn), 2.34-2.50, 2.58 (18H & 4H, m & 
t, J = 6.9 Hz, ((NCCH2CH2)2NCH2CH2CH2)2NCH2(CH2)8CH2C02Bn), 2.86 (8H, t, J  = 
6.7 Hz, ((NCCH2CH2)2N(CH2)3)2N(CH2)ioC02Bn), 5.12 (2H, s, 
((NC(CH2)2)2N(CH2)3)2N(CH2)ioC02CH2C6H5), 7.36 (5H, m, 
((NC(CH2)2)2N(CH2)3)2N(CH2)ioC02CH2C6H5).
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l3C NMR (CDCh) 6 : 17.25 (((NCCH2CH2)2N(CH2)3)2N(CH2)ioC02 Bn), 25.23 
(1C, ((NC(CH2)2)2N(CH2)3)2N(CH2)8CH2CH2C 0 2Bn), 27.92 (1C, 
((NC(CH2)2)2N(CH2)3)2N(CH2)2CH2(CH2 )7C02Bn), 29.39,29.50, 29.67, 29.88 (8 C, 
((NC(CH2)2)2NCH2CH2CH2)2NCH2CH2CH2(CH2)5CH2CH2 C02Bn), 34.61 (1C, 
((NC(CH2 )2)2NCH2CH2CH2)2N(CH2)9CH2C02Bn), 50.0 
(((NCCH2CH2 )2N(CH2 )3 )2N(CH2 )ioC0 2Bn), 51.83, 51.99 (4C, 
((NC(CH2 )2)2NCH2CH2CH2)2N(CH2)ioC02Bn), 54.37 (1C, 
((NC(CH2)2)2N(CH2 )3)2NCH2(CH2)9C02Bn), 66.30 (1C, 
((NC(CH2 )2)2N(CH2)3)2N(CH2)ioC02CH2C6H5), 118.97
(((NC(CH2 )2 )2N(CH2 )3 )2N(CH2 )ioC0 2 Bn), 128.40, 128.81, 129.31, 136.50 (5C, benzyl), 
173.91 (1C, benzyl ester C=0).
IR v /cm ' 1 (NaCl): 3050 (wk., aromatic C-H stretch), 2927, 2854 (st., C-H stretch), 
2247 (st., C=N stretch), 1733 (st., C=0 stretch), 1456, 1421 (st., C-H deformation), 1250, 
1141 (st., C-O & C-N stretch).
MS m/z (+ve ES): 618 (M+H+, 99 %).
HRMS (+ve ESI): Measured mass -  618.4508. Actual mass for M+H+ - 618.4490.
“I 1 A
(16) Benzyl 6-bromohexanoate.
To 6 -bromohexanoic acid (7.8 g, 40 mmol), dimethylaminopyridine (0.48 g, 4 
mmol) and benzyl alcohol (4.66 ml, 4.87 g, 45 mmol) in dry dichloromethane, under 
argon at 0°C was added dicyclohexylcarbodiimide (9.28 g, 45 mmol). The reaction was 
left to stir at room temperature for 2 0  hours after which time it was concentrated in vacuo, 
dissolved in diethyl ether (100 ml) and filtered. The filtrate was concentrated in vacuo 
and the remaining oil was purified by N.P.S.G. chromatography, eluting with chloroform 
only to yield 10.72 g (94 %) of a pale yellow oil.
O
355
'H NMR (CDCI3 ) 5: 1.50 (2H, qn, BrC2H4 CH2 C2H4 COOCH2 C6 H5), 1.68 (2H, m, 
BrC3 H6 CH2 CH2 COOCH2C6 H5 ), 1.89 (2H, m, BrCH2CH2 C3 H6 COOCH2 C6 H5 ), 2.40 (2H, 
t, J =  7.40 Hz, BrC4 H8 CH2 COOCH2 C6 H5 ), 3.41 (2H, t, 7 =  6.75 Hz, 
BrCH2 C4 H8COOCH2C6 H5 ), 5.15 (2H, s, Br(CH2 )5COOCH2 C6H5 ), 7.37-7.41 (5H, m, 
Br(CH2)5COOCH2C6H5).
13C NMR (CDCI3 ) 5: 22.20 (1C, C3), 25.76 (1C, C4), 30.52 (1C, C2), 31.59 (1C, 
C5), 32.18 (1C, C6 ), 64.32 (1C, -CH2 C6 H5), 126.35 (3C, benzyl ortho & para), 126.70 
(2C, benzyl meta), 171.37 (1C, C=0).
IR v /cm ' 1 (NaCl): 3033 (wk., aromatic C-H stretch), 2933, 2855 (st., aliphatic C- 
H stretch), 1736 (vst., C=0 stretch), 1454 (med., C-H bend & aromatic C=C stretch), 
1255, 1168 (st., ester C-0 stretch).
MS m/z (+ve ESI): 286 ([Ci3H 180 2 8 lBr]+, 7 %), 284 ([C13H |8 0 2 7 9 Br]+, 7 %), 91 
([C7H7]+, 99 %).
HRMS (+ve ESI): Measured mass -  285.0482. Actual mass for M+H+ - 285.0490.
(17) ll-(Bis-(3-(benzyloxycarbonyl-(2-cyanoethyl)-amino)- 
propyl))-aminoundecanoic acid benzyl ester.
o
o
To bis-(3-(benzyloxycarbonyl-(2-cyanoethyl)-amino)-propyl)-amine (11) (5.29 g, 
10.49 mmol) in dimethylformamide (25 ml) was added 11-bromoundecanoic acid benzyl
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ester (14) (4.44 g, 12.5 mmol), anhydrous potassium carbonate (2.07 g, 15.0 mmol) and 
potassium iodide (0.166 g, 1.0 mmol). The reaction was heated to 35°C and left stirring 
under argon for one week.
After one week, the reaction was concentrated in vacuo, re-dissolved in xylene 
and again concentrated in vacuo. To the remaining oil/solid was added dichloromethane 
(100 ml) and sat. aq. NaHC0 3  (100 ml). The organic phase was separated from the 
aqueous phase, which was partitioned twice with dichloromethane ( 2  x 100 ml). The 
organic fractions were combined, dried over anhydrous sodium sulphate and concentrated 
in vacuo to give a yellow oil. The product was purified by N.P.S.G. chromatography 
eluting initially with ethyl acetate and then gradually changing to ethyl 
acetate/triethylamine (98:2) to yield 4.88 g (59.6 %) of a yellow oil.
'HNMR(CDC13) 5: 1.19-1.44 (14H, m, 
(NC(CH2)2(Cbz)N(CH2)3)2NCH2(CH2)7CH2CH2C02Bn), 1.60-1.67 (6H, m, 
(NC(CH2)2(Cbz)NCH2CH2CH2)2N(CH2)8CH2CH2C02Bn), 2.25-2.39 (8H, m, 
(NC(CH2)2(Cbz)NCH2CH2CH2)2NCH2(CH2)8CH2C02Bn), 2.55-2.65 (4H, m, 
(NCCH2CH2(Cbz)N(CH2)3)2N(CH2)ioC02Bn), 3.35 (4H, m, 
(NC(CH2)2(Cbz)NCH2CH2CH2)2N(CH2)ioC02Bn), 3.52 (4H, m, 
(NCCH2CH2(Cbz)N(CH2)3)2N(CH2)ioC02Bn), 5.12 (2H, s, 
(NC(CH2)2(Cbz)N(CH2)3)2N(CH2),oC02CH2C6H5), 5.15 (4H, s, 
(NC(CH2)2(C6H5CH202C)N(CH2)3)2N(CH2)ioC02Bn), 7.36 (15H, m, 
(N C (C H 2 )2 (C 6 H 5 C H 2 0 2C )N (C H 2 )3 )2 N (C H 2 ) ioC 0 2 C H 2 C 6 H 5).
,3C NMR (CDC13) 5: 17.21, 17.95 ((NCCH2CH2(Cbz)N(CH2)3)2N(CH2)ioC02 Bn), 
25.26 (1C, (NC(CH2 )2(Cbz)N(CH2)3)2N(CH2)8CH2CH2C02Bn), 26.23, 26.95 
((NC(CH2)2(Cbz)NCH2 CH2CH2)2N(CH2)ioC02Bn), 27.90 (1C, 
(NC(CH2)2(Cbz)N(CH2)3)2NCH2 CH2CH2(CH2)7C02Bn), 29.44, 29.55, 29.74, 29.92,
29.94 (6C, (NC(CH2)2(Cbz)N(CH2)3)2NCH2CH2CH2(CH2)5(CH2)2C02Bn), 34.63 (1C, 
(NC(CH2)2(Cbz)N(CH2)3)2N(CH2)9CH2C02Bn), 43.84, 44.86 
((NCCH2CH2(Cbz)N(CH2)3)2N(CH2)ioC02Bn), 47.25 
((NC(CH2)2(Cbz)NCH2(CH2)2)2N(CH2)ioC02Bn), 51.36, 54.18 (3C, 
(NC(CH2)2(Cbz)N(CH2)2CH2)2NCH2(CH2)9C02Bn), 66.35 (1C, 
(NC(CH2)2(Cbz)N(CH2)3)2N(CH2)ioC02CH2C6H5), 67.75 
((NC(CH2)2(C6H5CH202C)N(CH2)3)2N(CH2),oC02Bn), 118.23 
((NC(CH2)2(Cbz)N(CH2)3)2N(CH2)ioC02Bn), 128.36, 128.53, 128.85, 129.34, 136.38
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(18C, (NC(CH2 )2 (C6 H5CH2 0 2 C)N(CH2 )3 )2N(CH2 )ioC0 2 CH2C6 H5 ), 155.79 (2C, Cbz 
C=0), 173.96 (1C, benzyl ester C=0).
IR v /cm ' 1 (NaCl): 3348, 3064, 3033 (wk., aromatic C-H stretch), 2929, 2855 (st., 
aliphatic C-H stretch), 2249 (wk., C=N stretch), 1699, 1695 (vst., ester & carbamate C=0 
stretch), 1475, 1419 (med., aromatic C=C stretch & aliphatic C-H bend), 1368, 1216 
(med., C-N & C-0 stretch).
MS m/z (+ve ES): 781 (M+H+, 99.9 %).
HRMS (+ve ESI): Measured mass -  780.7687. Actual mass for M+H+ - 780.4694.
(18) 6-(Bis-(3-(benzyloxycarbonyl-(2-cyanoethyl)-amino)- 
propyl))-aminohexanoic acid benzyl ester.
To bis-(3-(benzyloxycarbonyl-(2-cyanoethyl)-amino)-propyl)-amine (11) (3.79 g, 
7.50 mmol) in dimethylformamide (18 ml) was added 6 -bromohexanoic acid benzyl ester 
(16) (2.43 g, 8.50 mmol), anhydrous potassium carbonate (2.07 g, 15.0 mmol) and 
potassium iodide (0.166 g, 1.0 mmol). The reaction was heated to 35°C and left stirring 
under argon for one week.
After one week, the reaction was concentrated in vacuo, re-dissolved in xylene 
and again concentrated in vacuo. To the remaining oil/solid was added dichloromethane 
(100 ml) and sat. aq. NaHCC>3 (100 ml). The organic phase was separated from the 
aqueous phase, which was partitioned twice with dichloromethane ( 2  x 100 ml). The
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organic fractions were combined, dried over anhydrous sodium sulphate and concentrated 
in vacuo to give a yellow oil. The product was purified by N.P.S.G. chromatography 
eluting initially with ethyl acetate and then gradually changing to ethyl 
acetate/triethylamine (98:2) to yield 3.51 g (65.9 %) of a yellow oil.
‘H NMR (CDC13) 6 : 1.22-1.40 (2H, m, 
(NC(CH2)2(Cbz)N(CH2)3)2NCH2 CH2CH2(CH2)2C02Bn), 1.67 (6 H, m, 
(NC(CH2)2(Cbz)NCH2CH2CH2)2N(CH2)3CH2CH2C02Bn), 2.26-2.44 (8 H, m, 
(NC(CH2)2(Cbz)NCH2CH2CH2)2NCH2(CH2)3CH2 C02Bn), 2.55-2.65 (4H, m, 
(NCCH2CH2(Cbz)N(CH2)3)2N(CH2)5C02 Bn), 3.36 (4H, m, 
(NC(CH2)2(Cbz)NCH2CH2 CH2)2N(CH2)5C02Bn), 3.53 (4H, m, 
(NCCH2CH2 (Cbz)N(CH2 )3 )2N(CH2 )5C0 2 Bn), 5.13 (2H, s, 
(NC(CH2 )2 (Cbz)N(CH2 )3 )2N(CH2 )5 C0 2 CH2 C6H5 ), 5.16 (4H, s, 
(NC(CH2)2(C6 H5 CH202C)N(CH2)3)2N(CH2)5C02Bn), 7.36 (15H, m, 
(NC(CH2)2(C6H5CH202C)N(CH2)3)2N(CH2)5C02CH2C6H5).
13C NMR(CDC13) 6 : 17.19, 17.90 (2C, 
(NCCH2CH2(Cbz)N(CH2 )3 )2N(CH2 )5C0 2 Bn), 25.15, 26.71, 27.28 (5C, 
(NC(CH2)2(Cbz)NCH2CH2 CH2)2NCH2(CH2)3CH2C02Bn), 34.50 (1C, 
(NC(CH2 )2(Cbz)N(CH2)3)2N(CH2)4CH2 C02Bn), 43.79, 44.84 
((NCCH2 CH2 (Cbz)N(CH2 )3 )2N(CH2 )5 C0 2 Bn), 47.22 
((NC(CH2 )2 (Cbz)NCH2 (CH2 )2 )2N(CH2 )5 C0 2 Bn), 51.35, 53.72 (3C, 
(NC(CH2)2(Cbz)N(CH2)2CH2)2NCH2(CH2)4C02 Bn), 66.35 (1C, 
(NC(CH2)2(Cbz)N(CH2)3)2N(CH2)5C02CH2 C6H5), 67.73 
((NC(CH2)2(C6H5 CH202C)N(CH2)3)2N(CH2)5C02Bn), 118.56 
((NC(CH2 )2 (Cbz)N(CH2 )3 )2N(CH2 )5 C0 2 Bn), 128.42, 128.82, 128.85, 136.42, 136.63 
(18C, (NC(CH2 )2 (C6 H5 CH2 0 2 C)N(CH2 )3 )2N(CH2 )5 C0 2 CH2C6H5 ), 156.24 (2C, Cbz 
C=0), 173.69 (1C, benzyl ester C=0).
IR v /cm ' 1 (NaCl): 3033 (wk., aromatic C-H stretch), 2942, 2863 (st., aliphatic C- 
H stretch), 2250 (wk., C=N stretch), 1700, 1695 (vst., ester & carbamate C=0 stretch), 
1476, 1420 (med., aromatic C=C stretch & aliphatic C-H bend), 1369, 1216 (med., C-N 
& C-0 stretch).
359
MS m/z (+ve ES): 733 (M+Na+, 29 %), 711 (M+H+, 99 %), 91 ([C6H5 CH2]+, 9
%).
HRMS (+ve ESI): Measured mass -  710.39185. Actual mass for M+H+ - 
710.39121.
(19) 6-(Bis-(3-((3-(bis-(2-cyanoethyl)-amino)-propyl)-(2- 
cyanoethyl)amino)-propyl))-aminohexanoic acid benzyl ester.
k
To bis-(3-(benzyloxycarbonyl-(2-cyanoethyl)-amino)-propyl)-amine (13) (3.35 g,
5.94 mmol) in dimethylformamide (15 ml) was added 6 -bromohexanoic acid benzyl ester 
(16) (1.996 g, 7.0 mmol), anhydrous potassium carbonate (1.93 g, 14.0 mmol) and 
potassium iodide (0.166 g, 1.0 mmol). The reaction was heated to 37°C and left stirring 
under argon, in the dark.
After one week, the reaction was concentrated in vacuo, re-dissolved in xylene 
and again concentrated in vacuo. To the remaining oil/solid was added dichloromethane 
(100 ml) and sat. aq. NaHCCb (100 ml). The organic phase was separated from the 
aqueous phase, which was partitioned twice with dichloromethane ( 2  x 100 ml). The 
organic fractions were combined, dried over anhydrous sodium sulphate and concentrated 
in vacuo to give a yellow oil. The product was purified by N.P.S.G. chromatography 
eluting initially with ethyl acetate/triethylamine (98:2) and then gradually changing to 
ethyl acetate/methanol/triethylamine (90:8:2) to yield 3.67 g (87.2 %) of a yellow oil.
‘H NMR (CDCI3) 8 : 1.33 (2H, m, 
((NC(CH2 )2 )2N(CH2 )3 (NC(CH2 )2)N(CH2)3)2N(CH2)2CH2 (CH2 )2C0 2 Bn), 1.45 (2H, m,
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((NC(CH2)2)2N(CH2)3(NC(CH2)2)N(CH2)3)2NCH2CH2(CH2)3C02Bn), 1.59-1.70 (14H, m, 
((NC(CH2)2)2NCH2CH2CH2(NC(CH2)2)NCH2CH2CH2)2N(CH2)3CH2CH2C02Bn),2.35- 
2.64 (32H, m,
((NCCH2CH2)2NCH2CH2CH2(NCCH2CH2)NCH2CH2CH2)2NCH2(CH2)3CH2C02Bn),
2.75 (4H, t, J =  6.4 Hz, ((NCCH2CH2)2N(CH2)3(NCCH2CH2)N(CH2)3)2N(CH2)5C02Bn), 
2.85 (8H, t , J =  6.6 Hz,
((NCCH2CH2)2N(CH2)3(NCCH2CH2)N(CH2)3)2N(CH2)5C02CH2C6H5), 5.12 (2H, s, 
((NCCH2CH2)2N(CH2)3(NCCH2CH2)N(CH2)3)2N(CH2)2C02CH2C6H5), 7.35 (5H, m, 
((NCCH2CH2)2N(CH2)3(NCCH2CH2)N(CH2)3)2N(CH2)5C02CH2C6H5).
13C NMR (CDC13) 6: 16.88 
( ( (N C C H 2 C H 2 )2 N (C H 2 )3 ( N C C H 2C H 2 )N (C H 2 )3 ) 2 N ( C H 2 )5 C 0 2 B n ) ,  1 7 . 1 8  
(((NCCH2CH2)2N(CH2)3(NCCH2CH2)N(CH2)3)2N(CH2)5C02Bn), 24.95, 25.19 
(((NCCH2CH2)2N(CH2)3(NCCH2CH2)N(CH2)3)2N(CH2)2CH2CH2CH2C02Bn), 25.77 
(((NCCH2CH2)2NCH2CH2CH2(NCCH2CH2)N(CH2)3)2N(CH2)5C02Bn), 26.95,27.37 
(3C, ((NCCH2CH2)2N(CH2)3(NCCH2CH2)NCH2CH2CH2)2NCH2CH2(CH2)3C02Bn),
34.54 (1C, ((NCCH2CH2)2N(CH2)3(NCCH2CH2)N(CH2)3)2N(CH2)4CH2C02Bn), 49.66 
(((NCCH2CH2)2N(CH2)3(NCCH2CH2)N(CH2)3)2NCH2(CH2)5C02Bn), 49.88 
(((NCCH2CH2)2N(CH2)3(NCCH2CH2)N(CH2)3)2N(CH2)5C02Bn), 51.33, 51.50, 52.14,
52.34 (8C, ((NC(CH2)2)2NCH2CH2CH2(NC(CH2)2)NCH2CH2CH2)2N(CH2)5C02Bn),
54.13 (1C, ((NCCH2CH2)2N(CH2)3(NCCH2CH2)N(CH2)3)2NCH2(CH2)4C02Bn), 66.33 
(1C,-0CH2C6H5), 119.06
(((NCCH2CH2)2N(CH2)3(NCCH2CH2)N(CH2)3)2N(CH2)5C02Bn), 119.67 
(((NCCH2CH2)2N(CH2)3(NCCH2CH2)N(CH2)3)2N(CH2)5C02Bn), 128.38, 128.82, 136.42 
(5C, -OCH2C6H5), 173.72 (1C, C=0).
IR v /cm'1 (NaCl): 3034 (wk., aromatic C-H stretch), 2948, 2821 (st., aliphatic C- 
H stretch), 2249 (med., C=N stretch), 1733 (st., C=0 stretch), 1465, 1420 (med., 
aromatic C=C stretch & aliphatic C-H bend), 1363, 1233, 1164 (med., C-N & C-0 
stretch).
MS m/z (+ve ES): 791 (M +Na\ 20 %), 769 (M+H+, 99 %).
HRMS (+ve ESI): Measured mass -  768.5390. Actual mass for M+H+ - 768.5395.
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20) ll-(Bis-(3-(bis-(3-(tert-butoxycarbonylamino)-propyl)- 
amino)-propyl))-aminoundecanoic acid benzyl ester.
Synthesis 1
To 1 l-(bis-(3-(bis-(2-cyanoethyl)-amino)-propyl)-amino)-imdecanoic acid benzyl 
ester (15) (2.40 g, 3.88 mmol) was added di-tert-butyl dicarbonate (8.47 g, 38.80 mmol,
10.0 eq.), triethylamine (13.52 ml, 9.81 g, 97 mmol, 25 eq.), Raney nickel (5 ml) and 
isopropanol (75 ml). This mixture was then placed in a Parr hydrogenator and 
hydrogenated at 180 psi. for 10 days, at room temperature (c . 15°C).
After ten days a further volume of isopropanol (75 ml) was added to the reaction 
mixture which was then filtered through a bed of Celite. The filtrate was concentrated in 
vacuo to give a yellow oil. The product was isolated from this oil by N.P.S.G. 
chromatography eluting initially with ethyl acetate only and then gradually changing to 
ethyl acetate/methanol/triethylamine (90:9:1) to yield 3.09 g (76.8 %) of a viscous yellow 
oil.
lH NMR (CDCl3/500 MHz) 5: 1.26-1.66 (28H, m, 
((BocHNCH2CH2CH2)2NCH2CH2CH2)2NCH2(CH2)8CH2CC>2Bn), 1.42 (36 H,
C(CH3)3), 2.34-2.44 (20H, m,
((BocHNCH2CH2CH2)2NCH2CH2CH2)2NCH2(CH2)8CH2C02Bn), 3.16 (8H, m, 
((BocHNCH2CH2CH2)2NCH2CH2CH2)2N(CH2)ioC02Bn), 5.12 (2H, s, -OCH2C6H5), 5.35 
(4H, bs, ((BocHN(CH2)3)2N(CH2)3)2N(CH2)ioC02Bn), 7.35 (5H, m,
OCH2C6H5).
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13C NMR (CDCI3/5 OO MHz) 5: 24.60, 25.24, 27.35, 27.95, 28.53, 28.77, 28.93, 
29.43, 29.55, 29.72, 29.92 (26C,
(((CH3)3C02CHNCH2CH2CH2)2NCH2CH2CH2)2NCH2(CH2)8CH2CC>2Bn), 34.61 (1C, 
((BocHN(CH2)3)2N(CH2)3)2N(CH2)9CH2C02Bn), 39.71 
(((BocHNCH2CH2CH2)2N(CH2)3)2N(CH2)ioC02Bn), 52.41 (8C, 
((BocHNCH2CH2CH2)2NCH2CH2CH2)2N(CH2)ioC02Bn), 54.35 (1C, 
((BocHN(CH2)3)2N(CH2)3)2NCH2(CH2)9C02Bn), 66.34 (1C, -OCH2C6H5), 79.15 (4C, - 
OC(CH3)3), 128.45, 128.83, 136.42 (5C, -OCH2C6H5), 156.38 (4C, carbamate C=0), 
173.98 (1C, ester C=0).
IR v / c m 1 (NaCl): 3347 (med., N-H stretch), 2931, 2855, 2806 (vst., C-H stretch), 
1683 (vst., carbamate & ester C=0 stretch), 1505 (st., N-H bend), 1455 (med., carbamate 
C-N stretch), 1366 (med., ter/-butyl C-H stretch), 1251, 1169 (med., C-N & C-O stretch 
& aromatic C-H bend).
MS m/z (+ve ES): 1057 (M+Na\ 15 %), 1035 (M+H+, 99 %), 934 
([C5,H96N70 8]+, 9 %).
HRMS (+ve ESI): Measured mass -  1034.7874. Actual mass for M+H+ -
1034.7839.
Synthesis 2
To (3-((3-(3-(bis-(3-ter/-butoxycarbonylamino-propyl)-amino)-propylamino)- 
propyl)-(3-tert-butoxycarbonylamino-propyl)-amino)-propyl)-carbamic acid ter/-butyl 
ester (42) (1.04 g, 1.368 mmol), anhydrous potassium carbonate (0.284 g, 2.052 mmol, 2 
eq.) and potassium iodide (0.034 g, 0.205 mmol, 0.15 eq.) under argon, in dry 
dimethylformamide (10 ml) was added benzyl 11-bromoundecanoate (14) (0.559 g, 1.573 
mmol, 1.15 eq.). The reaction was then heated to 40°C.
After one week the reaction was concentrated in vacuo to remove 
dimethylformamide and to the resulting oil/solid was added an excess of 0.5 M aqueous 
citric acid so that the pH of the solution rapidly changed to pH 4. To this aqueous solution 
was then added dichloromethane (50 ml) and the pH was then adjusted to pH 9 by 
addition of solid NaHCC>3 with continuous stirring. Once pH 9 had been attained, the two
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layers were partitioned and the aqueous layer was extracted with two further volumes of 
dichloromethane (2 x 50 ml). The organic fractions were combined, dried over anhydrous 
Na2 SC>4 and concentrated in vacuo to give a brown oil. The product was recovered from 
this oil by N.P.S.G. chromatography eluting with chloroform/methanol/triethylamine 
(96:2:2) to yield 0.770 g (55 %) of a yellow oil.
'H NMR (CDC13) 5: 1.26 (12H, m, 
((BocHN(CH2)3)2N(CH2)3)2NCH2CH2(CH2)6CH2CH2 C02Bn), 1.44 (38H, m, 
((BocHN(CH2 )3)2N(CH2)3)2NCH2CH2(CH2)8C02 Bn), 1.51-1.64 (14H, m, 
((BocHNCH2CH2CH2)2NCH2CH2CH2)2N(CH2)8CH2CH2 C02Bn), 2.33-2.44 (20H, m, 
((BocHNCH2CH2CH2)2NCH2 CH2CH2)2NCH2(CH2)8CH2C02Bn), 3.16 (8 H, m, 
((BocHNCH2 CH2 CH2 )2NCH2 CH2 CH2 )2 N(CH2 )ioC0 2 Bn), 5.11 (2H, s, -OCH2 C6H5), 5.37 
(4H, bs, ((BocHN(CH2 )3 )2N(CH2 )3 )2N(CH2 )ioC0 2Bn), 7.35 (5H, m,
OCH2 C6 H5).
13C NMR (CDCI3 ) 6 : 24.59, 25.25, 27.35, 27.95, 28.78, 29.44, 29.56, 29.73, 29.93 
(26C, ((BocHNCH2CH2CH2)2NCH2CH2CH2)2NCH2(CH2)8CH2 C02Bn), 34.62 (1C, 
((BocHN(CH2 )3)2N(CH2)3)2N(CH2)9CH2 C02Bn), 39.71 (4C, 
((BocHNCH2CH2CH2)2N(CH2)3)2N(CH2)ioC02Bn), 52.41 (8 C, 
((BocHNCH2CH2CH2)2NCH2CH2CH2)2N(CH2)ioC02Bn), 54.33 (1C, 
((BocHN(CH2 )3)2N(CH2)3)2NCH2(CH2)9C02Bn), 66.36 (1C, -OCH2 C6 H5), 79.16 (4C, - 
OC(CH3)3), 128.46, 128.84, 136.42 (5C, -OCH2C6H5), 156.38 (4C, carbamate C=0),
174.0 (1C, ester C=0).
IR v /cm" 1 (NaCl): 3354 (med., N-H stretch), 2931, 2855, 2806 (vst., C-H stretch), 
1683 (vst., carbamate & ester C=0 stretch), 1505 (st., N-H bend), 1455 (med., carbamate 
C-N stretch), 1366 (med., tert-butyl C-H stretch), 1251, 1169 (med., C-N & C-0 stretch 
& aromatic C-H bend).
MS m/z (+ve ES): 1057 (M+Na+, 15 %), 1035 (M+H+, 99 %).
HRMS (+ve ESI): Measured mass -  1034.7863. Actual mass for M+H+ -
1034.7839.
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(21) Bis-(3-(bis-(3-(tert-butoxycarbonylamino)-propyl)- 
amino)-propyl)-undecanoic acid.
To a solution of N,N- bis-(3-(bis-(3-(tert-butoxycarbonylamino)-propyl)-amino)- 
propyl)-undecanoic acid benzyl ester (20) (3.0 g, 2.90 mmol) in acetone (75 ml) was 
added an aqueous solution of potassium carbonate at pH 11. The resulting solution was 
left to stir at room temperature for 24 hours.
After 24 hours R.P. silica (30 g) was added to the reaction which was then 
concentrated in vacuo to remove acetone. The remaining solution/solid was filtered and 
the recovered R.P. silica was washed with pH 7.0 buffer solution (100 ml) and then 
copious quantities of water. The R.P. silica was then washed with acetonitrile (3 x 50 ml) 
followed by chloroform (2 x 50 ml). The organic filtrates were combined, dried over 
anhydrous sodium sulphate and concentrated in vacuo to give a very viscous yellow oil. 
After one week under high vacuum 2.59 g (92 %) of product was recovered.
'H NMR (CDC13) 5: 1.23-1.64 (64H, m, 
(((CH3)3C02CHNCH2CH2CH2)2NCH2CH2CH2)2NCH2(CH2)8CH2C02H), 2.08 (2H, m, 
((BocHNCH2CH2CH2)2NCH2CH2CH2)2N(CH2)9CH2C02H), 2.41-2.46 (18H, m, 
((BocNCH2CH2CH2)2NCH2CH2CH2)2NCH2(CH2)9C02H), 3.15 (8H, m, 
((BocHNCH2CH2CH2)2NCH2CH2CH2)2N(CH2)ioC02H), 5.40 (4H, bs, 
((BocHNCH2CH2CH2)2NCH2CH2CH2)2N(CH2)ioC02H).
13C NMR (CDCI3 ) 6: 24.25, 26.45, 27.37, 28.81, 29.71(26C, 
((BpcHNCH2CH2CH2)2NCH2CH2CH2)2NCH2(CH2)8CH2C02H), 37.76 (1C, 
((BocHN(CH2)3)2N(CH2)3)2N(CH2)9CH2C02H), 39.66 (4C, 
((BocHNCH2CH2CH2)2N(CH2)3)2N(CH2)ioC02H), 52.29 (8C, 
((BocHNCH2CH2CH2)2NCH2CH2CH2)2N(CH2)ioC02H), 54.22 (1C,
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((BocHN(CH2)3)2N(CH2)3)2NCH2(CH2)9C02H), 79.19 (4C, -OC(CH3)3), 156.38 (4C, 
carbamate C =0). (Not all signals are listed as some are to weak to be detected.)
IR v /cm'1 (NaCl/nujol): 3347 (wk., O-H stretch), 2853 (st., C-H stretch), 1725, 
1685 (st., acid & carbamate C=0 stretch), 1456 (med., carbamate C-N stretch), 1366 
(med., ter/-butyl C-H stretch), 1302, 1154 (med., C-N & C-0 stretch & aromatic C-H 
bend).
MS m/z (+ve ES): 983 (M+K+, 99 %), 967 (M+Na+, 69 %), 944 (M+H+, 80 %), 
844 ([C44H9o0 8N7]+, 15 %).
HRMS (+ve ESI): Measured mass -  944.7390. Actual mass for M+H+ - 944.7369.
(22) N,N-Bis-(3-trifluoroacetamidopropyl)- 
toluenesulfonamide.
To A//V-bis-(3-trifluoroacetamidopropyl)amine (2) (8.08 g, 25.0 mmol) and 
triethylamine (3.48 ml, 2.53 g, 25.0 mmol) in dry dichloromethane (150 ml), under argon 
was addedp-toluenesulfonyl chloride (4.77 g, 25.0 mmol) in dry dichloromethane (75 
ml). The reaction was left to stir at room temperature for 24 hours.
After 24 hours, the reaction was partitioned with sat. aq. NaHCC>3 , the aqueous 
phase being back extracted twice with dichloromethane (2 x 150 ml). The organic 
fractions were combined, dried over anhydrous sodium sulphate and concentrated in 
vacuo to give an orange oil. This oil was purified by N.P.S.G. chromatography eluting 
initially with dichloromethane and then gradually changing to diethyl ether to yield 11.50 
g (96.3 %) of a white solid.
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M.P.: 58-60°C.
'H NMR (CDCI3 ) 5: 1.84 (4H, qn, J  = 6.5 Hz & 6.5 Hz, 
(F3 C0 CHNCH2CH2 CH2 )2NS0 2 C6 H4 CH3 ), 2.44 (3H, s, 
(F3C0 CHN(CH2 )3 )2NS0 2 C6 H4 CH3 ), 3.16 (4H, t, J =  6.5 Hz, 
(F3C0 CHNCH2 CH2CH2 )2NS0 2 C6 H4 CH3 ), 3.49 (4H, q, J = 6.5 Hz, 
(F3C0CHNCH2CH2CH2)2NS02C6 H4CH3), 7.31 (2H, m, 
(F3 C0 CHN(CH2 )3 )2NS0 2 C6 H4 CH3 ), 7.33, 7.64 (4H, 2 x d, J =  8.4 Hz, 
(F3COCHN(CH2)3)2NS02C6H4CH3).
13C NMR (CDCI3 ) 6 : 21.81 (1C, ^C O C H N tC H z^N S C b C e^ C ^ ), 28.77 
((F3COCHNCH2CH2CH2)2NSO2C6H4CH3),37.0 
((F3C0CHNCH2CH2CH2)2NS02C6H4 CH3), 47.79 
((F3C0 CHNCH2CH2 CH2 )2NS0 2 C6 H4 CH3 ), 116.22 (2C, q, J C-f = 288 Hz, 
(F3C0CHN(CH2)3)2NS02C6H4CH3), 127.33, 130.45, 135.35, 144.67 (6 C, 
(F3COCHN(CH2 )3 )2NS0 2 C6H4 CH3 ), 157.91 (2C, q, J C-f = 37 Hz, 
(F3C0CHN(CH2)3)2NS02C6H4CH3).
IR v /cm-1 (NaCl): 3318 (st., amide N-H stretch), 3070 (wk., aromatic C-H 
stretch), 2931, 2879 (wk., aliphatic C-H stretch), 1704 (st., amide C=0 stretch), 1558 (st., 
amide N-H bend), 1338 (st., sulfonamide S=0 stretch), 1209, 1183, 1150 (st., 
sulfonamide S=0 & C-N stretch).
MS m/z (+ve ES): 516 (M+K+, 15 %), 500 (M+Na+, 99 %), 478 (M+H+, 15 %).
HRMS (+ve ion FAB): Measured mass -  478.1234. Actual mass for M+H+ - 
478.1235.
(23) N,N-Bis-(3-aminopropyl)-toluenesulfonamide.
To A//V-bis-(3-trifluoroacetamidopropyl)-toluenesulfonamide (22) (4.10 g, 8.59 
mmol) in ethanol (5 ml) was added hydrazine monohydrate (5 ml, c. 10 eq.). The reaction 
was then heated to 80°C for 2 hours. After 2 hours the reaction was allowed to cool to 
room temperature and then concentrated in vacuo to remove ethanol. The remaining 
solution was partitioned twelve times with toluene (12 x 50 ml). The organic fractions 
were combined, dried over anhydrous sodium sulphate and concentrated in vacuo to give
5.59 g (95 %) of a yellow oil, which required no further purification.
lH NMR (DMSO) 5: 1.52 (4H, m , J =  6 . 6  Hz & 7.5 Hz, 
(H2NCH2CH2 CH2 )2NTos), 1.68 (4H, bs, (H2N(CH2 )3 )2NTos), 2.39 (3H, s, 
(H2N(CH2 )3 )2N S0 2 C6 H4 CH3), 2.51 (4H, q, J =  6 . 6  Hz, (H2NCH2 CH2 CH2 )2NTos), 3.09 
(4H, t, J =  7.5 Hz, (H2NCH2CH2 CH2 )2NTos), 7.36, 7.67 (4H, 2 x d, J = 8.2 Hz, 
(H2N(CH2 )3 )2N S0 2C6 H4 CH3).
13C NMR (DMSO) 5: 21.88 (1C, (H2 N(CH2 )3 )2N S0 2 C6 H4 CH3), 33.08 
((H2NCH2CH2CH2 )2NTos), 39.81 ((H2NCH2 CH2 CH2 )2NTos), 46.89 (2C, 
(H2NCH2 CH2CH2 ) 2NTos), 127.78, 130.69, 137.36, 143.79 (6 C, 
(H2N(CH2 )3 )2N S0 2 C6 H4 CH3).
IR v /cm ' 1 (NaCl): 3433, 3310 (st., N-H stretch symmetric & asymmetric), 2924, 
2855 (st., aliphatic C-H stretch), 1676 (st., N-H bend), 1400 (med., aliphatic C-H bend), 
1335, 1205, 1136 (st., S=0 stretch & C-N stretch).
MS m/z (+ve ES): 286 (M+H+, 99.9 %).
HRMS (+ve ES): Measured mass -  286.1589. Actual mass for M+H+ - 286.1583.
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(24) N,N-Bis-(3-(bis-(2-cyanoethyl)-amino)-propyl)- 
toluenesulfonamide.
To A,7V-bis-(3-aminopropyl)-toluenesulfonamide (23) (4.28 g, 15.0 mmol) stirring 
in acrylonitrile (99.49 ml, 79.59 g, 1.5 mol, 100 eq.) was added acetic acid (3.46 ml, 3.60 
g, 60 mmol, 4 eq.). The reaction was then heated to reflux under argon.
After 72 hours the reaction was allowed to cool to room temperature and 
dichloromethane (400 ml) was then added. To the resulting solution, whilst stirring was 
slowly added sat. aq. NaHC03 until the mixture was at pH 9. The organic and aqueous 
layers were then separated and the aqueous phase was partitioned with dichloromethane 
(300 ml). The organic fractions were combined, dried over anhydrous sodium sulphate 
and concentrated in vacuo to give an orange oil. This oil was purified by N.P.S.G. 
chromatography eluting with ethyl acetate only to yield 7.39 g (99.0 %) of a yellow oil.
‘H NMR (DMSO) 6 : 1.74 (4H, m, J = 6.7 Hz & 7.4 Hz, 
((NCCH2CH2 )2NCH2 CH2 CH2)2NTos), 2.42 (3H, s, 
((NCCH2CH2 )2N(CH2 )3 )2NS0 2 C6 H4 CH3), 2.48 (4H, t,J =  6 . 6  Hz, 
((NCCH2CH2 )2NCH2CH2CH2)2NTos), 2.56 (4H, t, J = 6.7 Hz, 
((NCCH2CH2 )2NCH2 CH2CH2)2NTos), 2.82 (4H, t, J =  6 . 6  Hz, 
((NCCH2CH2 )2NCH2CH2CH2 )2NTos), 3.18 (4H, t, J =  1.4 Hz, 
((NCCH2CH2 )2NCH2CH2 CH2)2NTos), 7.32, 7.69 (4H, 2 x d, J = 8.2 Hz, 
((NCCH2CH2)2N(CH2)3)2NS02C6H4 CH3).
13C NMR (DMSO) 5: 17.21 ( ( ( N C C H z C ^ ^ C ^ ^ N T o s ) ,  21.77 (1C, 
((NC(CH2)2)2N(CH2)3)2NS02C6H4CH3), 27.77 (((NC(CH2 )2 )2NCH2 CH2 CH2 )2NTos), 
47.51 (((NC(CH2 )2)2NCH2CH2CH2)2NS02 Tos), 49.89 (((NCCH2 CH2 )2N(CH2 )3 )2NTos), 
51.02 (((NC(CH2 )2 )2NCH2 CH2 CH2 ) 2 NTos), 119.08 (((NCCH2 CH2 )2N(CH2 )3 )2NTos), 
127.34, 130.13, 136.64, 143.77 (6 C, ((NC(CH2 )2)2N(CH2)3)2NS02C6 H4CH3).
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IR v /cm ' 1 (NaCl): 2954, 2840 (st., aliphatic C-H stretch), 2247 (st., C=N stretch), 
1456 (med., aliphatic C-H bend), 1336, 1155 (st., S=0 stretch & C-N stretch).
MS m/z (+ve ES): 996 (2M+H+, 11 %), 521 (M+Na+, 12 %), 499 (M+H+, 99 %). 
HRMS (+ve ESI): Measured mass -  520.2487. Actual mass for M+Na+ - 
520.2465.
(25) N,N-Bis-(3-(2-cyanoethylamino)-propyl)- 
toluenesulfonamide.
To A/A-bis-(3-aminopropyl)-toluenesulfonamide (23) (9.99 g, 35 mmol) in 
water/acetonitrile (1:6, 100 ml) was added acrylonitrile (4.84 ml, 3.90 g, 73.5 mmol, 2.1 
eq.) and potassium carbonate (4.90 g, 25 mmol, 2.0 eq.). The reaction mixture was then 
heated to 55°C in a sealed tube for 48 hours with vigorous stirring.
After 48 hours, the reaction mixture was allowed to cool to room temperature and 
then further cooled in an ice bath. The sealed tube was then opened and the reaction 
mixture was concentrated in vacuo to remove acetonitrile. To the remaining solution was 
added a solution of sat. aq. NaHCC>3 adjusted to pH 10 by addition of solid Na2 CC>3 (85 
ml). The resulting aqueous solution was partitioned three times with dichloromethane (3 
x 100 ml). The organic fractions were combined, dried over anhydrous sodium sulphate 
and concentrated in vacuo to give a yellow oil. This oil was purified by N.P.S.G. 
chromatography eluting with chloroform/methanol/triethylamine (96:2:2) to yield 12.97 g 
(95.0 %) of a yellow oil.
‘H NMR (DMSO) 6 : 1.64 (4H, m, J =  6.7 Hz & 7.4 Hz, 
(NCCH2CH2HNCH2CH2 CH2 )2NTos), 2.45 (3H, s,
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(NCCH2CH2HN(CH2 )3 )2NS0 2 C6 H4 CH3 ), 2.54 (4H, t, J = 6.7 Hz, 
(NCCH2CH2 HNCH2 CH2CH2 )2NTos), 2.60 (4H, t, J =  6.4 Hz, 
(NCCH2 CH2HNCH2 CH2CH2 )2NTos), 2.76 (4H, t, J = 6.4 Hz, 
(NCCH2CH2 HNCH2 CH2CH2 )2NTos), 3.16 (4H, t, J =  7.4 Hz, 
(NCCH2CH2HNCH2 CH2CH2 )2NTos), 7.45,1.1 A (4H, 2 x d, J = 8.2 Hz, 
(NCCH2CH2HN(CH2)3)2NS02C6 H4 CH3).
,3C NMR (DMSO) 5: 18.67 (2C, (NCCH2 CH2HN(CH2 )3 )2NTos), 21.80 (1C, 
(NCCH2CH2HN(CH2)3)2NS02C6 H4 CH3), 29.42 ((NCCH2CH2HNCH2 CH2CH2 )2NTos), 
45.49 ((NCCH2CH2HN(CH2 )3 )2NTos), 46.52 ((NCCH2 CH2HNCH2 CH2 CH2 )2NTos), 
47.10 ((NCCH2 CH2HNCH2 CH2 CH2 )2NS0 2Tos), 120.86 ((NCCH2 CH2HN(CH2 )3 )2NTos), 
127.72, 130.60, 137.36, 143.77 (6 C, (NCCH2CH2HN(CH2)3)2NS02C6H4 CH3).
IR v /cm ' 1 (NaCl): 3329 (wk., N-H stretch), 2931, 2844 (med., aliphatic C-H 
stretch), 2360, 2331 (med., C^N stretch), 1460 (med., aliphatic C-H bend), 1336, 1158 
(st., S=0 stretch & C-N stretch).
MS m/z (+ve ES): 414 (M+Na+, 99 %), 392 (M+H+, 23 %).
HRMS (+ve ESI): Measured mass -  414.1926. Actual mass for M+Na+ - 
414.1934.
(27) N,N-Bis-(3-(tert-butoxycarbonyl-(2-cyanoethyl)- 
amino)-propyl)-toluenesulfonamide.
To A,A-bis-(3-(2-cyanoethylamino)-propyl)-toluenesulfonamide (25) (1.61 g, 4.11 
mmol) in tetrahydrofuran (40 ml) under argon, at 0°C was added triethylamine (1.71 ml, 
1.25 g, 12.35 mmol, 3 eq.). To this solution was then slowly added di-/ert-butyl
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dicarbonate (1.885 g, 8.63 mmol, 2.1 eq.) in tetrahydrofuran (25 ml). Once addition was 
complete the reaction was allowed to warm to room temperature and left to stir for 24 
hours.
After 24 hours the reaction was concentrated in vacuo to remove tetrahydrofuran 
and to the remaining oil/solid was added dichloromethane (50 ml). This solution was 
partitioned with sat. aq. NaHC0 3  (50 ml), the aqueous solution being back extracted with 
dichloromethane (50 ml). The organic fraction were combined, dried over anhydrous 
sodium sulphate and concentrated in vacuo to give a yellow oil. This oil was purified by 
N.P.S.G. chromatography eluting initially with chloroform only and then gradually 
changing to chloroform/ethyl acetate (3:2) to yield 2.43 g (99.9 %) of a yellow oil.
'H NMR (CDC13) 5: 1.45 (18H, s, (N C (C H 2 )2 (C 3 H 9 C 0 2 C )N (C H 2 )3 )2N Tos), 1.82 
(4H, m, (N C C H 2 C H 2 (B oc)N C H 2 C H 2 C H 2 )2N Tos), 2.41 (3H, s, 
(N C C H 2C H 2 (B oc)N (C H 2 )3 )2N S 0 2C 6 H4CH3), 2.60 (4H, m, 
(N C C H 2 C H 2 (B oc)N C H 2 C H 2C H 2 )2N T os), 3.07, 3.28 (8 H, m & t, J = 7.1 Hz, 
(N C C H 2 C H 2 (B oc)N C H 2 C H 2 CH 2 )2N T os), 3.46 (4H, t, J = 6.2 Hz, 
(N C C H 2C H 2 (B oc)N C H 2C H 2C H 2 )2N T os), 7.29, 7.64 (4H, 2 x d, J = 8.2 Hz, 
(N C C H 2C H 2 (B oc)N (C H 2 )3)2N S 0 2 C 6 H4CH3).
I3C NMR (CDCI3 ) 6 : 17.39, 17.89 ((NCCH2 CH2 (Boc)N(CH2 )3 )2NTos), 21.79 
(1C, (N C (C H 2)2(B oc)N (C H 2)3)2N S 0 2C6H4CH3), 28.63 (8C, 
(N C (C H 2)2(C3H9C 0 2C )N C H 2C H 2C H 2)2N T os), 44.14, 44.27 
((N C C H 2C H 2(B oc)N (C H 2)3)2N T os), 45.77, 46.86 (4C, 
(N C (C H 2)2(B oc)N C H 2C H 2C H 2)2N T os), 81.02 (1C, 
(N C (C H 2)2(C 3H9C 0 2C )N C H 2C H 2C H 2)2N T os), 118.26, 118.48 
((N C C H 2C H 2(B oc)N (C H 2)3)2N T os), 127.35, 130.11, 136.34, 143.83 (6 C, 
(N CC H 2C H 2(B oc)N (C H 2)3)2N S 0 2C 6H 4CH3), 155.71 (2 C, Boc C = 0 ).
IR v /cm ' 1 (NaCl): 2979, 2936, 2875 (med., aliphatic C-H stretch), 2360, 2331 
(med., C^N stretch), 1694, 1683 (st., carbamate C=0 stretch), 1456 (med., aliphatic C-H 
bend), 1308, 1161, 1120 (st., S=0 stretch, C-0 stretch & C-N stretch).
MS m/z (+ve ES): 630 (M+K+, 5 %), 614 (M+Na+, 6 8  %), 592 (M+H+, 5 %), 492 
([C2 4H3804N5 S]+, 5 %), 392 ([C19H3 0O2N5 S]+, 2 %).
HRMS (+ve ESI): Measured mass -  614.2986. Actual mass for M+Na+ - 
614.2982.
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(28) N,N-Bis-(3-(tert-butoxycarbonyl-(3-aminopropyl)- 
amino)-propyl)-toluenesulfonamide.
A solution of 7V,A-bis-(3-(/er/-butoxycarbonyl-(2-cyanoethyl)-amino)-propyl)- 
toluenesulfonamide (27) (2.48 g, 4.19 mmol) in dry tetrahydrofuran (75 ml), under argon 
was heated to 40°C whilst stirring. To this solution was slowly added borane-dimethyl 
sulphide (1.59 ml, 1.27 g, 16.76 mmol, 4.0 eq.) and once addition was complete, the 
reaction was left to stir at 40°C for 3 hours. After 3 hours the reaction was heated to 55°C 
and left to stir at this temperature.
After 75 hours, the reaction was allowed to cool to room temperature and then 
further cooled to 0°C. Dry methanol was then very slowly added to the reaction stirring 
under argon at 0°C until no more evolution of hydrogen could be noticed. Once hydrogen 
evolution ceased, a further similar quantity of dry methanol was added and the reaction 
was then heated to 55°C. The reaction was left to stir at this temperature for 6  hours, after 
which time it was allowed to cool to room temperature and then concentrated in vacuo to 
give a yellow viscous oil.
This oil was not purified but was used directly for subsequent syntheses. Mass 
spectroscopy showed that the oil contained the desired product.
MS m/z (+ve ES): 623 (M+Na+, 5 %), 601 (M+H+, 99 %), 501 ([C m H ^N sS]*, 
45 %), 400 ([Ci9H3802N5 S]+, 4 %).
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29) N,N-Bis-(3-(tert-butoxycarbonyl-(3-(2-
cyanoethylamino)-propyl)-amino)-propyl)-toluenesulfonamide.
To A,7V-bis-(3-(tert-butoxycarbonyl-(3-aminopropyl)-amino)-propyl)- 
toluenesulfonamide (28) (assumed to be 4.19 mmol from previous step) in 
water/acetonitrile (1:6, 25 ml) was added acrylonitrile (0.552 ml, 0.445 g, 8.38 mmol, 2.0 
eq.) and potassium carbonate (0.87 g, 6.29 mmol, 1.5 eq.). The reaction mixture was then 
heated to 55°C in a sealed tube with vigorous stirring.
After 48 hours, the reaction mixture was allowed to cool to room temperature and 
then further cooled in an ice bath. The sealed tube was then opened and the reaction 
mixture was concentrated in vacuo to remove acetonitrile. To the remaining solution was 
added a solution of sat. aq. NaHCC>3 adjusted to pH 10 by addition of solid Na2C0 3  (-25 
ml). The resulting aqueous solution was partitioned five times with dichloromethane (5 x 
50 ml). The organic fractions were combined, dried over anhydrous sodium sulphate and 
concentrated in vacuo to give a yellow oil. This oil was purified by N.P.S.G. 
chromatography eluting with chloroform/hexane/methanol/triethylamine (71:25:2:2) to 
yield 2.02 g (68.3 %, over two steps) of a yellow oil.
'H NMR (CDC13) 5: 1.45 (18H, s, -C 0 2 C(CH3)3), 1.70 (4H, qn, 
(NCCH2CH2HNCH2 CH2 CH2 (Boc)N(CH2 )3 )2NTos), 1.78 (4H, m, 
(NCCH2CH2HN(CH2 )3 (Boc)NCH2 CH2 CH2 )2NTos), 2.42 (3H, s, -SO2 C6 H4 CH3 ), 2.53 
(4H, t, J = 6 . 6  Hz, (NCCH2 CH2HN(CH2 )3 (Boc)N(CH2 )3 )2NTos), 2.63 (4H, m, 
(NCCH2CH2HNCH2 CH2 CH2 (Boc)N(CH2 )3 )2NTos), 2.92 (4H, t, J =  6 . 6  Hz, 
(NCCH2 CH2 HN(CH2 )3 (Boc)N(CH2 )3 )2NTos), 3.09, 3.13-3.29 (12H, m, 
(NCCH2 CH2HNCH2 CH2 CH2 (Boc)NCH2 CH2 CH2 )2NTos), 7.29, 7.65 (4H, 2 x d,J =  8.2 
Hz, -SO2 C6H4 CH3).
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,3C NMR (CDCI3 ) 5: 18.87 ((NCCH2CH2 HN(CH2 )3 (Boc)N(CH2 )3 )2NTos), 21.69 
(1C, -SO2C6 H4 CH3 ), 28.23 ((NC(CH2 )2HN(CH2 )3(Boc)NCH2 CH2 CH2 )2NTos), 28.64 
(6 C, -C 0 2 C(CH3 )3), 29.22 ((N C C H zC ^H N C H zO ^C ^B oc^C H zbhN T os), 44.40, 
44.83, 45.30,46.16, 46.87 (10C,
(NCCH2 CH2 HNCH2 CH2CH2 (Boc)NCH2CH2CH2 )2NTos), 79.78 (-C 0 2C(CH3)3), 119.01 
((NCCH2CH2 HN(CH2 )3 (Boc)N(CH2 )3 )2NTos), 127.30, 129.94, 136.40, 143.54 (6 C ,- 
SO2C6 H4 CH3 ), 155.79 (2C, Boc C=0).
IR v /cm 1 (NaCl): 3323 (med., N-H stretch), 2973, 2869 (st., aliphatic C-H 
stretch), 2247 (wk., C=N stretch), 1674 (st., carbamate C=0 stretch), 1598 (wk., C=C 
stretch), 1480, 1463 (st., aliphatic C-H bend & aromatic C=C stretch), 1367 (med., tert- 
butyl C-H stretch), 1337, 1233, 1158 (st., S O , C-N & C-0 stretch).
MS m/z (+ve ES): 729 (M +Na\ 99 %), 707 (M+H+, 11 %), 607 ([C3oH5 2N7 0 4 S]+,
3 %).
HRMS (+ve ESI): Measured mass -  728.4139. Actual mass for M+Na+ - 
728.4139.
30) N,N-Bis-(3-(tert-butoxycarbonyl-(3-(tert- 
butoxycarbonyl-(2-cyanoethyl)-amino)-propyl)-amino)-propyl)- 
toluenesulfonamide.
To AZ7V-bis-(3-(te/7-butoxycarbonyl-(3-(2-cyanoethylamino)-propyl)-amino)- 
propyl)-toluenesulfonamide (29) (8.55 g, 12.11 mmol) and triethylamine (5.04 ml, 3.67 g, 
36.33 mmol, 3 eq.) under argon, stirring at 0°C in dry tetrahydrofuran (100 ml), was
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added di-/er/-butyl dicarbonate (5.55 g, 25.43 mmol, 2.1 eq.) in dry tetrahydrofuran (50 
ml). Once addition was complete, the reaction was allowed to warm to room temperature 
and then left to stir for 24 hours.
After 24 hours the reaction was concentrated in vacuo to remove tetrahydrofuran 
and then re-dissolved in dichloromethane (100 ml). This solution was partitioned with sat. 
aq. NaHC0 3  ( 1 0 0  ml), the aqueous phase being back-extracted with dichloromethane 
(100 ml). The organic fractions were combined, dried over anhydrous sodium sulphate 
and concentrated in vacuo to give a yellow oil. The product was isolated from this oil by 
N.P.S.G. chromatography eluting with chloroform/ethyl acetate (70:30) to give 7.0 g 
(63.7 %) of a colourless oil.
'H NMR (CDC13) 6 : 1.45 (18H, 2 x s, -C0 2 C(CH3)3), 1.48 (18H, s,
-C0 2 C(CH3 )3), 1.70 (8 H, m, (NC(CH2 )2 (Boc)NCH2 CH2 CH2 (Boc)NCH2 CH2 CH2 )2NTos),
1.78 (4H, m, (NCCH2 CH2HN(CH2 )3 (Boc)NCH2CH2 CH2 )2NTos), 2.42 (3H, s, - 
S0 2 C6 H4 CH3), 2.62 (4H, bs, (NCCH2 CH2 (Boc)N(CH2 )3 (Boc)N(CH2 )3 )2NTos), 3.08 (4H, 
t, J = 7.55 Hz, (NC(CH2 )2 (Boc)NCH2 CH2 CH2 (Boc)N(CH2 )3 )2NTos), 3.19 (8 H, m, 
(NC(CH2 )2(Boc)NCH2 CH2 CH2 (Boc)NCH2 CH2CH2 )2NTos), 3.28 (4H, t, J =  7.35 Hz, 
(NC(CH2 )2 (Boc)N(CH2 )2 (Boc)NCH2 CH2 CH2 )2NTos), 3.49 (4H, t, J = 6.65 Hz, 
(NCCH2 CH2 (Boc)N(CH2 )3 (Boc)N(CH2 )3)2NTos), 7.29, 7.65 (4H, 2 x d, J = 8.2 Hz, - 
S 0 2C6 H4 CH3).
13C NMR (CDCI3 ) 5: 17.27 ((NCCH2 CH2 (Boc)N(CH2 )3 (Boc)N(CH2 )3 )2NTos), 
21.73 ( 1 C, -S0 2 C6 H4 CH3), 28.44
((NC(CH2 )2 (Boc)NCH2 CH2 CH2 (Boc)NCH2 CH2 CH2)2NTos), 28.65, 28.74 (12C, 
C 0 2 C(CH3)3), 44.17 ((NCCH2 CH2 (Boc)N(CH2)3 (Boc)N(CH2 )3 )2NTos), 44.98, 46.97 (8 C, 
(NC(CH2 )2 (Boc)NCH2 CH2 CH2 (Boc)NCH2 CH2 CH2 )2NTos), 79.94, 80.85 (4C, - 
C 0 2C(CH3)3), 118.35 ((NCCH2 CH2 (Boc)N(CH2 )3 (Boc)N(CH2 )3 )2NTos), 127.32, 129.99, 
136.67, 143.56 (6 C, -S0 2 C6 H4 CH3), 155.65 (4C, Boc C=0).
IR v /cm ' 1 (NaCl): 2977, 2933, 2871 (st., aliphatic C-H stretch), 2249 (wk., C=N 
stretch), 1683 (vst., carbamate C O  stretch), 1599 (wk., C O  stretch), 1471, 1418 (st., 
aliphatic C-H bend & aromatic C O  stretch), 1367 (med., tert-butyl C-H stretch), 1304, 
1250, 1231, 1160 (st., S O , C-N & C-0 stretch).
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MS m/z (+ve ES): 945 (M+K+, 4 %), 929 (M+Na+, 99 %), 807 ([C4 oH6 8N7 0 8 S]+,
15%).
HRMS (+ve ESI): Measured mass -  928.5176. Actual mass for M+Na+ - 
928.5188.
(31) N,N-Bis-(3-(tert-butoxycarbonyl-(3-(tert- 
b utoxy curb onyl-(3-aminopropy I)-amino)-propyl)-amino)-propyl)- 
toluenesulfonamide.
A solution of A/A-bis-(3-(tert-butoxycarbonyl-(3-(ter/-butoxycarbonyl-(2- 
cyanoethyl)-amino)-propyl)-amino)-propyl)-toluenesulfonamide (30) (7.0 g, 7.72 mmol) 
in dry tetrahydrofuran (100 ml), under argon was heated to 40°C whilst stirring. To this 
solution was slowly added borane-dimethyl sulphide (3.66 ml, 2.93 g, 38.6 mmol, 5.0 eq.) 
and once addition was complete, the reaction was left to stir at 40°C for 3 hours. After 3 
hours the reaction was heated to 55°C.
After 75 hours, the reaction was allowed to cool to room temperature and then 
further cooled to 0°C. Dry methanol was then very slowly added to the reaction stirring 
under argon at 0°C until no more evolution of hydrogen could be noticed. Once hydrogen 
evolution ceased, a further similar quantity of dry methanol was added and the reaction 
was then heated to reflux. The reaction was refluxed for 3 hours, after which time it was 
allowed to cool to room temperature and then concentrated in vacuo to give a viscous 
yellow oil.
This oil was not purified but was used directly for subsequent syntheses. Mass 
spectroscopy showed that the oil contained the desired product.
MS m/z (+ve ES): 915 (M+H+, 99.9 %).
(32) N,N-Bis-(3-(tert-butoxycarbonyl-(3-(tert-
butoxycarbonyl-(3-(2-cyanoethylamino)-propyl)-amino)-propyl)-
amino)-propyl)-toluenesulfonamide.
o=s=o
> k
To A, A-bis-(3-(/er/-butoxycarbonyl-(3-(/er/-butoxycarbonyl-(3-aminopropyl)- 
amino)-propyl)-amino)-propyl)-toluenesulfonamide (31) (assumed to be 7.72 mmol from 
previous step) in water/acetonitrile (1:6, 40 ml) was added acrylonitrile (1.016 ml, 0.819 
g, 15.44 mmol, 2.0 eq.) and potassium carbonate (2.13 g, 15.44 mmol, 1 eq.). The 
reaction mixture was then heated to 55°C in a sealed tube for 48 hours with vigorous 
stirring.
After 48 hours, the reaction mixture was allowed to cool to room temperature and 
then further cooled in an ice bath. The sealed tube was then opened and the reaction 
mixture was concentrated in vacuo to remove acetonitrile. To the remaining solution was 
added a solution of sat. aq. NaHC0 3  adjusted to pH 10 by addition of solid Na2CC>3 (~35 
ml). The resulting aqueous solution was partitioned five times with dichloromethane (3 x 
50 ml). The organic fractions were combined, dried over anhydrous sodium sulphate and 
concentrated in vacuo to give a yellow oil. This oil was purified by N.P.S.G. 
chromatography eluting with chloroform/hexane/methanol/triethylamine (71:25:2:2) to 
yield 6.0 g (76.2 %, over two steps) of a colourless oil.
*H NMR (CDC13) 6 : 1.44 (18H, s,-C(CH3)3), 1.46 (18H, s, -C(CH3)3), 1.65-1.80 
(12H, m, (NCCH2 CH2HNCH2 CH2 CH2 (Boc)NCH2 CH2 CH2 (Boc)NCH2 CH2 CH2 )2NTos), 
2.41 (3H, s, -SO2 C6H4 CH3 ), 2.49 (4H, t,J =  6.70 Hz,
(NCCH2 CH2HN(CH2 )3 (Boc)N(CH2 )3 (Boc)N(CH2 )3 )2NTos), 2.63 (4H, t , J =  6.75 Hz, 
(NCCH2CH2HNCH2 CH2 CH2 (Boc)N(CH2 )3 (Boc)N(CH2 )3)2NTos), 2.91 (4H, t, J =  6.70 
Hz, (NCCH2CH2HN(CH2 )3 (Boc)N(CH2 )3 (Boc)N(CH2 )3 )2NTos), 3.06-3.18 (16H, m,
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(NCCH2CH2HNCH2CH2CH2(Boc)NCH2CH2CH2(Boc)NCH2CH2CH2)2NTos),3.26 (4H, 
t, J =  6 . 6  Hz, (NCCH2 CH2 HN(CH2 )3 (Boc)N(CH2 )3 (Boc)NCH2 CH2 CH2 )2NTos), 7.29,
7.65 (4H, 2 x d, J = 8.2 Hz, -SO2C6 H4 CH3 ).
13C NMR (CDCI3 ) 6 : 18.98 
((NCCH2CH2 HN(CH2 )3 (Boc)N(CH2 )3 (Boc)N(CH2 )3 )2NTos), 21.73 (1C, - S 0 2 C 6 H 4 CH3), 
28.35-28.76 (18C,
(NCCH2 CH2 HNCH2CH2 CH2 (Boc)NCH2 CH2CH2(Boc)NCH2 CH2 CH2 )2NTos), 44.90, 
45.21,45.46, 46.29, 46.92 (12C,
(NCCH2CH2HNCH2 CH2 CH2 (Boc)NCH2 CH2 CH2(Boc)NCH2 CH2 CH2 )2NTos), 79.75,
80.55 (-C0 2C(CH3)3), 118.97
((NCCH2CH2 HN(CH2 )3 (Boc)N(CH2 )3 (Boc)N(CH2 )3)2NTos), 127.41, 130.0, 136.76,
143.55 (6 C, -SO2C6H4 CH3 ), 155.67, 155.87 (4C, Boc C=0).
IR v /cm ' 1 (NaCl): 3325 (med., N-H stretch), 2931, 2869 (st., aliphatic C-H 
stretch), 2247 (wk., C=N stretch), 1674 (st., carbamate C=0 stretch), 1598 (wk., C=C 
stretch), 1456 (st., aliphatic C-H bend & aromatic C=C stretch), 1366 (med., tert-butyl C- 
H stretch), 1302, 1232, 1158 (st., S=0, C-N & C-0 stretch).
MS m/z (+ve ES): 1042 (M+Na+, 99.9 %), 1021 (M+H+, 4 %), 532 ([M+2Na+]/2,
3 %).
HRMS (+ve ESI): Measured mass -  1042.6386. Actual mass for M+Na+ - 
1042.6345.
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(33) N,N-Bis-(3-(tert-butoxycarbonyl-(3-(3-aminopropyl)- 
aminopropyl)-amino)-propyl)-toluenesulfonamide.
A solution of /V,7V-bis-(3-(ter/-butoxycarbonyl-(3-(2-cyanoethylamino)-propyl)- 
amino)-propyl)-toluenesulfonamide (29) (1.12 g, 1.586 mmol) in dry tetrahydrofuran (40 
ml), under argon was heated to 40°C whilst stirring. To this solution was slowly added 
borane-dimethyl sulphide (0.60 ml, 0.48 g, 6.35 mmol, 4.0 eq.) and once addition was 
complete, the reaction was left to stir at 40°C for 3 hours. After 3 hours the reaction was 
heated to 55°C.
After 75 hours, the reaction was allowed to cool to room temperature and then 
further cooled to 0°C. Dry methanol was then very slowly added to the reaction stirring 
under argon at 0°C until no more evolution of hydrogen could be noticed. Once hydrogen 
evolution ceased, a further similar quantity of dry methanol was added and the reaction 
was then heated to reflux. The reaction was refluxed for 3 hours, after which time it was 
allowed to cool to room temperature and then concentrated in vacuo to give a viscous 
yellow oil.
This oil was not purified but was used directly for subsequent syntheses. Mass 
spectroscopy showed that the oil contained the desired product.
MS m/z (+ve ES): 715 (M+H+, 40 %), 358 ([M+2H+]/2, 98 %).
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(34) N,N-Bis-(3-(tert-butoxycarbonyl-(3-(tert-
butoxycarbonyl-(3-(tert-butoxycarbonylamino)-propyl)-amino)-
propyl)-amino)-propyl)-toluenesulfonamide.
To A,AM)is-(3-(/ert-butoxycarbonyl-(3-(3-aminopropyl)-aminopropyl)-amino)- 
propyl)-toluenesulfonamide (33) (assumed to be 1.586 mmol from previous step) and 
potassium carbonate (0.658 g, 4.758 mmol, 3 eq.) in methanol (25 ml) was added solid di- 
tert-butyl dicarbonate (1.73 g, 7.93 mmol, 5 eq.). The reaction was then left to stir at 
room temperature under argon.
After 72 hours the reaction was concentrated in vacuo and then re-dissolved in 
dichloromethane (50 ml) and water (50 ml). The organic layer was separated and the 
aqueous phase was back extracted with dichloromethane (50 ml). The organic fractions 
were then combined, dried over anhydrous sodium sulphate and concentrated in vacuo to 
give a colourless oil. This oil was purified by N.P.S.G. chromatography eluting with 
chloroform/triethylamine (98:2) to yield 1.15 g (65.1 %, over two steps) of a viscous, 
colourless oil.
'H NMR (CDCb) 8 : 1.43 (54H, s, -C 0 2C(CH3)3), 1.64-1.76 (12H, m, 
(BocHNCH2CH2CH2(Boc)NCH2CH2CH2(Boc)NCH2CH2CH2 )2NTos), 2.40 (3H, s, - 
S0 2C6 H4 CH3), 3.08-3.17 (20H, m,
(BocHNCH2CH2CH2 (Boc)NCH2 CH2 CH2 (Boc)NCH2CH2 CH2 )2NTos), 3.25 (4H, m, 
(BocHN(CH2)3 (Boc)N(CH2 )3 (Boc)N(CH2 )2 CH2 )2NTos), 7.29, 7.64 (4H, 2 x d, 
-S0 2C6H4CH3).
13C NMR (CDC13) 8 : 21.74 (1C, -S0 2C6H4CH3), 28.33, 28.76 (24C, 
((CH3 )3C0 2CHNCH2 CH2CH2 ((CH3)3C0 2 C)NCH2CH2CH2((CH3 )3C0 2 C)NCH2 CH2 CH2 ) 2  
NTos), 37.73 ((BocHNCH2CH2CH2 (Boc)N(CH2 )3(Boc)N(CH2)3 )2NTos), 44.90 (8 C,
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(BocHNCH2CH2 CH2 (Boc)NCH2CH2CH2(Boc)NCH2CH2CH2 )2NTos), 46.89 
((BocHN(CH2 )3(Boc)N(CH2)3(Boc)N(CH2 )2CH2 )2NTos), 79.85 (2C, 1° amine Boc), 
79.97 (4C, 2° amine Boc), 127.43, 129.99, 136.78, 143.53 (6 C, -SO2& H 4 CH3 ), 155.66 
(4C, 2° amine Boc C=0), 156.42 (2C, 1° amine Boc C=0).
IR v /cm ' 1 (NaCl): 3366 (wk., N-H stretch), 3008,2977, 2932 (st., aliphatic C-H 
stretch), 1694, 1683 (vst., carbamate C=0 stretch), 1599 (wk., N-H bend), 1506, 1478, 
1419 (med., C-H bend and aromatic C=C stretch), 1392, 1367 (med., ter/-butyl C-H 
stretch), 1250, 1160 (st., C-N, C-0 & S=0 stretch).
MS m/z (+ve ES): 1153 (M+K+, 3 %), 1137 (M+Na+, 98 %).
HRMS (+ve ESI): Measured mass -  1136.6840. Actual mass for M+Na+ - 
1136.6862.
(35) N,N-Bis-(3-(tert-butoxycarbonyl-(3-(tert- 
butoxycarbonyl-(3-(3-aminopropyl)-amino)-propyl)-amino)- 
propyl)-amino)-propyl)-toluenesulfonamide.
H H
To a solution of A/A-Bis-(3-(/er/-butoxycarbonyl-(3-(ter/-butoxycarbonyl-(3-(2- 
cyanoethylamino)-propyl)-amino)-propyl)-amino)-propyl)-toluenesulfonamide (32) (5.99 
g, 5.87 mmol) in dry tetrahydrofuran (100 ml), under argon, at room temperature was 
slowly added borane-dimethyl sulphide (2.78 ml, 2.23 g, 29.35 mmol, 5.0 eq.) and once 
addition was complete, the reaction was left to stir at room temperature.
After one week, the reaction was heated to 45°C for 6  hours and then allowed to 
cool to room temperature. Dry methanol was then very slowly added to the reaction 
stirring under argon at room temperature until no more evolution of hydrogen could be
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observed. Once hydrogen evolution had ceased, a further similar quantity of dry methanol 
was added and the reaction was then heated to reflux. The reaction was refluxed for 3 
hours, after which time it was allowed to cool to room temperature and then concentrated 
in vacuo to give a viscous yellow oil.
This oil was not purified but was used directly for subsequent syntheses. Mass 
spectroscopy showed that the oil contained the desired product.
MS m/z (+ve ES): 1064 ([M+BH2+BH+B]+, 12 %), 1053 ([M+BH2+BH]+, 62 %), 
1041 ([M+BH2] \  40 %), 1028 (M+H+, 99 %).
36) N,N-Bis-(3-(tert-butoxycarbonyl-(3-(tert- 
butoxycarbonyl-(3-(tert-butoxycarbonyl-(3-(tert- 
butoxycarbonylamino)-propyl)-amino)-propyl)-amino)-propyl)- 
amino)-propyl)-toluenesulfonamide.
H N ^ O ^  ^ cA nH
N N N N N N
./4 s  /L  o=s —oO O O O O O I O O 0  0  0  0
> k  > k  X
To Ar,A^-bis-(3-(/er/-butoxycarbonyl-(3-(/er/-butoxycarbonyl-(3-(3-aminopropyl)- 
amino)-propyl)-amino)-propyl)-amino)-propyl)-toluenesulfonamide (35) (assumed to be 
5.87 mmol from previous step) and potassium carbonate (3.25 g, 23.48 mmol, 4 eq.) in 
tetrahydrofuran/water (3:1, 250 ml) was added di-tert-butyl dicarbonate (6.40 g, 29.35 
mmol, 5 eq.) in tetrahydrofuran (50 ml). The reaction was then left to stir at room 
temperature for 24 hours. After 24 hours a further quantity of di-te/7-butyl dicarbonate 
(3.84 g, 17.61 mmol, 3 eq.) in tetrahydrofuran (50 ml) was added. The reaction was then 
left to stir at room temperature.
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After 72 hours the reaction was concentrated in vacuo to remove tetrahydrofuran 
and the remaining aqueous solution was then partitioned with dichloromethane (150 ml). 
The organic layer was separated and the aqueous phase was extracted once more with 
dichloromethane (150 ml). The organic fractions were then combined, dried over 
anhydrous sodium sulphate and concentrated in vacuo to give a colourless oil. This oil 
was purified by N.P.S.G. chromatography eluting with diethyl ether/hexane (90:10) to 
yield 2.53 g (30 %, over two steps) of a viscous, colourless oil.
'H NMR (CDCU) 5: 1.42, 1.44 (72H, 2 * s ,  -C 0 2C(CH3)3), 1.62-1.73 (16H, m, 
(BocHNCH2CH2 CH2(Boc)NCH2CH2CH2 (Boc)NCH2CH2 CH2(Boc)NCH2CH2CH2 )2NTos 
), 2.40 (3H, s, -SC^CsHtQL), 3.07-3.27 (32H, m,
(BocHNCH2CH2CH2(Boc)NCH2CH2CH2(Boc)NCH2CH2CH2(Boc)NCH2CH2CH2)2NTos 
), 7.29, 7.64 (4H, 2 x d, -SOjCsEUCHj).
I3C NMR (CDC13) 5: 21.79 (1C, -S 0 2C6H4 CH3), 28.24,28.76 (24C, 
(BocHNCH2CH2CH2(Boc)NCH2CH2CH2(Boc)NCH2CH2CH2(Boc)NCH2CH2CH2)2NTos 
), 30.61 ((BocHNCH2 CH2CH2(Boc)N(CH2 )3(Boc)N(CH2 )3 (Boc)N(CH2)3)2NTos), 37.70 
((BocHNCH2CH2CH2(Boc)NCH2CH2CH2(Boc)NCH2CH2CH2(Boc)NCH2CH2CH2)2NTo 
s), 45.02 (12C,
(BocHNCH2CH2CH2(Boc)NCH2CH2CH2(Boc)NCH2CH2CH2(Boc)NCH2CH2CH2)2NTos 
), 46.80 ((BocHN(CH2 )3(Boc)N(CH2 )3(Boc)N(CH2)3(Boc)NCH2CH2 CH2 )2NTos), 79.69 
(2C, 1° amine Boc), 79.82 (6 C, 2° amine Boc), 127.41, 130.02, 136.75, 143.49 (6 C, - 
S0 2C6 H4 CH3), 155.65 (6 C, 2° amine Boc C=0), 156.36 (2C, 1° amine Boc C=0).
IR v /cm ' 1 (NaCl): 3368 (wk., N-H stretch), 2977,2933,2873 (st., aliphatic C-H 
stretch), 1700, 1675 (vst., carbamate C=0 stretch), 1560, 1419 (med., C-H bend and 
aromatic C=C stretch), 1366 (med., tert-butyl C-H stretch), 1250, 1160 (st., C-N, C-0 & 
S=0 stretch).
MS m/z (+ve ES): 1450 (M+Na+, 99.9 %).
HRMS (+ve ESI): Measured mass -  1450.9107. Actual mass for M+Na+ - 
1450.9068.
(37) N,N-Bis-(3-(bis-(3-aminopropyl)-amino)-propyl)- 
toluenesulfonamide.
A solution of N, 7V-bis-(3-(bis-(2-cyanoethyl)-amino)-propyl)-toluenesulfonamide 
(24) (7.40 g, 14.8 mmol) in dry tetrahydrofuran (200 ml), under argon was heated to 40°C 
whilst stirring. To this solution was slowly added borane-dimethyl sulphide (14.04 ml,
11.24 g, 148.0 mmol, 10.0 eq.) and once addition was complete, the reaction was left to 
stir at 40°C for 3 hours. After 3 hours the reaction was heated to 60°C and left to stir.
After 75 hours, the reaction was allowed to cool to room temperature and then 
further cooled to 0°C. Dry methanol was then very slowly added to the reaction stirring 
under argon at 0°C until no more evolution of hydrogen could be noticed. Once hydrogen 
evolution ceased, a further similar quantity of dry methanol was added and the reaction 
was then heated to reflux. The reaction was refluxed for 3 hours, after which time it was 
allowed to cool to room temperature and then concentrated in vacuo to give a colourless 
viscous oil.
This oil was not purified but was used directly for subsequent syntheses. Mass 
spectroscopy and I.R. spectroscopy showed that the oil contained the desired product.
IR v /cm ' 1 (NaCl): 3400-3100 (st., N-H stretch), 2900 (med., aliphatic C-H 
stretch), 1598 (st., N-H bend), 1455 (med., aliphatic C-H bend), 1338, 1090 (st., S=0 
stretch & C-N stretch).
MS m/z (+ve ES): 529 (M+Na+, 25 %), 515 (M+H+, 99 %).
HRMS (+ve ESI): Measured mass -  514.3889. Actual mass for M+H+ - 514.3897.
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38) N,N-Bis-(3-(bis-(3-tert-butoxycarbonylamino-propyl)- 
amino)-propyl)-toluenesulfonamide.
To A,AM)is-(3-(bis-(3-aminopropyl)-amino)-propyl)-toluenesulfonarnide (37) 
(assumed to be 4.76 mmol from previous step) and triethylamine (3.96 ml, 2.89 g, 28.56 
mmol, 6 . 0  eq.) stirring in tetrahydrofuran ( 1 0 0  ml), under argon was added di-ter/-butyl 
dicarbonate (6.23 g, 28.56 mmol, 6.0 eq.) in tetrahydrofuran (25 ml). Once addition was 
complete, the reaction was left to stir at room temperature.
After 4 days the reaction was concentrated in vacuo and then re-dissolved in 
dichloromethane (100 ml) and water (50 ml). This solution was partitioned first with sat. 
aq. Na2 C0 3  ( 1 0 0  ml) and the aqueous layer was then back-extracted with a further 
volume of dichloromethane (100 ml). The organic fractions were combined, dried over 
anhydrous sodium sulphate and concentrated in vacuo to give a colourless viscous oil. 
This oil was initially purified by N.P.S.G. chromatography eluting with 
chloroform/piperidine (92:8). The oil recovered from this purification was then further 
purified by N.P.S.G. chromatography eluting with chloroform/methanol/triethylamine 
(92.5:5:2.5) to yield 3.19 g (73.3 %) of a colourless viscous oil.
'H NMR (CDC13) 5: 1.43 (36H, s, -C0 2 C(CH3)3), 1.56-1.66 (12H, m, 
((BocHNCH2 CH2 CH2 )2NCH2 CH2 CH2 )2NTos), 2.36-2.41 (15H, m, 
((BocHNCH2CH2CH2)2NCH2CH2 CH2)2NS02C6H4CH3), 3.07-3.16 (12H, m, 
((BocHNCH2 CH2 CH2 )2NCH2 CH2 CH2 )2NTos), 5.20 (bs, 
((BocHNCH2 CH2 CH2 )2NCH2CH2 CH2 )2NTos), 7.29, 7.65 (4H, 2 x d, J =  8.2 Hz, 
SO2 C6H4 CH3).
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l3C NMR (CDCI3 ) 5: 21.75 (1C, -S0 2C6 H4 CH3), 26.92, 27.48 (6 C, 
((BocHNCH2CH2CH2 )2NCH2CH2CH2 )2NTos), 28.77 (12C, -C 0 2C(CH3)3), 39.48 
(((BocHNCH2CH2CH2 )2N(CH2)3 )2NTos), 47.46 
(((BocHN(CH2 )3 )2NCH2CH2CH2)2NTos), 51.64, 52.13 (6 C, 
((BocHNCH2CH2 CH2 )2NCH2CH2CH2 )2NTos), 79.20 (4C, -C 0 2C(CH3)3),
127.42, 129.99, 136.92, 143.47 (6 C, -S0 2C6 H4 CH3), 156.39 (4C, Boc C=0).
IR v /cm ' 1 (NaCl): 3358 (med., N-H stretch), 2932,2868, 2811 (med., aliphatic C- 
H stretch), 1700 (st., carbamate C=0 stretch), 1507 (med., N-H bend & aromatic C=C 
stretch), 1392, 1366 (med., tert-butyl C-H stretch), 1250, 1162 (st., C-O, C-N & S=0 
stretch).
MS m/z (+ve ES): 937 (M+Na+, 3 %), 915 (M+H+, 3 %), 458 ([M+2H+]/2, 99 %), 
320 ([M+2Na++H+]/3, 5 %), 241 ([M+2Na++2H+]/4, 30 %).
HRMS (+ve ESI): Measured mass -  914.5961. Actual mass for M+H+ - 914.5994.
(39) N,N-Bis-(3-(bis-(3-(bis-(2-cyanoethyl)-amino)-propyl)~ 
amino)-propyl)-toluenesulfonamide.
To a stirring solution of A,A-bis-(3-(bis-(3-aminopropyl)-amino)-propyl)- 
toluenesulfonamide (37) (assumed to be 14.80 mmol from previous step) in acrylonitrile 
(200 ml, 160 g, 3 mol, 200 eq.) was added acetic acid (10.25 ml, 10.66 g, 177.60 mmol, 
12 eq.). The reaction, under argon was then heated to reflux.
After 72 hours the reaction was allowed to cool to room temperature and 
dichloromethane (500 ml) was then added. To the resulting solution, whilst stirring was 
slowly added sat. aq. NaHCC>3 until the mixture was at pH 9. The organic and aqueous
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layers were then separated and the aqueous phase was partitioned twice with 
dichloromethane (2 x 500 ml). The organic fractions were combined, dried over 
anhydrous sodium sulphate and concentrated in vacuo to give an orange oil. An initial 
purification of this oil was carried out by N.P.S.G. chromatography, eluting with 
chloroform/piperidine (92:8). The oil recovered from this was then purified by N.P.S.G. 
chromatography eluting with chloroform/methanol/triethylamine (92:4:4) to yield 4.69 g 
(34 %, over two steps) of a colourless oil.
*H NMR (CDC13) 6 : 1.59 (8 H, m, (((NC(CH2 )2 )2NCH2 CH2 CH2 )2N(CH2 )3 )2NTos), 
1.69 (4H, m, (((NC(CH2 )2 )2N(CH2)3 )2NCH2CH2 CH2 )2NTos), 2.41 (3H, s, -SO2 C6H4 CH3 ), 
2.44-2.58 (36H, m, (((N C C H zC H z^N C I^C H z^^N ^C H zC H zhN Tos), 2.83 (16H, t, 
J =  6 . 6  Hz, (((NCCH2 CH2 )2N(CH2)3 )2N(CH2 )3 )2NTos), 3.11 (4H, m, 
(((NC(CH2 )2 )2N(CH2 )3 )2NCH2 CH2CH2 )2NTos), 7.31, 7.66 (4H, 2 x d, J = 8.2 Hz, - 
SO2C6H4CH3).
13C NMR (CDCI3 ) 6 : 17.28 ((((NCCH2CH2 )2N(CH2 )3 )2N(CH2 )3 )2NTos), 21.8 (1C, 
-SO2C6 H4 CH3 ), 25.36 ((((NC(CH2 )2 )2NCH2 CH2CH2)2N(CH2 )3 )2NTos), 26.97 
((((NC(CH2 )2 )2N(CH2 )3 )2NCH2 CH2 CH2)2NTos), 47.45 
((((NC(CH2 )2 )2N(CH2 )3 )2NCH2 CH2 CH2 )2NTos), 49.95 
((((NCCH2 CH2 )2N(CH2 )3 )2N(CH2 )3 )2NTos), 51.50, 51.74, 51.91 (10C, 
(((NCCH2 CH2 )2NCH2 CH2 CH2 )2NCH2CH2 CH2 )2NTos), 119.20 
((((NC(CH2 )2 )2N(CH2 )3 )2N(CH2 )3 )2NTos), 127.40, 130.05, 136.94, 143.51 (6 C, 
SO2C6 H4 CH3 ).
IR v /cm ' 1 (NaCl): 2950, 2825 (st., aliphatic C-H stretch), 2249 (st., C=N stretch), 
1465, 1420 (st., aromatic C=C stretch & aliphatic C-H bend), 1334, 1156 (st., S=0 stretch 
& C-N stretch).
MS m/z (+ve ES): 961 (M+Na+, 8  %), 939 (M+H+, 99 %).
HRMS (+ve ESI): Measured mass -  938.5997. Actual mass for M+H+ - 938.6021.
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40) N,N-Bis-(3-(bis-(3-(bis-(3-aminopropyl)-amino)- 
propyl)-amino)-propyl)-toluenesulfonamide.
o=s=o
H?N ^  N N v  NH,V W
A solution of /V,/V-bis-(3-(bis-(3-(bis-(2-cyanoethyl)-amino)-propyl)-amino)- 
propyl)-toluenesulfonamide (39) (11.38 g, 12.12 mmol) in dry tetrahydrofuran (300 ml), 
under argon was heated to 40°C whilst stirring. To this solution was slowly added borane- 
dimethyl sulphide (22.99 ml, 18.42 g, 242.4 mmol, 20.0 eq.) and once addition was 
complete, the reaction was left to stir at 40°C for 3 hours. After 3 hours the reaction was 
heated to 60°C.
After 75 hours, the reaction was allowed to cool to room temperature and then 
further cooled to 0°C. Dry methanol was then very slowly added to the reaction stirring 
under argon at 0°C until no more evolution of hydrogen could be noticed. Once hydrogen 
evolution ceased, a further similar quantity of dry methanol was added and the reaction 
was then heated to reflux. The reaction was refluxed for 3 hours, after which time it was 
allowed to cool to room temperature and then concentrated in vacuo to give a viscous 
yellow oil.
This oil was not purified but was used directly for subsequent syntheses. Mass 
spectroscopy showed that the oil contained the desired product.
MS m/z (+ve ES): 971 (M+H+, 15 %), 486 ([M+2H+]/2, 90 %).
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(42) (3-((3-(3-(Bis-(3-tert-butoxycarbonylamino-propyl)- 
amino)-propylamino)-propyl)-(3-tert-butoxycarbonylamino- 
propyl)-amino)-propyl)-carbamic acid tert-butyl ester.
Synthesis 1
Into a stirring solution of N,N- bis-(3-(bis-(3-ter/-butoxycarbonylamino-propyl)- 
amino)-propyl)-toluenesulfonamide (38) (3.70 g, 4.04 mmol) in tetrahydrofuran (100 ml) 
at -78°C, under argon was condensed liquid ammonia (c. 150 ml). Sodium metal was 
then added to this solution at -78°C until the reaction remained light blue in colour. Once 
this light blue colour was persistent, the reaction was left to stir at -78°C.
After 3 hours, methanol was carefully added to the reaction until it was no longer 
blue in colour. The reaction was then allowed to slowly warm to room temperature and 
the ammonia allowed to boil off. Once the reaction had reached room temperature, sat. 
aq. NaHC0 3  was added ( 1 0 0  ml) and the reaction was concentrated in vacuo to remove 
tetrahydrofuran. The remaining solution was partitioned three times with dichloromethane 
( 3  x 100 ml). The organic fractions were combined, dried over anhydrous sodium 
sulphate and concentrated in vacuo to give a viscous brown oil. The product was isolated 
from this oil by N.P.S.G. chromatography eluting with
chloroform/methanol/triethylamine (94:3:3) to yield 0.71 g (23.1 %) of a colourless oil.
Synthesis 2
A two-chamber preparative electrochemical cell divided by a porosity #4 glass frit 
was set up with a mercury pool (surface area - 2 0  cm ) as the cathode, a stainless steel 
tube (surface area -60 cm2) as the anode and a 4.0 M Et4N+Br' in 
acetonitrile/mercury/mercury (II) chloride reference electrode (in the cathodic chanber).
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The anodic and cathodic chambers were filled with 0.01 M tetraethylammonium bromide 
in acetonitrile ( - 2 0 0  ml in each chamber) and to the anodic chamber was then added a 
further quantity of solid tetraethylammonium bromide (40 eq., 92.8 mmol, 19.49 g). The 
electrolyte in the cathodic chamber was cooled to 8 °C by means of a cold-finger 
connected to a chilled water supply and also de-oxygenated by bubbling argon through 
the solution. The electrochemical cell was then electrolysed at -2.55 V by means of a 
potentiostat, until the current could be clearly observed to have stabilised. To the cathodic 
chamber was subsequently added phenol (25 eq., 58 mmol, 5.46 g) and the 
electrochemical cell was once again electrolysed at -2.55 V until the current could be 
clearly observed to have stabilised.
Once pre-treatment was complete, N,N- bis-(3-(bis-(3-ter/-butoxycarbonylamino- 
propyl)-amino)-propyl)-toluenesulfonamide (38) (2.12 g, 2.32 mmol) was dissolved in 
some electrolyte from the cathodic chamber and was then added to the cathodic chamber. 
The electrochemical cell was electrolysed at -2.45V for approximately 72 hours, the 
reaction being monitored by thin layer chromatography and mass spectroscopy. Once the 
reaction was determined to be complete, the potentiostat was shut down and the 
electrochemical cell was disconnected from the potentiostat. The cathodic 
electrolyte/solution was then transferred to a round bottom flask, ensuring that whilst the 
cathodic chambers was being drained the anodic chamber was also being drained so that 
no anodic electrolyte passed into the cathodic chamber. To the cathodic 
electrolyte/solution was added sat. aq. Na2 C(> 3  (50 ml) and the acetonitrile was then 
removed by concentrating in vacuo. To the remaining aqueous solution was added 
chloroform (100 ml) and 5 M aqueous sodium hydroxide (150 ml). The two layers were 
partitioned and the aqueous layer was extracted with a further two volumes of chloroform 
(2 x 100 ml). The organic fractions were combined, dried over anhydrous Na2 SC>4 and 
concentrated in vacuo to give a dark brown oil. The product was recovered from this oil 
by N.P.S.G. chromatography eluting initially with chloroform/methanol/triethylamine 
(92:4:4) and then gradually changing to chloroform/methanol/triethylamine (85:5:10) to 
yield 1.16 g ( 6 6  %) of a pale yellow oil.
*H NMR (CDCI3 ) 6 : 1.42 (36H, s, -C 0 2 C(CH3)3), 1.60 (8 H, m, J =  6 . 6  Hz, 
((BocHNCH2 CH2 CH2)2NCH2 CH2 CH2 )2NH), 1.72 (4H, m, 
((BocHNCH2 CH2 CH2)2NCH2 CH2 CH2 )2NH), 2.42 (8 H, t,J =  6 . 6  Hz, 
((BocHNCH2 CH2 CH2 )2NCH2 CH2 CH2)2NH), 2.44 (4H, m, 
((BocHNCH2 CH2CH2 )2NCH2 CH2 CH2)2NH), 2.75 (4H, m,
((BocHNCH2CH2CH2 )2NCH2CH2CH2 )2NH), 3.12 (8 H, m, 
((BocHNCH2 CH2CH2)2NCH2CH2CH2 )2NH), 5.35 (bs, 
((BocHNCH2CH2CH2 )2NCH2CH2 CH2 )2NH).
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l3C NM R (CDC13) 5: 25.98 (2C, ((BocH NC H jCH iCH i^N CH jC H jCH jhNH ),
27.24 (((B ocHNCH2CH2CH2)2NCH2CH2CH2)2NH), 28.67 (12C, -C 0 2C(CH3)3), 39.32  
(((B ocHNCH2CH2CH2)2N(CH2)3)2NH)> 48.42 (((B ocHN(CH2)3)2NCH2CH2CH2)2NH), 
51.92 (((B ocHNCH2CH2CH2)2NCH2CH2CH2)2NH), 52.45 (2C,
((BocHNCH2CH2CH2)2NCH2CH2CH2 )2NH), 79.11 (4C, -C 0 2C(CH3)3), 156.36 (4C, Boc 
C=0).
IR v /cm ' 1 (NaCl): 3356 (st., N-H stretch), 2950, 2811 (st., aliphatic C-H stretch), 
1700 (st., carbamate C=0 stretch), 1507 (med., N-H bend), 1392, 1363 (med., tert-buXy\ 
C-H stretch), 1250, 1157 (st., C-O & C-N stretch).
MS m/z (+ve ES): 783 (M+Na+, 6  %), 761 (M+H+, 99 %), 392 ([M+Na++H+]/2, 3 
%), 381 ([M+2H+]/2, 17 %).
HRMS (+ve ESI): Measured mass -  760.5906. Actual mass for M+H+ - 760.5906.
(43) (3-tert-Butoxylcarbonylamino-propyl)-(3-tert- 
butoxycarbonyl-(3-(3-(tert-butoxycarbonyl-(3-(tert- 
butoxycarbonyl-(3-tert-butoxycarbonylamino-propyl)-amino)- 
propyl)-amino)-propylamino)-propyl)-amino)-propyl)-carbamic 
acid tert-butyl ester.
A two-chamber preparative electrochemical cell divided by a porosity #4 glass frit 
was set up with a mercury pool (surface area - 2 0  cm2) as the cathode, a stainless steel
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2 "t"tube (surface area ~60 cm ) as the anode and a {4.0 M Et»N Br' in 
acetonitrile/mercury/mercury (II) chloride} reference electrode (in the cathodic chanber). 
The anodic and cathodic chambers were filled with 0.01 M tetraethylammonium bromide 
in acetonitrile ( - 2 0 0  ml in each chamber) and to the anodic chamber was then added a 
further quantity of solid tetraethylammonium bromide (40 eq., 222 mmol, 46 g). The 
electrolyte in the cathodic chamber was cooled to 8 °C by means of a cold-finger 
connected to a chilled water supply and also de-oxygenated by bubbling argon through 
the solution. The electrochemical cell was then electrolysed at -2.55 V by means of a 
potentiostat, until the current could be clearly observed to have stabilised. To the cathodic 
chamber was subsequently added phenol (25 eq., 139 mmol, 13.0 g) and the 
electrochemical cell was once again electrolysed at -2.55 V until the current could be 
clearly observed to have stabilised.
Once pre-treatment was complete, TV,V-bis-(3-(te/7-butoxycarbonyl-(3-(ter/- 
butoxycarbonyl-(3-(ter/-butoxycarbonylamino)-propyl)-amino)-propyl)-amino)-propyl)- 
toluenesulfonamide (34) (6.18 g, 5.545 mmol) was dissolved in some electrolyte from the 
cathodic chamber and was then added to the cathodic chamber. The electrochemical cell 
was electrolysed at -2.45V for approximately 72 hours, the reaction being monitored by 
thin layer chromatography and mass spectroscopy. Once the reaction was determined to 
be complete, the potentiostat was shut down and the electrochemical cell was 
disconnected from the potentiostat. The cathodic electrolyte/solution was then transferred 
to a round bottom flask, ensuring that whilst the cathodic chambers was being drained the 
anodic chamber was also being drained so that no anodic electrolyte passed into the 
cathodic chamber. To the cathodic electrolyte/solution was added sat. aq. Na2 C0 3  (75 ml) 
and the acetonitrile was then removed by concentrating in vacuo. To the remaining 
aqueous solution was added chloroform (150 ml) and 5 M aqueous sodium hydroxide 
(250 ml). The two layers were partitioned and the aqueous layer was extracted with a 
further two volumes of chloroform (2 x 150 ml). The organic fractions were combined, 
dried over anhydrous Na2 SC>4 and concentrated in vacuo to give a dark brown oil. The 
product was recovered from this oil by N.P.S.G. chromatography eluting with 
chloroform/methanol/triethylamine (94:3:3) to yield 4.03 g (75.7 %) of a pale yellow oil.
‘H NMR (DMSO) 8 : 1.41 (18H, s, 1° amine, -C 0 2C(CH3)3), 1.42 (36H, s, 2° 
amine, -C 0 2 C(CH3)3), 1.57-1.74 (12H, m,
(BocHNCH2CH2CH2 (Boc)NCH2CH2 CH2(Boc)NCH2 CH2 CH2 )2NH), 2.53 (4H, m, 
(BocHN(CH2 )3(Boc)N(CH2)3 (Boc)NCH2CH2 CH2 )2NH), 2.92 (4H, m,
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(BocHNCH2 CH2CH2 (Boc)N(CH2 )3 (Boc)N(CH2 )3 )2NH), 3.10-3.22 (16H, m, 
(BocHNCH2CH2 CH2 (Boc)NCH2 CH2CH2 (Boc)NCH2 CH2 CH2 )2NH), 6.73 (2H, bs, 
(BocHN(CH2 )3 (Boc)N(CH2 )3 (Boc)N(CH2 )3 )2NH).
,3C NMR (DMSO) 6 : 28.9-29.07 (24C, 
(BocHNCH2CH2CH2 (Boc)NCH2 CH2 CH2 (Boc)NCH2CH2 CH2 )2NH), 38.48 
((BocHNCH2CH2 CH2 (Boc)N(CH2 )3 (Boc)N(CH2 )3 )2NH), 45.13, 47.23 (10C, 
(BocHNCH2CH2 CH2 (Boc)NCH2CH2CH2 (Boc)NCH2 CH2 CH2 )2NH), 78.25 (2C, 1° amine 
Boc), 79.17 (4C, 2° amine Boc), 155.42, 155.45 (4C, 2° amine Boc C O ), 156.37 (2C, 1° 
amine Boc C=0).
IR v /cm ' 1 (NaCl): 3355 (st., N-H stretch), 2928, 2871 (st., aliphatic C-H stretch), 
1694, 1663 (vst., carbamate C=0 stretch), 1560 (wk., N-H bend), 1364 (med., tert-butyl 
C-H stretch), 1250, 1154 (st., C-N & C-0 stretch).
MS m/z (+ve ES): 983 (M+Na+, 4 %), 961 (M+H+, 99 %).
HRMS (+ve ESI): Measured mass -  960.6976. Actual mass for M+H+ - 960.6955.
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(44) (3-(tert-Butoxycarbonyl-(3-tert-butoxycarbonylamino- 
propyl)-amino)-propyl)-(3-tert-butoxycarbonyl-(3-(3-(tert- 
butoxycarbonyl-(3-(tert-butoxycarbonyl-(3-(tert-butoxycarbonyl- 
(3-tert-butoxycarbonylamino-propyl)-amino)-propyl)-amino)- 
propyl)-amino)-propylamino)-propyl)-amino)-propyl)-carbamic 
acid tert-butyl ester.
HN
0  I
NH
N' ^  'N' ^  'N'
0 ^ 0  0 ^ 0  0 ^ 0  
> k
N' ^  'NT v  'N
0 ^ 0  0 ^ 0  0 ^ 0  X X
A two-chamber preparative electrochemical cell divided by a porosity #4 glass frit 
was set up with a mercury pool (surface area ~ 2 0  cm ) as the cathode, a stainless steel 
tube (surface area -60 cm2) as the anode and a {4.0 M Et4N+Br‘ in 
acetonitrile/mercury/mercury (II) chloride} reference electrode (in the cathodic chamber). 
The anodic and cathodic chambers were filled with 0.01 M tetraethylammonium bromide 
in acetonitrile ( - 2 0 0  ml in each chamber) and to the anodic chamber was then added a 
further quantity of solid tetraethylammonium bromide (40 eq., 70 mmol, 14.7 g). The 
electrolyte in the cathodic chamber was cooled to 8 °C by means of a cold-finger 
connected to a chilled water supply and also de-oxygenated by bubbling argon through 
the solution. The electrochemical cell was then electrolysed at -2.55 V by means of a 
potentiostat, until the current could be clearly observed to have stabilised. To the cathodic 
chamber was subsequently added phenol (25 eq., 43.7 mmol, 4.12 g) and the 
electrochemical cell was once again electrolysed at -2.55 V until the current could be 
clearly observed to have stabilised.
Once pre-treatment was complete, A,A-bis-(3-(^-butoxycarbonyl-(3-(/er/- 
butoxycarbonyl-(3-(tert-butoxycarbonyl-(3-(te/Y-butoxycarbonylamino)-propyl)-amino)-
propyl)-amino)-propyl)-amino)-propyl)-toluenesulfonamide (36) (2.50 g, 1.7495 mmol) 
was dissolved in some electrolyte from the cathodic chamber and was then added to the 
cathodic chamber. The electrochemical cell was electrolysed at -2.45V for 
approximately 72 hours, the reaction being monitored by thin layer chromatography and 
mass spectroscopy. Once the reaction was determined to be complete, the potentiostat 
was shut down and the electrochemical cell was disconnected from the potentiostat. The 
cathodic electrolyte/solution was then transferred to a round bottom flask, ensuring that 
whilst the cathodic chambers was being drained the anodic chamber was also being 
drained so that no anodic electrolyte passed into the cathodic chamber. To the cathodic 
electrolyte/solution was added sat. aq. Na2CC>3 (40 ml) and the acetonitrile was then 
removed by concentrating in vacuo. To the remaining aqueous solution was added 
chloroform (75 ml) and 5 M aqueous sodium hydroxide (150 ml). The two layers were 
partitioned and the aqueous layer was extracted with a further two volumes of chloroform 
(2 x 75 ml). The organic fractions were combined, dried over anhydrous Na2 SC>4 and 
concentrated in vacuo to give a dark brown oil. The product was recovered from this oil 
by N.P.S.G. chromatography eluting with chloroform/triethylamine (98:2) to yield 1.77 g 
(79.4 %) of a pale yellow oil.
'H NMR (CDCh) 8 : 1.43 (72H, bs, -C 0 2C(CH3)3 ), 1.63-1.73 (16H, m, 
(BocHNCH2CH2CH2(Boc)NCH2 CH2 CH2(Boc)NCH2CH2 CH2(Boc)NCH2CH2CH2)2NH), 
2.56 (4H, m, (BocHN(CH2 )3 (Boc)N(CH2)3(Boc)N(CH2 )3 (Boc)NCH2CH2CH2 )2NH), 3.12- 
3.36 (28H, m,
(BocHNCH2CH2CH2 (Boc)NCH2 CH2CH2(Boc)NCH2 CH2CH2(Boc)NCH2 CH2 CH2)2NH).
I3C NMR (CDC13) 8 : 27.16, 28.56,29.28 (32C, 
(BocHNCH2CH2 CH2(Boc)NCH2CH2CH2 (Boc)NCH2CH2CH2 (Boe)NCH2CH2CH2 )2NH), 
37.37, 37.74 (2C, (BocHNCHzCHzCHj/BocMCHzMBocMCHjMBocMCftWaNH), 
44.85 (12C,
(BocHNCH2 CH2CH2 (Boc)NCH2 CH2 CH2 (Boc)NCH2CH2 CH2(Boc)NCH2CH2 CH2)2NH),
47.01,47.63 ((BocHN(CH2 )3 (Boc)N(CH2 )3(Boc)N(CH2 )3(Boc)NCH2 CH2 CH2)2NH), 
79.06, 79.52, 79.76 (8 C, Boc), 155.45, 155.64,156.15, (8 C, Boc C=0).
IR v /cm ' 1 (NaCl): 3348 (med., N-H stretch), 2931, 2871 (st., aliphatic C-H 
stretch), 1699, 1668 (vst., carbamate C=0 stretch), 1366 (med., tert-butyl C-H stretch), 
1250, 1160 (st., C-N & C-0 stretch).
MS m/z (+ve ES): 1298 (M+Na+, 35 %), 1275 (M+H+, 99.9 %).
HRMS (+ve ESI): Measured mass -  1274.9170. Actual mass for M+H+ - 
1274.9160.
(45) 1 l-(A^ALBis-(3-(^r^-butoxycarbonyl-(3-(^rr- 
butoxycarbonyl-(3-(terf-butoxycarbonylamino)-propyl)- 
amino)-propyl)-amino)-propyl)-aminoundecanoic acid benzyl 
ester.
HN' ^  ' N '  ^  ' N ‘
0 ^ 0  0 ^ 0  0 ^ 0  
> k  > k
N' N' Nf v  'NH
^  . A ,
To (3-/ert-butoxylcarbonylamino-propyl)-(3-tert-butoxycarbonyl-(3-(3-(tert- 
butoxycarbonyl-(3-(/er/-butoxycarbonyl-(3-^^-butoxycarbonylamino-propyl)-amino)- 
propyl)-amino)-propylamino)-propyl)-amino)-propyl)-carbamic acid tert-butyl ester (43) 
(0.61 g, 0.6352 mmol), anhydrous potassium carbonate (0.20 g, 1.45 mmol, 2.3 eq.) and 
potassium iodide (0.0166 g, 0.1 mmol, 0.16 eq.) under argon, in dry dimethylformamide 
(5 ml) was added benzyl 11-bromoundecanoate (14) (0.258 g, 0.725 mmol, 1.14 eq.). The 
reaction was then heated to 35°C in the absence of light.
After one week the reaction was concentrated in vacuo to remove 
dimethylformamide and to the resulting oil/solid was added sufficient sat. aq. NaHC0 3  in 
order to adjust the pH of the resulting solution to pH 9. To this aqueous solution was then 
added chloroform (50 ml), the two layers were partitioned and the aqueous layer was 
extracted with two further volumes of chloroform (2 x 50 ml). The organic fractions were 
combined, dried over anhydrous Na2S0 4  and concentrated in vacuo to give a brown oil. 
The product was recovered from this oil by N.P.S.G. chromatography eluting with 
chloroform/hexane/methanol/triethylamine (71:25:2:2) to yield 0.750 g (94 %) of a 
yellow oil.
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'H NMR (CDCh) 5: 1.21-1.24 (12H, m, 
(BocHN(CH2)3(Boc)N(CH2)3(Boc)N(CH2)3)2NCH2CH2(CH2)6CH2CH2C02Bn), 1.42-1.44 
(56H, m, (BocHN(CH2)3(Boc)N(CH2)3(Boc)N(CH2)3)2NCH2CH2(CH2)8C0 2Bn), 1.60- 
1.75 (14H, m,
(BocHNCH2CH2CH2(Boc)NCH2CH2CH2(Boc)NCH2CH2CH2)2N(CH2)8CH2CH2C02Bn), 
2.30-2.39 (8 H, m,
(BocHN(CH2)3(Boc)N(CH2)3(Boc)NCH2CH2CH2)2NCH2(CH2)8CH2C02Bn), 3.06-3.26 
(20H, m,
(BocHNCH2CH2CH2(Boc)NCH2CH2CH2(Boc)NCH2CH2CH2)2N(CH2)ioC02Bn),5.10 
(2H, s, -OCH2C6H5), 7.35 (5H, m, -OCH2C6H5).
13C NMR (CDCI3) 6 : 25.26, 26.43, 27.23, 27.96, 28.77, 28.82, 29.44, 29.56,
29.75, 29.94 (32C,
(BocHNCH2CH2CH2(Boc)NCH2CH2CH2(Boc)NCH2CH2CH2)2NCH2(CH2)8CH2C02Bn),
34.63 (1C, (BocHN(CH2)3(Boc)N(CH2)3(Boc)N(CH2)3)2N(CH2)9CH2C02Bn), 37.92 
((BocHNCH2CH2CH2(Boc)N(CH2)3(Boc)N(CH2)3)2N(CH2)ioC02Bn), 44.58 
((BocHNCH2CH2CH2(Boc)N(CH2)3(Boc)N(CH2)3)2N(CH2)ioC02Bn), 45.21 (4C, 
(BocHN(CH2)3(Boc)NCH2CH2CH2(Boc)N(CH2)3)2N(CH2)ioC02Bn), 45.9 
((BocHN(CH2)3(Boc)N(CH2)3(Boc)NCH2CH2CH2)2N(CH2)ioC02Bn), 51.87 
((BocHN(CH2)3(Boc)N(CH2)3(Boc)NCH2CH2CH2)2N(CH2)ioC02Bn), 54.25 (1C, 
(BocHN(CH2)3(Boc)N(CH2)3(Boc)N(CH2)3)2NCH2(CH2)9C02Bn), 66.33 (1C,
CH2C6H5), 79.24, 79.56, 79.92 (6C, -C02C(CH3)3), 128.44, 128.83, 136.50 (6C, 
CH2C6H5), 155.73, 156.32 (6C, Boc C=0), 173.90 (1C, ester C=0).
IR v /cm’1 (NaCl): 3361 (med., N-H stretch), 2973, 2929, 2857, 2811 (st., C-H 
stretch), 1700, 1695, 1684, 1675 (vst., carbamate & ester C=0 stretch), 1517 (med., N-H 
bend), 1456 (med., carbamate C-N stretch), 1366 (med., tert-butyl C-H stretch), 1300, 
1249, 1164 (med., C-N & C-O stretch & aromatic C-H bend).
MS m/z (+ve ES): 1273 (M+K+, 14 %), 1256 (M+Na+, 47 %), 1235 (M+H+, 99
%).
HRMS (+ve ESI): Measured mass -  1234.8898. Actual mass for M+H+ - 
1234.8887.
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